

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/003157 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number:
PCT/US2003/020389

(22) International Filing Date: 26 June 2003 (26.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/392,415 26 June 2002 (26.06.2002) US
60/441,377 21 January 2003 (21.01.2003) US
60/441,502 21 January 2003 (21.01.2003) US
60/441,405 21 January 2003 (21.01.2003) US
60/441,447 21 January 2003 (21.01.2003) US
60/441,392 21 January 2003 (21.01.2003) US
60/441,381 21 January 2003 (21.01.2003) US

(71) Applicants (for all designated States except US): TRANS-
GENRES, LLC [US/US]; Suite 110, 1750 Valley View
Lane, Dallas, TX 75243 (US). THE BOARD OF SUPER-
VISORS OF LOUISIANA STATE UNIVERSITY AND
AGRICULTURAL AND MECHANICAL COLLEGE
[US/US]; P.O. Box 25055, Baton Rouge, LA 70894-5055
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COOPER, Richard,
K. [US/US]; 535 Woodleigh Drive, Baton Rouge, LA
70810 (US). CADD, Gary, G. [US/US]; 501 Turner
Road, Apartment 1111, Grapevine, TX 76051 (US).
FIORETTI, William, C. [US/US]; 2225 Lakeridge Road
Drive, Grapevine, TX 76051 (US). DEBOER, Kenneth,
F. [US/US]; 10720 Gee Norman Road, Belgrade, MT
59714 (US).

(74) Agents: PRATT, John, S. et al.; Kilpatrick Stockton LLP,
Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

Published:

- without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: GENE REGULATION IN TRANSGENIC ANIMALS USING A TRANSPOSON-BASED VECTOR



(57) Abstract: Administration of modified transposon-based vectors has been used to achieve stable incorporation of exogenous genes into animals. These transgenic animals produce transgenic progeny. Further, these transgenic animals produce large quantities of desired molecules encoded by the transgene. Transgenic egg-laying animals produce large quantities of desired molecules encoded by the transgene and deposit these molecules in the egg.

WO 2004/003157 A2

5

GENE REGULATION IN TRANSGENIC ANIMALS USING A TRANSPOSON-BASED VECTOR

10 The U.S. Government has certain rights in this invention. The development of
this invention was partially funded by the United States Government under a HATCH
grant from the United States Department of Agriculture, partially funded by the
United States Government with Formula 1433 funds from the United States
Department of Agriculture and partially funded by the United States Government
15 under contract DAAD 19-02016 awarded by the Army.

FIELD OF THE INVENTION

 The present invention relates generally to cell-specific gene regulation in
transgenic animals. Animals may be made transgenic through administration of a
20 transposon-based vector through any method of administration including pronuclear
injection, or intraembryonic, intratesticular, intraoviductal or intravenous
administration. These transgenic animals contain the gene of interest in all cells,
including germ cells. Animals may also be made transgenic by targeting specific cells
for uptake and gene incorporation of the transposon-based vectors. Stable
25 incorporation of a gene of interest into cells of the transgenic animals is demonstrated
by expression of the gene of interest in a cell, wherein expression is regulated by a
promoter sequence. The promoter sequence may be provided as a transgene along
with the gene of interest or may be endogenous to the cell. The promoter sequence
may be constitutive or inducible, wherein inducible promoters include tissue-specific
30 promoters, developmentally regulated promoters and chemically inducible promoters.

BACKGROUND OF THE INVENTION

 Transgenic animals are desirable for a variety of reasons, including their
potential as biological factories to produce desired molecules for pharmaceutical,
35 diagnostic and industrial uses. This potential is attractive to the industry due to the
inadequate capacity in facilities used for recombinant production of desired molecules
and the increasing demand by the pharmaceutical industry for use of these facilities.
Numerous attempts to produce transgenic animals have met several problems,

including low rates of gene incorporation and unstable gene incorporation. Accordingly, improved gene technologies are needed for the development of transgenic animals for the production of desired molecules.

5 Improved gene delivery technologies are also needed for the treatment of disease in animals and humans. Many diseases and conditions can be treated with gene-delivery technologies, which provide a gene of interest to a patient suffering from the disease or the condition. An example of such disease is Type 1 diabetes. Type 1 diabetes is an autoimmune disease that ultimately results in destruction of the insulin producing β -cells in the pancreas. Although patients with Type 1 diabetes
10 may be treated adequately with insulin injections or insulin pumps, these therapies are only partially effective. Insulin replacement, such as via insulin injection or pump administration, cannot fully reverse the defect in the vascular endothelium found in the hyperglycemic state (Pieper et al., 1996. Diabetes Res. Clin. Pract. Suppl. S157-S162). In addition, hyper- and hypoglycemia occurs frequently despite intensive
15 home blood glucose monitoring. Finally, careful dietary constraints are needed to maintain an adequate ratio of consumed calories consumed. This often causes major psychosocial stress for many diabetic patients. Development of gene therapies providing delivery of the insulin gene into the pancreas of diabetic patients could overcome many of these problems and result in improved life expectancy and quality
20 of life.

Several of the prior art gene delivery technologies employed viruses that are associated with potentially undesirable side effects and safety concerns. The majority of current gene-delivery technologies useful for gene therapy rely on virus-based delivery vectors, such as adeno and adeno-associated viruses, retroviruses, and other
25 viruses, which have been attenuated to no longer replicate. (Kay, M.A., et al. 2001. Nature Medicine 7:33-40).

There are multiple problems associated with the use of viral vectors. First, they are not tissue-specific. In fact, a gene therapy trial using adenovirus was recently halted because the vector was present in the patient's sperm (Gene trial to proceed
30 despite fears that therapy could change child's genetic makeup. The New York Times, December 23, 2001). Second, viral vectors are likely to be transiently incorporated, which necessitates re-treating a patient at specified time intervals. (Kay, M.A., et al. 2001. Nature Medicine 7:33-40). Third, there is a concern that a viral-based vector could revert to its virulent form and cause disease. Fourth, viral-based
35 vectors require a dividing cell for stable integration. Fifth, viral-based vectors indiscriminately integrate into various cells and tissues, which can result in undesirable germline integration. Sixth, the required high titers needed to achieve the desired effect have resulted in the death of one patient and they are believed to be

responsible for induction of cancer in a separate study. (Science, News of the Week, October 4, 2002).

Accordingly, what is needed is a new vector to produce transgenic animals and humans with stably incorporated genes, which vector does not cause disease or other unwanted side effects. There is also a need for DNA constructs that would be stably incorporated into the tissues and cells of animals and humans, including cells in the resting state, which are not replicating. There is a further recognized need in the art for DNA constructs capable of delivering genes to specific tissues and cells of animals and humans.

When incorporating a gene of interest into an animal for the production of a desired protein or when incorporating a gene of interest in an animal or human for the treatment of a disease, it is often desirable to selectively activate incorporated genes using inducible promoters. These inducible promoters are regulated by substances either produced or recognized by the transcription control elements within the cell in which the gene is incorporated. In many instances, control of gene expression is desired in transgenic animals or humans so that incorporated genes are selectively activated at desired times and/or under the influence of specific substances. Accordingly, what is needed is a means to selectively activate genes introduced into the genome of cells of a transgenic animal or human. This can be taken a step further to cause incorporation to be tissue-specific, which prevents widespread gene incorporation throughout a patient's body (animal or human). This decreases the amount of DNA needed for a treatment, decreases the chance of incorporation in gametes, and targets gene delivery, incorporation, and expression to the desired tissue where the gene is needed to function.

25

SUMMARY OF THE INVENTION

The present invention addresses the problems described above by providing new, effective and efficient compositions for producing transgenic animals and for treating disease in animals or humans. Transgenic animals include all egg-laying animals and milk-producing animals. Transgenic animals further include but are not limited to avians, fish, amphibians, reptiles, insects, mammals and humans. In a preferred embodiment, the animal is an avian animal. In another preferred embodiment, the animal is a milk-producing animal, including but not limited to bovine, porcine, ovine and equine animals. Animals are made transgenic through administration of a composition comprising a transposon-based vector designed for stable incorporation of a gene of interest for production of a desired protein, together

with an acceptable carrier. A transfection reagent is optionally added to the composition before administration.

The transposon-based vectors of the present invention include a transposase, operably-linked to a first promoter, and a coding sequence for a protein or peptide of interest operably-linked to a second promoter, wherein the coding sequence for the protein or peptide of interest and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase. The transposon-based vector also includes the following characteristics: a) one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:13) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of the codons for the first several N-terminal amino acids of the transposase, wherein the nucleotide at the third base position of each codon was changed to an A or a T without changing the corresponding amino acid; c) addition of one or more stop codons to enhance the termination of transposase synthesis; and/or, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene.

Use of the compositions of the present invention results in highly efficient and stable incorporation of a gene of interest into the genome of transfected animals. For example, transgenic avians have been mated and produce transgenic progeny in the G1 generation. The transgenic progeny have been mated and produce transgenic progeny in the G2 generation.

The present invention also provides for tissue-specific incorporation and/or expression of a gene of interest. Tissue-specific incorporation of a gene of interest may be achieved by placing the transposase gene under the control of a tissue-specific promoter, whereas tissue-specific expression of a gene of interest may be achieved by placing the gene of interest under the control of a tissue-specific promoter. In some embodiments, the gene of interest is transcribed under the influence of an ovalbumin, or other oviduct specific, promoter. Linking the gene of interest to an oviduct specific promoter in an egg-laying animal results in synthesis of a desired molecule and deposition of the desired molecule in a developing egg. The present invention further provides for stable incorporation and expression of genes in the epithelial cells of the mammary gland in milk-producing animals. Transcription of the gene of interest in the epithelial cells of the mammary gland results in synthesis of a desired molecule

and deposition of the desired molecule in the milk. A preferred molecule is a protein. In some embodiments, the desired molecule deposited in the milk is an antiviral protein, an antibody, or a serum protein.

5 In other embodiments, specific incorporation of the proinsulin gene into liver cells of a diabetic animal results in the improvement of the animal's condition. Such improvement is achieved by placing a transposase gene under the control of a liver-specific promoter, which drives integration of the gene of interest in liver cells of the diabetic animal.

10 The present invention advantageously produces a high number of transgenic animals having a gene of interest stably incorporated. These transgenic animals successfully pass the desired gene to their progeny. The transgenic animals of the present invention also produce large amounts of a desired molecule encoded by the transgene. Transgenic egg-laying animals, particularly avians, produce large amounts of a desired protein that is deposited in the egg for rapid harvest and purification. 15 Transgenic milk-producing animals produce large amounts of a desired protein that is deposited in the milk for rapid harvest and purification.

Any desired gene may be incorporated into the novel transposon-based vectors of the present invention in order to synthesize a desired molecule in the transgenic animals. Proteins, peptides and nucleic acids are preferred desired molecules to be 20 produced by the transgenic animals of the present invention. Particularly preferred proteins are antibody proteins.

This invention provides a composition useful for the production of transgenic hens capable of producing substantially high amounts of a desired protein or peptide. Entire flocks of transgenic birds may be developed very quickly in order to produce 25 industrial amounts of desired molecules. The present invention solves the problems inherent in the inadequate capacity of fermentation facilities used for bacterial production of molecules and provides a more efficient and economical way to produce desired molecules. Accordingly, the present invention provides a means to produce large amounts of therapeutic, diagnostic and reagent molecules.

30 Transgenic chickens are excellent in terms of convenience and efficiency of manufacturing molecules such as proteins and peptides. Starting with a single transgenic rooster, thousands of transgenic offspring can be produced within a year. (In principle, up to forty million offspring could be produced in just three

generations). Each transgenic female is expected to lay at least 250 eggs/year, each potentially containing hundreds of milligrams of the selected protein. Flocks of chickens numbering in the hundreds of thousands are readily handled through established commercial systems. The technologies for obtaining eggs and
5 fractionating them are also well known and widely accepted. Thus, for each therapeutic, diagnostic, or other protein of interest, large amounts of a substantially pure material can be produced at relatively low incremental cost.

A wide range of recombinant peptides and proteins can be produced in transgenic egg-laying animals and milk-producing animals. Enzymes, hormones,
10 antibodies, growth factors, serum proteins, commodity proteins, biological response modifiers, peptides and designed proteins may all be made through practice of the present invention. For example, rough estimates suggest that it is possible to produce in bulk growth hormone, insulin, or Factor VIII, and deposit them in transgenic egg whites, for an incremental cost in the order of one dollar per gram. At such prices it
15 is feasible to consider administering such medical agents by inhalation or even orally, instead of through injection. Even if bioavailability rates through these avenues were low, the cost of a much higher effective-dose would not be prohibitive.

In one embodiment, the egg-laying transgenic animal is an avian. The method of the present invention may be used in avians including Ratites, Psittaciformes,
20 Falconiformes, Piciformes, Strigiformes, Passeriformes, Coraciiformes, Ralliformes, Cuculiformes, Columbiformes, Galliformes, Anseriformes, and Herodiones. Preferably, the egg-laying transgenic animal is a poultry bird. More preferably, the bird is a chicken, turkey, duck, goose or quail. Another preferred bird is a ratite, such as, an emu, an ostrich, a rhea, or a cassowary. Other preferred birds are partridge,
25 pheasant, kiwi, parrot, parakeet, macaw, falcon, eagle, hawk, pigeon, cockatoo, song birds, jay bird, blackbird, finch, warbler, canary, toucan, mynah, or sparrow.

In another embodiment, the transgenic animal is a milk-producing animal, including but not limited to bovine, ovine, porcine, equine, and primate animals. Milk-producing animals include but are not limited to cows, goats, horses, pigs,
30 buffalo, rabbits, non-human primates, and humans.

Accordingly, it is an object of the present invention to provide novel transposon-based vectors.

It is another object of the present invention to provide novel transposon-based vectors that encode for the production of desired proteins or peptides in cells.

It is an object of the present invention to produce transgenic animals through administration of a transposon-based vector.

5 Another object of the present invention is to produce transgenic animals through administration of a transposon-based vector, wherein the transgenic animals produce desired proteins or peptides.

Yet another object of the present invention is to produce transgenic animals through administration of a transposon-based vector, wherein the transgenic animals
10 produce desired proteins or peptides and deposit the proteins or peptides in eggs or milk.

It is a further object of the present invention to produce transgenic animals through intraembryonic, intratesticular or intraoviductal administration of a transposon-based vector.

15 It is further an object of the present invention to provide a method to produce transgenic animals through administration of a transposon-based vector that are capable of producing transgenic progeny.

Yet another object of the present invention is to provide a method to produce transgenic animals through administration of a transposon-based vector that are
20 capable of producing a desired molecule, such as a protein, peptide or nucleic acid.

Another object of the present invention is to provide a method to produce transgenic animals through administration of a transposon-based vector, wherein such administration results in modulation of endogenous gene expression.

It is another object of the present invention to provide transposon-vectors
25 useful for cell- or tissue-specific expression of a gene of interest in an animal or human with the purpose of gene therapy.

It is yet another object of the present invention to provide a method to produce transgenic avians through administration of a transposon-based vector that are capable of producing proteins, peptides or nucleic acids.

30 It is another object of the present invention to produce transgenic animals through administration of a transposon-based vector encoding an antibody or a fragment thereof.

Still another object of the present invention is to provide a method to produce transgenic avians through administration of a transposon-based vector that are capable of producing proteins or peptides and depositing these proteins or peptides in the egg.

Another object of the present invention is to provide transgenic avians that
5 contain a stably incorporated transgene.

Still another object of the present invention is to provide eggs containing desired proteins or peptides encoded by a transgene incorporated into the transgenic avian that produces the egg.

It is further an object of the present invention to provide a method to produce
10 transgenic milk-producing animals through administration of a transposon-based vector that are capable of producing proteins, peptides or nucleic acids.

Still another object of the present invention is to provide a method to produce transgenic milk-producing animals through administration of a transposon-based vector that are capable of producing proteins or peptides and depositing these proteins
15 or peptides in their milk.

Another object of the present invention is to provide transgenic milk-producing animals that contain a stably incorporated transgene.

Another object of the present invention is to provide transgenic milk-producing animals that are capable of producing proteins or peptides and depositing
20 these proteins or peptides in their milk.

Yet another object of the present invention is to provide milk containing desired molecules encoded by a transgene incorporated into the transgenic milk-producing animals that produce the milk.

Still another object of the present invention is to provide milk containing
25 desired proteins or peptides encoded by a transgene incorporated into the transgenic milk-producing animals that produce the milk.

A further object of the present invention to provide a method to produce transgenic sperm through administration of a transposon-based vector to an animal.

A further object of the present invention to provide transgenic sperm that
30 contain a stably incorporated transgene.

An advantage of the present invention is that transgenic animals are produced with higher efficiencies than observed in the prior art.

Another advantage of the present invention is that these transgenic animals possess high copy numbers of the transgene.

Another advantage of the present invention is that the transgenic animals produce large amounts of desired molecules encoded by the transgene.

5 Still another advantage of the present invention is that desired molecules are produced by the transgenic animals much more efficiently and economically than prior art methods, thereby providing a means for large scale production of desired molecules, particularly proteins and peptides.

10 These and other objects, features and advantages of the present invention will become apparent after a review of the following detailed description of the disclosed embodiments and claims.

BRIEF DESCRIPTION OF THE FIGURES

15 Figure 1 depicts schematically a transposon-based vector containing a transposase operably linked to a first promoter and a gene of interest operably-linked to a second promoter, wherein the gene of interest and its operably-linked promoter are flanked by insertion sequences (IS) recognized by the transposase. "Pro" designates a promoter. In this and subsequent figures, the size of the actual nucleotide sequence is not necessarily proportionate to the box representing that sequence.

20

Figure 2 depicts schematically a transposon-based vector for targeting deposition of a polypeptide in an egg white wherein Ov pro is the ovalbumin promoter, Ov protein is the ovalbumin protein and PolyA is a polyadenylation sequence. The TAG sequence includes a spacer, the gp41 hairpin loop from HIV I and a protein cleavage site.

25

Figure 3 depicts schematically a transposon-based vector for targeting deposition of a polypeptide in an egg white wherein Ovo pro is the ovomucoid promoter and Ovo SS is the ovomucoid signal sequence. The TAG sequence includes a spacer, the gp41 hairpin loop from HIV I and a protein cleavage site.

30

Figure 4 depicts schematically a transposon-based vector for targeting deposition of a polypeptide in an egg yolk wherein Vit pro is the vitellogenin promoter and Vit targ is the vitellogenin targeting sequence.

5 Figure 5 depicts schematically a transposon-based vector for expression of antibody heavy and light chains. Prepro indicates a prepro sequence from cecropin and pro indicates a pro sequence from cecropin.

10 Figure 6 depicts schematically a transposon-based vector for expression of antibody heavy and light chains. Ent indicates an enterokinase cleavage sequence.

15 Figure 7 depicts schematically egg white targeted expression of antibody heavy and light chains from one vector in either tail-to-tail (Figure 7A) or tail-to-head (Figure 7B) configuration. In the tail-to-tail configuration, the ovalbumin signal sequence adjacent to the gene for the light chain contains on its 3' end an enterokinase cleavage site (not shown) to allow cleavage of the signal sequence from the light chain, and the ovalbumin signal sequence adjacent to the gene for the heavy chain contains on its 5' end an enterokinase cleavage site (not shown) to allow cleavage of the signal sequence from the heavy chain. In the tail-to-head configuration, the
20 ovalbumin signal sequence adjacent to the gene for the heavy chain and the light chain contains on its 3' end an enterokinase cleavage site (not shown) to allow cleavage of the signal sequence from the heavy or light chain.

DETAILED DESCRIPTION OF THE INVENTION

25 The present invention provides a new, effective and efficient method of producing transgenic animals, particularly egg-laying animals and milk-producing animals, through administration of a composition comprising a transposon-based vector designed for stable incorporation of a gene of interest for production of a desired molecule.

30 Definitions

It is to be understood that as used in the specification and in the claims, "a" or "an" can mean one or more, depending upon the context in which it is used. Thus, for example, reference to "a cell" can mean that at least one cell can be utilized.

The term "antibody" is used interchangeably with the term "immunoglobulin" and is defined herein as a protein synthesized by an animal or a cell of the immune system in response to the presence of a foreign substance commonly referred to as an "antigen" or an "immunogen". The term antibody includes fragments of antibodies.

- 5 Antibodies are characterized by specific affinity to a site on the antigen, wherein the site is referred to an "antigenic determinant" or an "epitope". Antigens can be naturally occurring or artificially engineered. Artificially engineered antigens include but are not limited to small molecules, such as small peptides, attached to haptens such as macromolecules, for example proteins, nucleic acids, or polysaccharides.
- 10 Artificially designed or engineered variants of naturally occurring antibodies and artificially designed or engineered antibodies not occurring in nature are all included in the current definition. Such variants include conservatively substituted amino acids and other forms of substitution as described in the section concerning proteins and polypeptides.

- 15 As used herein, the term "egg-laying animal" includes all amniotes such as birds, turtles, lizards and monotremes. Monotremes are egg-laying mammals and include the platypus and echidna. The term "bird" or "fowl," as used herein, is defined as a member of the Aves class of animals which are characterized as warm-blooded, egg-laying vertebrates primarily adapted for flying. Avians include, without
- 20 limitation, Ratites, Psittaciformes, Falconiformes, Piciformes, Strigiformes, Passeriformes, Coraciformes, Ralliformes, Cuculiformes, Columbiformes, Galliformes, Anseriformes, and Herodiones. The term "Ratite," as used herein, is defined as a group of flightless, mostly large, running birds comprising several orders and including the emus, ostriches, kiwis, and cassowaries. The term "Psittaciformes",
- 25 as used herein, includes parrots and refers to a monofamilial order of birds that exhibit zygodactylism and have a strong hooked bill. A "parrot" is defined as any member of the avian family Psittacidae (the single family of the Psittaciformes), distinguished by the short, stout, strongly hooked beak. The term "chicken" as used herein denotes chickens used for table egg production, such as egg-type chickens, chickens reared for
- 30 public meat consumption, or broilers, and chickens reared for both egg and meat production ("dual-purpose" chickens). The term "chicken" also denotes chickens produced by primary breeder companies, or chickens that are the parents,

grandparents, great-grandparents, etc. of those chickens reared for public table egg, meat, or table egg and meat consumption.

The term "egg" is defined herein as a large female sex cell enclosed in a porous, calcarous or leathery shell, produced by birds and reptiles. The term "ovum" is defined as a female gamete, and is also known as an egg. Therefore, egg production in all animals other than birds and reptiles, as used herein, is defined as the production and discharge of an ovum from an ovary, or "ovulation". Accordingly, it is to be understood that the term "egg" as used herein is defined as a large female sex cell enclosed in a porous, calcarous or leathery shell, when a bird or reptile produces it, or it is an ovum when it is produced by all other animals.

The term "milk-producing animal" refers herein to mammals including, but not limited to, bovine, ovine, porcine, equine, and primate animals. Milk-producing animals include but are not limited to cows, llamas, camels, goats, reindeer, zebu, water buffalo, yak, horses, pigs, rabbits, non-human primates, and humans.

The term "gene" is defined herein to include a coding region for a protein, peptide or polypeptide.

The term "vector" is used interchangeably with the terms "construct", "DNA construct" and "genetic construct" to denote synthetic nucleotide sequences used for manipulation of genetic material, including but not limited to cloning, subcloning, sequencing, or introduction of exogenous genetic material into cells, tissues or organisms, such as birds. It is understood by one skilled in the art that vectors may contain synthetic DNA sequences, naturally occurring DNA sequences, or both. The vectors of the present invention are transposon-based vectors as described herein.

When referring to two nucleotide sequences, one being a regulatory sequence, the term "operably-linked" is defined herein to mean that the two sequences are associated in a manner that allows the regulatory sequence to affect expression of the other nucleotide sequence. It is not required that the operably-linked sequences be directly adjacent to one another with no intervening sequence(s).

The term "regulatory sequence" is defined herein as including promoters, enhancers and other expression control elements such as polyadenylation sequences, matrix attachment sites, insulator regions for expression of multiple genes on a single construct, ribosome entry/attachment sites, introns that are able to enhance expression, and silencers.

Transposon-Based Vectors

While not wanting to be bound by the following statement, it is believed that the nature of the DNA construct is an important factor in successfully producing transgenic animals. The "standard" types of plasmid and viral vectors that have previously been almost universally used for transgenic work in all species, especially avians, have low efficiencies and may constitute a major reason for the low rates of transformation previously observed. The DNA (or RNA) constructs previously used often do not integrate into the host DNA, or integrate only at low frequencies. Other factors may have also played a part, such as poor entry of the vector into target cells. The present invention provides transposon-based vectors that can be administered to an animal that overcome the prior art problems relating to low transgene integration frequencies. Two preferred transposon-based vectors of the present invention in which a transposase, gene of interest and other polynucleotide sequences may be introduced are termed pTnMCS (SEQ ID NO:36) and pTnMod (SEQ ID NO:1).

The transposon-based vectors of the present invention produce integration frequencies an order of magnitude greater than has been achieved with previous vectors. More specifically, intratesticular injections performed with a prior art transposon-based vector (described in U.S. Patent No. 5,719,055) resulted in 41% sperm positive roosters whereas intratesticular injections performed with the novel transposon-based vectors of the present invention resulted in 77% sperm positive roosters. Actual frequencies of integration were estimated by either or both comparative strength of the PCR signal from the sperm and histological evaluation of the testes and sperm by quantitative PCR.

The transposon-based vectors of the present invention include a transposase gene operably-linked to a first promoter, and a coding sequence for a desired protein or peptide operably-linked to a second promoter, wherein the coding sequence for the desired protein or peptide and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase. The transposon-based vector also includes one or more of the following characteristics: a) one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:13) at the 3' end of the first promoter to enhance expression of the transposase; b) modifications of the codons for the first several N-terminal amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c)

addition of one or more stop codons to enhance the termination of transposase synthesis; and, d) addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene. Figure 1 shows a schematic representation of several components of the transposon-based vector. The present invention further includes vectors containing more than one gene of interest, wherein a second or subsequent gene of interest is operably-linked to the second promoter or to a different promoter. It is also to be understood that the transposon-based vectors shown in the Figures are representational of the present invention and that the order of the vector elements may be different than that shown in the Figures, that the elements may be present in various orientations, and that the vectors may contain additional elements not shown in the Figures.

Transposases and Insertion Sequences

In a further embodiment of the present invention, the transposase found in the transposase-based vector is an altered target site (ATS) transposase and the insertion sequences are those recognized by the ATS transposase. However, the transposase located in the transposase-based vectors is not limited to a modified ATS transposase and can be derived from any transposase. Transposases known in the prior art include those found in AC7, Tn5SEQ1, Tn916, Tn951, Tn1721, Tn 2410, Tn1681, Tn1, Tn2, Tn3, Tn4, Tn5, Tn6, Tn9, Tn10, Tn30, Tn101, Tn903, Tn501, Tn1000 ($\gamma\delta$), Tn1681, Tn2901, AC transposons, Mp transposons, Spm transposons, En transposons, Dotted transposons, Mu transposons, Ds transposons, dSpm transposons and I transposons. According to the present invention, these transposases and their regulatory sequences are modified for improved functioning as follows: a) the addition one or more modified Kozak sequences comprising ACCATG (SEQ ID NO:13) at the 3' end of the promoter operably-linked to the transposase; b) a change of the codons for the first several amino acids of the transposase, wherein the third base of each codon was changed to an A or a T without changing the corresponding amino acid; c) the addition of one or more stop codons to enhance the termination of transposase synthesis; and/or, d) the addition of an effective polyA sequence operably-linked to the transposase to further enhance expression of the transposase gene.

Although not wanting to be bound by the following statement, it is believed that the modifications of the first several N-terminal codons of the transposase gene increase transcription of the transposase gene, in part, by increasing strand

dissociation. It is preferable that between approximately 1 and 20, more preferably 3 and 15, and most preferably between 4 and 12 of the first N-terminal codons of the transposase are modified such that the third base of each codon is changed to an A or a T without changing the encoded amino acid. In one embodiment, the first ten N-terminal codons of the transposase gene are modified in this manner. It is also preferred that the transposase contain mutations that make it less specific for preferred insertion sites and thus increases the rate of transgene insertion as discussed in U.S. Patent No. 5,719,055.

In some embodiments, the transposon-based vectors are optimized for expression in a particular host by changing the methylation patterns of the vector DNA. For example, prokaryotic methylation may be reduced by using a methylation deficient organism for production of the transposon-based vector. The transposon-based vectors may also be methylated to resemble eukaryotic DNA for expression in a eukaryotic host.

Transposases and insertion sequences from other analogous eukaryotic transposon-based vectors that can also be modified and used are, for example, the *Drosophila* P element derived vectors disclosed in U.S. Patent No. 6,291,243; the *Drosophila* mariner element described in Sherman et al. (1998); or the sleeping beauty transposon. See also Hackett et al. (1999); D. Lampe et al., 1999. Proc. Natl. Acad. Sci. USA, 96:11428-11433; S. Fischer et al., 2001. Proc. Natl. Acad. Sci. USA, 98:6759-6764; L. Zagoraiou et al., 2001. Proc. Natl. Acad. Sci. USA, 98:11474-11478; and D. Berg et al. (Eds.), Mobile DNA, Amer. Soc. Microbiol. (Washington, D.C., 1989). However, it should be noted that bacterial transposon-based elements are preferred, as there is less likelihood that a eukaryotic transposase in the recipient species will recognize prokaryotic insertion sequences bracketing the transgene.

Many transposases recognize different insertion sequences, and therefore, it is to be understood that a transposase-based vector will contain insertion sequences recognized by the particular transposase also found in the transposase-based vector. In a preferred embodiment of the invention, the insertion sequences have been shortened to about 70 base pairs in length as compared to those found in wild-type transposons that typically contain insertion sequences of well over 100 base pairs.

While the examples provided below incorporate a "cut and insert" Tn10 based vector that is destroyed following the insertion event, the present invention also

encompasses the use of a "rolling replication" type transposon-based vector. Use of a rolling replication type transposon allows multiple copies of the transposon/transgene to be made from a single transgene construct and the copies inserted. This type of transposon-based system thereby provides for insertion of multiple copies of a transgene into a single genome. A rolling replication type transposon-based vector may be preferred when the promoter operably-linked to gene of interest is endogenous to the host cell and present in a high copy number or highly expressed. However, use of a rolling replication system may require tight control to limit the insertion events to non-lethal levels. Tn1, Tn2, Tn3, Tn4, Tn5, Tn9, Tn21, Tn501, Tn551, Tn951, Tn1721, Tn2410 and Tn2603 are examples of a rolling replication type transposon, although Tn5 could be both a rolling replication and a cut and insert type transposon.

Stop Codons and PolyA Sequences

In one embodiment, the transposon-based vector contains two stop codons operably-linked to the transposase and/or to the gene of interest. In an alternate embodiment, one stop codon of UAA or UGA is operably linked to the transposase and/or to the gene of interest. As used herein an "effective polyA sequence" refers to either a synthetic or non-synthetic sequence that contains multiple and sequential nucleotides containing an adenine base (an A polynucleotide string) and that increases expression of the gene to which it is operably-linked. A polyA sequence may be operably-linked to any gene in the transposon-based vector including, but not limited to, a transposase gene and a gene of interest. In one embodiment, a polyA sequence comprises the polynucleotide sequence provided in SEQ ID NO:28. A preferred polyA sequence is optimized for use in the host animal or human. In one embodiment, the polyA sequence is optimized for use in a bird, and more specifically, a chicken. The chicken optimized polyA sequence generally contains a minimum of 60 base pairs, and more preferably between approximately 60 and several hundred base pairs, that precede the A polynucleotide string and thereby separate the stop codon from the A polynucleotide string. A chicken optimized polyA sequence may also have a reduced amount of CT repeats as compared to a synthetic polyA sequence. In one embodiment of the present invention, the polyA sequence comprises a conalbumin polyA sequence as provided in SEQ ID NO:33 and as taken from GenBank accession # Y00407, base pairs 10651-11058.

Promoters and Enhancers

The first promoter operably-linked to the transposase gene and the second promoter operably-linked to the gene of interest can be a constitutive promoter or an inducible promoter. Constitutive promoters include, but are not limited to, immediate
5 early cytomegalovirus (CMV) promoter, herpes simplex virus 1 (HSV1) immediate early promoter, SV40 promoter, lysozyme promoter, early and late CMV promoters, early and late HSV promoters, β -actin promoter, tubulin promoter, Rous-Sarcoma virus (RSV) promoter, and heat-shock protein (HSP) promoter. Inducible promoters include tissue-specific promoters, developmentally-regulated promoters and
10 chemically inducible promoters. Examples of tissue-specific promoters include the glucose 6 phosphate (G6P) promoter, vitellogenin promoter, ovalbumin promoter, ovomucoid promoter, conalbumin promoter, ovotransferrin promoter, prolactin promoter, kidney uromodulin promoter, and placental lactogen promoter. In one embodiment, the vitellogenin promoter includes a polynucleotide sequence of SEQ ID
15 NO:17. The G6P promoter sequence may be deduced from a rat G6P gene untranslated upstream region provided in GenBank accession number U57552.1. Examples of developmentally-regulated promoters include the homeobox promoters and several hormone induced promoters. Examples of chemically inducible promoters include reproductive hormone induced promoters and antibiotic inducible
20 promoters such as the tetracycline inducible promoter and the zinc-inducible metallothioneine promoter.

Other inducible promoter systems include the Lac operator repressor system inducible by IPTG (isopropyl beta-D-thiogalactoside) (Cronin, A. et al. 2001. *Genes and Development*, v. 15), ecdysone-based inducible systems (Hoppe, U. C. et al.
25 2000. *Mol. Ther.* 1:159-164); estrogen-based inducible systems (Brasemann, S. et al. 1993. *Proc. Natl. Acad. Sci.* 90:1657-1661); progesterone-based inducible systems using a chimeric regulator, GLVP, which is a hybrid protein consisting of the GAL4 binding domain and the herpes simplex virus transcriptional activation domain, VP16, and a truncated form of the human progesterone receptor that retains the ability to
30 bind ligand and can be turned on by RU486 (Wang, et al. 1994. *Proc. Natl. Acad. Sci.* 91:8180-8184); CID-based inducible systems using chemical inducers of dimerization (CIDs) to regulate gene expression, such as a system wherein rapamycin induces dimerization of the cellular proteins FKBP12 and FRAP (Belshaw, P. J. et al. 1996. *J.*

Chem. Biol. 3:731-738; Fan, L. et al. 1999. Hum. Gene Ther. 10:2273-2285; Shariat, S.F. et al. 2001. Cancer Res. 61:2562-2571; Spencer, D.M. 1996. Curr. Biol. 6:839-847). Chemical substances that activate the chemically inducible promoters can be administered to the animal containing the transgene of interest via any method known to those of skill in the art.

Other examples of cell or tissue-specific and constitutive promoters include but are not limited to smooth-muscle SM22 promoter, including chimeric SM22alpha/telokin promoters (Hoggatt A.M. et al., 2002. Circ Res. 91(12):1151-9); ubiquitin C promoter (Biochim Biophys Acta, 2003. Jan. 3;1625(1):52-63); Hsf2 promoter; murine COMP (cartilage oligomeric matrix protein) promoter; early B cell-specific mb-1 promoter (Sigvardsson M., et al., 2002. Mol. Cell Biol. 22(24):8539-51); prostate specific antigen (PSA) promoter (Yoshimura I. et al., 2002, J. Urol. 168(6):2659-64); exorh promoter and pineal expression-promoting element (Asaoka Y., et al., 2002. Proc. Natl. Acad. Sci. 99(24):15456-61); neural and liver ceramidase gene promoters (Okino N. et al., 2002. Biochem. Biophys. Res. Commun. 299(1):160-6); PSP94 gene promoter/enhancer (Gabril M.Y. et al., 2002. Gene Ther. 9(23):1589-99); promoter of the human FAT/CD36 gene (Kuriki C., et al., 2002. Biol. Pharm. Bull. 25(11):1476-8); VL30 promoter (Staplin W.R. et al., 2002. Blood October 24, 2002); IL-10 promoter (Brenner S., et al., 2002. J. Biol. Chem. December 18, 2002).

Examples of avian promoters include, but are not limited to, promoters controlling expression of egg white proteins, such as ovalbumin, ovotransferrin (conalbumin), ovomucoid, lysozyme, ovomucin, g2 ovoglobulin, g3 ovoglobulin, ovoflavoprotein, ovostatin (ovomacroglobin), cystatin, avidin, thiamine-binding protein, glutamyl aminopeptidase minor glycoprotein 1, minor glycoprotein 2; and promoters controlling expression of egg-yolk proteins, such as vitellogenin, very low-density lipoproteins, low density lipoprotein, cobalamin-binding protein, riboflavin-binding protein, biotin-binding protein (Awade, 1996. Z. Lebensm. Unters. Forsch. 202:1-14). An advantage of using the vitellogenin promoter is that it is active during the egg-laying stage of an animal's life-cycle, which allows for the production of the protein of interest to be temporally connected to the import of the protein of interest into the egg yolk when the protein of interest is equipped with an appropriate targeting sequence.

Liver-specific promoters of the present invention include, but are not limited to, the following promoters, vitellogenin promoter, G6P promoter, cholesterol-7-alpha-hydroxylase (CYP7A) promoter, phenylalanine hydroxylase (PAH) promoter, protein C gene promoter, insulin-like growth factor I (IGF-I) promoter, bilirubin
5 UDP-glucuronosyltransferase promoter, aldolase B promoter, furin promoter, metallothioneine promoter, albumin promoter, and insulin promoter.

Also included in the present invention are promoters that can be used to target expression of a protein of interest into the milk of a milk-producing animal including, but not limited to, β lactoglobulin promoter, whey acidic protein promoter, lactalbumin
10 promoter and casein promoter.

Promoters associated with cells of the immune system may also be used. Acute phase promoters such as interleukin (IL)-1 and IL-2 may be employed. Promoters for heavy and light chain Ig may also be employed. The promoters of the T cell receptor components CD4 and CD8, B cell promoters and the promoters of
15 CR2 (complement receptor type 2) may also be employed. Immune system promoters are preferably used when the desired protein is an antibody protein.

Also included in this invention are modified promoters/enhancers wherein elements of a single promoter are duplicated, modified, or otherwise changed. In one embodiment, steroid hormone-binding domains of the ovalbumin promoter are moved
20 from about -6.5 kb to within approximately the first 1000 base pairs of the gene of interest. Modifying an existing promoter with promoter/enhancer elements not found naturally in the promoter, as well as building an entirely synthetic promoter, or drawing promoter/enhancer elements from various genes together on a non-natural backbone, are all encompassed by the current invention.

25 Accordingly, it is to be understood that the promoters contained within the transposon-based vectors of the present invention may be entire promoter sequences or fragments of promoter sequences. For example, in one embodiment, the promoter operably linked to a gene of interest is an approximately 900 base pair fragment of a chicken ovalbumin promoter (SEQ ID NO:40). The constitutive and inducible
30 promoters contained within the transposon-based vectors may also be modified by the addition of one or more modified Kozak sequences of ACCATG (SEQ ID NO:13).

As indicated above, the present invention includes transposon-based vectors containing one or more enhancers. These enhancers may or may not be operably-

linked to their native promoter and may be located at any distance from their operably-linked promoter. A promoter operably-linked to an enhancer is referred to herein as an "enhanced promoter." The enhancers contained within the transposon-based vectors are preferably enhancers found in birds, and more preferably, an ovalbumin enhancer, but are not limited to these types of enhancers. In one embodiment, an approximately 675 base pair enhancer element of an ovalbumin promoter is cloned upstream of an ovalbumin promoter with 300 base pairs of spacer DNA separating the enhancer and promoter. In one embodiment, the enhancer used as a part of the present invention comprises base pairs 1-675 of a Chicken Ovalbumin enhancer from GenBank accession #S82527.1. The polynucleotide sequence of this enhancer is provided in SEQ ID NO:37.

Also included in some of the transposon-based vectors of the present invention are cap sites and fragments of cap sites. In one embodiment, approximately 50 base pairs of a 5' untranslated region wherein the capsite resides are added on the 3' end of an enhanced promoter or promoter. An exemplary 5' untranslated region is provided in SEQ ID NO:38. A putative cap-site residing in this 5' untranslated region preferably comprises the polynucleotide sequence provided in SEQ ID NO:39.

In one embodiment of the present invention, the first promoter operably-linked to the transposase gene is a constitutive promoter and the second promoter operably-linked to the gene of interest is a tissue-specific promoter. In this embodiment, use of the first constitutive promoter allows for constitutive activation of the transposase gene and incorporation of the gene of interest into virtually all cell types, including the germline of the recipient animal. Although the gene of interest is incorporated into the germline generally, the gene of interest is only expressed in a tissue-specific manner. It should be noted that cell- or tissue-specific expression as described herein does not require a complete absence of expression in cells or tissues other than the preferred cell or tissue. Instead, "cell-specific" or "tissue-specific" expression refers to a majority of the expression of a particular gene of interest in the preferred cell or tissue, respectively.

When incorporation of the gene of interest into the germline is not preferred, the first promoter operably-linked to the transposase gene can be a tissue-specific promoter. For example, transfection of a transposon-based vector containing a transposase gene operably-linked to a liver-specific promoter such as the G6P

promoter or vitellogenin promoter provides for activation of the transposase gene and incorporation of the gene of interest in the cells of the liver but not into the germline and other cells generally. In this second embodiment, the second promoter operably-linked to the gene of interest can be a constitutive promoter or an inducible promoter.

- 5 In a preferred embodiment, both the first promoter and the second promoter are a G6P promoter. In embodiments wherein tissue-specific expression or incorporation is desired, it is preferred that the transposon-based vector is administered directly to the tissue of interest or to an artery leading to the tissue of interest.

Accordingly, cell specific promoters may be used to enhance transcription in
10 selected tissues. In birds, for example, promoters that are found in cells of the fallopian tube, such as ovalbumin, conalbumin, ovomucoid and/or lysozyme, are used in the vectors to ensure transcription of the gene of interest in the epithelial cells and tubular gland cells of the fallopian tube, leading to synthesis of the desired protein encoded by the gene and deposition into the egg white. In mammals, promoters
15 specific for the epithelial cells of the alveoli of the mammary gland, such as prolactin, insulin, beta lactoglobulin, whey acidic protein, lactalbumin, casein, and/or placental lactogen, are used in the design of vectors used for transfection of these cells for the production of desired proteins for deposition into the milk. In liver cells, the G6P promoter may be employed to drive transcription of the gene of interest for protein
20 production. Proteins made in the liver of birds may be delivered to the egg yolk.

In order to achieve higher or more efficient expression of the transposase gene, the promoter and other regulatory sequences operably-linked to the transposase gene may be those derived from the host. These host specific regulatory sequences can be tissue specific as described above or can be of a constitutive nature. For
25 example, an avian actin promoter and its associated polyA sequence can be operably-linked to a transposase in a transposase-based vector for transfection into an avian. Examples of other host specific promoters that could be operably-linked to the transposase include the myosin and DNA or RNA polymerase promoters.

Directing Sequences

30 In some embodiments of the present invention, the gene of interest is operably-linked to a directing sequence or a sequence that provides proper conformation to the desired protein encoded by the gene of interest. As used herein, the term "directing sequence" refers to both signal sequences and targeting sequences.

An egg directing sequence includes, but is not limited to, an ovomucoid signal sequence, an ovalbumin signal sequence and a vitellogenin targeting sequence. The term "signal sequence" refers to an amino acid sequence, or the polynucleotide sequence that encodes the amino acid sequence, that directs the protein to which it is
5 linked to the endoplasmic reticulum in a eukaryote, and more preferably the translocational pores in the endoplasmic reticulum, or the plasma membrane in a prokaryote, or mitochondria, such as for the purpose of gene therapy of mitochondrial diseases. Signal and targeting sequences can be used to direct a desired protein into, for example, the milk, when the transposon-based vectors are administered to a milk-
10 producing animal.

Signal sequences can also be used to direct a desired protein into, for example, a secretory pathway for incorporation into the egg yolk or the egg white, when the transposon-based vectors are administered to a bird or other egg-laying animal. One example of such a transposon-based vector is provided in Figure 3 wherein the gene
15 of interest is operably linked to the ovomucoid signal sequence. The present invention also includes a gene of interest operably-linked to a second gene containing a signal sequence. An example of such an embodiment is shown in Figure 2 wherein the gene of interest is operably-linked to the ovalbumin gene that contains an ovalbumin signal sequence. Other signal sequences that can be included in the
20 transposon-based vectors include, but are not limited to the ovotransferrin and lysozyme signal sequences.

As also used herein, the term "targeting sequence" refers to an amino acid sequence, or the polynucleotide sequence encoding the amino acid sequence, which amino acid sequence is recognized by a receptor located on the exterior of a cell.
25 Binding of the receptor to the targeting sequence results in uptake of the protein or peptide operably-linked to the targeting sequence by the cell. One example of a targeting sequence is a vitellogenin targeting sequence that is recognized by a vitellogenin receptor (or the low density lipoprotein receptor) on the exterior of an oocyte. In one embodiment, the vitellogenin targeting sequence includes the
30 polynucleotide sequence of SEQ ID NO:18. In another embodiment, the vitellogenin targeting sequence includes all or part of the vitellogenin gene. Other targeting sequences include VLDL and Apo E, which are also capable of binding the vitellogenin receptor. Since the ApoE protein is not endogenously expressed in birds,

its presence may be used advantageously to identify birds carrying the transposon-based vectors of the present invention.

Genes of Interest Encoding Desired Proteins

A gene of interest selected for stable incorporation is designed to encode any
5 desired protein or peptide or to regulate any cellular response. In some embodiments, the desired proteins or peptides are deposited in an egg or in milk. It is to be understood that the present invention encompasses transposon-based vectors containing multiple genes of interest. The multiple genes of interest may each be operably-linked to a separate promoter and other regulatory sequence(s) or may all be
10 operably-linked to the same promoter and other regulatory sequences(s). In one embodiment, multiple gene of interest are linked to a single promoter and other regulatory sequence(s) and each gene of interest is separated by a cleavage site or a pro portion of a signal sequence.

Protein and peptide hormones are a preferred class of proteins in the present
15 invention. Such protein and peptide hormones are synthesized throughout the endocrine system and include, but are not limited to, hypothalamic hormones and hypophysiotropic hormones, anterior, intermediate and posterior pituitary hormones, pancreatic islet hormones, hormones made in the gastrointestinal system, renal hormones, thymic hormones, parathyroid hormones, adrenal cortical and medullary
20 hormones. Specifically, hormones that can be produced using the present invention include, but are not limited to, chorionic gonadotropin, corticotropin, erythropoietin, glucagons, IGF-1, oxytocin, platelet-derived growth factor, calcitonin, follicle-stimulating hormone, leutinizing hormone, thyroid-stimulating hormone, insulin, gonadotropin-releasing hormone and its analogs, vasopressin, octreotide,
25 somatostatin, prolactin, adrenocorticotrophic hormone, antidiuretic hormone, thyrotropin-releasing hormone (TRH), growth hormone-releasing hormone (GHRH), dopamine, melatonin, thyroxin (T₄), parathyroid hormone (PTH), glucocorticoids such as cortisol, mineralocorticoids such as aldosterone, androgens such as testosterone, adrenaline (epinephrine), noradrenaline (norepinephrine), estrogens such
30 as estradiol, progesterone, glucagons, calcitrol, calciferol, atrial-natriuretic peptide, gastrin, secretin, cholecystokinin (CCK), neuropeptide Y, ghrelin, PYY₃₋₃₆, angiotensinogen, thrombopoietin, and leptin. By using appropriate polynucleotide sequences, species-specific hormones may be made by transgenic animals.

In one embodiment of the present invention, the gene of interest is a proinsulin gene and the desired molecule is insulin. Proinsulin consists of three parts: a C-peptide and two long strands of amino acids (called the alpha and beta chains) that later become linked together to form the insulin molecule. Figures 2 and 3 are schematics of transposon-based vector constructs containing a proinsulin gene operably-linked to an ovalbumin promoter and ovalbumin protein or an ovomucoid promoter and ovomucoid signal sequence, respectively. In these embodiments, proinsulin is expressed in the oviduct tubular gland cells and then deposited in the egg white. One example of a proinsulin polynucleotide sequence is shown in SEQ ID NO:21, wherein the C-peptide cleavage site spans from Arg at position 31 to Arg at position 65.

Serum proteins including lipoproteins such as high density lipoprotein (HDL), HDL-Milano and low density lipoprotein, albumin, clotting cascade factors, factor VIII, factor IX, fibrinogen, and globulins are also included in the group of desired proteins of the present invention. Immunoglobulins are one class of desired globulin molecules and include but are not limited to IgG, IgM, IgA, IgD, IgE, IgY, lambda chains, kappa chains and fragments thereof; Fc fragments, and Fab fragments. Desired antibodies include, but are not limited to, naturally occurring antibodies, human antibodies, humanized antibodies, and hybrid antibodies. Genes encoding modified versions of naturally occurring antibodies or fragments thereof and genes encoding artificially designed antibodies or fragments thereof may be incorporated into the transposon-based vectors of the present invention. Desired antibodies also include antibodies with the ability to bind specific ligands, for example, antibodies against proteins associated with cancer-related molecules, such as anti-her 2, or anti-CA125. Accordingly, the present invention encompasses a transposon-based vector containing one or more genes encoding a heavy immunoglobulin (Ig) chain and a light Ig chain. Further, more than one gene encoding for more than one antibody may be administered in one or more transposon-based vectors of the present invention. In this manner, an egg may contain more than one type of antibody in the egg white, the egg yolk or both.

In one embodiment, a transposon-based vector contains a heavy Ig chain and a light Ig chain, both operably linked to a promoter. Figures 5 and 6 schematically depict exemplary constructs of this embodiment. More specifically, Figure 5 shows a

construct containing a cecropin pre-pro sequence and a cecropin pro sequence, wherein the pre sequence functions to direct the resultant protein into the endoplasmic reticulum and the pro sequences and the pro sequences are cleaved upon secretion of the protein from a cell into which the construct has been transfected. Figure 6 shows
5 a construct containing an enterokinase cleavage site. In this embodiment, it may be required to further remove several additional amino acids from the light chain following cleavage by enterokinase. In another embodiment, the transposon-based vector comprises a heavy Ig chain operably-linked to one promoter and a light Ig chain operably-linked to another promoter. Figure 7 schematically depicts an
10 exemplary construct of this embodiment. The present invention also encompasses a transposon-based vector containing genes encoding portions of a heavy Ig chain and/or portions of a light Ig chain. The present invention further includes a transposon-based vector containing a gene that encodes a fusion protein comprising a heavy and/or light Ig chain, or portions thereof.

15 Antibodies used as therapeutic reagents include but are not limited to antibodies for use in cancer immunotherapy against specific antigens, or for providing passive immunity to an animal or a human against an infectious disease or a toxic agent. Antibodies used as diagnostic reagents include, but are not limited to antibodies that may be labeled and detected with a detector, for example antibodies
20 with a fluorescent label attached that may be detected following exposure to specific wavelengths. Such labeled antibodies may be primary antibodies directed to a specific antigen, for example, rhodamine-labeled rabbit anti-growth hormone, or may be labeled secondary antibodies, such as fluorescein-labeled goat-anti chicken IgG. Such labeled antibodies are known to one of ordinary skill in the art. Labels useful
25 for attachment to antibodies are also known to one of ordinary skill in the art. Some of these labels are described in the "Handbook of Fluorescent Probes and Research Products", ninth edition, Richard P. Haugland (ed) Molecular Probes, Inc. Eugene, OR), which is incorporated herein in its entirety.

Antibodies produced with using the present invention may be used as
30 laboratory reagents for numerous applications including radioimmunoassay, western blots, dot blots, ELISA, immunoaffinity columns and other procedures requiring antibodies as known to one of ordinary skill in the art. Such antibodies include

primary antibodies, secondary antibodies and tertiary antibodies, which may be labeled or unlabeled.

Antibodies that may be made with the practice of the present invention include, but are not limited to primary antibodies, secondary antibodies, designer antibodies, anti-protein antibodies, anti-peptide antibodies, anti-DNA antibodies, anti-RNA antibodies, anti-hormone antibodies, anti-hypophysiotropic peptides, antibodies against non-natural antigens, anti-anterior pituitary hormone antibodies, anti-posterior pituitary hormone antibodies, anti-venom antibodies, anti-tumor marker antibodies, antibodies directed against epitopes associated with infectious disease, including, anti-viral, anti-bacterial, anti-protozoal, anti-fungal, anti-parasitic, anti-receptor, anti-lipid, anti-phospholipid, anti-growth factor, anti-cytokine, anti-monokine, anti-idiotypic, and anti-accessory (presentation) protein antibodies. Antibodies made with the present invention, as well as light chains or heavy chains, may also be used to inhibit enzyme activity.

Antibodies that may be produced using the present invention include, but are not limited to, antibodies made against the following proteins: Bovine γ -Globulin, Serum; Bovine IgG, Plasma; Chicken γ -Globulin, Serum; Human γ -Globulin, Serum; Human IgA, Plasma; Human IgA₁, Myeloma; Human IgA₂, Myeloma; Human IgA₂, Plasma; Human IgD, Plasma; Human IgE, Myeloma; Human IgG, Plasma; Human IgG, Fab Fragment, Plasma; Human IgG, F(ab')₂ Fragment, Plasma; Human IgG, Fc Fragment, Plasma; Human IgG₁, Myeloma; Human IgG₂, Myeloma; Human IgG₃, Myeloma; Human IgG₄, Myeloma; Human IgM, Myeloma; Human IgM, Plasma; Human Immunoglobulin, Light Chain κ , Urine; Human Immunoglobulin, Light Chains κ and λ , Plasma; Mouse γ -Globulin, Serum; Mouse IgG, Serum; Mouse IgM, Myeloma; Rabbit γ -Globulin, Serum; Rabbit IgG, Plasma; and Rat γ -Globulin, Serum. In one embodiment, the transposon-based vector comprises the coding sequence of light and heavy chains of a murine monoclonal antibody that shows specificity for human seminoprotein (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively).

A further non-limiting list of antibodies that recognize other antibodies is as follows: Anti-Chicken IgG, heavy (H) & light (L) Chain Specific (Sheep); Anti-Goat γ -Globulin (Donkey); Anti-Goat IgG, Fc Fragment Specific (Rabbit); Anti-Guinea Pig γ -Globulin (Goat); Anti-Human Ig, Light Chain, Type κ Specific; Anti-Human Ig,

Light Chain, Type λ Specific; Anti-Human IgA, α -Chain Specific (Goat); Anti-Human IgA, Fab Fragment Specific; Anti-Human IgA, Fc Fragment Specific; Anti-Human IgA, Secretory; Anti-Human IgE, ϵ -Chain Specific (Goat); Anti-Human IgE, Fc Fragment Specific; Anti-Human IgG, Fc Fragment Specific (Goat); Anti-Human IgG, γ -Chain Specific (Goat); Anti-Human IgG, Fc Fragment Specific; Anti-Human IgG, Fd Fragment Specific; Anti-Human IgG, H & L Chain Specific (Goat); Anti-Human IgG₁, Fc Fragment Specific; Anti-Human IgG₂, Fc Fragment Specific; Anti-Human IgG₂, Fd Fragment Specific; Anti-Human IgG₃, Hinge Specific; Anti-Human IgG₄, Fc Fragment Specific; Anti-Human IgM, Fc Fragment Specific; Anti-Human IgM, μ -Chain Specific; Anti-Mouse IgE, ϵ -Chain Specific; Anti-Mouse γ -Globulin (Goat); Anti-Mouse IgG, γ -Chain Specific (Goat); Anti-Mouse IgG, γ -Chain Specific (Goat) F(ab')₂ Fragment; Anti-Mouse IgG, H & L Chain Specific (Goat); Anti-Mouse IgM, μ -Chain Specific (Goat); Anti-Mouse IgM, H & L Chain Specific (Goat); Anti-Rabbit γ -Globulin (Goat); Anti-Rabbit IgG, Fc Fragment Specific (Goat); Anti-Rabbit IgG, H & L Chain Specific (Goat); Anti-Rat γ -Globulin (Goat); Anti-Rat IgG, H & L Chain Specific; Anti-Rhesus Monkey γ -Globulin (Goat); and, Anti-Sheep IgG, H & L Chain Specific.

Another non-limiting list of the antibodies that may be produced using the present invention is provided in product catalogs of companies such as Phoenix Pharmaceuticals, Inc. (www.phoenixpeptide.com; 530 Harbor Boulevard, Belmont, CA), Peninsula Labs San Carlos CA, SIGMA, St.Louis, MO www.sigma-aldrich.com, Cappel ICN, Irvine, California, www.icnbiomed.com, and Calbiochem, La Jolla, California, www.calbiochem.com, which are all incorporated herein by reference in their entirety. The polynucleotide sequences encoding these antibodies may be obtained from the scientific literature, from patents, and from databases such as GenBank. Alternatively, one of ordinary skill in the art may design the polynucleotide sequence to be incorporated into the genome by choosing the codons that encode for each amino acid in the desired antibody. Antibodies made by the transgenic animals of the present invention include antibodies that may be used as therapeutic reagents, for example in cancer immunotherapy against specific antigens, as diagnostic reagents and as laboratory reagents for numerous applications including immunoneutralization, radioimmunoassay, western blots, dot blots, ELISA, immunoprecipitation and immunoaffinity columns. Some of these antibodies include,

but are not limited to, antibodies which bind the following ligands: adrenomedulin, amylin, calcitonin, amyloid, calcitonin gene-related peptide, cholecystokinin, gastrin, gastric inhibitory peptide, gastrin releasing peptide, interleukin, interferon, cortistatin, somatostatin, endothelin, sarafotoxin, glucagon, glucagon-like peptide, insulin, atrial natriuretic peptide, BNP, CNP, neurokinin, substance P, leptin, neuropeptide Y, melanin concentrating hormone, melanocyte stimulating hormone, orphanin, endorphin, dynorphin, enkephalin, enkephalin, leumorphin, peptide F, PACAP, PACAP-related peptide, parathyroid hormone, urocortin, corticotrophin releasing hormone, PHM, PHI, vasoactive intestinal polypeptide, secretin, ACTH, angiotensin, angiotensin, bombesin, endostatin, bradykinin, FMRF amide, galanin, gonadotropin releasing hormone (GnRH) associated peptide, GnRH, growth hormone releasing hormone, inhibin, granulocyte-macrophage colony stimulating factor (GM-CSF), motilin, neurotensin, oxytocin, vasopressin, osteocalcin, pancreastatin, pancreatic polypeptide, peptide YY, proopiomelanocortin, transforming growth factor, vascular endothelial growth factor, vesicular monoamine transporter, vesicular acetylcholine transporter, ghrelin, NPW, NPB, C3d, prokineticin, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, prolactin, growth hormone, beta-lipotropin, melatonin, kallikriens, kinins, prostaglandins, erythropoietin, p146 (SEQ ID NO:18 amino acid sequence, SEQ ID NO:19, nucleotide sequence), estrogen, testosterone, corticosteroids, mineralocorticoids, thyroid hormone, thymic hormones, connective tissue proteins, nuclear proteins, actin, avidin, activin, agrin, albumin, and prohormones, propeptides, splice variants, fragments and analogs thereof.

The following is yet another non-limiting of antibodies that can be produced by the methods of present invention: abciximab (ReoPro), abciximab anti-platelet aggregation monoclonal antibody, anti-CD11a (hu1124), anti-CD18 antibody, anti-CD20 antibody, anti-cytomegalovirus (CMV) antibody, anti-digoxin antibody, anti-hepatitis B antibody, anti-HER-2 antibody, anti-idiotypic antibody to GD3 glycolipid, anti-IgE antibody, anti-IL-2R antibody, antimetastatic cancer antibody (mAb 17-1A), anti-rabies antibody, anti-respiratory syncytial virus (RSV) antibody, anti-Rh antibody, anti-TCR, anti-TNF antibody, anti-VEGF antibody and fab fragment thereof, rattlesnake venom antibody, black widow spider venom antibody, coral snake venom antibody, antibody against very late antigen-4 (VLA-4), C225 humanized antibody to EGF receptor, chimeric (human & mouse) antibody against TNF α ,

antibody directed against GPIIb/IIIa receptor on human platelets, gamma globulin, anti-hepatitis B immunoglobulin, human anti-D immunoglobulin, human antibodies against *S aureus*, human tetanus immunoglobulin, humanized antibody against the epidermal growth receptor-2, humanized antibody against the α subunit of the interleukin-2 receptor, humanized antibody CTLA4IG, humanized antibody to the IL-2 R α -chain, humanized anti-CD40-ligand monoclonal antibody (5c8), humanized mAb against the epidermal growth receptor-2, humanized mAb to rous sarcoma virus, humanized recombinant antibody (IgG1k) against respiratory syncytial virus (RSV), lymphocyte immunoglobulin (anti-thymocyte antibody), lymphocyte immunoglobulin, mAb against factor VII, MDX-210 bi-specific antibody against HER-2, MDX-22, MDX-220 bi-specific antibody against TAG-72 on tumors, MDX-33 antibody to Fc γ R1 receptor, MDX-447 bi-specific antibody against EGF receptor, MDX-447 bispecific humanized antibody to EGF receptor, MDX-RA immunotoxin (ricin A linked) antibody, Medi-507 antibody (humanized form of BTI-322) against CD2 receptor on T-cells, monoclonal antibody LDP-02, muromonab-CD3(OKT3) antibody, OKT3 ("muromomab-CD3") antibody, PRO 542 antibody, ReoPro ("abciximab") antibody, and TNF-IgG fusion protein.

The antibodies prepared using the methods of the present invention may also be designed to possess specific labels that may be detected through means known to one of ordinary skill in the art. The antibodies may also be designed to possess specific sequences useful for purification through means known to one of ordinary skill in the art. Specialty antibodies designed for binding specific antigens may also be made in transgenic animals using the transposon-based vectors of the present invention.

Production of a monoclonal antibody using the transposon-based vectors of the present invention can be accomplished in a variety of ways. In one embodiment, two vectors may be constructed: one that encodes the light chain, and a second vector that encodes the heavy chain of the monoclonal antibody. These vectors may then be incorporated into the genome of the target animal by methods disclosed herein. In an alternative embodiment, the sequences encoding light and heavy chains of a monoclonal antibody may be included on a single DNA construct. For example, the coding sequence of light and heavy chains of a murine monoclonal antibody that show specificity for human seminoprotein can be expressed using transposon-based

constructs of the present invention (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively).

Further included in the present invention are proteins and peptides synthesized by the immune system including those synthesized by the thymus, lymph nodes, spleen, and the gastrointestinal associated lymph tissues (GALT) system. The immune system proteins and peptides proteins that can be made in transgenic animals using the transposon-based vectors of the present invention include, but are not limited to, alpha-interferon, beta-interferon, gamma-interferon, alpha-interferon A, alpha-interferon 1, G-CSF, GM-CSF, interleukin-1 (IL-1), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, TNF- α , and TNF- β . Other cytokines included in the present invention include cardiotrophin, stromal cell derived factor, macrophage derived chemokine (MDC), melanoma growth stimulatory activity (MGSA), macrophage inflammatory proteins 1 alpha (MIP-1 alpha), 2, 3 alpha, 3 beta, 4 and 5.

Lytic peptides such as p146 are also included in the desired molecules of the present invention. In one embodiment, the p146 peptide comprises an amino acid sequence of SEQ ID NO:19. The present invention also encompasses a transposon-based vector comprising a p146 nucleic acid comprising a polynucleotide sequence of SEQ ID NO:20.

Enzymes are another class of proteins that may be made through the use of the transposon-based vectors of the present invention. Such enzymes include but are not limited to adenosine deaminase, alpha-galactosidase, cellulase, collagenase, dnaseI, hyaluronidase, lactase, L-asparaginase, pancreatin, papain, streptokinase B, subtilisin, superoxide dismutase, thrombin, trypsin, urokinase, fibrinolysin, glucocerebrosidase and plasminogen activator. In some embodiments wherein the enzyme could have deleterious effects, additional amino acids and a protease cleavage site are added to the carboxy end of the enzyme of interest in order to prevent expression of a functional enzyme. Subsequent digestion of the enzyme with a protease results in activation of the enzyme.

Extracellular matrix proteins are one class of desired proteins that may be made through the use of the present invention. Examples include but are not limited to collagen, fibrin, elastin, laminin, and fibronectin and subtypes thereof. Intracellular

proteins and structural proteins are other classes of desired proteins in the present invention.

Growth factors are another desired class of proteins that may be made through the use of the present invention and include, but are not limited to, transforming growth factor- α ("TGF- α "), transforming growth factor- β (TGF- β), platelet-derived growth factors (PDGF), fibroblast growth factors (FGF), including FGF acidic isoforms 1 and 2, FGF basic form 2 and FGF 4, 8, 9 and 10, nerve growth factors (NGF) including NGF 2.5s, NGF 7.0s and beta NGF and neurotrophins, brain derived neurotrophic factor, cartilage derived factor, growth factors for stimulation of the production of red blood cells, growth factors for stimulation of the production of white blood cells, bone growth factors (BGF), basic fibroblast growth factor, vascular endothelial growth factor (VEGF), granulocyte colony stimulating factor (G-CSF), insulin like growth factor (IGF) I and II, hepatocyte growth factor, glial neurotrophic growth factor (GDNF), stem cell factor (SCF), keratinocyte growth factor (KGF), transforming growth factors (TGF), including TGFs alpha, beta, beta1, beta2, beta3, skeletal growth factor, bone matrix derived growth factors, bone derived growth factors, erythropoietin (EPO) and mixtures thereof.

Another desired class of proteins that may be made may be made through the use of the present invention include but are not limited to leptin, leukemia inhibitory factor (LIF), tumor necrosis factor alpha and beta, ENBREL, angiostatin, endostatin, thrombospondin, osteogenic protein-1, bone morphogenetic proteins 2 and 7, osteonectin, somatomedin-like peptide, and osteocalcin.

A non-limiting list of the peptides and proteins that may be made may be made through the use of the present invention is provided in product catalogs of companies such as Phoenix Pharmaceuticals, Inc. (www.phoenixpeptide.com; 530 Harbor Boulevard • Belmont, CA), Peninsula Labs San Carlos CA, SIGMA, St. Louis, MO www.sigma-aldrich.com, Cappel ICN, Irvine, California, www.icnbiomed.com, and Calbiochem, La Jolla, California, www.calbiochem.com. The polynucleotide sequences encoding these proteins and peptides of interest may be obtained from the scientific literature, from patents, and from databases such as GenBank. Alternatively, one of ordinary skill in the art may design the polynucleotide sequence to be incorporated into the genome by choosing the codons that encode for each amino acid in the desired protein or peptide.

Some of these desired proteins or peptides that may be made through the use of the present invention include but are not limited to the following: adrenomedulin, amylin, calcitonin, amyloid, calcitonin gene-related peptide, cholecystokinin, gastrin, gastric inhibitory peptide, gastrin releasing peptide, interleukin, interferon, cortistatin, 5 somatostatin, endothelin, sarafotoxin, glucagon, glucagon-like peptide, insulin, atrial natriuretic peptide, BNP, CNP, neurokinin, substance P, leptin, neuropeptide Y, melanin concentrating hormone, melanocyte stimulating hormone, orphanin, endorphin, dynorphin, enkephalin, leumorphin, peptide F, PACAP, PACAP-related peptide, parathyroid hormone, urocortin, corticotrophin releasing hormone, PHM, 10 PHI, vasoactive intestinal polypeptide, secretin, ACTH, angiotensin, angiostatin, bombesin, endostatin, bradykinin, FMRF amide, galanin, gonadotropin releasing hormone (GnRH) associated peptide, GnRH, growth hormone releasing hormone, inhibin, granulocyte-macrophage colony stimulating factor (GM-CSF), motilin, neurotensin, oxytocin, vasopressin, osteocalcin, pancreastatin, pancreatic polypeptide, 15 peptide YY, proopiomelanocortin, transforming growth factor, vascular endothelial growth factor, vesicular monoamine transporter, vesicular acetylcholine transporter, ghrelin, NPW, NPB, C3d, prokineticin, thyroid stimulating hormone, luteinizing hormone, follicle stimulating hormone, prolactin, growth hormone, beta-lipotropin, melatonin, kallikriens, kinins, prostaglandins, erythropoietin, p146 (SEQ ID NO:19, 20 amino acid sequence, SEQ ID NO:20, nucleotide sequence), thymic hormones, connective tissue proteins, nuclear proteins, actin, avidin, activin, agrin, albumin, and prohormones, propeptides, splice variants, fragments and analogs thereof.

Other desired proteins that may be made by the transgenic animals of the present invention include bacitracin, polymixin b, vancomycin, cyclosporine, anti- 25 RSV antibody, alpha-1 antitrypsin (AAT), anti-cytomegalovirus antibody, anti-hepatitis antibody, anti-inhibitor coagulant complex, anti-rabies antibody, anti-Rh(D) antibody, adenosine deaminase, anti-digoxin antibody, antivenin crotalidae (rattlesnake venom antibody), antivenin latrodectus (black widow spider venom antibody), antivenin micrurus (coral snake venom antibody), aprotinin, corticotropin 30 (ACTH), diphtheria antitoxin, lymphocyte immune globulin (anti-thymocyte antibody), protamine, thyrotropin, capreomycin, α -galactosidase, gramicidin, streptokinase, tetanus toxoid, tyrothricin, IGF-1, proteins of varicella vaccine, anti-TNF antibody, anti-IL-2r antibody, anti-HER-2 antibody, OKT3 ("muromonab-

CD3") antibody, TNF-IgG fusion protein, ReoPro ("abciximab") antibody, ACTH
 fragment 1-24, desmopressin, gonadotropin-releasing hormone, histrelin, leuprolide,
 lypressin, nafarelin, peptide that binds GPIIb/GPIIIa on platelets (integrilin),
 goserelin, capreomycin, colistin, anti-respiratory syncytial virus, lymphocyte immune
 5 globulin (Thymoglovin, Atgam), panorex, alpha-antitrypsin, botulinin, lung surfactant
 protein, tumor necrosis receptor-IgG fusion protein (enbrel), gonadorelin, proteins of
 influenza vaccine, proteins of rotavirus vaccine, proteins of haemophilus b conjugate
 vaccine, proteins of poliovirus vaccine, proteins of pneumococcal conjugate vaccine,
 proteins of meningococcal C vaccine, proteins of influenza vaccine, megakaryocyte
 10 growth and development factor (MGDF), neuroimmunophilin ligand-A (NIL-A),
 brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor
 (GDNF), leptin (native), leptin B, leptin C, IL-1RA (interleukin-1RA), R-568, novel
 erythropoiesis-stimulating protein (NESP), humanized mAb to rous sarcoma virus
 (MEDI-493), glutamyl-tryptophan dipeptide IM862, LFA-3TIP immunosuppressive,
 15 humanized anti-CD40-ligand monoclonal antibody (5c8), gelsonin enzyme, tissue
 factor pathway inhibitor (TFPI), proteins of meningitis B vaccine, antimetastatic
 cancer antibody (mAb 17-1A), chimeric (human & mouse) mAb against TNF α , mAb
 against factor VII, relaxin, capreomycin, glycopeptide (LY333328), recombinant
 human activated protein C (rhAPC), humanized mAb against the epidermal growth
 20 receptor-2, altepase, anti-CD20 antigen, C2B8 antibody, insulin-like growth factor-1,
 atrial natriuretic peptide (anaritide), tenectapase, anti-CD11a antibody (hu 1124),
 anti-CD18 antibody, mAb LDP-02, anti-VEGF antibody, fab fragment of anti-VEGF
 Ab, APO2 ligand (tumor necrosis factor-related apoptosis-inducing ligand), rTGF- β
 (transforming growth factor- β), alpha-antitrypsin, ananain (a pineapple enzyme),
 25 humanized mAb CTLA4IG, PRO 542 (mAb), D2E7 (mAb), calf intestine alkaline
 phosphatase, α -L-iduronidase, α -L-galactosidase (humanglutamic acid decarboxylase,
 acid sphingomyelinase, bone morphogenetic protein-2 (rhBMP-2), proteins of HIV
 vaccine, T cell receptor (TCR) peptide vaccine, TCR peptides, V beta 3 and V beta
 13.1. (IR502), (IR501), BI 1050/1272 mAb against very late antigen-4 (VLA-4),
 30 C225 humanized mAb to EGF receptor, anti-idiotypic antibody to GD3 glycolipid,
 antibacterial peptide against *H. pylori*, MDX-447 bispecific humanized mAb to EGF
 receptor, anti-cytomegalovirus (CMV), Medi-491 B19 parvovirus vaccine, humanized
 recombinant mAb (IgG1k) against respiratory syncytial virus (RSV), urinary tract

infection vaccine (against "pili" on *Escherichia coli* strains), proteins of lyme disease vaccine against *B. burgdorferi* protein (DbpA), proteins of Medi-501 human papilloma virus-11 vaccine (HPV), *Streptococcus pneumoniae* vaccine, Medi-507 mAb (humanized form of BTI-322) against CD2 receptor on T-cells, MDX-33 mAb to FcγR1 receptor, MDX-RA immunotoxin (ricin A linked) mAb, MDX-210 bi-specific mAb against HER-2, MDX-447 bi-specific mAb against EGF receptor, MDX-22, MDX-220 bi-specific mAb against TAG-72 on tumors, colony-stimulating factor (CSF) (molgramostim), humanized mAb to the IL-2 R α-chain (basiliximab), mAb to IgE (IGE 025A), myelin basic protein-altered peptide (MSP771A), humanized mAb against the epidermal growth receptor-2, humanized mAb against the α subunit of the interleukin-2 receptor, low molecular weight heparin, anti-hemophilic factor, and bactericidal/permeability-increasing protein (r-BPI).

The peptides and proteins made using the present invention may be labeled using labels and techniques known to one of ordinary skill in the art. Some of these labels are described in the "Handbook of Fluorescent Probes and Research Products", ninth edition, Richard P. Haugland (ed) Molecular Probes, Inc. Eugene, OR), which is incorporated herein in its entirety. Some of these labels may be genetically engineered into the polynucleotide sequence for the expression of the selected protein or peptide. The peptides and proteins may also have label-incorporation "handles" incorporated to allow labeling of an otherwise difficult or impossible to label protein.

It is to be understood that the various classes of desired peptides and proteins, as well as specific peptides and proteins described in this section may be modified as described below by inserting selected codons for desired amino acid substitutions into the gene incorporated into the transgenic animal.

The present invention may also be used to produce desired molecules other than proteins and peptides including, but not limited to, lipoproteins such as high density lipoprotein (HDL), HDL-Milano, and low density lipoprotein, lipids, carbohydrates, siRNA and ribozymes. In these embodiments, a gene of interest encodes a nucleic acid molecule or a protein that directs production of the desired molecule.

The present invention further encompasses the use of inhibitory molecules to inhibit endogenous (i.e., non-vector) protein production. These inhibitory molecules include antisense nucleic acids, siRNA and inhibitory proteins. In one embodiment, a

transposon-based vector containing an ovalbumin DNA sequence, that upon transcription forms a double stranded RNA molecule, is transfected into an animal such as a bird and the bird's production of endogenous ovalbumin protein is reduced by the interference RNA mechanism (RNAi). Additionally, inducible knockouts or
5 knockdowns of the endogenous protein may be created to achieve a reduction or inhibition of endogenous protein production.

Modified Desired Proteins and Peptides

"Proteins", "peptides," "polypeptides" and "oligopeptides" are chains of amino acids (typically L-amino acids) whose alpha carbons are linked through peptide bonds
10 formed by a condensation reaction between the carboxyl group of the alpha carbon of one amino acid and the amino group of the alpha carbon of another amino acid. The terminal amino acid at one end of the chain (i.e., the amino terminal) has a free amino group, while the terminal amino acid at the other end of the chain (i.e., the carboxy terminal) has a free carboxyl group. As such, the term "amino terminus" (abbreviated
15 N-terminus) refers to the free alpha-amino group on the amino acid at the amino terminal of the protein, or to the alpha-amino group (imino group when participating in a peptide bond) of an amino acid at any other location within the protein. Similarly, the term "carboxy terminus" (abbreviated C-terminus) refers to the free carboxyl group on the amino acid at the carboxy terminus of a protein, or to the
20 carboxyl group of an amino acid at any other location within the protein.

Typically, the amino acids making up a protein are numbered in order, starting at the amino terminal and increasing in the direction toward the carboxy terminal of the protein. Thus, when one amino acid is said to "follow" another, that amino acid is positioned closer to the carboxy terminal of the protein than the preceding amino acid.

25 The term "residue" is used herein to refer to an amino acid (D or L) or an amino acid mimetic that is incorporated into a protein by an amide bond. As such, the amino acid may be a naturally occurring amino acid or, unless otherwise limited, may encompass known analogs of natural amino acids that function in a manner similar to the naturally occurring amino acids (i.e., amino acid mimetics). Moreover, an amide
30 bond mimetic includes peptide backbone modifications well known to those skilled in the art.

Furthermore, one of skill will recognize that, as mentioned above, individual substitutions, deletions or additions which alter, add or delete a single amino acid or a

small percentage of amino acids (typically less than about 5%, more typically less than about 1%) in an encoded sequence are conservatively modified variations where the alterations result in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following six groups each contain amino acids that are conservative substitutions for one another:

- 1) Alanine (A), Serine (S), Threonine (T);
- 2) Aspartic acid (D), Glutamic acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 10 4) Arginine (R), Lysine (K);
- 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

A conservative substitution is a substitution in which the substituting amino acid (naturally occurring or modified) is structurally related to the amino acid being substituted, i.e., has about the same size and electronic properties as the amino acid being substituted. Thus, the substituting amino acid would have the same or a similar functional group in the side chain as the original amino acid. A "conservative substitution" also refers to utilizing a substituting amino acid which is identical to the amino acid being substituted except that a functional group in the side chain is protected with a suitable protecting group.

Suitable protecting groups are described in Green and Wuts, "Protecting Groups in Organic Synthesis", John Wiley and Sons, Chapters 5 and 7, 1991, the teachings of which are incorporated herein by reference. Preferred protecting groups are those which facilitate transport of the peptide through membranes, for example, by reducing the hydrophilicity and increasing the lipophilicity of the peptide, and which can be cleaved, either by hydrolysis or enzymatically (Ditter et al., 1968. J. Pharm. Sci. 57:783; Ditter et al., 1968. J. Pharm. Sci. 57:828; Ditter et al., 1969. J. Pharm. Sci. 58:557; King et al., 1987. Biochemistry 26:2294; Lindberg et al., 1989. Drug Metabolism and Disposition 17:311; Tunek et al., 1988. Biochem. Pharm. 37:3867; Anderson et al., 1985 Arch. Biochem. Biophys. 239:538; and Singhal et al., 1987. FASEB J. 1:220). Suitable hydroxyl protecting groups include ester, carbonate and carbamate protecting groups. Suitable amine protecting groups include acyl groups and alkoxy or aryloxy carbonyl groups, as described above for N-terminal protecting

groups. Suitable carboxylic acid protecting groups include aliphatic, benzyl and aryl esters, as described below for C-terminal protecting groups. In one embodiment, the carboxylic acid group in the side chain of one or more glutamic acid or aspartic acid residues in a peptide of the present invention is protected, preferably as a methyl, ethyl, benzyl or substituted benzyl ester, more preferably as a benzyl ester.

Provided below are groups of naturally occurring and modified amino acids in which each amino acid in a group has similar electronic and steric properties. Thus, a conservative substitution can be made by substituting an amino acid with another amino acid from the same group. It is to be understood that these groups are non-limiting, i.e. that there are additional modified amino acids which could be included in each group.

Group I includes leucine, isoleucine, valine, methionine and modified amino acids having the following side chains: ethyl, n-propyl n-butyl. Preferably, Group I includes leucine, isoleucine, valine and methionine.

Group II includes glycine, alanine, valine and a modified amino acid having an ethyl side chain. Preferably, Group II includes glycine and alanine.

Group III includes phenylalanine, phenylglycine, tyrosine, tryptophan, cyclohexylmethyl glycine, and modified amino residues having substituted benzyl or phenyl side chains. Preferred substituents include one or more of the following: halogen, methyl, ethyl, nitro, —NH_2 , methoxy, ethoxy and —CN . Preferably, Group III includes phenylalanine, tyrosine and tryptophan.

Group IV includes glutamic acid, aspartic acid, a substituted or unsubstituted aliphatic, aromatic or benzylic ester of glutamic or aspartic acid (e.g., methyl, ethyl, n-propyl iso-propyl, cyclohexyl, benzyl or substituted benzyl), glutamine, asparagine, —CO—NH— alkylated glutamine or asparagines (e.g., methyl, ethyl, n-propyl and iso-propyl) and modified amino acids having the side chain $\text{—(CH}_2\text{)}_3\text{—COOH}$, an ester thereof (substituted or unsubstituted aliphatic, aromatic or benzylic ester), an amide thereof and a substituted or unsubstituted N-alkylated amide thereof. Preferably, Group IV includes glutamic acid, aspartic acid, methyl aspartate, ethyl aspartate, benzyl aspartate and methyl glutamate, ethyl glutamate and benzyl glutamate, glutamine and asparagine.

Group V includes histidine, lysine, ornithine, arginine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline and 2-amino-4-guanidinobutanoic acid, homologs of lysine, homologs of arginine and homologs of ornithine. Preferably, Group V includes histidine, lysine, arginine and ornithine. A homolog of an amino acid includes from 1 to about 3 additional or subtracted methylene units in the side chain.

Group VI includes serine, threonine, cysteine and modified amino acids having C1-C5 straight or branched alkyl side chains substituted with $-\text{OH}$ or $-\text{SH}$, for example, $-\text{CH}_2\text{CH}_2\text{OH}$, $-\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$ or $-\text{CH}_2\text{CH}_2\text{OHCH}_3$. Preferably, Group VI includes serine, cysteine or threonine.

In another aspect, suitable substitutions for amino acid residues include "severe" substitutions. A "severe substitution" is a substitution in which the substituting amino acid (naturally occurring or modified) has significantly different size and/or electronic properties compared with the amino acid being substituted. Thus, the side chain of the substituting amino acid can be significantly larger (or smaller) than the side chain of the amino acid being substituted and/or can have functional groups with significantly different electronic properties than the amino acid being substituted. Examples of severe substitutions of this type include the substitution of phenylalanine or cyclohexylmethyl glycine for alanine, isoleucine for glycine, a D amino acid for the corresponding L amino acid, or $-\text{NH}-\text{CH}[(\text{CH}_2)_5-\text{COOH}]-\text{CO}-$ for aspartic acid. Alternatively, a functional group may be added to the side chain, deleted from the side chain or exchanged with another functional group. Examples of severe substitutions of this type include adding of valine, leucine or isoleucine, exchanging the carboxylic acid in the side chain of aspartic acid or glutamic acid with an amine, or deleting the amine group in the side chain of lysine or ornithine. In yet another alternative, the side chain of the substituting amino acid can have significantly different steric and electronic properties than the functional group of the amino acid being substituted. Examples of such modifications include tryptophan for glycine, lysine for aspartic acid and $(\text{CH}_2)_4\text{COOH}$ for the side chain of serine. These examples are not meant to be limiting.

In another embodiment, for example in the synthesis of a peptide 26 amino acids in length, the individual amino acids may be substituted according in the following manner:

- AA₁ is serine, glycine, alanine, cysteine or threonine;
- 5 AA₂ is alanine, threonine, glycine, cysteine or serine;
- AA₃ is valine, arginine, leucine, isoleucine, methionine, ornithine, lysine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline or 2-amino-4-guanidinobutanoic acid;
- AA₄ is proline, leucine, valine, isoleucine or methionine;
- 10 AA₅ is tryptophan, alanine, phenylalanine, tyrosine or glycine;
- AA₆ is serine, glycine, alanine, cysteine or threonine;
- AA₇ is proline, leucine, valine, isoleucine or methionine;
- AA₈ is alanine, threonine, glycine, cysteine or serine;
- AA₉ is alanine, threonine, glycine, cysteine or serine;
- 15 AA₁₀ is leucine, isoleucine, methionine or valine;
- AA₁₁ is serine, glycine, alanine, cysteine or threonine;
- AA₁₂ is leucine, isoleucine, methionine or valine;
- AA₁₃ is leucine, isoleucine, methionine or valine;
- AA₁₄ is glutamine, glutamic acid, aspartic acid, asparagine, or a substituted or
- 20 unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- AA₁₅ is arginine, N-nitroarginine, β -cycloarginine, γ -hydroxy-arginine, N-amidinocitruline or 2-amino-4-guanidino-butanoic acid
- AA₁₆ is proline, leucine, valine, isoleucine or methionine;
- AA₁₇ is serine, glycine, alanine, cysteine or threonine;
- 25 AA₁₈ is glutamic acid, aspartic acid, asparagine, glutamine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- AA₁₉ is aspartic acid, asparagine, glutamic acid, glutamine, leucine, valine, isoleucine, methionine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;
- 30 AA₂₀ is valine, arginine, leucine, isoleucine, methionine, ornithine, lysine, N-nitroarginine, β -cycloarginine, γ -hydroxyarginine, N-amidinocitruline or 2-amino-4-guanidinobutanoic acid;
- AA₂₁ is alanine, threonine, glycine, cysteine or serine;

AA₂₂ is alanine, threonine, glycine, cysteine or serine;

AA₂₃ is histidine, serine, threonine, cysteine, lysine or ornithine;

AA₂₄ is threonine, aspartic acid, serine, glutamic acid or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid;

5 AA₂₅ is asparagine, aspartic acid, glutamic acid, glutamine, leucine, valine, isoleucine, methionine or a substituted or unsubstituted aliphatic or aryl ester of glutamic acid or aspartic acid; and

AA₂₆ is cysteine, histidine, serine, threonine, lysine or ornithine.

10 It is to be understood that these amino acid substitutions may be made for longer or shorter peptides than the 26 mer in the preceding example above, and for proteins.

In one embodiment of the present invention, codons for the first several N-terminal amino acids of the transposase are modified such that the third base of each codon is changed to an A or a T without changing the corresponding amino acid. It is
15 preferable that between approximately 1 and 20, more preferably 3 and 15, and most preferably between 4 and 12 of the first N-terminal codons of the gene of interest are modified such that the third base of each codon is changed to an A or a T without changing the corresponding amino acid. In one embodiment, the first ten N-terminal codons of the gene of interest are modified in this manner.

20 When several desired proteins, protein fragments or peptides are encoded in the gene of interest to be incorporated into the genome, one of skill in the art will appreciate that the proteins, protein fragments or peptides may be separated by a spacer molecule such as, for example, a peptide, consisting of one or more amino acids. Generally, the spacer will have no specific biological activity other than to join
25 the desired proteins, protein fragments or peptides together, or to preserve some minimum distance or other spatial relationship between them. However, the constituent amino acids of the spacer may be selected to influence some property of the molecule such as the folding, net charge, or hydrophobicity. The spacer may also be contained within a nucleotide sequence with a purification handle or be flanked by
30 proteolytic cleavage sites.

Such polypeptide spacers may have from about 5 to about 40 amino acid residues. The spacers in a polypeptide are independently chosen, but are preferably all the same. The spacers should allow for flexibility of movement in space and are

therefore typically rich in small amino acids, for example, glycine, serine, proline or alanine. Preferably, peptide spacers contain at least 60%, more preferably at least 80% glycine or alanine. In addition, peptide spacers generally have little or no biological and antigenic activity. Preferred spacers are (Gly-Pro-Gly-Gly)_x (SEQ ID NO:5) and (Gly₄-Ser)_y, wherein x is an integer from about 3 to about 9 and y is an integer from about 1 to about 8. Specific examples of suitable spacers include

(Gly-Pro-Gly-Gly)₃

SEQ ID NO:6 Gly Pro Gly Gly Gly Pro Gly Gly Gly Pro Gly Gly

(Gly₄-Ser)₃

10 SEQ ID NO:7 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
or (Gly₄-Ser)₄

SEQ ID NO:8 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
Gly Gly Gly Gly Ser.

15 Nucleotide sequences encoding for the production of residues which may be useful in purification of the expressed recombinant protein may also be built into the vector. Such sequences are known in the art and include the glutathione binding domain from glutathione S-transferase, polylysine, hexa-histidine or other cationic amino acids, thioredoxin, hemagglutinin antigen and maltose binding protein.

20 Additionally, nucleotide sequences may be inserted into the gene of interest to be incorporated so that the protein or peptide can also include from one to about six amino acids that create signals for proteolytic cleavage. In this manner, if a gene is designed to make one or more peptides or proteins of interest in the transgenic animal, specific nucleotide sequences encoding for amino acids recognized by enzymes may be incorporated into the gene to facilitate cleavage of the large protein or peptide
25 sequence into desired peptides or proteins or both. For example, nucleotides encoding a proteolytic cleavage site can be introduced into the gene of interest so that a signal sequence can be cleaved from a protein or peptide encoded by the gene of interest. Nucleotide sequences encoding other amino acid sequences which display pH sensitivity or chemical sensitivity may also be added to the vector to facilitate
30 separation of the signal sequence from the peptide or protein of interest.

In one embodiment of the present invention, a TAG sequence is linked to the gene of interest. The TAG sequence serves three purposes: 1) it allows free rotation of the peptide or protein to be isolated so there is no interference from the native

protein or signal sequence, i.e. vitellogenin, 2) it provides a "purification handle" to isolate the protein using column purification, and 3) it includes a cleavage site to remove the desired protein from the signal and purification sequences. Accordingly, as used herein, a TAG sequence includes a spacer sequence, a purification handle and
5 a cleavage site. The spacer sequences in the TAG proteins contain one or more repeats shown in SEQ ID NO:25. A preferred spacer sequence comprises the sequence provided in SEQ ID NO:26. One example of a purification handle is the gp41 hairpin loop from HIV I. Exemplary gp41 polynucleotide and polypeptide sequences are provided in SEQ ID NO:24 and SEQ ID NO:23, respectively.
10 However, it should be understood that any antigenic region may be used as a purification handle, including any antigenic region of gp41. Preferred purification handles are those that elicit highly specific antibodies. Additionally, the cleavage site can be any protein cleavage site known to one of ordinary skill in the art and includes an enterokinase cleavage site comprising the Asp Asp Asp Asp Lys sequence (SEQ
15 ID NO:9) and a furin cleavage site. Constructs containing a TAG sequence are shown in Figures 2 and 3. In one embodiment of the present invention, the TAG sequence comprises a polynucleotide sequence of SEQ ID NO:22.

Methods of Administering Transposon-Based Vectors

In addition to the transposon-based vectors described above, the present
20 invention also includes methods of administering the transposon-based vectors to an animal, methods of producing a transgenic animal wherein a gene of interest is incorporated into the germline of the animal and methods of producing a transgenic animal wherein a gene of interest is incorporated into cells other than the germline cells of the animal. The transposon-based vectors of the present invention may be
25 administered to an animal via any method known to those of skill in the art, including, but not limited to, intraembryonic, intratesticular, intraoviduct, intraperitoneal, intraarterial, intravenous, topical, oral, nasal, and pronuclear injection methods of administration, or any combination thereof. The transposon-based vectors may also be administered within the lumen of an organ, into an organ, into a body cavity, into
30 the cerebrospinal fluid, through the urinary system or through any route to reach the desired cells.

The transposon-based vectors may be delivered through the vascular system to be distributed to the cells supplied by that vessel. For example, the compositions may

be placed in the artery supplying the ovary or supplying the fallopian tube to transfect cells in those tissues. In this manner, follicles could be transfected to create a germline transgenic animal. Alternatively, supplying the compositions through the artery leading to the oviduct would preferably transfect the tubular gland and epithelial cells. Such transfected cells could manufacture a desired protein or peptide for deposition in the egg white. Administration of the compositions through the portal vein would target uptake and transformation of hepatic cells. Administration through the urethra and into the bladder would target the transitional epithelium of the bladder. Administration through the vagina and cervix would target the lining of the uterus. Administration through the internal mammary artery would transfect secretory cells of the lactating mammary gland to perform a desired function, such as to synthesize and secrete a desired protein or peptide into the milk.

In a preferred embodiment, the animal is an egg-laying animal, and more preferably, an avian. In one embodiment, between approximately 1 and 50 μg , preferably between 1 and 20 μg , and more preferably between 5 and 10 μg of transposon-based vector DNA is administered to the oviduct of a bird. Optimal ranges depending upon the type of bird and the bird's stage of sexual maturity. Intraoviduct administration of the transposon-based vectors of the present invention result in a PCR positive signal in the oviduct tissue, whereas intravascular administration results in a PCR positive signal in the liver. In other embodiments, the transposon-based vector is administered to an artery that supplies the oviduct or the liver. These methods of administration may also be combined with any methods for facilitating transfection, including without limitation, electroporation, gene guns, injection of naked DNA, and use of dimethyl sulfoxide (DMSO).

The present invention includes a method of intraembryonic administration of a transposon-based vector to an avian embryo comprising the following steps: 1) incubating an egg on its side at room temperature for two hours to allow the embryo contained therein to move to top dead center (TDC); 2) drilling a hole through the shell without penetrating the underlying shell membrane; 3) injecting the embryo with the transposon-based vector in solution; 4) sealing the hole in the egg; and 5) placing the egg in an incubator for hatching. Administration of the transposon-based vector can occur anytime between immediately after egg lay (when the embryo is at Stage X) and hatching. Preferably, the transposon-based vector is administered between 1 and

7 days after egg lay, more preferably between 1 and 2 days after egg lay. The transposon-based vectors may be introduced into the embryo in amounts ranging from about 5.0 μg to 10 μg , preferably 1.0 μg to 100 μg . Additionally, the transposon-based vector solution volume may be between approximately 1 μl to 75 μl in quail
5 and between approximately 1 μl to 500 μl in chicken.

The present invention also includes a method of intratesticular administration of a transposon-based vector including injecting a bird with a composition comprising the transposon-based vector, an appropriate carrier and an appropriate transfection reagent. In one embodiment, the bird is injected before sexual maturity, preferably
10 between approximately 4-14 weeks, more preferably between approximately 6-14 weeks and most preferably between 8-12 weeks old. In another embodiment, a mature bird is injected with a transposon-based vector an appropriate carrier and an appropriate transfection reagent. The mature bird may be any type of bird, but in one example the mature bird is a quail.

15 A bird is preferably injected prior to the development of the blood-testis barrier, which thereby facilitates entry of the transposon-based vector into the seminiferous tubules and transfection of the spermatogonia or other germline cells. At and between the ages of 4, 6, 8, 10, 12, and 14 weeks, it is believed that the testes of chickens are likely to be most receptive to transfection. In this age range, the
20 blood/testis barrier has not yet formed, and there is a relatively high number of spermatogonia relative to the numbers of other cell types, e.g., spermatids, etc. See J. Kumaran et al., 1949. Poultry Sci., 29:511-520. See also E. Oakberg, 1956. Am. J. Anatomy, 99:507-515; and P. Kluin et al., 1984. Anat. Embryol., 169:73-78.

The transposon-based vectors may be introduced into a testis in an amount
25 ranging from about 0.1 μg to 10 μg , preferably 1 μg to 10 μg , more preferably 3 μg to 10 μg . In a quail, about 5 μg is a preferred amount. In a chicken, about 5 μg to 10 μg per testis is preferred. These amounts of vector DNA may be injected in one dose or multiple doses and at one site or multiple sites in the testis. In a preferred embodiment, the vector DNA is administered at multiple sites in a single testis, both
30 testes being injected in this manner. In one embodiment, injection is spread over three injection sites: one at each end of the testis, and one in the middle. Additionally, the transposon-based vector solution volume may be between approximately 1 μl to 75 μl in quail and between approximately 1 μl to 500 μl in chicken. In a preferred

embodiment, the transposon-based vector solution volume may be between approximately 20 μ l to 60 μ l in quail and between approximately 50 μ l to 250 μ l in chicken. Both the amount of vector DNA and the total volume injected into each testis may be determined based upon the age and size of the bird.

5 According to the present invention, the transposon-based vector is administered in conjunction with an acceptable carrier and/or transfection reagent. Acceptable carriers include, but are not limited to, water, saline, Hanks Balanced Salt Solution (HBSS), Tris-EDTA (TE) and lyotropic liquid crystals. Transfection reagents commonly known to one of ordinary skill in the art that may be employed
10 include, but are not limited to, the following: cationic lipid transfection reagents, cationic lipid mixtures, polyamine reagents, liposomes and combinations thereof; SUPERFECT®, Cytofectene, BioPORTER®, GenePORTER®, NeuroPORTER®, and perfectin from Gene Therapy Systems; lipofectamine, cellfectin, DMRIE-C oligofectamine, and PLUS reagent from InVitrogen; Xtreme gene, fugene, DOSPER
15 and DOTAP from Roche; Lipotaxi and Genejammer from Strategene; and Escort from SIGMA. In one embodiment, the transfection reagent is SUPERFECT®. The ratio of DNA to transfection reagent may vary based upon the method of administration. In one embodiment, the transposon-based vector is administered intratesticularly and the ratio of DNA to transfection reagent can be from 1:1.5 to
20 1:15, preferably 1:2 to 1:10, all expressed as wt/vol. Transfection may also be accomplished using other means known to one of ordinary skill in the art, including without limitation electroporation, gene guns, injection of naked DNA, and use of dimethyl sulfoxide (DMSO).

 Depending upon the cell or tissue type targeted for transfection, the form of
25 the transposon-based vector may be important. Plasmids harvested from bacteria are generally closed circular supercoiled molecules, and this is the preferred state of a vector for gene delivery because of the ease of preparation. In some instances, transposase expression and insertion may be more efficient in a relaxed, closed circular configuration or in a linear configuration. In still other instances, a purified
30 transposase protein may be co-injected with a transposon-based vector containing the gene of interest for more immediate insertion. This could be accomplished by using a transfection reagent complexed with both the purified transposase protein and the transposon-based vector.

Testing for and Breeding Animals Carrying the Transgene

Following administration of a transposon-based vector to an animal, DNA is extracted from the animal to confirm integration of the gene of interest. Actual frequencies of integration are estimated both by comparative strength of the PCR signal, and by histological evaluation of the tissues by quantitative PCR. Another method for estimating the rate of transgene insertion is the so-called primed in situ hybridization technique (PRINS). This method determines not only which cells carry a transgene of interest, but also into which chromosome the gene has inserted, and even what portion of the chromosome. Briefly, labeled primers are annealed to chromosome spreads (affixed to glass slides) through one round of PCR, and the slides are then developed through normal in situ hybridization procedures. This technique combines the best features of in situ PCR and fluorescence in situ hybridization (FISH) to provide distinct chromosome location and copy number of the gene in question. The 28s rRNA gene will be used as a positive control for spermatogonia to confirm that the technique is functioning properly. Using different fluorescent labels for the transgene and the 28s gene causes cells containing a transgene to fluoresce with two different colored tags.

Breeding experiments are also conducted to determine if germline transmission of the transgene has occurred. In a general bird breeding experiment performed according to the present invention, each male bird was exposed to 2-3 different adult female birds for 3-4 days each. This procedure was continued with different females for a total period of 6-12 weeks. Eggs were collected daily for up to 14 days after the last exposure to the transgenic male, and each egg was incubated in a standard incubator. In the first series of experiments the resulting embryos were examined for transgene presence at day 3 or 4 using PCR.

Any male producing a transgenic embryo was bred to additional females. Eggs from these females were incubated, hatched, and the chicks tested for the exogenous DNA. Any embryos that died were necropsied and examined directly for the transgene or protein encoded by the transgene, either by fluorescence or PCR. The offspring that hatched and were found to be positive for the exogenous DNA were raised to maturity. These birds were bred to produce further generations of transgenic birds, to verify efficiency of the transgenic procedure and the stable

incorporation of the transgene into the germ line. The resulting embryos were examined for transgene presence at day 3 or 4 using PCR.

It is to be understood that the above procedure can be modified to suit animals other than birds and that selective breeding techniques may be performed to amplify
5 gene copy numbers and protein output.

Production of Desired Proteins or Peptides in Egg White

In one embodiment, the transposon-based vectors of the present invention may be administered to a bird for production of desired proteins or peptides in the egg white. These transposon-based vectors preferably contain one or more of an
10 ovalbumin promoter, an ovomucoid promoter, an ovalbumin signal sequence and an ovomucoid signal sequence. Oviduct-specific ovalbumin promoters are described in B. O'Malley et al., 1987. EMBO J., vol. 6, pp. 2305-12; A. Qiu et al., 1994. Proc. Nat. Acad. Sci. (USA), vol. 91, pp. 4451-4455; D. Monroe et al., 2000. Biochim. Biophys. Acta, 1517 (1):27-32; H. Park et al., 2000. Biochem., 39:8537-8545; and T.
15 Muramatsu et al., 1996. Poult. Avian Biol. Rev., 6:107-123. Examples of transposon-based vectors designed for production of a desired protein in an egg white are shown in Figures 2 and 3.

Production of Desired Proteins or Peptides in Egg Yolk

The present invention is particularly advantageous for production of
20 recombinant peptides and proteins of low solubility in the egg yolk. Such proteins include, but are not limited to, membrane-associated or membrane-bound proteins, lipophilic compounds; attachment factors, receptors, and components of second messenger transduction machinery. Low solubility peptides and proteins are particularly challenging to produce using conventional recombinant protein
25 production techniques (cell and tissue cultures) because they aggregate in water-based, hydrophilic environments. Such aggregation necessitates denaturation and re-folding of the recombinantly-produced proteins, which may deleteriously affect their structure and function. Moreover, even highly soluble recombinant peptides and proteins may precipitate and require denaturation and renaturation when produced in
30 sufficiently high amounts in recombinant protein production systems. The present invention provides an advantageous resolution of the problem of protein and peptide solubility during production of large amounts of recombinant proteins.

In one embodiment of the present invention, deposition of a desired protein into the egg yolk is accomplished by attaching a sequence encoding a protein capable of binding to the yolk vitellogenin receptor to a gene of interest that encodes a desired protein. This transposon-based vector can be used for the receptor-mediated uptake
5 of the desired protein by the oocytes. In a preferred embodiment, the sequence ensuring the binding to the vitellogenin receptor is a targeting sequence of a vitellogenin protein. The invention encompasses various vitellogenin proteins and their targeting sequences. In a preferred embodiment, a chicken vitellogenin protein targeting sequence is used, however, due to the high degree of conservation among
10 vitellogenin protein sequences and known cross-species reactivity of vitellogenin targeting sequences with their egg-yolk receptors, other vitellogenin targeting sequences can be substituted. One example of a construct for use in the transposon-based vectors of the present invention and for deposition of an insulin protein in an egg yolk is provided in SEQ ID NO:27. In this embodiment, the transposon-based
15 vector contains a vitellogenin promoter, a vitellogenin targeting sequence, a TAG sequence, a pro-insulin sequence and a synthetic polyA sequence. The present invention includes, but is not limited to, vitellogenin targeting sequences residing in the N-terminal domain of vitellogenin, particularly in lipovitellin I. In one embodiment, the vitellogenin targeting sequence contains the polynucleotide
20 sequence of SEQ ID NO:18.

In a preferred embodiment, the transposon-based vector contains a transposase gene operably-linked to a liver-specific promoter and a gene of interest operably-linked to a liver-specific promoter and a vitellogenin targeting sequence. Figure 4 shows an example of such a construct. In another preferred embodiment, the
25 transposon-based vector contains a transposase gene operably-linked to a constitutive promoter and a gene of interest operably-linked to a liver-specific promoter and a vitellogenin targeting sequence.

Isolation and Purification of Desired Protein or Peptide

For large-scale production of protein, an animal breeding stock that is
30 homozygous for the transgene is preferred. Such homozygous individuals are obtained and identified through, for example, standard animal breeding procedures or PCR protocols.

Once expressed, peptides, polypeptides and proteins can be purified according to standard procedures known to one of ordinary skill in the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel electrophoresis, high performance liquid chromatography, immunoprecipitation and the like.

5 Substantially pure compositions of about 50 to 99% homogeneity are preferred, and 80 to 95% or greater homogeneity are most preferred for use as therapeutic agents.

In one embodiment of the present invention, the animal in which the desired protein is produced is an egg-laying animal. In a preferred embodiment of the present invention, the animal is an avian and a desired peptide, polypeptide or protein is

10 isolated from an egg white. Egg white containing the exogenous protein or peptide is separated from the yolk and other egg constituents on an industrial scale by any of a variety of methods known in the egg industry. See, e.g., W. Stadelman et al. (Eds.), Egg Science & Technology, Haworth Press, Binghamton, NY (1995). Isolation of the exogenous peptide or protein from the other egg white constituents is accomplished

15 by any of a number of polypeptide isolation and purification methods well known to one of ordinary skill in the art. These techniques include, for example, chromatographic methods such as gel permeation, ion exchange, affinity separation, metal chelation, HPLC, and the like, either alone or in combination. Another means that may be used for isolation or purification, either in lieu of or in addition to

20 chromatographic separation methods, includes electrophoresis. Successful isolation and purification is confirmed by standard analytic techniques, including HPLC, mass spectroscopy, and spectrophotometry. These separation methods are often facilitated if the first step in the separation is the removal of the endogenous ovalbumin fraction of egg white, as doing so will reduce the total protein content to be further purified by

25 about 50%.

To facilitate or enable purification of a desired protein or peptide, transposon-based vectors may include one or more additional epitopes or domains. Such epitopes or domains include DNA sequences encoding enzymatic or chemical cleavage sites including, but not limited to, an enterokinase cleavage site; the glutathione binding

30 domain from glutathione S-transferase; polylysine; hexa-histidine or other cationic amino acids; thioredoxin; hemagglutinin antigen; maltose binding protein; a fragment of gp41 from HIV; and other purification epitopes or domains commonly known to one of skill in the art.

In one representative embodiment, purification of desired proteins from egg white utilizes the antigenicity of the ovalbumin carrier protein and particular attributes of a TAG linker sequence that spans ovalbumin and the desired protein. The TAG sequence is particularly useful in this process because it contains 1) a highly antigenic epitope, a fragment of gp41 from HIV, allowing for stringent affinity purification, and, 2) a recognition site for the protease enterokinase immediately juxtaposed to the desired protein. In a preferred embodiment, the TAG sequence comprises approximately 50 amino acids. A representative TAG sequence is provided below.

10 Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys
Gly Trp Ile Gly Leu Leu Asp Asp Asp Asp Lys (SEQ ID NO:22)

The underlined sequences were taken from the hairpin loop domain of HIV gp-41 (SEQ ID NO:23). Sequences in italics represent the cleavage site for enterokinase (SEQ ID NO:9). The spacer sequence upstream of the loop domain was made from repeats of (Pro Ala Asp Asp Ala) (SEQ ID NO:25) to provide free rotation and promote surface availability of the hairpin loop from the ovalbumin carrier protein.

Isolation and purification of a desired protein is performed as follows:

- 20 1. Enrichment of the egg white protein fraction containing ovalbumin and the transgenic ovalbumin-TAG-desired protein.
2. Size exclusion chromatography to isolate only those proteins within a narrow range of molecular weights (a further enrichment of step 1).
3. Ovalbumin affinity chromatography. Highly specific antibodies to ovalbumin will eliminate virtually all extraneous egg white proteins except ovalbumin and the transgenic ovalbumin-TAG-desired protein.
- 25 4. gp41 affinity chromatography using anti-gp41 antibodies. Stringent application of this step will result in virtually pure transgenic ovalbumin-TAG-desired protein.
- 30 5. Cleavage of the transgene product can be accomplished in at least one of two ways:
 - a. The transgenic ovalbumin-TAG-desired protein is left attached to the gp41 affinity resin (beads) from step 4 and the protease enterokinase is

5 added. This liberates the transgene target protein from the gp41 affinity resin while the ovalbumin-TAG sequence is retained. Separation by centrifugation (in a batch process) or flow through (in a column purification), leaves the desired protein together with enterokinase in solution. Enterokinase is recovered and reused.

10 b. Alternatively, enterokinase is immobilized on resin (beads) by the addition of poly-lysine moieties to a non-catalytic area of the protease. The transgenic ovalbumin-TAG-desired protein eluted from the affinity column of step 4 is then applied to the protease resin. Protease action cleaves the ovalbumin-TAG sequence from the desired protein and leaves both entities in solution. The immobilized enterokinase resin is recharged and reused.

c. The choice of these alternatives is made depending upon the size and chemical composition of the transgene target protein.

15 6. A final separation of either of these two (5a or 5b) protein mixtures is made using size exclusion, or enterokinase affinity chromatography. This step allows for desalting, buffer exchange and/or polishing, as needed.

Cleavage of the transgene product (ovalbumin-TAG-desired protein) by enterokinase, then, results in two products: ovalbumin-TAG and the desired protein.
20 More specific methods for isolation using the TAG label is provided in the Examples. Some desired proteins may require additions or modifications of the above-described approach as known to one of ordinary skill in the art. The method is scaleable from the laboratory bench to pilot and production facility largely because the techniques applied are well documented in each of these settings.

25 It is believed that a typical chicken egg produced by a transgenic animal of the present invention will contain at least 0.001 mg, from about 0.001 to 1.0 mg, or from about 0.001 to 100.0 mg of exogenous protein, peptide or polypeptide, in addition to the normal constituents of egg white (or possibly replacing a small fraction of the latter).

30 One of skill in the art will recognize that after biological expression or purification, the desired proteins, fragments thereof and peptides may possess a conformation substantially different than the native conformations of the proteins, fragments thereof and peptides. In this case, it is often necessary to denature and

reduce protein and then to cause the protein to re-fold into the preferred conformation. Methods of reducing and denaturing proteins and inducing re-folding are well known to those of skill in the art.

Production of Protein or Peptide in Milk

5 In addition to methods of producing eggs containing transgenic proteins or peptides, the present invention encompasses methods for the production of milk containing transgenic proteins or peptides. These methods include the administration of a transposon-based vector described above to a mammal. In one embodiment, the transposon-based vector contains a transposase operably-linked to a constitutive
10 promoter and a gene of interest operably-linked to mammary specific promoter. Genes of interest can include, but are not limited to antiviral and antibacterial proteins and immunoglobulins.

Treatment of Disease and Animal Improvement

In addition to production and isolation of desired molecules, the transposon-
15 based vectors of the present invention can be used for the treatment of various genetic disorders. For example, one or more transposon-based vectors can be administered to a human or animal for the treatment of a single gene disorder including, but not limited to, Huntington's disease, alpha-1-antitrypsin deficiency Alzheimer's disease, various forms of breast cancer, cystic fibrosis, galactosemia, congenital
20 hypothyroidism, maple syrup urine disease, neurofibromatosis 1, phenylketonuria, sickle cell disease, and Smith-Lemli-Opitz (SLO/RSH) Syndrome. Other diseases caused by single gene disorders that may be treated with the present invention include, autoimmune diseases, shipping fever in cattle, mastitis, bacterial or viral diseases, alteration of skin pigment in animals. In these embodiments, the
25 transposon-based vector contains a non-mutated, or non-disease causing form of the gene known to cause such disorder. Preferably, the transposase contained within the transposase-based vector is operably linked to an inducible promoter such as a tissue-specific promoter such that the non-mutated gene of interest is inserted into a specific tissue wherein the mutated gene is expressed in vivo.

30 In one embodiment of the present invention, a transposon-based vector comprising a gene encoding proinsulin is administered to diabetic animals or humans for incorporation into liver cells in order to treat or cure diabetes. The specific incorporation of the proinsulin gene into the liver is accomplished by placing the

transposase gene under the control of liver-specific promoter, such as G6P. This approach is useful for treatment of both Type I and Type II diabetes. The G6P promoter has been shown to be glucose responsive (Arguad, D., et al. 1996. Diabetes 45:1563-1571), and thus, glucose-regulated insulin production is achieved using DNA
5 constructs of the present invention. Integrating a proinsulin gene into liver cells circumvents the problem of destruction of pancreatic islet cells in the course of Type I diabetes.

In another embodiment, shortly after diagnosis of Type I diabetes, the cells of the immune system destroying pancreatic β -cells are selectively removed using the
10 transposon-based vectors of the present invention, thus allowing normal β -cells to repopulate the pancreas.

For treatment of Type II diabetes, a transposon-based vector containing a proinsulin gene is specifically incorporated into the pancreas by placing the transposase gene under the control of a pancreas-specific promoter, such as an insulin
15 promoter. In this embodiment, the vector is delivered to a diabetic animal or human via injection into an artery feeding the pancreas. For delivery, the vector is complexed with a transfection agent. The artery distributes the complex throughout the pancreas, where individual cells receive the vector DNA. Following uptake into
20 the target cell, the insulin promoter is recognized by transcriptional machinery of the cell, the transposase encoded by the vector is expressed, and stable integration of the proinsulin gene occurs. It is expected that a small percentage of the transposon-based vector is transported to other tissues, and that these tissues are transfected. However, these tissues are not stably transfected and the proinsulin gene is not incorporated into the cells' DNA due to failure of these cells to activate the insulin promoter. The
25 vector DNA is likely lost when the cell dies or degraded over time.

In other embodiments, one or more transposon-based vectors are administered to an avian for the treatment of a viral or bacterial infection/disease including, but not limited to, Colibacillosis (Coliform infections), Mycoplasmosis (CRD, Air sac, Sinusitis), Fowl Cholera, Necrotic Enteritis, Ulcerative Enteritis (Quail disease),
30 Pullorum Disease, Fowl Typhoid, Botulism, Infectious Coryza, Erysipelas, Avian Pox, Newcastle Disease, Infectious Bronchitis, Quail Bronchitis, Lymphoid Leukosis, Marek's Disease (Visceral Leukosis), Infectious Bursal Disease (Gumboro). In these

embodiments, the transposon-based vectors may be used in a manner similar to traditional vaccines.

In still other embodiments, one or more transposon-based vectors are administered to an animal for the production of an animal with enhanced growth characteristics and nutrient utilization.

The transposon-based vectors of the present invention can be used to transform any animal cell, including but not limited to: cells producing hormones, cytokines, growth factors, or any other biologically active substance; cells of the immune system; cells of the nervous system; muscle (striatal, cardiac, smooth) cells; vascular system cells; endothelial cells; skin cells; mammary cells; and lung cells, including bronchial and alveolar cells. Transformation of any endocrine cell by a transposon-based vector is contemplated as a part of a present invention. In one aspect of the present invention, cells of the immune system may be the target for incorporation of a desired gene or genes encoding for production of antibodies. Accordingly, the thymus, bone marrow, beta lymphocytes (or B cells), gastrointestinal associated lymphatic tissue (GALT), Peyer's patches, bursa Fabricius, lymph nodes, spleen, and tonsil, and any other lymphatic tissue, may all be targets for administration of the compositions of the present invention.

The transposon-based vectors of the present invention can be used to modulate (stimulate or inhibit) production of any substance, including but not limited to a hormone, a cytokine, or a growth factor, by an animal or a human cell. Modulation of a regulated signal within a cell or a tissue, such as production of a second messenger, is also contemplated as a part of the present invention. Use of the transposon-based vectors of the present invention is contemplated for treatment of any animal or human disease or condition that results from underproduction (such as diabetes) or overproduction (such as hyperthyroidism) of a hormone or other endogenous biologically active substance. Use of the transposon-based vectors of the present invention to integrate nucleotide sequences encoding RNA molecules, such as anti-sense RNA or short interfering RNA, is also contemplated as a part of the present invention.

Additionally, the transposon-based vectors of the present invention may be used to provide cells or tissues with "beacons", such as receptor molecules, for binding of therapeutic agents in order to provide tissue and cell specificity for the

therapeutic agents. Several promoters and exogenous genes can be combined in one vector to produce progressive, controlled treatments from a single vector delivery.

The following examples will serve to further illustrate the present invention without, at the same time, however, constituting any limitation thereof. On the contrary, it is to be clearly understood that resort may be had to various embodiments, modifications and equivalents thereof which, after reading the description herein, may suggest themselves to those skilled in the art without departing from the spirit of the invention.

10

EXAMPLE 1

Preparation of Transposon-Based Vector pTnMod

A vector was designed for inserting a desired coding sequence into the genome of eukaryotic cells, given below as SEQ ID NO:1. The vector of SEQ ID NO:1, termed pTnMod, was constructed and its sequence verified.

15

This vector employed a cytomegalovirus (CMV) promoter. A modified Kozak sequence (ACCATG) (SEQ ID NO:13) was added to the promoter. The nucleotide in the wobble position in nucleotide triplet codons encoding the first 10 amino acids of transposase was changed to an adenine (A) or thymine (T), which did not alter the amino acid encoded by this codon. Two stop codons were added and a synthetic polyA was used to provide a strong termination sequence. This vector uses a promoter designed to be active soon after entering the cell (without any induction) to increase the likelihood of stable integration. The additional stop codons and synthetic polyA insures proper termination without read through to potential genes downstream.

25

The first step in constructing this vector was to modify the transposase to have the desired changes. Modifications to the transposase were accomplished with the primers High Efficiency forward primer (Hef) Altered transposase (ATS)-Hef 5' ATCTCGAGACCATGTGTGIGAACTIGATATTTTACATGATTCTCTTTACC 3' (SEQ ID NO:10) and Altered transposase- High efficiency reverse primer (Her) 5' GATTGATCATTATCATAATTTCCCAAAGCGTAACC 3' (SEQ ID NO:11, a reverse complement primer). In the 5' forward primer ATS-Hef, the sequence CTCGAG (SEQ ID NO:12) is the recognition site for the restriction enzyme Xho I, which permits directional cloning of the amplified gene. The sequence ACCATG

30

(SEQ ID NO:13) contains the Kozak sequence and start codon for the transposase and the underlined bases represent changes in the wobble position to an A or T of codons for the first 10 amino acids (without changing the amino acid coded by the codon). Primer ATS-Her (SEQ ID NO:11) contains an additional stop codon TAA in addition to native stop codon TGA and adds a Bcl I restriction site, TGATCA (SEQ ID NO:14), to allow directional cloning. These primers were used in a PCR reaction with pTnLac (p defines plasmid, tn defines transposon, and lac defines the beta fragment of the lactose gene, which contains a multiple cloning site) as the template for the transposase and a FailSafe™ PCR System (which includes enzyme, buffers, dNTP's, MgCl₂ and PCR Enhancer; Epicentre Technologies, Madison, WI). Amplified PCR product was electrophoresed on a 1% agarose gel, stained with ethidium bromide, and visualized on an ultraviolet transilluminator. A band corresponding to the expected size was excised from the gel and purified from the agarose using a Zymo Clean Gel Recovery Kit (Zymo Research, Orange, CA). Purified DNA was digested with restriction enzymes Xho I (5') and Bcl I (3') (New England Biolabs, Beverly, MA) according to the manufacturer's protocol. Digested DNA was purified from restriction enzymes using a Zymo DNA Clean and Concentrator kit (Zymo Research).

Plasmid gWhiz (Gene Therapy Systems, San Diego, CA) was digested with restriction enzymes Sal I and BamH I (New England Biolabs), which are compatible with Xho I and Bcl I, but destroy the restriction sites. Digested gWhiz was separated on an agarose gel, the desired band excised and purified as described above. Cutting the vector in this manner facilitated directional cloning of the modified transposase (mATS) between the CMV promoter and synthetic polyA.

To insert the mATS between the CMV promoter and synthetic polyA in gWhiz, a Stratagene T4 Ligase Kit (Stratagene, Inc. La Jolla, CA) was used and the ligation set up according to the manufacturer's protocol. Ligated product was transformed into *E. coli* Top10 competent cells (Invitrogen Life Technologies, Carlsbad, CA) using chemical transformation according to Invitrogen's protocol. Transformed bacteria were incubated in 1 ml of SOC (GIBCO BRL, CAT# 15544-042) medium for 1 hour at 37° C before being spread to LB (Luria-Bertani media (broth or agar)) plates supplemented with 100 µg/ml ampicillin (LB/amp plates). These plates were incubated overnight at 37° C and resulting colonies picked to

LB/amp broth for overnight growth at 37° C. Plasmid DNA was isolated using a modified alkaline lysis protocol (Sambrook et al., 1989), electrophoresed on a 1% agarose gel, and visualized on a U.V. transilluminator after ethidium bromide staining. Colonies producing a plasmid of the expected size (approximately 6.4 kbp) were cultured in at least 250 ml of LB/amp broth and plasmid DNA harvested using a Qiagen Maxi-Prep Kit (column purification) according to the manufacturer's protocol (Qiagen, Inc., Chatsworth, CA). Column purified DNA was used as template for sequencing to verify the changes made in the transposase were the desired changes and no further changes or mutations occurred due to PCR amplification. For sequencing, Perkin-Elmer's Big Dye Sequencing Kit was used. All samples were sent to the Gene Probes and Expression Laboratory (LSU School of Veterinary Medicine) for sequencing on a Perkin-Elmer Model 377 Automated Sequencer.

Once a clone was identified that contained the desired mATS in the correct orientation, primers CMVf-NgoM IV (5' TTGCCGGCATCAGATTGGCTAT (SEQ ID NO:15); underlined bases denote NgoM IV recognition site) and Syn-polyA-BstE II (5' AGAGGTCACCGGGTCAATTCTTCAGCACCTGGTA (SEQ ID NO:16); underlined bases denote BstE II recognition site) were used to PCR amplify the entire CMV promoter, mATS, and synthetic polyA for cloning upstream of the transposon in pTnLac. The PCR was conducted with FailSafe™ as described above, purified using the Zymo Clean and Concentrator kit, the ends digested with NgoM IV and BstE II (New England Biolabs), purified with the Zymo kit again and cloned upstream of the transposon in pTnLac as described below.

Plasmid pTnLac was digested with NgoM IV and BstE II to remove the ptac promoter and transposase and the fragments separated on an agarose gel. The band corresponding to the vector and transposon was excised, purified from the agarose, and dephosphorylated with calf intestinal alkaline phosphatase (New England Biolabs) to prevent self-annealing. The enzyme was removed from the vector using a Zymo DNA Clean and Concentrator-5. The purified vector and CMVp/mATS/polyA were ligated together using a Stratagene T4 Ligase Kit and transformed into *E. coli* as described above.

Colonies resulting from this transformation were screened (mini-preps) as describe above and clones that were the correct size were verified by DNA sequence

analysis as described above. The vector was given the name pTnMod (SEQ ID NO:1) and includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to base pairs 1-130 of pBluescriptII sk(-).

5 Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 133 -1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems), corresponding to bp 229-1873 of pGWiz. The CMV promoter was modified by the addition of an ACC sequence upstream of ATG.

10 Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons for stability of the transposase mRNA and for the expression of protein. More specifically, in each of the
15 codons for the first ten amino acids of the transposase, G or C was changed to A or T when such a substitution would not alter the amino acid that was encoded.

Base pairs 2988-2993 are two engineered stop codons.

Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

20 Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of 10 pGWiz.

Base pairs 3415 - 3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding λ DNA that is residual from pNK2859.

25 Base pairs 3762 - 3831 are the 70 bp of the left insertion sequence recognized by the transposon Tn10.

Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 3838 - 4527 are the multiple cloning site from pBluescriptII sk(20),
30 corresponding to bp 924-235 of pBluescriptII sk(-). This multiple cloning site may be used to insert any coding sequence of interest into the vector.

Base pairs 4528-4532 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4533 - 4602 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 4603 - 4644 are non-coding λ DNA that is residual from pNK2859.

Base pairs 4645 - 5488 are non-coding DNA that is residual from pNK2859.

5 Base pairs 5489 - 7689 are from the pBluescriptII sk(-) base vector - (Stratagene, Inc.), corresponding to bp 761-2961 of pBluescriptII sk(-).

Completing pTnMod is a pBlueScript backbone that contains a colE I origin of replication and an antibiotic resistance marker (ampicillin).

10 It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

15 All plasmid DNA was isolated by standard procedures. Briefly, *Escherichia coli* containing the plasmid was grown in 500 mL aliquots of LB broth (supplemented with an appropriate antibiotic) at 37°C overnight with shaking. Plasmid DNA was recovered from the bacteria using a Qiagen Maxi-Prep kit (Qiagen, Inc., Chatsworth, CA) according to the manufacturer's protocol. Plasmid DNA was resuspended in 500 μ L of PCR-grade water and stored at -20°C until used.

EXAMPLE 2

20 *Preparation of Transposon-Based Vector pTnMod (CMV/Red)*

25 A vector was designed for inserting a reporter gene (DsRed) under the control of the CMV promoter into the genome of vertebrate cells given below as SEQ ID NO:2. The reporter gene chosen was the DsRed gene, driven by the immediate early cytomegalovirus promoter, to produce a plasmid called pTnCMV/DsRed. The DsRed gene product is a red fluorescent protein from an IndoPacific sea anemone, *Discosoma* sp., which fluoresces bright red at 558 nm. It is to be understood that the reporter gene, i.e., the DsRed gene, is only one embodiment of the present invention and that any gene of interest may be inserted into the plasmid in place of the DsRed reporter gene in any Experiment described herein.

30 The vector of SEQ ID NO:2, named pTnMod (CMV/Red), was constructed, and its sequence verified by re-sequencing. SEQ ID NO:2, pTnMod (CMV/Red), includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to bp 1-130 of pBluescriptII sk(-).

Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

5 Base pairs 133 -1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems, corresponding to bp 229-1873 of pGWiz.

Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites used in constructing the vector.

10 Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons as discussed above.

Base pairs 2988-2993 are two engineered stop codons.

Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

15 Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of pGWiz.

Base pairs 3415 - 3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding λ DNA that is residual from pNK2859.

20 Base pairs 3762 - 3831 are the 70 bp of the left insertion sequence recognized by the transposon Tn10.

Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 3838 - 4044 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 924-718 of pBluescriptII sk(-).

25 Base pairs 4045-4048 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4049-5693 are the CMV promoter/enhancer, taken from vector pGWiz (Gene Therapy Systems), corresponding to bp 229-1873 of pGWiz.

30 Base pairs 5694-5701 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 5702 - 6617 are the DsRed reporter coding sequence, including polyA sequence, from pDsRed1.1 (Clontech), corresponding to bp 77 - 992 of pDsRed1.1.

Base pairs 6618 - 7101 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 718-235 of pBluescriptII sk(-).

Base pairs 7102-7106 are a residue from ligation of restriction enzyme sites used in constructing the vector.

5 Base pairs 7107 - 7176 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 7177 - 7218 are non-coding λ DNA that is residual from pNK2859.

Base pairs 7219 - 8062 are non-coding DNA that is residual from pNK2859.

10 Base pairs 8063 - 10263 are from the pBluescriptII sk(-) base vector (Stratagene, Inc.), corresponding to bp 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s).

EXAMPLE 3

15 *Preparation of Transposon-Based Vector pTnMod (Oval/Red) - Chicken*

A vector was designed for inserting a reporter gene (DsRed) under the control of the ovalbumin promoter, and including the ovalbumin signal sequence, into the genome of a bird. One version of this vector is given below as SEQ ID NO:3. The vector of SEQ ID NO:3, named pTnMod (Oval/Red) - Chicken, includes chicken
20 ovalbumin promoter and signal sequences.

SEQ ID NO:3, pTnMod (Oval/Red) - Chicken, includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to bp 1-130 of pBluescriptII sk(-).

25 Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 133 -1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems, corresponding to bp 229-1873 of pGWiz.

30 Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons as discussed above.

Base pairs 2988-2993 are two engineered stop codons.

Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of pGWiz.

5 Base pairs 3415 --3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding λ DNA that is residual from 10 pNK2859.

10 Base pairs 3762 - 3831 are the 70 bp of the left insertion sequence recognized by the transposon Tn10.

Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 3838 - 4044 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 924-718 of pBluescriptII sk(-).

15 Base pairs 4045-4049 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4050 - 4951 contain upstream elements of the (including SDRE, steroid-dependent response element). See GenBank accession number J00895 M24999, bp 431-1332. Base pairs 4952-4959 are a residue from ligation of
20 restriction enzyme sites used in constructing the vector.

Base pairs 4960 - 5112 are the chicken ovalbumin signal sequence (GenBank accession number J00895 M24999, bp 2996-3148).

Base pairs 5113-5118 are a residue from ligation of restriction enzyme sites used in constructing the vector.

25 Base pairs 5119 - 6011 are the DsRed reporter coding sequence, including polyA sequence, from pDsRed1.1 (Clontech), corresponding to bp 100 - 992 of pDsRed1.1.

Base pairs 6012-6017 are a residue from ligation of restriction enzyme sites used in constructing the vector.

30 Base pairs 6018 - 6056 are part of the multiple cloning site of the ZeroBlunt Topo cloning vector (Invitrogen), corresponding to bp 337-377 of ZeroBlunt.

Base pairs 6057-6062 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 6063 - 6495 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 667-235 of pBluescriptII sk(-).

Base pairs 6496-6500 are a residue from ligation of restriction enzyme sites used in constructing the vector.

5 Base pairs 6501 - 6570 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 6571 - 6612 are non-coding λ DNA that is residual from pNK2859.

Base pairs 6613 - 7477 are non-coding DNA that is residual from pNK2859.

10 Base pairs 7478 - 9678 are from the pBluescriptII sk(-) base vector (Stratagene, Inc.), corresponding to bp 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s).

EXAMPLE 4

15 *Preparation of Transposon-Based Vector pTnMod(Oval/Red) - Quail*

A vector was designed for inserting a reporter gene (DsRed) under the control of the ovalbumin promoter, and including the ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:4. The vector of SEQ ID NO:4, named pTnMod (Oval/Red) - Quail, has been constructed, and selected portions of the
20 sequence have been verified by re-sequencing.

SEQ ID NO:4, pTnMod (Oval/Red) - Quail, includes the following components:

Base pairs 1-130 are a remainder of F1(-) on from pBluescriptII sk(-) (Stratagene), corresponding to bp 1-130 of pBluescriptII sk(-).

25 Base pairs 131 - 132 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 133 - 1777 are the CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems), corresponding to bp 229-1873 of pGWiz.

30 Base pairs 1778-1779 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 1780 - 2987 are the coding sequence for the transposase, modified from Tn10 (GenBank accession J01829) by optimizing codons as discussed above.

Base pairs 2988-2993 are two engineered stop codons. Base pair 2994 is a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 2995 - 3410 are a synthetic polyA sequence taken from the pGWiz vector (Gene Therapy Systems), corresponding to bp 1922-2337 of pGWiz.

5 Base pairs 3415 - 3718 are non-coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are non-coding λ DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 base pairs of the left insertion sequence recognized by the transposon Tn10.

10 Base pairs 3832-3837 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 3838 - 4044 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 924-718 of pBluescriptII sk(-).

15 Base pairs 4045-4049 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4050 - 4934 are the Japanese quail ovalbumin promoter (including SDRE, steroid-dependent response element). The Japanese quail ovalbumin promoter was isolated by its high degree of homology to the chicken ovalbumin promoter (GenBank accession number J00895 M24999, base pairs 431-1332). Some deletions
20 were noted in the quail sequence, as compared to the chicken sequence.

Base pairs 4935-4942 are a residue from ligation of restriction enzyme sites used in constructing the vector.

Base pairs 4943 - 5092 are the Japanese quail ovalbumin signal sequence. The quail signal sequence was isolated by its high degree of homology to the chicken
25 signal sequence (GenBank accession number J00895 M24999, base pairs 2996-3148). Some deletions were noted in the quail sequence, as compared to the chicken sequence.

Base pairs 5093-5098 are a residue from ligation of restriction enzyme sites used in constructing the vector.

30 Base pairs 5099 - 5991 are the DsRed reporter coding sequence, including polyA sequence, from pDsRed1.1 (Clontech), corresponding to bp 100 - 992 of pDsRed 1.1.

Base pairs 5998 - 6036 are part of the multiple cloning site of the ZeroBlunt Topo cloning vector (Invitrogen), corresponding to base pairs 337-377 of ZeroBlunt.

Base pairs 6043 - 6475 are part of the multiple cloning site from pBluescriptII sk(-), corresponding to bp 667-235 of pBluescriptII sk(-).

Base pairs 6481 - 6550 are the 70 bp of the right insertion sequence recognized by the transposon Tn10.

Base pairs 6551 - 6592 are non-coding λ DNA that is residual from pNK2859.

Base pairs 6593 - 7457 are non-coding DNA that is residual from pNK2859.

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s).

Transfection of Stage X Japanese Quail Eggs with pTnMod(Oval/Red) – Quail via embryo injection

Transgenic Japanese quail were produced by transfecting Stage X embryos and the heritability of the transgene delivered by embryo transfection was established. More specifically, fertile eggs were collected in the morning and placed at 15° C until enough were collected for injection, but were held no longer than 7 days. Stage X embryos (eggs) were assigned to one of two treatment groups. Before treatment, each egg was incubated on its side at room temperature for about 2 hours to allow the embryo to move to “top dead center” (TDC). Each egg was transfected by drilling a 1 mm hole (directly above the embryo) through the shell without penetrating the underlying shell membrane. A 0.5 ml syringe fitted with a 28 gauge needle was used to deliver DNA complexed to a transfecting reagent, i.e. SUPERFECT®, in a 50 µl volume. An adhesive disc was used to seal the hole and provide a label for treatment identification. After all eggs were transfected, they were set in an incubator with the adhesive disc pointing upward for hatching.

Each bird that hatched was bled at one week of age, DNA was extracted from blood cells, and PCR was conducted using 28s primers as a positive control and primers specific to DsRed. Any bird that was negative was terminated, while positive birds were monitored to determine maintenance of the transgene. Birds consistently positive were maintained until sexual maturity and bred. Positive male and female birds were mated. The eggs of mated hens were hatched and the resulting chicks, the G1 generation, were evaluated to determine if they were transgenic. All G1s resulting from this mating were bled and PCR conducted as described above.

Egg injection: Two treatment groups and one control group were used for this experiment. Vector pTnMod (Oval/Red) in supercoiled form (Treatment 1) and in linear form (Treatment 2) were used to transfect 15 eggs per treatment. To obtain linear DNA for this experiment, pTnMod (Oval/Red) was digested with NgoM IV, column purified, and resuspended in TE buffer.

Each egg was injected with 0.75 µg of DNA complexed with SUPERFECT® in a 1:3 ratio in a total injection volume of 50 µl Hank's Balanced Salt solution (HBSS) was used to bring the volume to 50 µl. The DNA Superfect mixture must be allowed to incubate (for complex formation) at room temperature for 10 minutes prior to injection and must be used within 40 minutes post initial mixing. Eggs were incubated as described above after injection.

Results: In the supercoiled injection group, 2 females and 1 male were identified as PCR positive using primers specific to the DsRed coding sequence. These birds were mated as described above. Blood was taken from the G1 chicks and PCR was conducted. The results showed that the transgene was incorporated into the gametes of these birds. The G1 chicks from these birds were examined on a weekly basis until it was verified that the gene was not present or enough transgenic G1s were obtained to initiate a breeding flock of fully transgenic birds. Eggs from these G1 chicks expressed DsRed protein in the albumin portion of their eggs.

EXAMPLE 6

Intratesticular Injection of Chickens with pTnMod(CMV/Red) (SEQ ID NO:2)

Immature birds of different ages (4, 6, 8, 10, 12, and 14 weeks) were placed under anesthesia and injected in the testes with the construct pTnMod(CMV/Red). A saline solution containing 1-5 µg of purified DNA vector, mixed with SUPERFECT® transfecting reagent (Qiagen, Valencia, CA) in a 1:6 (wt:vol) ratio. The volume of saline was adjusted so that the total volume injected into each testis was 150-200 µl, depending on the age and size of the bird. For the 4- and 6-week-old chickens, 1 µg DNA in 150 µl was injected in each testis, divided into three doses of 50 µl each. For

the older birds, 200 μ l total volume was injected, containing either 3 μ g DNA (for 8-week-old birds) or 5 μ g DNA (for older birds) per testis. First, one testis was surgically exposed prior to injection. After injection, the incision was sutured, and the sequence was repeated for the alternate testis.

5 From six to nine months post-surgery, weekly sperm samples were taken from each injected bird, as well as from control birds. Each sperm sample was evaluated for uptake and expression of the injected gene. Samples were evaluated by PCR on whole sperm, within one week after collection.

Approximately 100 male white leghorn chickens, in groups of 5-26, at ages 4,
10 6, 8, 10, 12, and 14 weeks, were used as this is the age range in which it is expected that the testes are likely to be most "receptive." In this age range, the blood/testis barrier has not yet formed, and there is a relatively high number of spermatogonia relative to the numbers of other cell types, e.g., spermatids, etc. See J. Kumaran et al., 1949. Poultry Sci., vol. 29, pp. 511-520. See also E. Oakberg, 1956. Am. J. Anatomy,
15 vol. 99, pp. 507-515; and P. Kluin et al., 1984. Anat. EmbryoL, vol. 169, pp. 73-78.

The experimental and control males were obtained from commercial sources at one day of age, and maintained in brooders until used. The male birds were housed in temperature-controlled spaces in individual standard caging as they approached maturity. They were given water and standard commercial feed ad lib. They were
20 kept initially in a 23:1 hour light/dark cycle, stepped down at approximately weekly intervals to a 15:8 hour light/dark cycle, as this regimen has been reported to optimize sexual maturity and fertility.

Surgical and DNA Injection Procedures

At the appropriate ages, groups of individual males were starved overnight and
25 then subjected to transgene delivery by direct intratesticular injection of DNA by experienced animal surgeons. Each male was anesthetized with isoflurane via a simplified gas machine.

Various devices and anesthesia machines have previously been described for administering isoflurane (and other gaseous anesthetics) to birds. See Alsage et al.,
30 Poultry Sci., 50:1876-1878 (1971); Greenlees et al., Am. J. Vet. Res., vol. 51, pp. 757-758 (1990). However, these prior techniques are somewhat cumbersome and complex to implement. A novel and much simpler system to administer isoflurane (or other gaseous) anesthesia was developed due to the deficiencies in the prior art, a

system that we found worked well on all ages of chicks. A standard nose cone was placed over the chick's head, similar to the system that has been used for decades to administer ether to mice. A plastic tube approximately 3.5 cm in diameter and 12 cm long was filled with cotton, into which was poured approximately 2 mL isoflurane (Abbott Laboratories, Chicago). The chick's head was placed partially into the cylinder, and was held in place there intermittently throughout the surgery as required to maintain the proper plane of anesthesia, without overdosing.

Each anesthetized bird was positioned on its side on an animal board with cords tractioning the wings and feet to allow access to the testes area. The area was swabbed with 0.5% chlorhexidine, and a 2 cm dorsolateral incision was made in the skin over the testis (similar to the procedure commonly used for caponization). A small-animal retractor was used to spread the last two ribs, exposing the testis. The DNA solution was then mixed with SUPERFECT® (Qiagen) according to the manufacturer's protocol, approximately a 1:6 wt/vol ratio, to a final concentration of 0.01 - 0.05 µg/µl. This resulted in 1 - 5 µg total DNA (in a 150-200 µl volume) being injected into each testis, spread over three injection sites: one at each end of the testis, and one in the middle.

The injection device was a standard 25 gauge, 1/2 inch (1.27 cm) hypodermic needle, attached to a 50, 100, or 200 µl syringe. Approximately 5 mm of the needle tip was bent at a 90 degree angle, to facilitate insertion into the testes. Approximately 50 - 70 µl of the DNA-SUPERFECT® solution was injected into each of three sites per testis. The multiple injections were calculated to suffuse the DNA throughout the whole testis, the idea being to promote contact between DNA and spermatogonia as much as feasible. We estimated that our procedure resulted in the injection of about 100,000 DNA molecules per spermatogonium. The construct used in these tests was a highly potent constitutive modified CMV promoter, operatively linked to the dsRed gene as shown in SEQ ID NO:2.

Following injection, the incision was closed in two layers with 4-0 absorbable suture, and then the contralateral testis was similarly exposed and injected. Following surgery, each bird was returned to its cage to recover. One hundred thirteen males were ultimately used in the experimental regimen to increase the overall likelihood of success, along with 4 control birds (16 weeks 20 old) subjected to sham surgery (with injections containing only the transfection reagent).

Evaluation of Birds

Thus, a total of 113 white leghorn chickens were injected with the DNA vector in groups of 5-26 at varying ages. Fourteen birds were transformed at 4 weeks, 23 birds at 6 weeks; 26 birds at 8 weeks; 23 birds at 10 weeks; 5 birds at 12 weeks; and 22 birds at 14 weeks. Sixteen birds died before they could be sampled, so to date, 97 roosters have been sampled, plus the four controls. Birds were evaluated at 18-24 weeks of age for (a) potential transformation in the sperm, and (b) successful testis transfection. Sperm samples were obtained from each rooster by manual manipulation using standard techniques. The sperm were washed, and their DNA was extracted following the techniques of G. Mann et al., 1993. J. Reprod. Fert., 99:505-12. The samples were then frozen until analyzed. Evaluation was conducted by PCR analysis to detect DNA integration into the sperm, or into any of the testicular cells. Additionally, selected testes were harvested at the end of the sperm sampling period.

Of 97 birds tested, at least 22 showed probable positive results. Positive results were observed at all transformation ages, except for 4 weeks, which was not tested. At least two birds were confirmed positive by PCR of sperm, conducted four months after the initial injection. These results were transient in many cases, however since it was believed that the DsRed gene product used in these initial proof of concept experiments was toxic. Nevertheless, the positive PCR results presumptively demonstrated that the transgene was incorporated into spermatogonia (before puberty), and that it was carried in transgenic sperm. Such sperm could then transmit the gene to subsequent generations, resulting in the production of true, germ-line transgenic "founder" birds.

To further confirm that the DNA had been incorporated into the sperm, and that contaminating vector was not being detected from other sources, it was confirmed through PCR on sperm of experimental birds, and on positive and negative controls that the sperm of the experimental birds lacked DNA encoding the transposase. The design of the preferred transposon-based vector is such that the sequence encoding the transposase is contained in the vector, but is not incorporated into the transformed chromosome. Thus, presence of the exogenous coding sequence, coupled with absence of the transposase gene, is strong evidence for incorporation of the exogenous coding sequence, or transgene.

These results demonstrated proof of concept, as positive PCR results were obtained from the sperm of treated birds. Interpretation of these preliminary results was made more difficult by the fact that the modified CMV promoter used in the experiment was probably too "hot." As the DsRed product is not secreted from the cells, the product built up intracellularly to levels that were toxic, frequently killing the cells. Even this result, of course, means that the transformation was successful. The transgene could not have killed the cells otherwise.

In order to resolve to the problem with toxicity of the DsRed gene product, experiments were conducted using a different reporter gene operably linked to the ovalbumin promoter, so that the transgene was expressed in the egg white. These experiments are provided in Examples 12-15 below.

EXAMPLE 7

Transfection of Male White Leghorn Chickens Using the Vector pTnMod(Oval/Red) – Quail (SEQ ID NO:4) via Testicular Injections

In further experiments conducted on leghorn chickens, it was demonstrated that chickens injected intratesticularly at 8, 10, 12, or 14 weeks of age, had, on average, approximately 40% positive sperm between 6 and 8 months after injection. In other experiments, successful transfection was achieved with chickens injected at 13 weeks of age.

Forty-nine white leghorn roosters approximately 8, 10, 12, or 14 weeks of age were obtained and housed. Birds were identified, wing banded, and assigned to a treatment group. If appropriate (based on testes size and vascularization), one testis was caponized and the entire DNA injection volume was delivered to the remaining testis. Thirty-two males received DNA injections of 5µg DNA/testis at a 1:3 ratio of DNA to SUPERFECT®. The remaining birds were used as controls. After injection, all birds were mated with at least 5 females and observed until sexual maturity and egg-laying began. All eggs collected prior to peak egg production (approximately 24 weeks of age for the hens) were incubated and candled to determine embryo presence. Any embryos identified were incubated to hatch to extract DNA, PCR was conducted, and transgene presence was determined.

Roosters positive for the pTnMod(Oval/Red) – Quail construct were kept to produce F1 offspring (eggs collected at peak production). Offspring from this hatch

were bled, DNA extracted from the blood, and PCR conducted using primers specific for the DsRed gene. It was determined that 77% of the offspring were transgenic.

EXAMPLE 8

5 *Transfection of Mature Male Japanese Quail using the vector pTnMod(Oval/Red) – Quail (SEQ ID NO:4) via Testicular Injections*

Twelve sexually mature males (at approximately 13 weeks of age) underwent surgery for testicular injection as described above for chickens. At 21-28 days of age, the birds were identified, leg banded, debeaked, and separated based on sex.
10 Injections comprised 5 µg/testes of the vector in concentrations 1:3 or 1:10 for SUPERFECT® or a 1:1 ratio with Mirrus. The study consisted of 3 treatment groups with 5 males in the 1:3 DNA:SUPERFECT® group, 3 males in the 1:10 DNA:SUPERFECT® group, and 4 males in the 1:1 Mirrus group. All surgeries were conducted in one day.

15 Any unincorporated DNA was allowed to clear from the testes by holding the birds for 19 days before mating with females. At 15 weeks of age, 2 age-matched females were housed with each treated male. The presence of the transfected DNA was determined in the fertilized eggs during the second week of egg lay. The subsequent eggs collected from parents producing positively identified transgenic
20 eggs were collected and stored until taken to hatch.

PCR performed on the sperm of quail injected at three months of age indicated successful incorporation of the DsRed transgene into the quail sperm.

EXAMPLE 9

25 *Transfection of Immature Male Japanese Quail using the vector pTnMod(Oval/Red) – Quail (SEQ ID NO:4) via Testicular Injections*

Approximately 450 quail eggs were set and hatched. At 21-28 days of age, the birds were identified, wingbanded, debeaked, and separated based on sex. At 4 weeks of age, 65 male birds underwent surgery and testicular injections as described above.
30 Injections comprised a control and 2 µg/testes of the vector in varying concentrations (0, 1/3, 1/5, and 1/10) of three different transfection reagents: 1) SUPERFECT®, 2) Mirus/Panvera and 3) Dosper. The study comprised 13 treatment groups with 5 males per group. One transfection reagent was administered per day.

At 7 weeks of age, 2 age-matched females were housed with each treated male. The presence of the transfected DNA was determined in the fertilized eggs during the second week of egg lay. The subsequent eggs collected from parents producing positively identified transgenic eggs were collected and stored until taken to hatch. PCR performed on the sperm of quail injected at four and five weeks of age indicated successful incorporation of the DsRed transgene into the quail sperm.

EXAMPLE 10

*Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/p146/PA) -*10 *Chicken*

A vector is designed for inserting a p146 gene under the control of a chicken ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:29.

Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

20 Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 - 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922- 2337 of pGWiz.

Base pairs 3415 - 3718 are non coding DNA that is residual from vector pNK2859.

25 Base pairs 3719 - 3761 are λ DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 - 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

30 Base pairs 4050 - 4951 are a chicken ovalbumin promoter (including SDRE) that corresponds to base pairs 431-1332 of the chicken ovalbumin promoter in GenBank Accession Number J00895 M24999.

Base pairs 4958 - 6115 are a chicken ovalbumin signal sequence and Ovalbumin gene that correspond to base pairs 66-1223 of GenBank Accession Number V00383.1 (The STOP codon being omitted).

Base pairs 6122 - 6271 are a TAG sequence containing a gp41 hairpin loop from HIV 1, an enterokinase cleavage site and a spacer (synthetic).

Base pairs 6272 - 6316 are a p146 sequence (synthetic) with 2 added stop codons.

Base pairs 6324 - 6676 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6682 - 7114 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

Base pairs 7120 - 7189 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7190 - 7231 are λ DNA that is residual from pNK2859.

Base pairs 7232 - 8096 are non coding DNA that is residual from pNK2859.

Base pairs 8097 - 10297 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

EXAMPLE 11

Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/p146/PA) - Quail

A vector is designed for inserting a p146 gene under the control of a quail ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:30.

Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 – 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922-2337 of pGWiz.

Base pairs 3415 – 3718 are non coding DNA that is residual from vector pNK2859.

5 Base pairs 3719 – 3761 are λ DNA that is residual from pNK2859.

Base pairs 3762 – 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 – 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

10 Base pairs 4050 - 4938 are the Japanese quail ovalbumin promoter (including SDRE, steroid-dependent response element). The Japanese quail ovalbumin promoter was isolated by its high degree of homology to the chicken ovalbumin promoter (GenBank accession number J00895 M24999, base pairs 431-1332).

15 Bp 4945 - 6092 are a quail ovalbumin signal sequence and ovalbumin gene that corresponds to base pairs 54 – 1201 of GenBank accession number X53964.1. (The STOP codon being omitted).

Base pairs 6097 - 6246 are a TAG sequence containing a gp41 hairpin loop from HIV I, an enterokinase cleavage site and a spacer (synthetic).

20 Base pairs 6247 – 6291 are a p146 sequence (synthetic) with 2 added stop codons.

Base pairs 6299 – 6651 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6657 - 7089 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

25 Base pairs 7095- 7164 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7165 - 7206 are λ DNA that is residual from pNK2859.

Base pairs 7207 – 8071 are non coding DNA that is residual from pNK2859.

30 Base pairs 8072 - 10272 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

5

EXAMPLE 12

Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/ProIns/PA) – Chicken

A vector is designed for inserting a proinsulin gene under the control of a chicken ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal
10 sequence, into the genome of a bird given below as SEQ ID NO:31.

Base pairs 1 - 130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector
15 pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 - 3410 are a synthetic polyA from pGWiz (Gene Therapy
20 Systems) corresponding to base pairs 1922- 2337 of pGWiz.

Base pairs 3415 - 3718 are non coding DNA that is residual from vector pNK2859.

Base pairs 3719 - 3761 are λ DNA that is residual from pNK2859.

Base pairs 3762 - 3831 are the 70 base pairs of the left insertion sequence
25 (IS10) recognized by the transposon Tn10.

Base pairs 3838 - 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

Base pairs 4050 - 4951 are a chicken ovalbumin promoter (including SDRE) that corresponds to base pairs 431-1332 of the chicken ovalbumin promoter in
30 GenBank Accession Number J00895 M24999.

Base pairs 4958 - 6115 are a chicken ovalbumin signal sequence and ovalbumin gene that correspond to base pairs 66-1223 of GenBank Accession Number V00383.1. (The STOP codon being omitted).

Base pairs 6122 - 6271 are a TAG sequence containing a gp41 hairpin loop from HIV I, an enterokinase cleavage site and a spacer (synthetic).

Base pairs 6272 - 6531 are a proinsulin gene.

Base pairs 6539 - 6891 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6897 - 7329 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

Base pairs 7335- 7404 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7405 - 7446 are λ DNA that is residual from pNK2859.

Base pairs 7447 - 8311 are non coding DNA that is residual from pNK2859.

Base pairs 8312 - 10512 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

EXAMPLE 13

Preparation of Transposon-Based Vector pTnMod(Oval/ENT TAG/ProIns/PA) - Quail

A vector is designed for inserting a proinsulin gene under the control of a chicken ovalbumin promoter, and a ovalbumin gene including an ovalbumin signal sequence, into the genome of a bird given below as SEQ ID NO:32.

25

Base pairs 1 -130 are a remainder of F1(-) ori of pBluescriptII sk(-) (Stratagene) corresponding to base pairs 1-130 of pBluescriptII sk(-).

Base pairs 133 - 1777 are a CMV promoter/enhancer taken from vector pGWiz (Gene Therapy Systems) corresponding to base pairs 229-1873 of pGWiz.

30

Base pairs 1780 - 2987 are a transposase, modified from Tn10 (GenBank accession number J01829).

Base pairs 2988-2993 are an engineered stop codon.

Base pairs 2995 – 3410 are a synthetic polyA from pGWiz (Gene Therapy Systems) corresponding to base pairs 1922- 2337 of pGWiz.

Base pairs 3415 – 3718 are non coding DNA that is residual from vector pNK2859.

5 Base pairs 3719 – 3761 are λ DNA that is residual from pNK2859.

Base pairs 3762 – 3831 are the 70 base pairs of the left insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 3838 – 4044 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 924-718 of pBluescriptII sk(-).

10 Base pairs 4050 - 4938 are the Japanese quail ovalbumin promoter (including SDRE, steroid-dependent response element). The Japanese quail ovalbumin promoter was isolated by its high degree of homology to the chicken ovalbumin promoter (GenBank accession number J00895 M24999, base pairs 431-1332). Some deletions were noted in the quail sequence, as compared to the chicken sequence.

15 Base pairs 4945 - 6092 are a quail ovalbumin signal sequence and ovalbumin gene that corresponds to base pairs 54 – 1201 of GenBank accession number X53964.1. (The STOP codon being omitted).

Base pairs 6093 - 6246 are a TAG sequence containing a gp41 hairpin loop from HIV I an enterokinase cleavage site and a spacer (synthetic).

20 Base pairs 6247 – 6507 are a proinsulin gene.

Base pairs 6514 – 6866 are a synthetic polyadenylation sequence from pGWiz (Gene Therapy Systems) corresponding to base pairs 1920 - 2272 of pGWiz.

Base pairs 6867 - 7303 are a multiple cloning site from pBlueScriptII sk(-) corresponding to base pairs 667-235 of pBluescriptII sk(-).

25 Base pairs 7304- 7379 are the 70 base pairs of the right insertion sequence (IS10) recognized by the transposon Tn10.

Base pairs 7380 - 7421 are λ DNA that is residual from pNK2859.

Base pairs 7422 – 8286 are non coding DNA that is residual from pNK2859.

30 Base pairs 8287 - 10487 are pBlueScript sk(-) base vector (Stratagene, Inc.) corresponding to base pairs 761-2961 of pBluescriptII sk(-).

It should be noted that all non-coding DNA sequences described above can be replaced with any other non-coding DNA sequence(s). Missing nucleotide sequences in the above construct represent restriction site remnants.

5

EXAMPLE 14

Transfection of Immature Leghorn Roosters using a Transposon-based Vector containing a Proinsulin Gene via Testicular Injections

Vectors containing the elements Oval promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A (SEQ ID NO:31) and CMV promoter/Oval gene/GP41
10 Enterokinase TAG/Proinsulin/Poly A (SEQ ID NO:42) were each injected into the testes of 11 week old white leghorn roosters. These birds were held under normal conditions until sexual maturity was reached.

At the time of sexual maturity, each bird was handled and manipulated to obtain sperm. Sperm samples were collected in Hank's Buffered Salt Solution
15 (HBSS) and stored at either -20° C or 4° C until needed. DNA was extracted from sperm using a MoBio Ultra Clean DNA Bloodspin Kit (MoBio laboratories, Solana Beach CA). Fifty microliters of sperm was used in the DNA extraction protocol and the purified genomic DNA eluted in 100 µl of water. In each PCR reaction, approximately 0.5 – 0.75 µg of genomic DNA was used with primers anchored in the
20 entag-1 (5') and the synthetic polyA-2 (3'), which amplify a 685 bp fragment. Five of nine birds gave positive reactions for the presence of the appropriate vector construct. These birds were then mated with normal females.

Birds that did not yield positive results with PCR on the sperm were sacrificed, their testes removed, and DNA extracted using an approximately 25 mg
25 piece of tissue in a Qiagen DNEasy Tissue Kit; purified DNA was eluted in 200 µl water and PCR conducted as described above. Two of these birds gave a very strong, positive PCR reaction.

EXAMPLE 15

30 *Transfection of Japanese Quail using a Transposon-based Vector containing a Proinsulin Gene via Oviduct Injections*

Two experiments were conducted in Japanese quail using transposon-based vectors containing either Oval promoter/Oval gene/GP41 Enterokinase

TAG/Proinsulin/Poly A (SEQ ID NO:31) or CMV promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A (SEQ ID NO:42).

In the first experiment, the Oval promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A containing construct was injected into the oviduct of sexually mature quail; three hens received 5 µg at a 1:3 Superfect ratio and three received 10 µg at a 1:3 Superfect ratio. As of the writing of the present application, at least one bird that received 10 µg of DNA was producing human proinsulin in egg white (other birds remain to be tested). This experiment indicates that 1) the DNA has been stable for at least 3 months; 2) protein levels are comparable to those observed with a constitutive promoter such as the CMV promoter; and 3) sexually mature birds can be injected and results obtained without the need for cell culture.

In the second experiment, the transposon-based vector containing CMV promoter/Oval gene/GP41 Enterokinase TAG/Proinsulin/Poly A was injected into the oviduct of sexually immature Japanese quail. A total of 9 birds were injected. Of the 8 survivors, 3 produced human proinsulin in the white of their eggs for over 6 weeks. An ELISA assay described in detail below was developed to detect GP41 in the fusion peptide (Oval gene/GP41 Enterokinase TAG/Proinsulin) since the GP41 peptide sequence is unique and not found as part of normal egg white protein. In all ELISA assays, the same birds produced positive results and all controls worked as expected.

ELISA Procedure: Individual egg white samples were diluted in sodium carbonate buffer, pH 9.6, and added to individual wells of 96 well microtiter ELISA plates at a total volume of 0.1 ml. These plates were then allowed to coat overnight at 4°C. Prior to ELISA development, the plates were allowed warm to room temperature. Upon decanting the coating solutions and blotting away any excess, non-specific binding of antibodies was blocked by adding a solution of phosphate buffered saline (PBS), 1% (w/v) BSA, and 0.05% (v/v) Tween 20 and allowing it to incubate with shaking for a minimum of 45 minutes. This blocking solution was subsequently decanted and replaced with a solution of the primary antibody (Goat Anti-GP41 TAG) diluted in fresh PBS/BSA/Tween 20. After a two hour period of incubation with the primary antibody, each plate was washed with a solution of PBS and 0.05% Tween 20 in an automated plate washer to remove unbound antibody. Next, the secondary antibody, Rabbit anti-Goat Alkaline Phosphatase-conjugated, was diluted in PBS/BSA/Tween 20 and allowed to incubate 1 hour. The plates were then

subjected to a second wash with PBS/Tween 20. Antigen was detected using a solution of *p*-Nitrophenyl Phosphate in Diethanolamine Substrate Buffer for Alkaline Phosphatase and measuring the absorbance at 30 minutes and 1 hour.

5

EXAMPLE 16

Optimization of Intra-oviduct and Intra-ovarian Arterial Injections

Overall transfection rates of oviduct cells in a flock of chicken or quail hens are enhanced by synchronizing the development of the oviduct and ovary within the flock. When the development of the oviducts and ovaries are uniform across a group
10 of hens and when the stage of oviduct and ovarian development can be determined or predicted, timing of injections is optimized to transfect the greatest number of cells. Accordingly, oviduct development is synchronized as described below to ensure that a large and uniform proportion of oviduct secretory cells are transfected with the gene of interest.

15 Hens are treated with estradiol to stimulate oviduct maturation as described in Oka and Schimke (T. Oka and RT Schimke, J. Cell Biol., 41, 816 (1969)), Palmiter, Christensen and Schimke (J Biol. Chem. 245(4):833-845, 1970). Specifically, repeated daily injections of 1 mg estradiol benzoate are performed sometime before the onset of sexual maturation, a period ranging from 1 – 14 weeks of age. After a
20 stimulation period sufficient to maximize development of the oviduct, hormone treatment is withdrawn thereby causing regression in oviduct secretory cell size but not cell number. At an optimum time after hormone withdrawal, the oviducts of treated hens are injected with the transposon-based vector. Hens are subjected to additional estrogen stimulation after an optimized time during which the transposon-
25 based vector is taken up into oviduct secretory cells. Re-stimulation by estrogen activates the transposon mechanism of the transposon-based vector, causing the integration of the gene of interest into the host genome. Estrogen stimulation is then withdrawn and hens continue normal sexual development. If a developmentally regulated promoter such as the ovalbumin promoter is used, expression of the
30 transposon-based vector initiates in the oviduct at the time of sexual maturation. Intra-ovarian artery injection during this window allows for high and uniform transfection efficiencies of ovarian follicles to produce germ-line transfections and possibly oviduct expression.

Other means are also used to synchronize the development, or regression, of the oviduct and ovary to allow high and uniform transfection efficiencies. Alterations of lighting and/or feed regimens, for example, cause hens to 'molt' during which time the oviduct and ovary regress. Molting is used to synchronize hens for transfection, and may be used in conjunction with other hormonal methods to control regression and/or development of the oviduct and ovary.

EXAMPLE 17

Isolation of Human Proinsulin Using Anti-TAG Column Chromatography

10 A HiTrap NHS-activated 1 mL column (Amersham) was charged with a 30 amino acid peptide that contained the gp-41 epitope containing gp-41's native disulfide bond that stabilizes the formation of the gp-41 hairpin loop. The 30 amino acid gp41 peptide is provided as SEQ ID NO:23. Approximately 10 mg of the peptide was dissolved in coupling buffer (0.2 M NaHCO₃, 0.5 M NaCl, pH 8.3 and
15 the ligand was circulated on the column for 2 hours at room temperature at 0.5 mL/minute. Excess active groups were then deactivated using 6 column volumes of 0.5 M ethanolamine, 0.5 M NaCl, pH 8.3 and the column was washed alternately with 6 column volumes of acetate buffer (0.1 M acetate, 0.5 M NaCl, pH 4.0) and ethanolamine (above). The column was neutralized using 1 X PBS. The column was
20 then washed with buffers to be used in affinity purification: 75 mM Tris, pH 8.0 and elution buffer, 100 mM glycine-HCl, 0.5 M NaCl, pH 2.7. Finally, the column was equilibrated in 75 mM Tris buffer, pH 8.0.

Antibodies to gp-41 were raised in goats by inoculation with the gp-41 peptide described above. More specifically, goats were inoculated, given a booster injection
25 of the gp-41 peptide and then bled. Serum was harvested by centrifugation. Approximately 30 mL of goat serum was filtered to 0.45 μ M and passed over a TAG column at a rate of 0.5 mL/min. The column was washed with 75 mM Tris, pH 8.0 until absorbance at 280 nm reached a baseline. Three column volumes (3 mL) of elution buffer (100 mM glycine, 0.5 M NaCl, pH 2.7) was applied, followed by 75
30 mM Tris buffer, pH 8.0, all at a rate of 0.5 mL/min. One milliliter fractions were collected. Fractions were collected into 200 μ L 1 M Tris, pH 9.0 to neutralize acidic fractions as rapidly as possible. A large peak eluted from the column, coincident with the application the elution buffer. Fractions were pooled. Analysis by SDS-PAGE

showed a high molecular weight species that separated into two fragments under reducing condition, in keeping with the heavy and light chain structure of IgG.

Pooled antibody fractions were used to charge two 1 mL HiTrap NHS-activated columns, attached in series. Coupling was carried out in the same manner as
5 that used for charging the TAG column.

Isolation of Ovalbumin-TAG-Proinsulin from Egg White

Egg white from quail and chickens treated by intra-oviduct injection of the CMV-ovalbumin-TAG-proinsulin construct were pooled. Viscosity was lowered by subjecting the allantoic fluid to successively finer pore sizes using negative pressure
10 filtration, finishing with a 0.22 μ M pore size. Through the process, egg white was diluted approximately 1:16. The clarified sample was loaded on the Anti-TAG column and eluted in the same manner as described for the purification of the anti-TAG antibodies. A peak of absorbance at 280 nm, coincident with the application of the elution buffer, indicated that protein had been specifically eluted from the Anti-
15 TAG column. Fractions containing the eluted peak were pooled for analysis.

The pooled fractions from the Anti-TAG affinity column were characterized by SDS-PAGE and western blot analysis. SDS-PAGE of the pooled fractions revealed a 60 kDal molecular weight band not present in control egg white fluid, consistent with the predicted molecular weight of the transgenic protein. Although some
20 contaminating bands were observed, the 60 kDal species was greatly enriched compared to the other proteins. An aliquot of the pooled fractions was cleaved overnight at room temperature with the protease, enterokinase. SDS-PAGE analysis of the cleavage product, revealed a band not present in the uncut material that co-migrated with a commercial human proinsulin positive control. Western blot analysis
25 showed specific binding to the 60 kDal species under non-reducing condition (which preserve the hairpin epitope of gp-41 by retaining the disulfide bond). Western analysis of the low molecular weight species that appeared upon cleavage with an anti-human proinsulin antibody, conclusively identified the cleaved fragment as human proinsulin.

30

EXAMPLE 18

Construction of a Transposon-based Transgene for the Expression of a Monoclonal Antibody

Production of a monoclonal antibody using transposon-based transgenic
5 methodology is accomplished in a variety of ways.

1) two vectors are constructed: one that encodes the light chain and a second vector that encodes the heavy chain of the monoclonal antibody. These vectors are then incorporated into the genome of the target animal by at least one of two methods: a) direct transfection of a single animal with both vectors (simultaneously or as separate
10 events); or, b) a male and a female of the species carry in their germline one of the vectors and then they are mated to produce progeny that inherit a copy of each.

2) the light and heavy chains are included on a single DNA construct, either separated by insulators and expression is governed by the same (or different) promoters, or by using a single promoter governing expression of both transgenes with the inclusion of
15 elements that permit separate transcription of both transgenes, such as an internal ribosome entry site.

The following example describes the production of a transposon-based DNA construct that contains both the coding region for a monoclonal light chain and a heavy chain on a single construct. Beginning with the vector pTnMod, the coding
20 sequences for the heavy and light chains are added, each preceded by an appropriate promoter and signal sequence. Using methods known to one skilled in the art, approximately 1 Kb of the proximal elements of the ovalbumin promoter are linked to the signal sequence of ovalbumin or some other protein secreted from the target tissue. Two copies of the promoter and signal sequence are added to the multiple
25 cloning site of pTnMod, leaving space and key restriction sites between them to allow the subsequent addition of the coding sequences of the light and heavy chains of the monoclonal antibody. Methods known to one skilled in the art allow the coding sequences of the light and heavy chains to be inserted in-frame for appropriate expression. For example, the coding sequence of light and heavy chains of a murine
30 monoclonal antibody that show specificity for human seminoprotein have recently been disclosed (GenBank Accession numbers AY129006 and AY129304 for the light and heavy chains, respectively). The light chain cDNA sequence is provided in SEQ

ID NO:34, whereas the cDNA of the heavy chain is reported as provided in SEQ ID NO:35.

Thus one skilled in the art can produce both the heavy and light chains of a monoclonal antibody in a single cell within a target tissue and species. If the modified cell contained normal posttranslational modification capabilities, the two chains would form their native configuration and disulfide attachments and be substrates for glycosylation. Upon secretion, then, the monoclonal antibody is accumulated, for example, in the egg white of a chicken egg, if the transgenes are expressed in the magnum of the oviduct.

It should also be noted that, although this example details production of a full-length murine monoclonal antibody, the method is quite capable of producing hybrid antibodies (e.g. a combination of human and murine sequences; 'humanized' monoclonal antibodies), as well as useful antibody fragments, known to one skilled in the art, such as Fab, Fc, F(ab) and Fv fragments. This method can be used to produce molecules containing the specific areas thought to be the antigen recognition sequences of antibodies (complementarity determining regions), linked, modified or incorporated into other proteins as desired.

EXAMPLE 19

Treatment of rats with a transposon-based vector for tissue-specific insulin gene incorporation

Rats are made diabetic by administering the drug streptozotocin (Zanosar, Upjohn, Kalamazoo, MI) at approximately 200 mg/kg. The rats are bred and maintained according to standard procedures. A transposon-based vector containing a proinsulin gene, an appropriate carrier, and, optionally, a transfection agent, are injected into rats' singhepatic (if using G6P) artery with the purpose of stable transformation. Incorporation of the insulin gene into the rat genome and levels of insulin expression are ascertained by a variety of methods known in the art. Blood and tissue samples from live or sacrificed animals are tested. A combination of PCR, Southern and Northern blots, *in-situ* hybridization and related nucleic acid analysis methods are used to determine incorporation of the vector-derived proinsulin DNA and levels of transcription of the corresponding mRNA in various organs and tissues of the rats. A combination of SDS-PAGE gels, Western Blot analysis, radioimmunoassay, and ELISA and other methods known to one of ordinary skill in

the art are used to determine the presence of insulin and the amount produced. Additional transfections of the vector are used to increase protein expression if the initial amounts of the expressed insulin are not satisfactory, or if the level of expression tapers off. The physiological condition of the rats is closely examined post-transfection to register positive or any negative effects of the gene therapy. Animals are examined over extended periods of time post-transfection in order to monitor the stability of gene incorporation and protein expression.

EXAMPLE 20

Exemplary Transposon-Based Vectors

The following example provides a description of various transposon-based vectors of the present invention and several constructs for insertion into the transposon-based vectors of the present invention. These examples are not meant to be limiting in any way. The constructs for insertion into a transposon-based vector are provided in a cloning vector labeled pTnMCS.

pTnMCS (base vector)

Bp 1 – 130 Remainder of F1 (-) ori of pBluescriptII sk(-) (Stratagene) bp1-130

Bp 133 – 1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp2 29-1873

Bp 1783 – 2991 Transposase, from Tn10 (GenBank accession #J01829) bp 108-1316

Bp 2992 – 3344 Non coding DNA from vector pNK2859

Bp 3345 – 3387 Lambda DNA from pNK2859

Bp 3388 – 3457 70 bp of IS10 left from Tn10

Bp 3464 – 3670 Multiple cloning site from pBluescriptII sk(-), thru the XmaI site bp924-718

Bp 3671 - 3715 Multiple cloning site from pBluescriptII sk(-), from the XmaI site thru the XhoI site. These base pairs are usually lost when cloning into pTnMCS.

Bp 717-673

Bp 3716 – 4153 Multiple cloning site from pBluescriptII sk(-), from the XhoI site bp672-235

Bp 4159 - 4228 70 bp of IS10 left from Tn10

Bp 4229 - 4270 Lambda DNA from pNK2859

Bp 4271 – 5114 Non-coding DNA from pNK2859

Bp 5115 - 7315 pBluescript sk (-) base vector (Stratagene, Inc.) bp 761-2961

pTnMCS (CMV-prepro-ent-hGH-CPA)

5 Bp 1 – 3670 from vector PTnMCS, bp 1 - 3670

Bp 3676 – 5320 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems), bp 230-1864

Bp 5326 - 5496 Capsite/Prepro taken from GenBank accession # X07404, bp 563 – 733

10 Bp 5504 - 5652 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 5653 – 6306 Human growth hormone taken from GenBank accession # V00519, bp 1-654

Bp 6313 – 6720 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058

15 Bp 6722 –10321 from cloning vector pTnMCS, bp 3716-7315

pTnMCS (CMV-CHOVg-ent-ProInsulin-synPA) (SEQ ID NO:41)

Bp 1 – 3670 from vector PTnMCS, bp 1 - 3670

20 Bp 3676 – 5320 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems), bp 230-1864

Bp 5327 –6480 Chicken ovalbumin gene taken from GenBank accession # V00383, bp 66-1219

25 Bp 6487 - 6636 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6637 – 6897 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377

Bp 6898 – 6942 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)

30 Bp 6943 - 7295 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271

Bp 7296 – 10895 from cloning vector pTnMCS, bp 3716-7315

pTnMCS (CMV-prepro-ent-ProInsulin-synPA)

- Bp 1 – 3670 from vector pTnMCS, bp 1 - 3670
- Bp 3676 – 5320 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems), bp 230-1864
- 5 Bp 5326 - 5496 Capsite/Prepro taken from GenBank accession # X07404, bp 563 – 733
- Bp 5504 - 5652 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 5653 – 5913 Human Proinsulin taken from GenBank accession # NM000207, bp
- 10 117-377
- Bp 5914 – 5958 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)
- Bp 5959 - 6310 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271
- 15 Bp 6313 – 9912 from cloning vector pTnMCS, bp 3716-7315

pTnMCS(Chicken OVep+OVg'+ENT+proins+syn polyA)

- Bp 1 – 3670 from vector pTnMCS, bp 1 - 3670
- Bp 3676 – 4350 Chicken Ovalbumin enhancer taken from GenBank accession
- 20 #S82527.1 bp 1-675
- Bp 4357 – 5692 Chicken Ovalbumin promoter taken from GenBank accession # J00895M24999 bp 1-1336
- Bp 5699 – 6917 Chicken Ovalbumin gene from GenBank Accession # V00383.1 bp 2-1220. (This sequence includes the 5'UTR, containing putative cap site, bp 5699-
- 25 5762.)
- Bp 6924 - 7073 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 7074 - 7334 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 7335 - 7379 Spacer DNA, derived as an artifact from the cloning vectors pTOPO
- 30 Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 7380 - 7731 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 7733 – 11332 from vector pTnMCS, bp 3716 - 7315

pTnMCS(Chicken OVep+prepro+ENT+proins+syn polyA)

- Bp 1 – 3670 from cloning vector pTnMCS, bp 1 - 3670
- Bp 3676 – 4350 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1 bp 1-675
- Bp 4357 – 5692 Chicken Ovalbumin promoter taken from GenBank accession # J00895-M24999 bp 1-1336
- Bp 5699 – 5869 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733
- 10 Bp 5876 - 6025 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6026 - 6286 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6287 - 6331 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- 15 Bp 6332 - 6683 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 6685 – 10284 from cloning vector pTnMCS, bp 3716 - 7315

pTnMCS(Quail OVep+OVg'+ENT+proins+syn polyA)

- 20 Bp 1 – 3670 from cloning vector pTnMCS, bp 1 - 3670
- Bp 3676 – 4333 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession # S82527.1, bp 1-675. (There are multiple base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of
- 25 bases does not correspond exactly.)
- Bp 4340 – 5705 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter, GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of
- 30 bases does not correspond exactly.)
- Bp 5712 – 6910 Quail Ovalbumin gene, EMBL accession # X53964, bp 1-1199. (This sequence includes the 5'UTR, containing putative cap site bp 5712-5764.)

- Bp 6917 - 7066 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 7067 - 7327 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 7328 - 7372 Spacer DNA, derived as an artifact from the cloning vectors pTOPO
- 5 Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- Bp 7373 - 7724 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 7726 - 11325 from cloning vector pTnMCS, bp 3716 - 7315
- 10 pTnMCS (CHOVep-prepro-ent-hGH-CPA)
- Bp 1 - 3670 from vector PTnMCS, bp 1-3670
- Bp 3676 - 4350 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1-675
- Bp 4357 - 5692 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336
- 15 Bp 5699 - 5869 Capsite/Prepro taken from GenBank accession # X07404, bp 563-733
- Bp 5877 - 6025 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6026 - 6679 Human growth hormone taken from GenBank accession # V00519, bp 1-654
- 20 Bp 6686 - 7093 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058
- Bp 7095 - 10694 from cloning vector pTnMCS, bp 3716-7315
- 25 pTnMCS(Quail OVep+prepro+ENT+proins+syn polyA)
- Bp 1 - 3670 from cloning vector pTnMCS, bp 1 - 3670
- Bp 3676 - 4333 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far- upstream chicken ovalbumin enhancer, GenBank accession #S82527.1, bp 1-675. (There are multiple base pair
- 30 substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)
- Bp 4340 - 5705 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter,

GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)

5 Bp 5712 – 5882 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733

Bp 5889 - 6038 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6039 - 6299 Human proinsulin GenBank Accession # NM000207 bp 117-377

10 Bp 6300 - 6344 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)

Bp 6345 - 6696 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271

Bp 6698 – 10297 from cloning vector pTnMCS, bp 3716 - 7315

15 PTnMOD

Bp 1 - 130 remainder of F1 (-) ori of pBluescriptII sk(-) (Stratagene) bp1-130

Bp 133 - 1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp229-1873

20 Bp 1783 - 2991 Transposase, modified from Tn10 (GenBank accession #J01829) bp 108-1316

Bp 2992 - 2994 Engineered stop codon

Bp 2996 - 3411 Synthetic polyA from gWIZ (Gene Therapy Systems) bp 1922 - 2337

Bp 3412 - 3719 Non-coding DNA from vector pNK2859

Bp 3720 - 3762 Lambda DNA from pNK2859

25 Bp 3763 - 3832 70 bp of IS10 left from Tn10

Bp 3839 – 4045 Multiple cloning site from pBluescriptII sk(-), thru the XmaI site bp 924-718

30 Bp 4046 - 4090 Multiple cloning site from pBluescriptII sk(-), from the XmaI site thru the XhoI site. These base pairs are usually lost when cloning into pTnMCS. bp 717-673

Bp 4091 – 4528 Multiple cloning site from pBluescriptII sk(-), from the XhoI site bp 672-235

Bp 4534 - 4603 70 bp of IS10 left from Tn10

Bp 4604 - 4645 Lambda DNA from pNK2859

Bp 4646 - 5489 Non-coding DNA from pNK2859

Bp 5490 - 7690 pBluescript sk (-) base vector (Stratagene, INC) bp 761-2961

5

pTnMOD (CHOVep-prepro-ent-hGH-CPA)

Bp 1 - 4045 from vector PTnMCS, bp 1 - 4045

Bp 4051 - 4725 Chicken Ovalbumin enhancer taken from GenBank accession # S82527.1, bp 1 - 675

10 Bp 4732 - 6067 Chicken Ovalbumin promoter taken from GenBank accession # J00899-M24999, bp 1-1336

Bp 6074 - 6245 Capsite/Prepro taken from GenBank accession # X07404, bp 563 - 733

15 Bp 6252 - 6400 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6401 - 7054 Human growth hormone taken from GenBank accession # V00519, bp 1-654

Bp 7061 - 7468 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058

20 Bp 7470 - 11069 from cloning vector pTnMCS, bp 3716-7315

pTnMOD (CMV-CHOVg-ent-ProInsulin-synPA) (SEQ ID NO:42)

Bp 1 - 4045 from vector PTnMCS, bp 1 - 4045

25 Bp 4051 - 5695 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864

Bp 5702 - 6855 Chicken ovalbumin gene taken from GenBank accession # V00383, bp 66-1219

Bp 6862 - 7011 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

30 Bp 7012 - 7272 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377

Bp 7273 - 7317 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)

Bp 7318 - 7670 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271

Bp 7672 - 11271 from cloning vector pTnMCS, bp 3716-7315

5 pTnMOD (CMV-prepro-ent-hGH-CPA)

Bp 1 - 4045 from vector PTnMCS, bp 1 - 4045

Bp 4051 - 5695 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864

10 Bp 5701 - 5871 Capsite/Prepro taken from GenBank accession # X07404, bp 563 - 733

Bp 5879 - 6027 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6028 - 6681 Human growth hormone taken from GenBank accession # V00519, bp 1-654

15 Bp 6688 - 7095 Conalbumin polyA taken from GenBank accession # Y00407, bp 10651-11058

Bp 7097 - 10696 from cloning vector pTnMCS, bp 3716-7315

pTnMOD (CMV-prepro-ent-ProInsulin-synPA)

20 Bp 1 - 4045 from vector PTnMCS, bp 1 - 4045

Bp 4051 - 5695 CMV promoter/enhancer taken from vector pGWIZ (Gene therapy systems), bp 230-1864

Bp 5701 - 5871 Capsite/Prepro taken from GenBank accession # X07404, bp 563 - 733

25 Bp 5879 - 6027 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 6028 - 6288 Human Proinsulin taken from GenBank accession # NM000207, bp 117-377

Bp 6289 - 6333 Spacer DNA, derived as an artifact from the cloning vectors pTOPO

30 Blunt II (Invitrogen) and pGWIZ (Gene Therapy Systems)

Bp 6334 - 6685 Synthetic polyA from the cloning vector pGWIZ (Gene Therapy Systems), bp 1920-2271

Bp 6687 - 10286 from cloning vector pTnMCS, bp 3716-7315

pTnMOD(Chicken OVep+OVg'+ENT+proins+syn polyA) (SEQ ID NO:43)

Bp 1 – 4045 from cloning vector pTnMOD, bp 1 - 4045

Bp 4051 – 4725 Chicken Ovalbumin enhancer taken from GenBank accession #

5 S82527.1 bp 1-675

Bp 4732 – 6067 Chicken Ovalbumin promoter taken from GenBank accession #

J00895-M24999 bp 1-1336

Bp 6074 – 7292 Chicken Ovalbumin gene from GenBank Accession # V00383.1 bp

2-1220. (This sequence includes the 5'UTR, containing putative cap site bp 6074-

10 6137.)

Bp 7299 - 7448 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 7449 - 7709 Human proinsulin GenBank Accession # NM000207 bp 117-377

Bp 7710 - 7754 Spacer DNA, derived as an artifact from the cloning vectors pTOPO

15 Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)

Bp 7755 - 8106 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271

Bp 8108 – 11707 from cloning vector pTnMCS, bp 3716 - 7315

20 pTnMOD(Chicken OVep+prepro+ENT+proins+syn polyA)

Bp 1 – 4045 from cloning vector pTnMCS, bp 1 - 4045

Bp 4051 – 4725 Chicken Ovalbumin enhancer taken from GenBank accession #

S82527.1 bp 1-675

Bp 4732 – 6067 Chicken Ovalbumin promoter taken from GenBank accession #

25 J00895-M24999 bp 1-1336

Bp 6074 – 6244 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733

Bp 6251 - 6400 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

30 Bp 6401 - 6661 Human proinsulin GenBank Accession # NM000207 bp 117-377

Bp 6662 - 6706 Spacer DNA, derived as an artifact from the cloning vectors pTOPO

Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)

Bp 6707 - 7058 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271

Bp 7060 - 10659 from cloning vector pTnMCS, bp 3716 - 7315

5 pTnMOD(Quail OVep+OVg'+ENT+proins+syn polyA)

Bp 1 - 4045 from cloning vector pTnMCS, bp 1 - 4045

10 Bp 4051 - 4708 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession # S82527.1, bp 1-675. (There are multiple base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)

15 Bp 4715 - 6080 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter, GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)

Bp 6087 - 7285 Quail Ovalbumin gene, EMBL accession # X53964, bp 1-1199. (This sequence includes the 5'UTR, containing putative cap site bp 6087-6139.)

20 Bp 7292 - 7441 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site

Bp 7442 - 7702 Human proinsulin GenBank Accession # NM000207 bp 117-377

Bp 7703 - 7747 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)

25 Bp 7748 - 8099 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271

Bp 8101 - 11700 from cloning vector pTnMCS, bp 3716 - 7315

pTnMOD(Quail OVep+prepro+ENT+proins+syn polyA)

Bp 1 - 4045 from cloning vector pTnMCS, bp 1 - 4045

30 Bp 4051 - 4708 Quail Ovalbumin enhancer: 658 bp sequence, amplified in-house from quail genomic DNA, roughly equivalent to the far-upstream chicken ovalbumin enhancer, GenBank accession #S82527.1, bp 1-675. (There are multiple

- base pair substitutions and deletions in the quail sequence, relative to chicken, so the number of bases does not correspond exactly.)
- Bp 4715 – 6080 Quail Ovalbumin promoter: 1366 bp sequence, amplified in-house from quail genomic DNA, roughly corresponding to chicken ovalbumin promoter,
- 5 GenBank accession # J00895-M24999 bp 1-1336. (There are multiple base pair substitutions and deletions between the quail and chicken sequences, so the number of bases does not correspond exactly.)
- Bp 6087 – 6257 Cecropin cap site and Prepro, Genbank accession # X07404 bp 563-733
- 10 Bp 6264 - 6413 Synthetic spacer sequence and hairpin loop of HIV gp41 with an added enterokinase cleavage site
- Bp 6414 - 6674 Human proinsulin GenBank Accession # NM000207 bp 117-377
- Bp 6675 - 6719 Spacer DNA, derived as an artifact from the cloning vectors pTOPO Blunt II (Invitrogen) and gWIZ (Gene Therapy Systems)
- 15 Bp 6720 - 7071 Synthetic polyA from the cloning vector gWIZ (Gene Therapy Systems) bp 1920 - 2271
- Bp 7073 – 10672 from cloning vector pTnMCS, bp 3716 - 7315
- PTnMod(CMV/Transposase/ChickOvep/prepro/ProteinA/ConpolyA)
- 20 BP 1-130 remainder of F1 (-) ori of pBluescriptII sk(-) (Stragagene) bp 1-130.
- BP 133-1777 CMV promoter/enhancer taken from vector pGWIZ (Gene Therapy Systems) bp 229-1873.
- BP 1780-2987 Transposase, modified from Tn10 (GenBank #J01829).
- BP 2988-2990 Engineered stop codon.
- 25 BP 2991-3343 non coding DNA from vector pNK2859.
- BP 3344-3386 Lambda DNA from pNK2859.
- BP 3387-3456 70bp of IS10 left from Tn10.
- BP 3457-3674 multiple cloning site from pBluescriptII sk(-) bp 924-707.
- BP 3675-5691 Chicken Ovalbumin enhancer plus promoter from a Topo Clone 10
- 30 maxi 040303 (5' XmaI, 3' BamHI)
- BP 5698-5865 prepro with Cap site amplified from cecropin of pMON200 GenBank # X07404 (5'BamHI, 3'KpnI)

BP 5872-7338 Protein A gene from GenBank# J01786, mature peptide bp 292-1755
(5'KpnI, 3'SacII)

BP 7345-7752 ConPolyA from Chicken conalbumin polyA from GenBank # Y00407
bp 10651-11058. (5'SacII, 3'XhoI)

5 BP 7753-8195 multiple cloning site from pBluescriptII sk(-) bp 677-235.

BP 8196-8265 70 bp of IS10 left from Tn10.

BP 8266-8307 Lamda DNA from pNK2859

BP 8308-9151 noncoding DNA from pNK2859

BP 9152-11352 pBluescriptII sk(-) base vector (Stratagene, INC.) bp 761-2961

10

All patents, publications and abstracts cited above are incorporated herein by
reference in their entirety. It should be understood that the foregoing relates only to
preferred embodiments of the present invention and that numerous modifications or
alterations may be made therein without departing from the spirit and the scope of the

15 present invention as defined in the following claims.

CLAIMS

We Claim:

1. A vector comprising:
 - a) a transposase gene operably linked to a first promoter; and
 - b) one or more genes of interest operably-linked to one or more additional promoters;
 - c) wherein the one or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by the transposase; and
 - d) wherein the first promoter comprises a modified Kozak sequence comprising ACCATG.
2. The vector of claim 1, wherein one to twenty codons at a beginning of the transposase gene are modified by changing a nucleotide at a third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon.
3. The vector of claim 2, wherein the transposase gene is modified in its first ten codons.
4. The vector of claim 1, wherein the transposase is a Tn10 transposase.
5. The vector of claim 1, wherein the first promoter is a constitutive promoter.
6. The vector of claim 1, wherein the first promoter is an inducible promoter.
7. The vector of claim 6, wherein the inducible promoter is an ovalbumin promoter or a vitellogenin promoter.
8. The vector of claim 1, wherein one gene of interest is operably-linked to a second promoter.
9. The vector of claim 8, wherein the second promoter is a constitutive promoter.

10. The vector of claim 8, wherein the second promoter is an inducible promoter.
- 5 11. The vector of claim 10, wherein the inducible promoter is an ovalbumin promoter or a vitellogenin promoter.
12. The vector of claim 1, further comprising a polyA sequence operably-linked to the transposase gene.
- 10 13. The vector of claim 12, wherein the polyA sequence is a conalbumin polyA sequence.
14. The vector of claim 1 or claim 12, further comprising two stop codons operably-linked to the transposase gene.
- 15 15. The vector of claim 1, wherein a first gene of interest is operably-linked to a second promoter and a second gene of interest is operably-linked to a third promoter.
- 20 16. The vector of claim 1, wherein a first and a second gene of interest are operably-linked to a second promoter.
17. The vector of claim 1, further comprising an enhancer operably-linked to the one or more genes of interest.
- 25 18. The vector of claim 17, wherein the enhancer comprises at least a portion of an ovalbumin enhancer.
19. The vector of claim 1, further comprising an egg directing sequence operably-linked to the one or more genes of interest.
- 30 20. The vector of claim 19, wherein the egg directing sequence is an ovalbumin signal sequence or an ovomucoid signal sequence.
- 35 21. The vector of claim 19, wherein the egg directing sequence is a vitellogenin targeting sequence.

22. A method for producing a transgenic animal comprising administering to the animal a vector comprising:
- a) a modified transposase gene operably linked to a first promoter; and
 - b) one or more genes of interest operably-linked to one or more additional promoters;
 - c) wherein the one or more genes of interest and their operably-linked promoters are flanked by transposase insertion sequences recognized by the transposase; and
 - d) wherein the first promoter comprises a modified Kozak sequence comprising ACCATG.
23. The method of claim 22, wherein one to twenty codons at a beginning of the transposase gene are modified by changing a nucleotide at a third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon.
24. The method of claim 23, wherein the transposase gene is modified in its first ten codons.
25. The method of claim 22, wherein the vector is administered via an intratesticular, intraarterial, intraoviductal or intraembryonic route.
26. The method of claim 22, wherein the transposase is a Tn10 transposase.
27. The method of claim 22, wherein the first promoter is a constitutive promoter.
28. The method of claim 22, wherein the first promoter is an inducible promoter.
29. The method of claim 28, wherein the inducible promoter is selected from the group consisting of an ovalbumin promoter, an ovomucoid promoter and a vitellogenin promoter.
30. The method of claim 22, wherein one gene of interest is operably linked to a second promoter.

31. The method of claim 30, wherein the second promoter is an inducible promoter.
- 5 32. The method of claim 31, wherein the inducible promoter is an ovalbumin promoter or a vitellogenin promoter.
33. The method of claim 22, wherein the vector further comprises a polyA sequence operably-linked to the transposase gene.
- 10 34. The method of claim 33, wherein the polyA sequence is a conalbumin polyA sequence.
35. The method of claim 22 or claim 33, wherein the vector further comprises two stop codons operably-linked to the transposase gene.
- 15 36. The method of claim 22, wherein a first gene of interest is operably-linked to a second promoter and a second gene of interest is operably-linked to a third promoter.
- 20 37. The method of claim 22, wherein a first and second gene of interest are operably linked to a second promoter.
38. The method of claim 22, further comprising an enhancer operably-linked to the one or more genes of interest.
- 25 39. The method of claim 38, wherein the enhancer comprises at least a portion of an ovalbumin enhancer.
- 30 40. The method of claim 22, wherein the animal is an avian animal.
41. The method of claim 40, wherein the avian animal is a chicken or a quail.
- 35 42. An egg produced by the avian animal of claim 40, wherein the egg contains one or more desired proteins encoded by the one or more genes of interest.

43. A transgenic sperm produced by the animal of claim 22.
44. A method of producing a desired protein comprising:
- a) administering to an animal a vector comprising a modified transposase gene operably linked to a first promoter, and a gene of interest encoding the desired protein operably-linked to a second promoter; and
 - b) isolating the desired protein produced in the animal; wherein
 - c) the gene of interest and its operably-linked promoter are flanked by transposase insertion sequences recognized by the transposase; and
 - d) the first promoter comprises a modified Kozak sequence comprising ACCATG.
45. The method of claim 44, wherein one to twenty codons at a beginning of the transposase gene are modified by changing a nucleotide at a third base position of the codon to an adenine or thymine without modifying the amino acid encoded by the codon.
46. The method of claim 44, wherein the animal is an egg-laying animal and the desired protein is isolated from an egg white.
47. The method of claim 44, wherein the vector further comprises a TAG sequence and wherein the desired protein is purified using the TAG sequence.
48. The method of claim 47, wherein the TAG sequence comprises a polynucleotide sequence encoding an antigenic portion of a gp41 protein, an enterokinase cleavage site and a spacer polynucleotide sequence.
49. The method of claim 47, wherein the TAG sequence comprises a polynucleotide sequence shown in SEQ ID NO:22.
50. The method of claim 44, wherein the desired protein is a lytic protein.
51. The method of claim 44, wherein the vector further comprises a second gene of interest operably-linked to a third promoter and wherein the genes of interest encode antibody polypeptides.

FIGURE 1



2/7

FIGURE 2



FIGURE 3



FIGURE 4




FIGURE 5

IS	Oval Pro	prepro	Heavy chain	pro	Light chain	polyA	IS
----	----------	--------	-------------	-----	-------------	-------	----

FIGURE 6

IS	Oval Pro	prepro	Light chain	ent	Heavy chain	polyA	IS
----	----------	--------	-------------	-----	-------------	-------	----

FIGURE 7

A.

Tail-to-Tail

IS	Oval Pro	Oval SS	Light chain	Poly A	Spacer DNA	Poly A	Heavy chain	Oval SS	Oval Pro	IS
----	----------	---------	-------------	--------	------------	--------	-------------	---------	----------	----

B.

Tail-to-Head

IS	Oval Pro	Oval SS	Light chain	Poly A	Spacer DNA	Oval Pro	Oval SS	Heavy chain	Poly A	IS
----	----------	---------	-------------	--------	------------	----------	---------	-------------	--------	----

Appendix A

SEQ ID NO:1 (pTnMod)

5	CTGACGCGCC	CTGTAGCGGC	GCATTAAGCG	CGGCGGGTGT	GGTGGTTACG	50
	CGCAGCGTGA	CCGCTACACT	TGCCAGCGCC	CTAGCGCCCG	CTCCTTTCGC	100
	TTTCTTCCCT	TCCTTTCTCG	CCACGTTTCG	CGGCATCAGA	TTGGCTATTG	150
	GCCATTGCAT	ACGTTGTATC	CATATCATAA	TATGTACATT	TATATTGGCT	200
	CATGTCCAAC	ATTACCGCCA	TGTTGACATT	GATTATTGAC	TAGTTATTAA	250
10	TAGTAATCAA	TTACGGGGTC	ATTAGTTCAT	AGCCCATATA	TGGAGTTCCG	300
	CGTTACATAA	CTTACGGTAA	ATGGCCCGCC	TGGCTGACCG	CCCAACGACC	350
	CCCGCCCAT	GACGTCAATA	ATGACGTATG	TTCCCATAGT	AACGCCAATA	400
	GGGACTTTCC	ATTGACGTCA	ATGGGTGGAG	TATTTACGGT	AAACTGCCCCA	450
	CTTGGCAGTA	CATCAAGTGT	ATCATATGCC	AAGTACGCCC	CCTATTGACG	500
15	TCAATGACGG	TAAATGGCCC	GCCTGGCATT	ATGCCCAGTA	CATGACCTTA	550
	TGGGACTTTC	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGCTATTAC	600
	CATGGTGATG	CGGTTTTGGC	AGTACATCAA	TGGGCGTGGA	TAGCGGTTTG	650
	ACTCACGGGG	ATTTCCAAGT	CTCCACCCCA	TTGACGTCAA	TGGGAGTTTG	700
	TTTTGGCACC	AAAATCAACG	GGACTTTCCA	AAATGTCGTA	ACAACCTCCGC	750
20	CCCATTGACG	CAAATGGGCG	GTAGGCGTGT	ACGGTGGGAG	GTCTATATAA	800
	GCAGAGCTCG	TTTAGTGAAC	CGTCAGATCG	CCTGGAGACG	CCATCCACGC	850
	TGTTTTGACC	TCCATAGAAG	ACACCGGGAC	CGATCCAGCC	TCCGCGGCCG	900
	GGAACGGTGC	ATTGGAACGC	GGATTCCCCG	TGCCAAGAGT	GACGTAAGTA	950
	CCGCCTATAG	ACTCTATAGG	CACACCCCTT	TGGCTCTTAT	GCATGCTATA	1000
25	CTGTTTTTGG	CTTGGGGCCT	ATACACCCCC	GCTTCCTTAT	GCTATAGGTG	1050
	ATGGTATAGC	TTAGCCTATA	GGTGTGGGTT	ATTGACCATT	ATTGACCACT	1100
	CCCCTATTGG	TGACGATACT	TTCCATTACT	AATCCATAAC	ATGGCTCTTT	1150
	GCCACAATA	TCTCTATTGG	CTATATGCCA	ATACTCTGTC	CTTCAGAGAC	1200
	TGACACGGAC	TCTGTATTTT	TACAGGATGG	GGTCCCATT	ATTATTTACA	1250
30	AATTCACATA	TACAACAACG	CCGTCCCCCG	TGCCCGCAGT	TTTTATTAAA	1300
	CATAGCGTGG	GATCTCCACG	CGAATCTCGG	GTACGTGTTC	CGGACATGGG	1350
	CTCTTCTCCG	GTAGCGGCGG	AGCTTCCACA	TCCGAGCCCT	GGTCCCATGC	1400
	CTCCAGCGGC	TCATGGTTCG	TCGGCAGCTC	CTTGCTCCTA	ACAGTGGAGG	1450
	CCAGACTTAG	GCACAGCACA	ATGCCCACCA	CCACCAGTGT	GCCGCACAAG	1500
35	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATT	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
	GTGCTGTTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCCCTT	1750
40	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTCA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
45	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCAT	GTACTTGTTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTGCACTAC	ACGGTCGTT	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTGAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
50	TCATTGTCAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
55	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTGCGA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
60	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850

ACGTACTCTC AACAGTTCGC TTAGGCATGG AAGTTTGTGC GCATTCTGGC 2900
 TACACAATAA CAAGGGAAGA CTTACTCGTG GCTGCAACCC TACTAGCTCA 2950
 AAATTTATTC ACACATGGTT ACGCTTTGGG GAAATTATGA TAATGATCCA 3000
 GATCACTTCT GGCTAATAAA AGATCAGAGC TCTAGAGATC TGTGTGTTGG 3050
 5 TTTTGTGTGG ATCTGCTGTG CCTTCTAGTT GCCAGCCATC TGTGTTTGC 3100
 CCCTCCCCCG TGCTTCCTT GACCCTGGAA GGTGCCACTC CCACTGTCCT 3150
 TTCCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT 3200
 CTATTCTGGG GGGTGGGGTG GGGCAGCACA GCAAGGGGGA GGATTGGGAA 3250
 GACAATAGCA GGCATGCTGG GGATGCGGTG GGCTCTATGG GTACCTCTCT 3300
 10 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CTCTCGGTAC CTCTCTCTCT 3350
 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CGGTACCAGG TGCTGAAGAA 3400
 TTGACCCGGT GACCAAAGGT GCCTTTTATC ATCACTTTAA AAATAAAAAA 3450
 CAATTACTCA GTGCCTGTTA TAAGCAGCAA TTAATTATGA TTGATGCCTA 3500
 CATCACAACA AAAACTGATT TAACAAATGG TTGGTCTGCC TTAGAAAGTA 3550
 15 TATTTGAACA TTATCTTGAT TATATTATTG ATAATAATAA AAACCTTATC 3600
 CCTATCCAAG AAGTGATGCC TATCATTGGT TGGAAATGAAC TTGAAAAAAA 3650
 TTAGCCTTGA ATACATTACT GGTAAGGTAA ACGCCATTGT CAGCAAATTG 3700
 ATCCAAGAGA ACCAACTTAA AGCTTTCCTG ACGGAATGTT AATTCTCGTT 3750
 GACCCTGAGC ACTGATGAAT CCCCTAATGA TTTTGGTAAA AATCATTAA 3800
 20 TTAAGGTGGA TACACATCTT GTCATATGAT CCCGGTAATG TGAGTTAGCT 3850
 CACTCATTAG GCACCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT 3900
 TGTGTGGAAT TGTGAGCGGA TAACAATTTT ACACAGGAAA CAGCTATGAC 3950
 CATGATTACG CCAAGCGCGC AATTAACCTT CACTAAAGGG AACAAAAGCT 4000
 GGAGCTCCAC CGCGGTGGCG GCCGCTCTAG AACTAGTGGA TCCCCGGGC 4050
 25 TGCAGGAATT CGATATCAAG CTTATCGATA CCGCTGACCT CGAGGGGGGG 4100
 CCCGGTACCC AATTCGCCCT ATAGTGAGTC GTATTACGCG CGCTCACTGG 4150
 CCGTCGTTTT ACAACGTCGT GACTGGGAAA ACCCTGGCGT TACCCAACCT 4200
 AATCGCCTTG CAGCACATCC CCCTTTCGCC AGCTGGCGTA ATAGCGAAGA 4250
 GGCCCGCACC GATCGCCCTT CCCAACAGTT GCGCAGCCTG AATGGCGAAT 4300
 30 GGAAATTGTA AGCGTTAATA TTTTGTAAAT ATTCGCGTTA AATTTTGTG 4350
 AAATCAGCTC ATTTTAAAC CAATAGGCCG AAATCGGCAA AATCCCTTAT 4400
 AAATCAAAAG AATAGACCGA GATAGGGTTG AGTGTGTGTC CAGTTTGGA 4450
 CAAGAGTCCA CTATTAAAGA ACGTGGACTC CAACGTCAA GGGCGAAAAA 4500
 CCGTCTATCA GGGCGATGGC CCACTACTCC GGGATCATAT GACAAGATGT 4550
 35 GTATCCACCT TAACTTAATG ATTTTACCA AAATCATTAG GGGATTTCATC 4600
 AGTGCTCAGG GTCAACGAGA ATTAACATTC CGTCAGGAAA GCTTATGATG 4650
 ATGATGTGCT TAAAACTTA CTCAATGGCT GGTATGCAT ATCGCAATAC 4700
 ATGCGAAAAA CCTAAAAGAG CTTGCCGATA AAAAAGGCCA ATTTATTGCT 4750
 ATTTACCGCG GCTTTTTATT GAGCTTGAAA GATAAATAAA ATAGATAGGT 4800
 40 TTTATTTGAA GCTAAATCTT CTTTATCGTA AAAAATGCCC TCTTGGGTTA 4850
 TCAAGAGGGT CATTATATTT CGCGGAATAA CATCATTTGG TGACGAAATA 4900
 ACTAAGCACT TGTCTCCTGT TTACTCCCTT GAGCTTGAGG GGTTAACATG 4950
 AAGGTCATCG ATAGCAGGAT AATAATACAG TAAAACGCTA AACCAATAAT 5000
 CCAAATCCAG CCATCCCAA TTGGTAGTGA ATGATTATAA ATAACAGCAA 5050
 45 ACAGTAATGG GCCAATAACA CCGGTTGCAT TGGTAAGGCT CACCAATAAT 5100
 CCCTGTAAAG CACCTTGCTG ATGACTCTTT GTTTGGATAG ACATCACTCC 5150
 CTGTAATGCA GGTAAGCGA TCCCACCACC AGCCAATAAA ATTAACACAG 5200
 GGAAAACTAA CCAACCTTCA GATATAACG CTAAAAAGGC AAATGCACTA 5250
 CTATCTGCAA TAAATCCGAG CAGTACTGCC GTTTTTTCGC CCATTTAGTG 5300
 50 GCTATTCTTC CTGCCACAAA GGCTTGGAAT ACTGAGTGTA AAAGACCAAG 5350
 ACCCGTAATG AAAAGCCAAC CATCATGCTA TTCATCATCA CGATTTCTGT 5400
 AATAGACCA CACCGTGCTG GATTGGCTAT CAATGCGCTG AAATAATAAT 5450
 CAACAAATGG CATCGTTAAA TAAGTGATGT ATACCGATCA GCTTTTGTTC 5500
 CCTTTAGTGA GGGTTAATTG CGCGCTTGGC GTAATCATGG TCATAGCTGT 5550
 55 TTCCTGTGTG AAATTGTTAT CCGCTCACA TTCCACACAA CATACGAGCC 5600
 GGAAGCATAA AGTGTAAGC CTGGGGTGCC TAATGAGTGA GCTAACTCAC 5650
 ATTAATTGCG TTGCGCTCAC TGCCCGCTTT CCAGTCGGGA AACCTGTCGT 5700
 GCCAGCTGCA TTAATGAATC GGCCAACGCG CGGGGAGAGG CGGTTTGCCT 5750
 ATTGGGCGCT CTTCCGCTTC CTCGCTCACT GACTCGCTGC GCTCGGTCGT 5800
 60 TCGGCTGCGG CGAGCGGTAT CAGCTCACTC AAAGGCGGTA ATACGGTTAT 5850
 CCACAGAATC AGGGGATAAC GCAGGAAAGA ACATGTGAGC AAAAGGCCAG 5900

CAAAAGGCCA GGAACCGTAA AAAGGCCGCG TTGCTGGCGT TTTTCCATAG 5950
 GCTCCGCCCC CCTGACGAGC ATCACA AAAA TCGACGCTCA AGTCAGAGGT 6000
 GGCGAAACCC GACAGGACTA TAAAGATACC AGGCGTTTCC CCCTGGAAGC 6050
 TCCCTCGTGC GCTCTCCTGT TCCGACCCTG CCGCTTACCG GATACCTGTC 6100
 5 CGCCTTTCTC CCTTCGGGAA GCGTGGCGCT TTCTCATAGC TCACGCTGTA 6150
 GGTATCTCAG TTCGGTGTAG GTCGTTGCT CCAAGCTGGG CTGTGTGCAC 6200
 GAACCCCCCG TTCAGCCCGA CCGCTGCGCC TTATCCGGTA ACTATCGTCT 6250
 TGAGTCCAAC CCGGTAAGAC ACGACTTATC GCCACTGGCA GCAGCCACTG 6300
 GTAACAGGAT TAGCAGAGCG AGGTATGTAG GCGGTGCTAC AGAGTTCTTG 6350
 10 AAGTGGTGGC CTAACACGG CTACACTAGA AGGACAGTAT TTGGTATCTG 6400
 CGCTCTGCTG AAGCCAGTTA CCTTCGGAAA AAGAGTTGGT AGCTCTTGAT 6450
 CCGGCAAACA AACCACCGCT GGTAGCGGTG GTTTTTTTGT TTGCAAGCAG 6500
 CAGATTACGC GCAGAAAAAA AGGATCTCAA GAAGATCCTT TGATCTTTTC 6550
 TACGGGGTCT GACGCTCAGT GGAACGAAAA CTCACGTAA GGGATTTTGG 6600
 15 TCATGAGATT ATCAAAAAGG ATCTTCACCT AGATCCTTTT AAATTAAAAA 6650
 TGAAGTTTTA AATCAATCTA AAGTATATAT GAGTAACTT GGTCTGACAG 6700
 TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC TGTCTATTTT 6750
 GTTCATCCAT AGTTGCCTGA CTCCCCGTCG TGTAGATAAC TACGATACGG 6800
 GAGGGCTTAC CATCTGGCCC CAGTGCTGCA ATGATACCGC GAGACCCACG 6850
 20 CTCACCGGCT CCAGATTTAT CAGCAATAAA CCAGCCAGCC GGAAGGGCCG 6900
 AGCGCAGAAG TGGTCCTGCA ACTTTATCCG CCTCCATCCA GTCTATTAAT 6950
 TGTGCGGGG AAGCTAGAGT AAGTAGTTCG CCAGTTAATA GTTTGCGCAA 7000
 CGTTGTTGCC ATTGCTACAG GCATCGTGGT GTCACGCTCG TCGTTTGGTA 7050
 TGGCTTCATT CAGCTCCGGT TCCCAACGAT CAAGGCGAGT TACATGATCC 7100
 25 CCCATGTTGT GCAAAAAGC GGTTAGCTCC TTCGGTCCTC CGATCGTTGT 7150
 CAGAAGTAAG TTGGCCGCGAG TGTTATCACT CATGGTTATG GCAGCACTGC 7200
 ATAATTCTCT TACTGTCATG CCATCCGTAA GATGCTTTTC TGTGACTGGT 7250
 GAGTACTCAA CCAAGTCATT CTGAGAATAG TGTATGCGGC GACCGAGTTG 7300
 CTCTTGCCCG GCGTCAATAC GGGATAATAC CGCGCCACAT AGCAGAACTT 7350
 30 TAAAAGTGCT CATCATTGGA AAACGTTCTT CGGGGCGAAA ACTCTCAAGG 7400
 ATCTTACCGC TGTGAGATC CAGTTCGATG TAACCCACTC GTGCACCCAA 7450
 CTGATCTTCA GCATCTTTTA CTTTCACCAG CGTTTCTGGG TGAGCAAAAA 7500
 CAGGAAGGCA AAATGCCGCA AAAAAGGGAA TAAGGGCGAC ACGGAAATGT 7550
 TGAATACTCA TACTCTTCCT TTTTCAATAT TATTGAAGCA TTTATCAGGG 7600
 35 TTATTGTCTC ATGAGCGGAT ACATATTTGA ATGTATTTAG AAAAATAAAC 7650
 AAATAGGGGT TCCGCGCACA TTTCCCGGAA AAGTGCCAC 7689

SEQ ID NO:2 (PTnMod (CMV/Red))

40 CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC 100
 TTTCTTCCCT TCCTTTCTCG CCACGTTTCG CGGCATCAGA TTGGCTATTG 150
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 45 CATGTCCAAC ATTACGCCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCAACGACC 350
 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AACTGCCCCA 450
 50 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA 550
 TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650
 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
 55 TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
 TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 60 CCGCCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 CTGTTTTTGG CTTGGGGCCT ATACACCCCC GCTTCCTTAT GCTATAGGTG 1050

	ATGGTATAGC	TTAGCCTATA	GGTGTGGGTT	ATTGACCATT	ATTGACCACT	1100
	CCCCTATTGG	TGACGATACT	TTCATTACT	AATCCATAAC	ATGGCTCTTT	1150
	GCCACAACATA	TCTCTATTGG	CTATATGCCA	ATACTCTGTC	CTTCAGAGAC	1200
	TGACACGGAC	TCTGTATTTT	TACAGGATGG	GGTCCCATT	ATTATTTACA	1250
5	AATTCACATA	TACAACAACG	CCGTCCCCCG	TGCCCCGAGT	TTTTATTAAA	1300
	CATAGCGTGG	GATCTCCACG	CGAATCTCGG	GTACGTGTTC	CGGACATGGG	1350
	CTCTTCTCCG	GTAGCGGCGG	AGCTTCCACA	TCCGAGCCCT	GGTCCCATGC	1400
	CTCCAGCGGC	TCATGGTCGC	TCGGCAGCTC	CTTGCTCCTA	ACAGTGGAGG	1450
	CCAGACTTAG	GCACAGCACA	ATGCCCACCA	CCACCAGTGT	GCCGCACAAG	1500
10	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATTC	TGATAAGAGT	CAGAGGTAA	TCCCGTTGCG	1650
	GTGCTGTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GAATAACAGA	CTGTTCTTT	1750
15	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTCA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
20	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCATT	GTACTTGTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTC	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
25	TCATTGTCAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
30	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTC	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
35	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTAATCTC	AACAGTTTCG	TTAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
40	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCCTGGAA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
45	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
50	CATCACAACA	AAAACCTGAT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
55	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCTT	CACTAAAGGG	AACAAAAGCT	4000
60	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGC	4050
	ATCAGATTGG	CTATTGGCCA	TTGCATACGT	TGTATCCATA	TCATAATATG	4100

	TACATTTATA	TTGGCTCATG	TCCAACATTA	CCGCCATGTT	GACATTGATT	4150
	ATTGACTAGT	TATTAATAGT	AATCAATTAC	GGGGTCATTA	GTTTCATAGCC	4200
	CATATATGGA	GTTCCGCGTT	ACATAACTTA	CGGTAAATGG	CCCGCCTGGC	4250
	TGACCGCCCA	ACGACCCCGG	CCCATTGACG	TCAATAATGA	CGTATGTTCC	4300
5	CATAGTAACG	CCAATAGGGA	CTTTCATTG	ACGTCAATGG	GTGGAGTATT	4350
	TACGGTAAAC	TGCCCACTTG	GCAGTACATC	AAGTGTATCA	TATGCCAAGT	4400
	ACGCCCCCTA	TTGACGTCAA	TGACGGTAAA	TGGCCCGCCT	GGCATTATGC	4450
	CCAGTACATG	ACCTTATGGG	ACTTTCCTAC	TTGGCAGTAC	ATCTACGTAT	4500
	TAGTCATCGC	TATTACCATG	GTGATGCGGT	TTTGGCAGTA	CATCAATGGG	4550
10	CGTGGATAGC	GGTTTGACTC	ACGGGGATTT	CCAAGTCTCC	ACCCCATTTGA	4600
	CGTCAATGGG	AGTTTGTTTT	GGCACCAAAA	TCAACGGGAC	TTTCCAAAAT	4650
	GTCGTAACAA	CTCCGCCCCA	TTGACGCAAA	TGGGCGGTAG	GCGTGTACGG	4700
	TGGGAGGTCT	ATATAAGCAG	AGCTCGTTTA	GTGAACCGTC	AGATCGCCTG	4750
	GAGACGCCAT	CCACGCTGTT	TTGACCTCCA	TAGAAGACAC	CGGGACCGAT	4800
15	CCAGCCTCCG	CGGCCGGGAA	CGGTGCATTG	GAACGCGGAT	TCCCCGTGCC	4850
	AAGAGTGACG	TAAGTACCGC	CTATAGACTC	TATAGGCACA	CCCCTTTGGC	4900
	TCTTATGCAT	GCTATACTGT	TTTGGCTTGG	GGGCCTATAC	ACCCCGCTT	4950
	CCTTATGCTA	TAGGTGATGG	TATAGCTTAG	CCTATAGGTG	TGGGTATTATG	5000
	ACCATTATTG	ACCACTCCCC	TATTGGTGAC	GATACTTTCC	ATTACTAATC	5050
20	CATAACATGG	CTCTTTGCCA	CAACTATCTC	TATTGGCTAT	ATGCCAATAC	5100
	TCTGTCCTTC	AGAGACTGAC	ACGGACTCTG	TATTTTTTACA	GGATGGGGTC	5150
	CCATTTATTA	TTTACAAATT	CACATATACA	ACAACGCCGT	CCCCCGTGCC	5200
	CGCAGTTTTT	ATTAAACATA	GCGTGGGATC	TCCACGCGAA	TCTCGGGTAC	5250
	GTGTTCCGGA	CATGGGCTCT	TCTCCGGTAG	CGGCGGAGCT	TCCACATCCG	5300
25	AGCCCTGGTC	CCATGCCTCC	AGCGGCTCAT	GGTCGCTCGG	CAGCTCCTTG	5350
	CTCCTAACAG	TGGAGGCCAG	ACTTAGGCAC	AGCACAATGC	CCACCACCAC	5400
	CAGTGTGCCG	CACAAGGCCG	TGGCGGTAGG	GTATGTGTCT	GAAAATGAGC	5450
	GTGGAGATTG	GGCTCGCACG	GCTGACGCAG	ATGGAAGACT	TAAGGCAGCG	5500
	GCAGAAGAAG	ATGCAGGCAG	CTGAGTTGTT	GTATTCTGAT	AAGAGTCAGA	5550
30	GGTAACTCCC	GTGCGGTGTC	TGTTAACGGT	GGAGGGCAGT	GTAGTCTGAG	5600
	CAGTACTCGT	TGCTGCCGCG	CGCGCCACCA	GACATAATAG	CTGACAGACT	5650
	AACAGACTGT	TCCTTTCCAT	GGGTCTTTTC	TGCAGTCACC	GTCTCGCGAC	5700
	AGGGATCCAC	CGGTCGCCAC	CATGGTGCGC	TCCTCCAAGA	ACGTCATCAA	5750
	GGAGTTCATG	CGCTTCAAGG	TGCGCATGGA	GGGCACCGTG	AACGGCCACG	5800
35	AGTTCGAGAT	CGAGGGCGAG	GGCGAGGGCC	GCCCCTACGA	GGGCCACAAC	5850
	ACCGTGAAGC	TGAAGGTGAC	CAAGGGCGGC	CCCCTGCCCT	TCGCCTGGGA	5900
	CATCCTGTCC	CCCCAGTTCC	AGTACGGCTC	CAAGGTGTAC	GTGAAGCACC	5950
	CCGCCGACAT	CCCCGACTAC	AAGAAGCTGT	CCTTCCCCGA	GGGCTTCAAG	6000
	TGGGAGCGCG	TGATGAACTT	CGAGGACGGC	GGCGTGGTGA	CCGTGACCCA	6050
40	GGACTCCTCC	CTGCAGGACG	GCTGCTTCAT	CTACAAGGTG	AAGTTCATCG	6100
	GCGTGAACCT	CCCCTCCGAC	GGCCCCGTAA	TGCAGAAGAA	GACCATGGGC	6150
	TGGGAGGCCT	CCACCGAGCG	CCTGTACCCC	CGCGACGGCG	TGCTGAAGGG	6200
	CGAGATCCAC	AAGGCCCTGA	AGCTGAAGGA	CGGCGGCCAC	TACCTGGTGG	6250
	AGTTCAGTC	CATCTACATG	GCCAAGAAGC	CCGTGCAGCT	GCCCGGCTAC	6300
45	TACTACGTGG	ACTCCAAGCT	GGACATCACC	TCCCACAACG	AGGACTACAC	6350
	CATCGTGGAG	CAGTACGAGC	GCACCGAGGG	CCGCCACCAC	CTGTTCTGT	6400
	AGCGGCCGCG	ACTCTAGATC	ATAATCAGCC	ATACCACATT	TGTAGAGGTT	6450
	TTACTTGCTT	TAAAAAACCT	CCCACACCTC	CCCCTGAACC	TGAAACATAA	6500
	AATGAATGCA	ATTGTTGTTG	TTAACTTGTT	TATTGCAGCT	TATAATGGTT	6550
50	ACAAATAAAG	CAATAGCATC	ACAAATTTCA	CAAATAAAGC	ATTTTTTTCA	6600
	CTGCATTCTA	GTTGTGGCCC	GGGCTGCAGG	AATTCGATAT	CAAGCTTATC	6650
	GATACCGCTG	ACCTCGAGGG	GGGGCCCGGT	ACCCAATTCG	CCCTATAGTG	6700
	AGTCGTATTA	CGCGCGCTCA	CTGGCCGTCG	TTTTACAACG	TCGTGACTGG	6750
	GAAAACCCTG	GCGTTACCCA	ACTTAATCGC	CTTGCAGCAC	ATCCCCCTTT	6800
55	CGCCAGCTGG	CGTAATAGCG	AAGAGGCCCG	CACCGATCGC	CCTTCCCAAC	6850
	AGTTGCGCAG	CCTGAATGGC	GAATGGAAAT	TGTAAGCGTT	AATATTTTGT	6900
	TAAAATTTCG	GTTAAATTTT	TGTTAAATCA	GCTCATTTTT	TAACCAATAG	6950
	GCCGAAATCG	GCAAAATCCC	TTATAAATCA	AAAGAATAGA	CCGAGATAGG	7000
	GTTGAGTGTT	GTTCCAGTTT	GGAACAAGAG	TCCACTATTA	AAGAACGTGG	7050
60	ACTCCAACGT	CAAAGGGCGA	AAAACCGTCT	ATCAGGGCGA	TGGCCCACTA	7100
	CTCCGGGATC	ATATGACAAG	ATGTGTATCC	ACCTTAACTT	AATGATTTTT	7150

	ACCAAAATCA	TTAGGGGATT	CATCAGTGCT	CAGGGTCAAC	GAGAATTAAC	7200
	ATTCCGTCAG	GAAAGCTTAT	GATGATGATG	TGCTTAAAAA	CTTACTCAAT	7250
	GGCTGGTTAT	GCATATCGCA	ATACATGCGA	AAAACCTAAA	AGAGCTTGCC	7300
	GATAAAAAAG	GCCAATTTAT	TGCTATTTAC	CGCGGCTTTT	TATTGAGCTT	7350
5	GAAAGATAAA	TAAAATAGAT	AGGTTTTATT	TGAAGCTAAA	TCTTCTTTAT	7400
	CGTAAAAAAT	GCCCTCTTGG	GTTATCAAGA	GGGTCATTAT	ATTTGCGGGA	7450
	ATAACATCAT	TTGGTGACGA	AATAACTAAG	CACTTGTCTC	CTGTTTACTC	7500
	CCCTGAGCTT	GAGGGGTAA	CATGAAGGTC	ATCGATAGCA	GGATAATAAT	7550
	ACAGTAAAC	GCTAAACCAA	TAATCCAAAT	CCAGCCATCC	CAAATTGGTA	7600
10	GTGAATGATT	ATAAATAACA	GCAAACAGTA	ATGGGCCAAT	AACACCGGTT	7650
	GCATTGGTAA	GGCTCACCAA	TAATCCCTGT	AAAGCACCTT	GCTGATGACT	7700
	CTTTGTTTGG	ATAGACATCA	CTCCCTGTAA	TGCAGGTAAA	GCGATCCAC	7750
	CACCAGCCAA	TAAAATTAAA	ACAGGGAAAA	CTAACCAACC	TTCAGATATA	7800
	AACGCTAAAA	AGGCAAATGC	ACTACTATCT	GCAATAAATC	CGAGCAGTAC	7850
15	TGCCGTTTTT	TCGCCCATT	AGTGGCTATT	CTTCCTGCCA	CAAAGGCTTG	7900
	GAATACTGAG	TGTAAAAGAC	CAAGACCCGT	AATGAAAAGC	CAACCATCAT	7950
	GCTATTCATC	ATCACGATTT	CTGTAATAGC	ACCACACCGT	GCTGGATTGG	8000
	CTATCAATGC	GCTGAAATAA	TAATCAACAA	ATGGCATCGT	TAAATAAGTG	8050
	ATGTATACCG	ATCAGCTTTT	GTTCCCTTTA	GTGAGGGTTA	ATTGCGCGCT	8100
20	TGGCGTAATC	ATGGTCATAG	CTGTTTCCTG	TGTGAAATTG	TTATCCGCTC	8150
	ACAATTCCAC	ACAACATACG	AGCCGGAAGC	ATAAAGTGTA	AAGCCTGGGG	8200
	TGCCTAATGA	GTGAGCTAAC	TCACATTAAT	TGCGTTGCGC	TCACTGCCCC	8250
	CTTTCCAGTC	GGGAAACCTG	TCGTGCCAGC	TGCATTAATG	AATCGGCCAA	8300
	CGCGCGGGGA	GAGGCGGTTT	GCGTATTGGG	CGCTCTTCCG	CTTCCTCGCT	8350
25	CACTGACTCG	CTGCGCTCGG	TCGTTCGGCT	GCGGCGAGCG	GTATCAGCTC	8400
	ACTCAAAGGC	GGTAATACGG	TTATCCACAG	AATCAGGGGA	TAACGCAGGA	8450
	AAGAACATGT	GAGCAAAAGG	CCAGCAAAAG	GCCAGGAACC	GTAAAAAGGC	8500
	CGCGTTGCTG	GCGTTTTTCC	ATAGGCTCCG	CCCCCTGAC	GAGCATCACA	8550
	AAAATCGACG	CTCAAGTCAG	AGGTGGCGAA	ACCCGACAGG	ACTATAAAGA	8600
30	TACCAGGCGT	TTCCCCCTGG	AAGCTCCCTC	GTGCGCTCTC	CTGTTCCGAC	8650
	CCTGCCGCTT	ACCGGATACC	TGTCCGCCTT	TCTCCCTTCG	GGAAGCGTGG	8700
	CGCTTTCTCA	TAGCTCACGC	TGTAGGTATC	TCAGTTCGGT	GTAGGTCGTT	8750
	CGCTCCAAGC	TGGGCTGTGT	GCACGAACCC	CCCGTTCAGC	CCGACCGCTG	8800
	CGCCTTATCC	GGTAACTATC	GTCTTGAGTC	CAACCCGGTA	AGACACGACT	8850
35	TATCGCCACT	GGCAGCAGCC	ACTGGTAACA	GGATTAGCAG	AGCGAGGTAT	8900
	GTAGGCGGTG	CTACAGAGTT	CTTGAAGTGG	TGGCCTAACT	ACGGCTACAC	8950
	TAGAAGGACA	GTATTTGGTA	TCTGCGCTCT	GCTGAAGCCA	GTTACCTTCG	9000
	GAAAAAGAGT	TGGTAGCTCT	TGATCCGGCA	AACAAACCAC	CGCTGGTAGC	9050
	GGTGGTTTTT	TTGTTTGCAA	GCAGCAGATT	ACGCGCAGAA	AAAAAGGATC	9100
40	TCAAGAAGAT	CCTTTGATCT	TTTCTACGGG	GTCTGACGCT	CAGTGGAACG	9150
	AAAACTCACG	TTAAGGGATT	TTGGTCATGA	GATTATCAAA	AAGGATCTTC	9200
	ACCTAGATCC	TTTTAAATTA	AAAATGAAGT	TTTAAATCAA	TCTAAAGTAT	9250
	ATATGAGTAA	ACTTGGTCTG	ACAGTTACCA	ATGCTTAATC	AGTGAGGCAC	9300
	CTATCTCAGC	GATCTGTCTA	TTTCGTTTAT	CCATAGTTGC	CTGACTCCCC	9350
45	GTCGTGTAGA	TAACTACGAT	ACGGGAGGGC	TTACCATCTG	GCCCCAGTGC	9400
	TGCAATGATA	CCGCGAGACC	CACGCTCACC	GGCTCCAGAT	TTATCAGCAA	9450
	TAAACCAGCC	AGCCGGAAGG	GCCGAGCGCA	GAAGTGGTCC	TGCAACTTTA	9500
	TCCGCTCCCA	TCCAGTCTAT	TAATTGTTGC	CGGGAAGCTA	GAGTAAGTAG	9550
	TTCCGCCAGTT	AATAGTTTGC	GCAACGTTGT	TGCCATTGCT	ACAGGCATCG	9600
50	TGGTGTACAG	CTCGTCGTTT	GGTATGGCTT	CATTGAGCTC	CGGTTCCCAA	9650
	CGATCAAGGC	GAGTTACATG	ATCCCCCATG	TTGTGCAAAA	AAGCGGTTAG	9700
	CTCCTTCGGT	CCTCCGATCG	TTGTCAGAAG	TAAGTTGGCC	GCAGTGTTAT	9750
	CACTCATGGT	TATGGCAGCA	CTGCATAATT	CTCTTACTGT	CATGCCATCC	9800
	GTAAGATGCT	TTTCTGTGAC	TGGTGAGTAC	TCAACCAAGT	CATTCTGAGA	9850
55	ATAGTGTATG	CGGCGACCGA	GTTGCTCTTG	CCCGGCGTCA	ATACGGGATA	9900
	ATACCGCGCC	ACATAGCAGA	ACTTTAAAAG	TGCTCATCAT	TGGAAAACGT	9950
	TCTTCGGGGC	GAAAACTCTC	AAGGATCTTA	CCGCTGTTGA	GATCCAGTTC	10000
	GATGTAACCC	ACTCGTGAC	CCAACGTATC	TTCAGCATCT	TTTACTTTCA	10050
	CCAGCGTTTC	TGGGTGAGCA	AAAACAGGAA	GGCAAAATGC	CGCAAAAAG	10100
60	GGAATAAGGG	CGACACGGAA	ATGTTGAATA	CTCATACTCT	TCCTTTTTCA	10150
	ATATTATTGA	AGCATTATATC	AGGGTTATTG	TCTCATGAGC	GGATACATAT	10200

TTGAATGTAT TTAGAAAAAT AAACAAATAG GGGTTCGCG CACATTTCCC 10250
CGAAAAGTGC CAC 10263

5 SEQ ID NO:3 (PTnMod (Oval/Red) Chicken)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTTCGC 100
TTTCTTCCCT TCCTTTCTCG CCACGTTTCGC CGGCATCAGA TTGGCTATTG 150
10 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350
CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
15 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAACGCCCCA 450
CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCAGTA CATGACCTTA 550
TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650
20 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750
CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
GCAGAGCTCG TTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
25 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
CCGCCTATAG ACTCTATAGG CACACCCTT TGGCTCTTAT GCATGCTATA 1000
CTGTTTTTGG CTTGGGGCCT ATACACCCCC GCTTCCTTAT GCTATAGGTG 1050
ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
CCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
30 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTAGAGAC 1200
TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250
AATTCACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300
CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CGGACATGGG 1350
CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
35 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450
CCAGACTTAG GCACAGCACA ATGCCACCA CCACAGTGT GCCGCACAAG 1500
GCCGTGGCGG TAGGGTATGT GTCTGAAAT GAGCGTGGAG ATTGGGCTCG 1550
CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
GCAGCTGAGT TGTTGTATTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650
40 GTGCTGTTAA CGGTGGAGGG CAGTGTAGTC TGAGCAGTAC TCGTTGCTGC 1700
CGCGCGCGCC ACCAGACATA ATAGCTGACA GACTAACAGA CTGTTCCCTT 1750
CCATGGGTCT TTTCTGCAGT CACCGTCGGA CCATGTGTGA ACTTGATATT 1800
TTACATGATT CTCTTTACCA ATTCTGCCCC GAATTACACT TAAAACGACT 1850
CAACAGCTTA ACGTTGGCTT GCCACGCATT ACTTGACTGT AAAACTCTCA 1900
45 CTCTTACCGA ACTTGGCCGT AACCTGCCAA CCAAAGCGAG AACAAAACAT 1950
AACATCAAAC GAATCGACCG ATTGTTAGGT AATCGTCACC TCCACAAAGA 2000
GCGACTCGCT GTATACCGTT GGCATGCTAG CTTTATCTGT TCGGGAATAC 2050
GATGCCCATT GTACTTGTG ACTGGTCTGA TATTCGTGAG CAAAAACGAC 2100
TTATGGTATT GCGAGCTTCA GTCGCACTAC ACGGTCGTTT TGTTACTCTT 2150
50 TATGAGAAAG CGTTCCCGCT TTCAGAGCAA TGTTCAAAGA AAGCTCATGA 2200
CCAATTTCTA GCCGACCTTG CGAGCATTCT ACCGAGTAAC ACCACACCGC 2250
TCATTGTCAG TGATGCTGGC TTAAAGTGC CATGGTATAA ATCCGTTGAG 2300
AAGCTGGGTT GGTACTGGT AAGTCGAGTA AGAGGAAAAG TACAATATGC 2350
AGACCTAGGA GCGGAAAAC GGAAACCTAT CAGCAACTTA CATGATATGT 2400
55 CATCTAGTCA CTCAAAGACT TTAGGCTATA AGAGGCTGAC TAAAAGCAAT 2450
CCAATCTCAT GCCAAATTCT ATTGTATAAA TCTCGCTCTA AAGGCCGAAA 2500
AAATCAGCGC TCGACACGGA CTCATTGTCA CCACCCGTCA CCTAAAATCT 2550
ACTCAGCGTC GGCAAAGGAG CCATGGGTTT TAGCAACTAA CTTACCTGTT 2600
GAAATTCGAA CACCCAAACA ACTTGTTAAT ATCTATTCGA AGCGAATGCA 2650
60 GATTGAAGAA ACCTTCCGAG ACTTGAAAAG TCCTGCCTAC GGACTAGGCC 2700
TACGCCATAG CCGAACGAGC AGCTCAGAGC GTTTTGATAT CATGCTGCTA 2750

	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
5	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCCTGGAA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
10	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
15	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATCACAACA	AAAAC TGATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
20	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCCTGAGC	ACTGATGAAT	CCCCAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
25	CATGATTACG	CCAAGCGCGC	AATTAACCTT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTCAGAA	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAATAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTCACAA	TTCCTCTGTC	4200
30	ATCTGCCAGG	CCATTAAGTT	ATTCATGGAA	GATCTTTGAG	GAACACTGCA	4250
	AGTTCATATC	ATAAACACAT	TTGAAATTGA	GTATTGTTTT	GCATTGTATG	4300
	GAGCTATGTT	TTGCTGTATC	CTCAGAAAAA	AAGTTTGTTA	TAAAGCATTC	4350
	ACACCCATAA	AAAGATAGAT	TTAAATATTC	CAGCTATAGG	AAAGAAAGTG	4400
	CGTCTGCTCT	TCACTCTAGT	CTCAGTTGGC	TCCTTCACAT	GCATGCTTCT	4450
35	TTATTTCTCC	TATTTTGTCA	AGAAAATAAT	AGGTCACGTC	TTGTTCTCAC	4500
	TTATGTCCTG	CCTAGCATGG	CTCAGATGCA	CGTTGTAGAT	ACAAGAAGGA	4550
	TCAAATGAAA	CAGACTTCTG	GTCTGTTACT	ACAACCATAG	TAATAAGCAC	4600
	ACTAACTAAT	AATTGCTAAT	TATGTTTTCC	ATCTCTAAGG	TTCCCACATT	4650
	TTTCTGTTTT	CTTAAAGATC	CCATTATCTG	GTTGTAAGTG	AAGCTCAATG	4700
40	GAACATGAGC	AATATTTCCC	AGTCTTCTCT	CCCATCCAAC	AGTCCTGATG	4750
	GATTAGCAGA	ACAGGCAGAA	AACACATTGT	TACCCAGAAT	TAAAAACTAA	4800
	TATTTGCTCT	CCATTCAATC	CAAAATGGAC	CTATTGAAAC	TAAAATCTAA	4850
	CCCAATCCCA	TTAAATGATT	TCTATGGCGT	CAAAGGTCAA	ACTTCTGAAG	4900
	GGAACCTGTG	GGTGGGTCAC	AATTCAGGCT	ATATATTCCC	CAGGGCTCAG	4950
45	CGGATCTCCA	TGGGCTCCAT	CGGTGCAGCA	AGCATGGAAT	TTTGTTTTGA	5000
	TGTATTCAAG	GAGCTCAAAG	TCCACCATGC	CAATGAGAAC	ATCTTCTACT	5050
	GCCCCATTGC	CATCATGTCA	GCTCTAGCCA	TGGTATACCT	GGGTGCAAAA	5100
	GACAGCACCA	GGGAATTCGT	GCGCTCCTCC	AAGAACGTCA	TCAAGGAGTT	5150
	CATGCGCTTC	AAGGTGCGCA	TGGAGGGCAC	CGTGAACGGC	CACGAGTTCT	5200
50	AGATCGAGGG	CGAGGGCGAG	GGCCGCCCTT	ACGAGGGCCA	CAACACCGTG	5250
	AAGCTGAAGG	TGACCAAGGG	CGGCCCCCTG	CCCTTCGCCT	GGGACATCCT	5300
	GTCCCCCAG	TTCCAGTACG	GCTCCAAGGT	GTACGTGAAG	CACCCCGCCG	5350
	ACATCCCCGA	CTACAAGAAG	CTGTCCTTCC	CCGAGGGCTT	CAAGTGGGAG	5400
	CGCGTGATGA	ACTTCGAGGA	CGCGGGCGTG	GTGACCGTGA	CCCAGGACTC	5450
55	CTCCCTGCAG	GACGGCTGCT	TCATCTACAA	GGTGAAGTTC	ATCGGCGTGA	5500
	ACTTCCCCTC	CGACGGCCCC	GTAATGCAGA	AGAAGACCAT	GGGCTGGGAG	5550
	GCCTCCACCG	AGCGCCTGTA	CCCCGCGAC	GGCGTGCTGA	AGGGCGAGAT	5600
	CCACAAGGCC	CTGAAGCTGA	AGGACGGCGG	CCACTACCTG	GTGGAGTTCA	5650
	AGTCCATCTA	CATGGCCAAG	AAGCCCGTGC	AGCTGCCCGG	CTACTACTAC	5700
60	GTGGACTCCA	AGCTGGACAT	CACCTCCAC	AACGAGGACT	ACACCATCGT	5750
	GGAGCAGTAC	GAGCGCACCG	AGGGCCGCCA	CCACCTGTTC	CTGTAGCGGC	5800

	CGCGACTCTA	GATCATAATC	AGCCATACCA	CATTTGTAGA	GGTTTTACTT	5850
	GCTTTAAAAA	ACCTCCCACA	CCTCCCCCTG	AACCTGAAAC	ATAAAATGAA	5900
	TGCAATTGTT	GTTGTTAACT	TGTTTATTGC	AGCTTATAAT	GGTTACAAAT	5950
	AAAGCAATAG	CATCACAAT	TTCACAAATA	AAGCATTTT	TTCAGTGCAT	6000
5	TCTAGTTGTG	GCTCGAGAAG	GGCGAATTCT	GCAGATATCC	ATCACACTGG	6050
	CGGCCGCTCG	AGGGGGGGCC	CGGTACCCAA	TTCCGCCCTAT	AGTGAGTCGT	6100
	ATTACGCGCG	CTCACTGGCC	GTCGTTTTAC	AACGTCGTGA	CTGGGAAAAC	6150
	CCTGGCGTTA	CCCAACTTAA	TCGCCTTGCA	GCACATCCCC	CTTTCGCCAG	6200
	CTGGCGTAAT	AGCGAAGAGG	CCCGCACCGA	TCGCCCTTCC	CAACAGTTGC	6250
10	GCAGCCTGAA	TGGCGAATGG	AAATTGTAAG	CGTTAATATT	TTGTTAAAAAT	6300
	TCGCGTTAAA	TTTTTGTTAA	ATCAGCTCAT	TTTTTAACCA	ATAGGCCGAA	6350
	ATCGGCAAAA	TCCCTTATAA	ATCAAAAGAA	TAGACCGAGA	TAGGGTTGAG	6400
	TGTTGTTCCA	GTTTGGAACA	AGAGTCCACT	ATTAAAGAAC	GTGGACTCCA	6450
	ACGTCAAAGG	GCGAAAAACC	GTCTATCAGG	GCGATGGCCC	ACTACTCCGG	6500
15	GATCATATGA	CAAGATGTGT	ATCCACCTTA	ACTTAATGAT	TTTTACCAAA	6550
	ATCATTAGGG	GATTCATCAG	TGCTCAGGGT	CAACGAGAAT	TAACATTCCG	6600
	TCAGGAAAGC	TTATGATGAT	GATGTGCTTA	AAAACCTACT	CAATGGCTGG	6650
	TTATGCATAT	CGCAATACAT	GCGAAAAACC	TAAAAGAGCT	TGCCGATAAA	6700
	AAAGGCCAAT	TTATTGCTAT	TTACCGCGGC	TTTTTATTGA	GCTTGAAAGA	6750
20	TAAATAAAAT	AGATAGGTTT	TATTTGAAGC	TAAATCTTCT	TTATCGTAAA	6800
	AAATGCCCTC	TTGGGTTATC	AAGAGGGTCA	TTATATTTTCG	CGGAATAACA	6850
	TCATTTGGTG	ACGAAATAAC	TAAGCACTTG	TCTCCTGTTT	ACTCCCCTGA	6900
	GCTTGAGGGG	TTAACATGAA	GGTCATCGAT	AGCAGGATAA	TAATACAGTA	6950
	AAACGCTAAA	CCAATAATCC	AAATCCAGCC	ATCCCAAATT	GGTAGTGAAT	7000
25	GATTATAAAT	AACAGCAAAC	AGTAATGGGC	CAATAACACC	GGTTGCATTG	7050
	GTAAGGCTCA	CCAATAATCC	CTGTAAAGCA	CCTTGCTGAT	GACTCTTTGT	7100
	TTGGATAGAC	ATCACTCCCT	GTAATGCAGG	TAAAGCGATC	CCACCACCAG	7150
	CCAATAAAAT	TAAAACAGGG	AAAACCTAAC	AACCTTCAGA	TATAAACGCT	7200
	AAAAAGGCAA	ATGCACTACT	ATCTGCAATA	AATCCGAGCA	GTACTGCCGT	7250
30	TTTTTCGCC	CATTTAGTGG	CTATTCTTCC	TGCCACAAAG	GCTTGGAATA	7300
	CTGAGTGTA	AAGACCAAGA	CCCGCTAATG	AAAAGCCAAC	CATCATGCTA	7350
	TTCCATCCAA	AACGATTTTC	GGTAAATAGC	ACCCACACCG	TTGCGGGAAT	7400
	TTGGCCTATC	AATTGCGCTG	AAAAATAAAT	AATCAACAAA	ATGGCATCGT	7450
	TTTAAATAAA	GTGATGTATA	CCGAATTCAG	CTTTTGTTCC	CTTTAGTGAG	7500
35	GGTTAATTGC	GCGCTTGGCG	TAATCATGGT	CATAGCTGTT	TCCTGTGTGA	7550
	AATTGTTATC	CGCTCACAAT	TCCACACAAC	ATACGAGCCG	GAAGCATAAA	7600
	GTGTAAAGCC	TGGGGTGCCT	AATGAGTGAG	CTAACTCACA	TTAATTGCGT	7650
	TGCGCTCACT	GCCCGCTTTC	CAGTCGGGAA	ACCTGTCTGT	CCAGCTGCAT	7700
	TAATGAATCG	GCCAACGCGC	GGGGAGAGGC	GGTTTGCGTA	TTGGGCGCTC	7750
40	TTCCGCTTCC	TCGCTCACTG	ACTCGCTGCG	CTCGGTCTGT	CGGCTGCGGC	7800
	GAGCGGTATC	AGCTCACTCA	AAGGCGGTAA	TACGGTTATC	CACAGAATCA	7850
	GGGGATAACG	CAGGAAAGAA	CATGTGAGCA	AAAGGCCAGC	AAAAGGCCAG	7900
	GAACCGTAAA	AAGGCCGCGT	TGCTGGCGTT	TTCCCATAGG	CTCCGCCCCC	7950
	CTGACGAGCA	TCACAAAAAT	CGACGCTCAA	GTCAGAGGTG	GCGAAACCCG	8000
45	ACAGGACTAT	AAAGATACCA	GGCGTTTCCC	CCTGGAAGCT	CCCTCGTGCG	8050
	CTCTCCTGTT	CCGACCCTGC	CGCTTACCGG	ATACCTGTCC	GCCTTTCTCC	8100
	CTTCGGGAAG	CGTGGCGCTT	TCTCATAGCT	CACGCTGTAG	GTATCTCAGT	8150
	TCGGTGTAGG	TCGTTGCTC	CAAGCTGGGC	TGTGTGCACG	AACCCCCCGT	8200
	TCAGCCCGAC	CGCTGCGCCT	TATCCGGTAA	CTATCGTCTT	GAGTCCAACC	8250
50	CGGTAAGACA	CGACTTATCG	CCACTGGCAG	CAGCCACTGG	TAACAGGATT	8300
	AGCAGAGCGA	GGTATGTAGG	CGGTGCTACA	GAGTTCTTGA	AGTGGTGGCC	8350
	TAACTACGGC	TACACTAGAA	GGACAGTATT	TGGTATCTGC	GCTCTGCTGA	8400
	AGCCAGTTAC	CTTCGGAAAA	AGAGTTGGTA	GCTCTTGATC	CGGCAAACAA	8450
	ACCACCGCTG	GTAGCGGTGG	TTTTTTTGT	TGCAAGCAGC	AGATTACGCG	8500
55	CAGAAAAAAA	GGATCTCAAG	AAGATCCTTT	GATCTTTTCT	ACGGGGTCTG	8550
	ACGCTCAGTG	GAACGAAAAC	TCACGTTAAG	GGATTTTGGT	CATGAGATTA	8600
	TCAAAAAGGA	TCTTCACCTA	GATCCTTTTA	AATTAAAAAT	GAAGTTTTAA	8650
	ATCAATCTAA	AGTATATATG	AGTAACTTGG	GTCTGACAGT	TACCAATGCT	8700
	TAATCAGTGA	GGCACCTATC	TCAGCGATCT	GTCTATTTTCG	TTTCATCCATA	8750
60	GTTGCCTGAC	TCCCCGTCGT	GATGATAACT	ACGATACGGG	AGGGCTTACC	8800
	ATCTGGCCCC	AGTGCTGCAA	TGATACCGCG	AGACCCACGC	TCACCGGCTC	8850

CAGATTTATC AGCAATAAAC CAGCGAGCCG GAAGGGCCGA GCGCAGAAGT 8900
 GGTCCTGCAA CTTTATCCGC CTCCATCCAG TCTATTAATT GTTGCCGGGA 8950
 AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGCAAC GTTGTTGCCA 9000
 TTGCTACAGG CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTC 9050
 5 AGCTCCGGTT CCCAACGATC AAGGCGAGTT ACATGATCCC CCATGTTGTG 9100
 CAAAAAAGCG GTTAGCTCCT TCGGTCTCTC GATCGTTGTC AGAAGTAAGT 9150
 TGGCCGCAGT GTTATCACTC ATGGTTATGG CAGCACTGCA TAATTCTCTT 9200
 ACTGTCATGC CATCCGTAAG ATGCTTTTCT GTGACTGGTG AGTACTCAAC 9250
 CAAGTCATTC TGAGAATAGT GTATGCGGCG ACCGAGTTGC TCTTGCCCGG 9300
 10 CGTCAATACG GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC 9350
 ATCATTGGAA AACGTTCTTC GGGGCGAAAA CTCTCAAGGA TCTTACCGCT 9400
 GTTGAGATCC AGTTCGATGT AACCCTCTCG TGCACCCAAC TGATCTTCAG 9450
 CATCTTTTAC TTTCAACCAGC GTTCTGGGT GAGCAAAAAC AGGAAGGCAA 9500
 AATGCCGCAA AAAAGGGAAT AAGGGCGACA CGGAAATGTT GAATACTCAT 9550
 15 ACTCTTCCTT TTTCAATATT ATTGAAGCAT TTATCAGGGT TATTGCTCTCA 9600
 TGAGCGGATA CATATTTGAA TGTATTTAGA AAAATAAACA AATAGGGGTT 9650
 CCGCGCACAT TTCCCCGAAA AGTGCCAC 9678

20 SEQ ID NO:4 (PTnMod (Oval/Red) Quail)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC 100
 TTTCTTCCCT TCCTTTCTCG CCACGTTTCG CGGCATCAGA TTGGCTATTG 150
 25 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
 CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350
 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 30 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGCCCA 450
 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA 550
 TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGGTGATG CGGTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650
 35 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
 TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
 TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
 40 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 CCGCCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 CTGTTTTTGG CTTGGGGCCT ATACACCCCTT GCTTCCTTAT GCTATAGGTG 1050
 ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
 45 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTGAGAGAC 1200
 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250
 AATTACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300
 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CGGACATGGG 1350
 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
 50 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGAGAG 1450
 CCAGACTTAG GCACAGCACA ATGCCACCA CCACCAGTGT GCCGCACAAG 1500
 GCCGTGGCGG TAGGGTATGT GTCTGAAAAT GAGCGTGGAG ATTGGGCTCG 1550
 CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
 GCAGCTGAGT TGTTGTATTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650
 55 GTGCTGTTAA CGGTGGAGGG CAGTGTAGTC TGAGCAGTAC TCGTTGCTGC 1700
 CGCGCGCGCC ACCAGACATA ATAGCTGACA GACTAACAGA CTGTTCTTTT 1750
 CCATGGGTCT TTTCTGCAGT CACCGTCGGA CCATGTGTGA ACTTGATATT 1800
 TTACATGATT CTCTTTACCA ATTCTGCCCC GAATTACACT TAAAACGACT 1850
 CAACAGCTTA ACGTTGGCTT GCCACGCATT ACTTGACTGT AAAACTCTCA 1900
 60 CTCTTACCGA ACTTGGCCGT AACCTGCCAA CCAAAGCGAG AACAAAACAT 1950
 AACATCAAAC GAATCGACCG ATTGTTAGGT AATCGTCACC TCCACAAAGA 2000

GCGACTCGCT GTATACCGTT GGCATGCTAG CTTTATCTGT TCGGGAATAC 2050
 GATGCCCATT GTACTTGTTG ACTGGTCTGA TATTCGTGAG CAAAAACGAC 2100
 TTATGGTATT GCGAGCTTCA GTCGCACTAC ACGGTCGTTT TGTTACTCTT 2150
 TATGAGAAAG CGTTCCCGCT TTCAGAGCAA TGTTCAAAGA AAGCTCATGA 2200
 5 CCAATTTCTA GCCGACCTTG CGAGCATTCT ACCGAGTAAC ACCACACCGC 2250
 TCATTGTCAG TGATGCTGGC TTAAAGTGC CATGGTATAA ATCCGTTGAG 2300
 AAGCTGGGTT GGTACTGGTT AAGTCGAGTA AGAGGAAAAG TACAATATGC 2350
 AGACCTAGGA GCGGAAAACCT GGAAACCTAT CAGCAACTTA CATGATATGT 2400
 CATCTAGTCA CTCAAAGACT TTAGGCTATA AGAGGCTGAC TAAAAGCAAT 2450
 10 CCAATCTCAT GCCAAATTCT ATTGATATAA TCTCGCTCTA AAGGCCGAAA 2500
 AAATCAGCGC TCGACACGGA CTCATTGTCA CCACCCGTCA CCTAAAATCT 2550
 ACTCAGCGTC GGCAAAGGAG CCATGGGTTT TAGCAACTAA CTTACCTGTT 2600
 GAAATTCGAA CACCCAAACA ACTTGTTAAT ATCTATTCGA AGCGAATGCA 2650
 GATTGAAGAA ACCTTCCGAG ACTTGAAAAG TCCTGCCTAC GGAAGTAGCC 2700
 15 TACGCCATAG CCGAACGAGC AGCTCAGAGC GTTTTGATAT CATGCTGCTA 2750
 ATCGCCCTGA TGCTTCAACT AACATGTTGG CTGCGGGCG TTCATGCTCA 2800
 GAAACAAGGT TGGGACAAGC ACTTCCAGGC TAACACAGTC AGAAATCGAA 2850
 ACGTACTCTC AACAGTTCGC TTAGGCATGG AAGTTTTGCG GCATTCTGGC 2900
 TACACAATAA CAAGGGAAGA CTTACTCGTG GCTGCAACCC TACTAGCTCA 2950
 20 AAATTTATTC ACACATGGTT ACGCTTTGGG GAAATTATGA TAATGATCCA 3000
 GATCACTTCT GGCTAATAAA AGATCAGAGC TCTAGAGATC TGTGTGTTGG 3050
 TTTTTGTGG ATCTGCTGTG CCTTCTAGTT GCCAGCCATC TGTTGTTTGC 3100
 CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC CCACTGTCCT 3150
 TTCCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT 3200
 25 CTATTCTGGG GGGTGGGGTG GGGCAGCACA GCAAGGGGGA GGATTGGGAA 3250
 GACAATAGCA GGCATGCTGG GGATGCGGTG GGCTCTATGG GTACCTCTCT 3300
 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CTCTCGGTAC CTCTCTCTCT 3350
 CTCTCTCTCT CTCTCTCTCT CTCTCTCTCT CGGTACCAGG TGCTGAAGAA 3400
 TTGACCCGGT GACCAAAGGT GCCTTTTATC ATCACTTTAA AAATAAAAAA 3450
 30 CAATTACTCA GTGCCTGTTA TAAGCAGCAA TTAATTATGA TTGATGCCTA 3500
 CATCACAACA AAAACTGATT TAACAAATGG TTGGTCTGCC TTAGAAAGTA 3550
 TATTTGAACA TTATCTTGAT TATATTATTG ATAATAATAA AAACCTTATC 3600
 CCTATCCAAG AAGTGATGCC TATCATTGGT TGGAATGAAC TTGAAAAAAA 3650
 TTAGCCTTGA ATACATTACT GGTAAGGTAA ACGCCATTGT CAGCAAATTG 3700
 35 ATCCAAGAGA ACCAACTTAA AGCTTTCCTG ACGGAATGTT AATTCTCGTT 3750
 GACCCTGAGC ACTGATGAAT CCCCTAATGA TTTTGGTAAA AATCATTAA 3800
 TTAAGGTGGA TACACATCTT GTCATATGAT CCCGGTAATG TGAGTTAGCT 3850
 CACTCATTAG GCACCCCAGG CTTTACACTT TATGCTTCCG GCTCGTATGT 3900
 TGTGTGGAAT TGTGAGCGGA TAACAATTTT ACACAGGAAA CAGCTATGAC 3950
 40 CATGATTACG CCAAGCGCGC AATTAACCTT CACTAAAGGG AACAAAAGCT 4000
 GGAGCTCCAC CGCGGTGGCG GCCGCTCTAG AACTAGTGGA TCCCCGGGG 4050
 AGGTCAGAAT GGTTCCTTTA CTGTTTGTC AATCTATTAT TTCAATACAG 4100
 AACAAAAGCT TCTATAACTG AAATATATTT GCTATTGTAT ATTATGATTG 4150
 TCCCTCGAAC CATGAACACT CCTCCAGCTG AATTTACAA TTCTCTGTC 4200
 45 ATCTGCCAGG CTGGAAGATC ATGGAAGATC TCTGAGGAAC ATTGCAAGTT 4250
 CATACCATAA ACTCATTTGG AATTGAGTAT TATTTTGCTT TGAATGGAGC 4300
 TATGTTTTGC AGTTCCTCA GAAGAAAAGC TTGTTATAAA GCGTCTACAC 4350
 CCATCAAAAG ATATATTTAA ATATTCCAAC TACAGAAAGA TTTTGTCTGC 4400
 TCTTCACTCT GATCTCAGTT GGTTTCTTCA CGTACATGCT TCTTTATTTG 4450
 50 CCTATTTTGT CAAGAAAATA ATAGGTCAAG TCCTGTTCTC ACTTATCTCC 4500
 TGCCTAGCAT GGCTTAGATG CACGTTGTAC ATTCAAGAAG GATCAAATGA 4550
 AACAGACTTC TGGTCTGTTA CAACAACCAT AGTAATAAAC AGACTAACTA 4600
 ATAATTGCTA ATTATGTTTT CCATCTCTAA GGTTCCACCA TTTTCTGTT 4650
 TTAAGATCCC ATTATCTGGT TGTAAGTAA GCTCAATGGA ACATGAACAG 4700
 55 TATTTCTCAG TCTTTTCTCC AGCAATCCTG ACGGATTAGA AGAACTGGCA 4750
 GAAAACACTT TGTTACCCAG AATTAAAAAC TAATATTTGC TCTCCCTTCA 4800
 ATCCAAAATG GACCTATTGA AACTAAAATC TGACCCAATC CCATTAAATT 4850
 ATTTCTATGG CGTCAAAGGT CAAACTTTTG AAGGGAACCT GTGGGTGGGT 4900
 CCCAATTCAG GCTATATATT CCCAGGGCT CAGCGGATCT CCATGGGCTC 4950
 60 CTCGTGCAGC AAGCATGGAA TTTTGCCTTG ATGTATTCAA GGAGCTCAA 5000
 GTCCACCATG CCAATGACAA CATGCTCTAC TCCCCCTTG CCATCTGTCA 5050

	ACTCTGGCCA	TGGTCTCCCT	GGGTGCAAAA	GACAGCACCA	GGGAATTCGT	5100
	GCGCTCCTCC	AAGAACGTCA	TCAAGGAGTT	CATGCGCTTC	AAGGTGCGCA	5150
	TGGAGGGCAC	CGTGAACGGC	CACGAGTTCG	AGATCGAGGG	CGAGGGCGAG	5200
	GGCCGCCCCCT	ACGAGGGCCA	CAACACCGTG	AAGCTGAAGG	TGACCAAGGG	5250
5	CGGCCCCCTG	CCCTTCGCCT	GGGACATCCT	GTCCCCCAG	TTCCAGTACG	5300
	GCTCCAAGGT	GTACGTGAAG	CACCCGCGG	ACATCCCCGA	CTACAAGAAG	5350
	CTGTCCTTCC	CCGAGGGCTT	CAAGTGGGAG	CGCGTGATGA	ACTTCGAGGA	5400
	CGGCGGCGTG	GTGACCGTGA	CCCAGGACTC	CTCCCTGCAG	GACGGCTGCT	5450
	TCATCTACAA	GGTGAAGTTC	ATCGGCGTGA	ACTTCCCCTC	CGACGGCCCC	5500
10	GTAATGCAGA	AGAAGACCAT	GGGCTGGGAG	GCCTCCACCG	AGCGCCTGTA	5550
	CCCCCGCGAC	GGCGTGCTGA	AGGGCGAGAT	CCACAAGGCC	CTGAAGCTGA	5600
	AGGACGGCGG	CCACTACCTG	GTGGAGTTCA	AGTCCATCTA	CATGGCCAAG	5650
	AAGCCCGTGC	AGCTGCCCCG	CTACTACTAC	GTGGACTCCA	AGCTGGACAT	5700
	CACCTCCAC	AACGAGGACT	ACACCATCGT	GGAGCAGTAC	GAGCGCACCG	5750
15	AGGGCCGCCA	CCACCTGTTT	CTGTAGCGGC	CGCGACTCTA	GATCATAATC	5800
	AGCCATACCA	CATTTGTAGA	GGTTTTACTT	GCTTTAAAAA	ACCTCCCACA	5850
	CCTCCCCCTG	AACCTGAAAC	ATAAAATGAA	TGCAATTGTT	GTTGTTAACT	5900
	TGTTTATTGC	AGCTTATAAT	GGTTACAAAT	AAAGCAATAG	CATCACAAAT	5950
	TTCACAAATA	AAGCATTTTT	TTCATGTCAT	TCTAGTTGTG	GCTCGAGAAG	6000
20	GGCGAATTCT	GCAGATATCC	ATCACACTGG	CGGCCGCTCG	AGGGGGGGCC	6050
	CGGTACCCAA	TTCGCCCTAT	AGTGAGTCGT	ATTACGCGCG	CTCACTGGCC	6100
	GTCGTTTTTAC	AACGTCGTGA	CTGGGAAAAC	CCTGGCGTTA	CCCAACTTAA	6150
	TCGCCTTGCA	GCACATCCCC	CTTTCGCCAG	CTGGCGTAAT	AGCGAAGAGG	6200
	CCCGCACCAG	TCGCCCTTCC	CAACAGTTGC	GCAGCCTGAA	TGGCGAATGG	6250
25	AAATTGTAAG	CGTTAATATT	TTGTTAAAAA	TCGCGTTAAA	TTTTTGTAA	6300
	ATCAGCTCAT	TTTTTAACCA	ATAGGCCGAA	ATCGGCAAAA	TCCCTTATAA	6350
	ATCAAAAGAA	TAGACCGAGA	TAGGGTTGAG	TGTTGTTCCA	GTTTGGAACA	6400
	AGAGTCCACT	ATTAAAGAAC	GTGGACTCCA	ACGTCAAAGG	GCGAAAAACC	6450
	GTCTATCAGG	GCGATGGCCC	ACTACTCCGG	GATCATATGA	CAAGATGTGT	6500
30	ATCCACCTTA	ACTTAATGAT	TTTTACCAAA	ATCATTAGGG	GATTTCATCAG	6550
	TGCTCAGGGT	CAACGAGAAT	TAACATTCCG	TCAGGAAAGC	TTATGATGAT	6600
	GATGTGCTTA	AAAACCTACT	CAATGGCTGG	TTATGCATAT	CGCAATACAT	6650
	GCGAAAAACC	TAAAAGAGCT	TGCCGATAAA	AAAGGCCAAT	TTATTGCTAT	6700
	TTACCGCGGC	TTTTTATTGA	GCTTGAAAGA	TAAATAAAAT	AGATAGGTTT	6750
35	TATTTGAAGC	TAAATCTTCT	TTATCGTAAA	AAATGCCCTC	TTGGGTATC	6800
	AAGAGGGTCA	TTATATTTCT	CGGAATAACA	TCATTTGGTG	ACGAAATAAC	6850
	TAAGCACTTG	TCTCCTGTTT	ACTCCCCTGA	GCTTGAGGGG	TTAACATGAA	6900
	GGTCATCGAT	AGCAGGATAA	TAATACAGTA	AAACGCTAAA	CCAATAATCC	6950
	AAATCCAGCC	ATCCCAAATT	GGTAGTGAAT	GATTATAAAT	AACAGCAAAC	7000
40	AGTAATGGGC	CAATAACACC	GGTTGCATTG	GTAAGGCTCA	CCAATAATCC	7050
	CTGTAAAGCA	CCTTGCTGAT	GACTCTTTGT	TTGGATAGAC	ATCACTCCCT	7100
	GTAATGCAGG	TAAAGCGATC	CCACCACCAG	CCAATAAAAT	TAAAACAGGG	7150
	AAAACCTAAC	AACCTTCAGA	TATAAACGCT	AAAAAGGCAA	ATGCACTACT	7200
	ATCTGCAATA	AATCCGAGCA	GTACTGCCGT	TTTTTCGCCC	CATTTAGTGG	7250
45	CTATTCTTCC	TGCCACAAAG	GCTTGGAATA	CTGAGTGTA	AAGACCAAGA	7300
	CCCGCTAATG	AAAAGCCAAC	CATCATGCTA	TTCCATCCAA	AACGATTTTC	7350
	GGTAAATAGC	ACCCACACCG	TTGCGGGAAT	TTGGCCTATC	AATTGCGCTG	7400
	AAAAATAAAT	AATCAACAAA	ATGGCATCGT	TTTAAATAAA	GTGATGTATA	7450
	CCGAATTCAG	CTTTTGTTC	CTTTAGTGAG	GGTTAATTGC	GCGCTTGGCG	7500
50	TAATCATGGT	CATAGCTGTT	TCCTGTGTGA	AATTGTTATC	CGCTCACAAT	7550
	TCCACACAAC	ATACGAGCCG	GAAGCATAAA	GTGTAAAGCC	TGGGGTGCCT	7600
	AATGAGTGAG	CTAACTCACA	TTAATTGCGT	TGCGCTCACT	GCCCGCTTTC	7650
	CAGTCGGGAA	ACCTGTCGTG	CCAGCTGCAT	TAATGAATCG	GCCAACGCGC	7700
	GGGGAGAGGC	GGTTTGCGTA	TTGGGCGCTC	TTCCGCTTCC	TCGCTCACTG	7750
55	ACTCGCTGCG	CTCGGTCGTT	CGGCTGCGGC	GAGCGGTATC	AGCTCACTCA	7800
	AAGGCGGTAA	TACGGTTATC	CACAGAATCA	GGGGATAACG	CAGGAAAGAA	7850
	CATGTGAGCA	AAAGGCCAGC	AAAAGGCCAG	GAACCGTAAA	AAGGCCGCGT	7900
	TGCTGGCGTT	TTCCCATAGG	CTCCGCCCCC	CTGACGAGCA	TCACAAAAAT	7950
	CGACGCTCAA	GTCAGAGGTG	GCGAAACCCG	ACAGGACTAT	AAAGATACCA	8000
60	GGCGTTTCCC	CCTGGAAGCT	CCCTCGTGCG	CTCTCCTGTT	CCGACCCTGC	8050
	CGCTTACCGG	ATACCTGTCC	GCCTTCTCTC	CTTCGGGAAG	CGTGGCGCTT	8100

5 TCTCATAGCT CACGCTGTAG GTATCTCAGT TCGGTGTAGG TCGTTCGCTC 8150
 CAAGCTGGGC TGTGTGCACG AACCCCCCGT TCAGCCCGAC CGCTGCGCCT 8200
 TATCCGGTAA CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG 8250
 CCACTGGCAG CAGCCACTGG TAACAGGATT AGCAGAGCGA GGTATGTAGG 8300
 CGGTGCTACA GAGTTCTTGA AGTGGTGGCC TAACTACGGC TACACTAGAA 8350
 GGACAGTATT TGGTATCTGC GCTCTGCTGA AGCCAGTTAC CTTCCGAAAA 8400
 AGAGTTGGTA GCTCTTGATC CGGCAAACAA ACCACCGCTG GTAGCGGTGG 8450
 TTTTTTTGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG 8500
 AAGATCCTTT GATCTTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC 8550
 10 TCACGTAAAG GGATTTTGGT CATGAGATTA TCAAAAAGGA TCTTCACCTA 8600
 GATCCTTTTA AATTAAAAAT GAAGTTTAA ATCAATCTAA AGTATATATG 8650
 AGTAAACTTG GTCTGACAGT TACCAATGCT TAATCAGTGA GGCACCTATC 8700
 TCAGCGATCT GTCTATTTCG TTCATCCATA GTTGCCCTGAC TCCCCGTCGT 8750
 GTAGATAACT ACGATACGGG AGGGCTTACC ATCTGGCCCC AGTGCTGCAA 8800
 15 TGATACCGCG AGACCCACGC TCACCGGCTC CAGATTTATC AGCAATAAAC 8850
 CAGCCAGCCG GAAGGGCCGA GCGCAGAAGT GGTCCCTGCAA CTTTATCCGC 8900
 CTCCATCCAG TCTATTAATT GTTGCCGGGA AGCTAGAGTA AGTAGTTCGC 8950
 CAGTTAATAG TTTGCGCAAC GTTGTTGCCA TTGCTACAGG CATCGTGGTG 9000
 TCACGCTCGT CGTTTGGTAT GGCTTCATTC AGCTCCGGTT CCCAACGATC 9050
 20 AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAGCG GTTAGCTCCT 9100
 TCGGTCTCTC GATCGTTGTC AGAAGTAAGT TGGCCGCGAGT GTTATCACTC 9150
 ATGGTTATGG CAGCACTGCA TAATTCTCTT ACTGTCATGC CATCCGTAAG 9200
 ATGCTTTTCT GTGACTGGTG AGTACTCAAC CAAGTCATTC TGAGAATAGT 9250
 GTATGCGGCG ACCGAGTTGC TCTTGCCCGG CGTCAATACG GGATAATACC 9300
 25 GCGCCACATA GCAGAACTTT AAAAGTGCTC ATCATTGGAA AACGTTCTTC 9350
 GGGGCGAAAA CTCTCAAGGA TCTTACCGCT GTTGAGATCC AGTTCGATGT 9400
 AACCCACTCG TGCACCCAAC TGATCTTCAG CATCTTTTAC TTTCAACAGC 9450
 GTTTCTGGGT GAGCAAAAAC AGGAAGGCAA AATGCCGCAA AAAAGGGAAT 9500
 AAGGGCGACA CGGAAATGTT GAATACTCAT ACTCTTCCTT TTTCAATATT 9550
 30 ATTGAAGCAT TTATCAGGGT TATTGTCTCA TGAGCGGATA CATATTTGAA 9600
 TGTATTTAGA AAAATAAACA AATAGGGGTT CCGCGCACAT TTCCCCGAAA 9650
 AGTGCCAC 9658

35 SEQ ID NO:5 (spacer)
(GPGG)_x

SEQ ID NO:6 (spacer)
GPGGGPGGPGG

40

SEQ ID NO:7 (spacer)
GGGSGGGSGGGGS

45

SEQ ID NO:8 (spacer)
GGGSGGGSGGGSGGGGS

50 SEQ ID NO:9 (enterokinase cleavage site)
DDDDK

55 SEQ ID NO:10 (altered transposase Hef forward primer)
ATCTCGAGACCATGTGTGAACTTGATATTTACATGATTCTCTTTACC

60 SEQ ID NO:11 (altered transposase Her reverse primer)
GATTGATCATTATCATAATTTCCCAAAGCGTAACC

- SEQ ID NO:12 (Xho I restriction site)
CTCGAG
- 5 SEQ ID NO:13 (modified Kozak sequence)
ACCATG
- 10 SEQ ID NO:14 (Bcl I restriction site)
TGATCA
- 15 SEQ ID NO:15 (CMVf-NgoM IV primer)
TTGCCGGCATCAGATTGGCTAT
- 20 SEQ ID NO:16 (Syn-polyAr-BstE II primer)
AGAGGTCACCGGGTCAATTCTTCAGCACCTGGTA
- 25 SEQ ID NO:17 (vitellogenin promoter)
TGAATGTGTT CTTGTGTTAT CAATATAAAT CACAGTTAGT GATGAAGTTG GCTGCAAGCC
TGCATCAGTT CAGCTACTTG GCTGCATTTT GTATTTGGTT CTGTAGGAAA TGCAAAAGGT
TCTAGGCTGA CCTGCACTTC TATCCCTCTT GCCTTACTGC TGAGAATCTC TGCAGGTTTT
AATTGTTTAC ATTTTGCTCC CATTTACTTT GGAAGATAAA ATATTTACAG AATGCTTATG
AAACCTTTGT TCATTTAAAA ATATTCCTGG TCAGCGTGAC CGGAGCTGAA AGAACACATT
GATCCCGTGA TTTCAATAAA TACATATGTT CCATATATTG TTTCTCAGTA GCCTCTTAAA
TCATGTGCGT TGGTGACAT ATGAATACAT GAATAGCAAA GGTTTATCTG GATTACGCTC
30 TGGCCTGCAG GAATGGCCAT AAACCAAAGC TGAGGGAAGA GGGAGAGTAT AGTCAATGTA
GATTATACTG ATTGCTGATT GGGTTATTAT CAGCTAGATA ACAACTTGGG TCAGGTGCCA
GGTCAACATA ACCTGGGCAA AACCAGTCTC ATCTGTGGCA GGACCATGTA CCAGCAGCCA
GCCGTGACCC AATCTAGGAA AGCAAGTAGC ACATCAATTT TAAATTTATT GTAAATGCCG
TAGTAGAAGT GTTTTACTGT GATACATTGA AACTTCTGGT CAATCAGAAA AAGGTTTTTT
35 ATCAGAGATG CCAAGGTATT ATTTGATTTT CTTTATTCGC CGTGAAGAGA ATTTATGATT
GCAAAAAGAG GAGTGTTTAC ATAACTGAT AAAAACTTG AGGAATTCAG CAGAAAACAG
CCACGTGTTT CTGAACATTC TTCCATAAAA GTCTCACCAT GCCTGGCAGA GCCCTATTCA
CCTTCGCT
- 40 SEQ ID NO:18 (vitellogenin targeting sequence)
ATGAGGGGGATCATACTGGCATTAGTGCTCACCCCTGTAGGCAGCCAGAAGTTTGACATTGGT
- 45 SEQ ID NO:19 (p146 protein)
KYKKALKKLAKLL
- 50 SEQ ID NO:20 (p146 coding sequence)
AAATACAAAAAAGCACTGAAAAAACTGGCAAACTGCTG
- 55 SEQ ID NO:21 (pro-insulin sequence)
TTTGTGAACCAACACCTGTGCGGCTCACACCTGGTGGAAGCTCTCTACCTAGTGTGCGGGGAACGAGGC
TTCTTCTACACACCCAAGACCCGCCGGGAGGCAGAGGACCTGCAGGTGGGGCAGGTGGAGCTGGGCGGG
GGCCCTGGTGCAGGCAGCCTGCAGCCCTTGGCCCTGGAGGGGTCCCTGCAGAAGCGTGGCATTGTGGAA
CAATGCTGTACCAGCATCTGCTCCCTCTACCAGCTGGAGAACTCTGCAACTAG
- 60 SEQ ID NO:22 (TAG sequence)

5 SEQ ID NO:23 (gp41 epitope)
Ala Thr Thr Cys Ile Leu Lys Gly Ser Cys Gly Trp Ile Gly Leu Leu

10 Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Thr Thr Cys Ile Leu Lys Gly
 Ser Cys Gly Trp Ile Gly Leu Leu Asp Asp Asp Asp Lys

15 Pro Ala Asp Asp Ala

20 Pro Ala Asp Asp Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp
Ala Pro Ala Asp Asp Ala Pro Ala Asp Asp

[illegible]

117

SEQ ID NO:29 (pTnMod(Oval/ENT tag/P146/PA) - Chicken)

	CTGACGCGCC	CTGTAGCGGC	GCATTAAGCG	CGGCGGGTGT	GGTGGTTACG	50
5	CGCAGCGTGA	CCGCTACACT	TGCCAGCGCC	CTAGCGCCCG	CTCCTTTCGC	100
	TTTCTTCCCT	TCCTTTCTCG	CCACGTTTCG	CGGCATCAGA	TTGGCTATTG	150
	GCCATTGCAT	ACGTTGTATC	CATATCATAA	TATGTACATT	TATATTGGCT	200
	CATGTCCAAC	ATTACCGCCA	TGTTGACATT	GATTATTGAC	TAGTTATTAA	250
	TAGTAATCAA	TTACGGGGTC	ATTAGTTCAT	AGCCCATATA	TGGAGTTCCG	300
10	CGTTACATAA	CTTACGGTAA	ATGGCCCGCC	TGGCTGACCG	CCCAACGACC	350
	CCCGCCCAT	GACGTCAATA	ATGACGTATG	TTCCCATAGT	AACGCCAATA	400
	GGGACTTTCC	ATTGACGTCA	ATGGGTGGAG	TATTTACGGT	AAACTGCCCA	450
	CTTGGCAGTA	CATCAAGTGT	ATCATATGCC	AAGTACGCCC	CCTATTGACG	500
	TCAATGACGG	TAAATGGCCC	GCCTGGCATT	ATGCCCAGTA	CATGACCTTA	550
15	TGGGACTTTC	CTACTTGGCA	GTACATCTAC	GTATTAGTCA	TCGCTATTAC	600
	CATGGTGATG	CGGTTTTGGC	AGTACATCAA	TGGGCGTGGA	TAGCGGTTTG	650
	ACTCACGGGG	ATTTCCAAGT	CTCCACCCCA	TTGACGTCAA	TGGGAGTTTG	700
	TTTTGGCACC	AAAATCAACG	GGACTTTCCA	AAATGTCGTA	ACAACTCCGC	750
	CCCATTGACG	CAAATGGGCG	GTAGGCGTGT	ACGGTGGGAG	GTCTATATAA	800
20	GCAGAGCTCG	TTTAGTGAAC	CGTCAGATCG	CCTGGAGACG	CCATCCACGC	850
	TGTTTTGACC	TCCATAGAAG	ACACCGGGAC	CGATCCAGCC	TCCGCGGCCG	900
	GGAACGGTGC	ATTGGAACGC	GGATTCCCCG	TGCCAAGAGT	GACGTAAGTA	950
	CCGCCTATAG	ACTCTATAGG	CACACCCCTT	TGGCTCTTAT	GCATGCTATA	1000
	CTGTTTTTGG	CTTGGGGCCT	ATACACCCCC	GCTTCCTTAT	GCTATAGGTG	1050
25	ATGGTATAGC	TTAGCCTATA	GGTGTGGGTT	ATTGACCATT	ATTGACCACT	1100
	CCCCTATTGG	TGACGATACT	TTCCATTACT	AATCCATAAC	ATGGCTCTTT	1150
	GCCACAACCTA	TCTCTATTGG	CTATATGCCA	ATACTCTGTC	CTTCAGAGAC	1200
	TGACACGGAC	TCTGTATTTT	TACAGGATGG	GGTCCCATT	ATTATTTACA	1250
	AATTCACATA	TACAACAACG	CCGTCCCCCG	TGCCCGCAGT	TTTTATTAAA	1300
30	CATAGCGTGG	GATCTCCACG	CGAATCTCGG	GTACGTGTTT	CGGACATGGG	1350
	CTCTTCTCCG	GTAGCGGCGG	AGCTTCCACA	TCCGAGCCCT	GGTCCCATGC	1400
	CTCCAGCGGC	TCATGGTCGC	TCGGCAGCTC	CTTGCTCCTA	ACAGTGGAGG	1450
	CCAGACTTAG	GCACAGCACA	ATGCCCACCA	CCACCAGTGT	GCCGCACAAG	1500
35	GCCGTGGCGG	TAGGGTATGT	GTCTGAAAAT	GAGCGTGGAG	ATTGGGCTCG	1550
	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATT	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
	GTGCTGTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCTTTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
40	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGAATAAC	2050
45	GATGCCCAT	GTACTTGTTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTT	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTCAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
50	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
55	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTGA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
60	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900

119

	CATGCAGAAA	TCAATGAAGC	AGGCAGAGAG	GTGGTAGGGT	CAGCAGAGGC	6000
	TGGAGTGGAT	GCTGCAAGCG	TCTCTGAAGA	ATTTAGGGCT	GACCATCCAT	6050
	TCCTCTTCTG	TATCAAGCAC	ATCGCAACCA	ACGCCGTTCT	CTTCTTTGGC	6100
	AGATGTGTTT	CCCCTCCGCG	GCCAGCAGAT	GACGCACCAG	CAGATGACGC	6150
5	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	6200
	CAGATGACGC	AACAACATGT	ATCCTGAAAG	GCTCTTGTGG	CTGGATCGGC	6250
	CTGCTGGATG	ACGATGACAA	AAAATACAAA	AAAGCACTGA	AAAAACTGGC	6300
	AAAACTGCTG	TAATGAGGGC	GCCTGGATCC	AGATCACTTC	TGGCTAATAA	6350
	AAGATCAGAG	CTCTAGAGAT	CTGTGTGTTG	GTTTTTTGTG	GATCTGCTGT	6400
10	GCCTTCTAGT	TGCCAGCCAT	CTGTTGTTTG	CCCCTCCCCC	GTGCCTTCCT	6450
	TGACCCTGGA	AGGTGCCACT	CCCCTGTCC	TTTCCTAATA	AAATGAGGAA	6500
	ATTGCATCGC	ATTGTCTGAG	TAGGTGTCAT	TCTATTCTGG	GGGGTGGGGT	6550
	GGGGCAGCAC	AGCAAGGGG	AGGATTGGGA	AGACAATAGC	AGGCATGCTG	6600
	GGGATGCGGT	GGGCTCTATG	GGTACCTCTC	TCTCTCTCTC	TCTCTCTCTC	6650
15	TCTCTCTCTC	TCTCTCGGTA	CCTCTCTCGA	GGGGGGGCC	GGTACCCAAT	6700
	TCGCCCTATA	GTGAGTCGTA	TTACGCGCGC	TACTGGCCG	TCGTTTACA	6750
	ACGTCGTGAC	TGGGAAAACC	CTGGCGTTAC	CCAACTTAAT	CGCCTTGCAG	6800
	CACATCCCCC	TTTCGCCAGC	TGGCGTAATA	GCGAAGAGGC	CCGCACCGAT	6850
	CGCCCTTCCC	AACAGTTGCG	CAGCCTGAAT	GGCGAATGGA	AATTGTAAGC	6900
20	GTTAATATTT	TGTTAAAATT	CGCGTTAAAT	TTTTGTAA	TCAGCTCATT	6950
	TTTTAACC	TAGGCCGAAA	TCGGCAAAAT	CCCTTATAAA	TCAAAAGAAT	7000
	AGACCGAGAT	AGGGTTGAGT	GTTGTTCCAG	TTTGGAACAA	GAGTCCACTA	7050
	TTAAAGAACG	TGGACTCCAA	CGTCAAAGGG	CGAAAAACCG	TCTATCAGGG	7100
	CGATGGCCCA	CTACTCCGGG	ATCATATGAC	AAGATGTGTA	TCCACCTTAA	7150
25	CTTAATGATT	TTTACCAAAA	TCATTAGGGG	ATTCATCAGT	GCTCAGGGTC	7200
	AACGAGAATT	AACATTCCGT	CAGGAAAGCT	TATGATGATG	ATGTGCTTAA	7250
	AAACTTACTC	AATGGCTGGT	TATGCATATC	GCAATACATG	CGAAAAACCT	7300
	AAAAGAGCTT	GCCGATAAAA	AAGGCCAATT	TATTGCTATT	TACCGCGGCT	7350
	TTTTATTGAG	CTTGAAAGAT	AAATAAAATA	GATAGGTTTT	ATTTGAAGCT	7400
30	AAATCTTCTT	TATCGTAAAA	AATGCCCTCT	TGGGTTATCA	AGAGGGTCAT	7450
	TATATTTTCG	GGAATAACAT	CATTTGGTGA	CGAAATAACT	AAGCACTTGT	7500
	CTCCTGTTTA	CTCCCTGAG	CTTGAGGGGT	TAACATGAAG	GTCATCGATA	7550
	GCAGGATAAT	AATACAGTAA	AACGCTAAAC	CAATAATCCA	AATCCAGCCA	7600
	TCCCAAATTG	GTAAGTGAATG	ATTATAAATA	ACAGCAAACA	GTAATGGGCC	7650
35	AATAACACCG	GTTGCATTGG	TAAGGCTCAC	CAATAATCCC	TGTAAAGCAC	7700
	CTTGCTGATG	ACTCTTTGTT	TGGATAGACA	TACTCCCTG	TAATGCAGGT	7750
	AAAGCGATCC	CACCACCAGC	CAATAAAATT	AAAACAGGGA	AAACTAACCA	7800
	ACCTTCAGAT	ATAAACGCTA	AAAAGGCAAA	TGCACTACTA	TCTGCAATAA	7850
	ATCCGAGCAG	TACTGCCGTT	TTTTCGCCCC	ATTTAGTGGC	TATTCTTCCT	7900
40	GCCACAAAGG	CTTGGAATAC	TGAGTGTA	AGACCAAGAC	CCGCTAATGA	7950
	AAAGCCAACC	ATCATGCTAT	TCCATCCAAA	ACGATTTTCG	GTAAATAGCA	8000
	CCCACACCGT	TGCGGGAATT	TGGCCTATCA	ATTGCGCTGA	AAAATAAATA	8050
	ATCAACAAAA	TGGCATCGTT	TTAAATAAAG	TGATGTATAC	CGAATTCAGC	8100
	TTTTGTTCCC	TTTAGTGAGG	GTTAATTGCG	CGCTTGGCGT	AATCATGGTC	8150
45	ATAGCTGTTT	CCTGTGTGAA	ATTGTTATCC	GCTCACAATT	CCACACAACA	8200
	TACGAGCCGG	AAGCATAAAG	TGTAAAGCCT	GGGGTGCCTA	ATGAGTGAGC	8250
	TAACACACAT	TAATTGCGTT	GCGCTCACTG	CCCGCTTTCC	AGTCGGGAAA	8300
	CCTGTGCTGC	CAGCTGCATT	AATGAATCGG	CCAACGCGCG	GGGAGAGGCG	8350
	GTTTGCGTAT	TGGGCGCTCT	TCCGCTTCCT	CGCTCACTGA	CTCGCTGCGC	8400
50	TCGGTCGTTT	GGCTGCGGCG	AGCGGTATCA	GCTCACTCAA	AGGCGGTAAT	8450
	ACGGTTATCC	ACAGAATCAG	GGGATAACGC	AGGAAAGAAC	ATGTGAGCAA	8500
	AAGGCCAGCA	AAAGGCCAGG	AACCGTAAAA	AGGCCGCGTT	GCTGGCGTTT	8550
	TTCCATAGGC	TCCGCCCCCC	TGACGAGCAT	CACAAAAATC	GACGCTCAAG	8600
	TCAGAGGTGG	CGAAACCCGA	CAGGACTATA	AAGATACCAG	GCGTTTCCCC	8650
55	CTGGAAGCTC	CCTCGTGCGC	TCTCCTGTTT	CGACCCCTGCC	GCTTACCGGA	8700
	TACCTGTCCG	CCTTTCTCCC	TTGGGGAAGC	GTGGCGCTTT	CTCATAGCTC	8750
	ACGCTGTAGG	TATCTCAGTT	CGGTGTAGGT	CGTTGCTCC	AAGCTGGGCT	8800
	GTGTGCACGA	ACCCCCCGTT	CAGCCCGACC	GCTGCGCCTT	ATCCGGTAAC	8850
	TATCGTCTTG	AGTCCAACCC	GGTAAGACAC	GACTTATCGC	CACTGGCAGC	8900
60	AGCCACTGGT	AACAGGATTA	GCAGAGCGAG	GTATGTAGGC	GGTGCTACAG	8950
	AGTTCTTGAA	GTGGTGCCCT	AACTACGGCT	ACACTAGAAG	GACAGTATTT	9000

5 GGTATCTGCG CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG 9050
 CTCTTGATCC GGCAAACAAA CCACCGCTGG TAGCGGTGGT TTTTGTGTTT 9100
 GCAAGCAGCA GATTACGCGC AGAAAAAAG GATCTCAAGA AGATCCTTTG 9150
 ATCTTTTCTA CGGGGTCTGA CGCTCAGTGG AACGAAACT CACGTTAAGG 9200
 GATTTTGGTC ATGAGATTAT CAAAAAGGAT CTTACCTAG ATCCTTTTAA 9250
 ATTAAAAATG AAGTTTAA TCAATCTAAA GTATATATGA GTAAACTTGG 9300
 TCTGACAGTT ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG 9350
 TCTATTTCTG TCATCCATAG TTGCCTGACT CCCCCTCGTG TAGATAACTA 9400
 CGATACGGGA GGGCTTACCA TCTGGCCCCA GTGCTGCAAT GATACCGCGA 9450
 10 GACCCACGCT CACCGGCTCC AGATTTATCA GCAATAAACC AGCCAGCCGG 9500
 AAGGGCCGAG CGCAGAAGTG GTCTGCAAC TTTATCCGCC TCCATCCAGT 9550
 CTATTAATTG TTGCCGGGAA GCTAGAGTAA GTAGTTCCGCC AGTTAATAGT 9600
 TTGCGCAACG TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC 9650
 GTTTGGTATG GCTTCATTCA GCTCCGGTTC CCAACGATCA AGGCGAGTTA 9700
 15 CATGATCCCC CATGTTGTGC AAAAAAGCGG TTAGCTCCTT CGGTCTCTCCG 9750
 ATCGTTGTCA GAAGTAAGTT GGCCGAGTG TTATCACTCA TGGTTATGGC 9800
 AGCACTGCAT AATTCTCTTA CTGTCATGCC ATCCGTAAGA TGCTTTTCTG 9850
 TGACTGGTGA GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA 9900
 CCGAGTTGCT CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG 9950
 20 CAGAACTTTA AAAGTGCTCA TCATTGGAAA ACGTTCTTCG GGGCGAAAAC 10000
 TCTCAAGGAT CTTACCGCTG TTGAGATCCA GTTCGATGTA ACCCACTCGT 10050
 GCACCCAAC TATCTTCTAGC ATCTTTTACT TTCACCAGCG TTTCTGGGTG 10100
 AGCAAAAACA GGAAGGCAAA ATGCCGCAAA AAAGGGAATA AGGCGACAC 10150
 GGAAATGTTG AATACTCATA CTCTTCTTTT TTCAATATTA TTGAAGCATT 10200
 25 TATCAGGGTT ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA 10250
 AAATAACAA ATAGGGGTTC CGCGCACATT TCCCCGAAAA GTGCCAC 10297

SEQ ID NO:30 (pTnMod(Oval/ENT tag/P146/PA) - QUAIL)
 30 CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC 100
 TTTCTTCCCT TCCTTCTCG CCACGTTCCG CGGCATCAGA TTGGCTATTG 150
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 35 CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
 TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
 CGTTACATAA CTTACGGTAA ATGGCCCCCG TGGCTGACCG CCCAACGACC 350
 CCCGCCCAT TACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGGCCA 450
 40 CTTGGCAGTA CATCAAGTG ATCATATGCC AAGTACGCCC CCTATTGACG 500
 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCAGTA CATGACCTTA 550
 TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650
 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
 45 TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
 TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 50 CCGCCTATAG ACTCTATAG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 CTGTTTTTGG CTTGGGGCCT ATACACCCCT GCTTCCTTAT GCTATAGGTG 1050
 ATGGTATAGC TTAGCCTATA GGTGTGGGT ATTGACCATT ATTGACCACT 1100
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTAGAGAC 1200
 55 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250
 AATTCACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300
 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CGGACATGGG 1350
 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
 CTCCAGCGGC TCATGGTCCG TCGGCAGCTC CTTGCTCCTA ACAGTGAGG 1450
 60 CCAGACTTAG GCACAGCACA ATGCCACCA CCACCAGTG GCCGCACAAG 1500
 GCCGTGGCGG TAGGGTATGT GTCTGAAAT GAGCGTGGAG ATTGGGCTCG 1550

	CACGGCTGAC	GCAGATGGAA	GACTTAAGGC	AGCGGCAGAA	GAAGATGCAG	1600
	GCAGCTGAGT	TGTTGTATTC	TGATAAGAGT	CAGAGGTAAC	TCCCGTTGCG	1650
	GTGCTGTTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCTTTT	1750
5	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTCA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
10	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCATT	GTACTTGTTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTC	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
15	TCATTGTCAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
20	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTC	TAGCAACTAA	CTTACCTGTT	2600
	GAAATTTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCTGA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
25	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
30	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
	CCCTCCCCCG	TGCCTTCCTT	GACCCTGGAA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
35	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
40	CATCACAACA	AAAACGATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
45	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCCT	CACTAAAGGG	AACAAAAGCT	4000
50	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTCAGAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAAAAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTCAACA	TTCCTCTGTC	4200
	ATCTGCCAGG	CTGGAAGATC	ATGGAAGATC	TCTGAGGAAC	ATTGCAAGTT	4250
55	CATACCATAA	ACTCATTTGG	AATTGAGTAT	TATTTTGCTT	TGAATGGAGC	4300
	TATGTTTTGC	AGTTCCCTCA	GAAGAAAAGC	TTGTTATAAA	GCGTCTACAC	4350
	CCATCAAAAAG	ATATATTTAA	ATATTCCAAC	TACAGAAAAG	TTTTGTCTGC	4400
	TCTTCACTCT	GATCTCAGTT	GGTTTCTTCA	CGTACATGCT	TCTTTATTTG	4450
	CCTATTTTGT	CAAGAAAATA	ATAGGTCAAG	TCCTGTTCTC	ACTTATCTCC	4500
60	TGCCTAGCAT	GGCTTAGATG	CACGTTGTAC	ATTCAAGAAG	GATCAAAATGA	4550
	AACAGACTTC	TGGTCTGTTA	CAACAACCAT	AGTAATAAAC	AGACTAACTA	4600

	ATAATTGCTA	ATTATGTTTT	CCATCTCTAA	GGTTCCCACA	TTTTTCTGTT	4650
	TTAAGATCCC	ATTATCTGGT	TGTAAGTCAA	GCTCAATGGA	ACATGAACAG	4700
	TATTTCTCAG	TCTTTTCTCC	AGCAATCCTG	ACGGATTAGA	AGAACTGGCA	4750
	GAAAACACTT	TGTTACCCAG	AATTAAAAAC	TAATATTTGC	TCTCCCTTCA	4800
5	ATCCAAAATG	GACCTATTGA	AACTAAAATC	TGACCCAATC	CCATTAAATT	4850
	ATTTCTATGG	CGTCAAAGGT	CAAACTTTTG	AAGGGAACCT	GTGGGTGGGT	4900
	CCCAATTCAG	GCTATATATT	CCCCAGGGCT	CAGCCAGTGG	ATCCATGGGC	4950
	TCCATCGGTG	CAGCAAGCAT	GGAATTTTGT	TTTGATGTAT	TCAAGGAGCT	5000
	CAAAGTCCAC	CATGCCAATG	ACAACATGCT	CTACTCCCCC	TTTGCCATCT	5050
10	TGTCAACTCT	GGCCATGGTC	TTCCTAGGTG	CAAAAGACAG	CACCAGGACC	5100
	CAGATAAATA	AGGTTGTTCA	CTTTGATAAA	CTTCCAGGAT	TCGGAGACAG	5150
	TATTGAAGCT	CAGTGTGGCA	CATCTGTAAA	TGTTCACTCT	TCACCTAGAG	5200
	ACATACTCAA	CCAAATCACC	AAACAAAATG	ATGCTTATTC	GTTGAGCCTT	5250
	GCCAGTAGAC	TTTATGCTCA	AGAGACATAC	ACAGTCGTGC	CGGAATACTT	5300
15	GCAATGTGTG	AAGGAACTGT	ATAGAGGAGG	CTTAGAATCC	GTCAACTTTC	5350
	AAACAGCTGC	AGATCAAGCC	AGAGGCCCTCA	TCAATGCCTG	GGTAGAAAGT	5400
	CAGACAAACG	GAATTATCAG	AAACATCCTT	CAGCCAAGCT	CCGTGGATTG	5450
	TCAAACCTGCA	ATGGTCCTGG	TTAATGCCAT	TGCCTTCAAG	GGACTGTGGG	5500
	AGAAAGCATT	TAAGGCTGAA	GACACGCAA	CAATACCTTT	CAGAGTGACT	5550
20	GAGCAAGAAA	GCAAACCTGT	GCAGATGATG	TACCAGATTG	GTTTATTTAA	5600
	AGTGGCATCA	ATGGCTTCTG	AGAAAATGAA	GATCCTGGAG	CTTCCATTTG	5650
	CCAGTGGAAC	AATGAGCATG	TTGGTGCTGT	TGCCTGATGA	TGTCTCAGGC	5700
	CTTGAGCAGC	TTGAGAGTAT	AATCAGCTTT	GAAAACTGA	CTGAATGGAC	5750
	CAGTTCTAGT	ATTATGGAAG	AGAGGAAGGT	CAAAGTGTAC	TTACCTCGCA	5800
25	TGAAGATGGA	GGAGAAATAC	AACCTCACAT	CTCTCTTAAT	GGCTATGGGA	5850
	ATTACTGACC	TGTTTCTGCT	TTCAGCCAAT	CTGTCTGGCA	TCTCCTCAGT	5900
	AGGGAGCCTG	AAGATATCTC	AAGCTGTCCA	TGCAGCACAT	GCAGAAATCA	5950
	ATGAAGCGGG	CAGAGATGTG	GTAGGCTCAG	CAGAGGCTGG	AGTGGATGCT	6000
	ACTGAAGAAT	TTAGGGCTGA	CCATCCATTC	CTCTTCTGTG	TCAAGCACAT	6050
30	CGAAACCAAC	GCCATTCTCC	TCTTTGGCAG	ATGTGTTTCT	CCGCGGCCAG	6100
	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	6150
	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCAACAA	CATGTATCCT	6200
	GAAAGGCTCT	TGTGGCTGGA	TCGGCCTGCT	GGATGACGAT	GACAAAAAAT	6250
	ACAAAAAAGC	ACTGAAAAAA	CTGGCAAAAC	TGCTGTAATG	AGGGCGCCTG	6300
35	GATCCAGATC	ACTTCTGGCT	AATAAAAGAT	CAGAGCTCTA	GAGATCTGTG	6350
	TGTTGGTTTT	TTGTGGATCT	GCTGTGCCTT	CTAGTTGCCA	GCCATCTGTT	6400
	GTTTGCCCTT	CCCCCGTGCC	TTCCTTGACC	CTGGAAGGTG	CCACTCCCAC	6450
	TGTCCTTTCC	TAATAAAATG	AGGAAATTGC	ATCGCATTGT	CTGAGTAGGT	6500
	GTCATTCTAT	TCTGGGGGGT	GGGGTGGGGC	AGCACAGCAA	GGGGGAGGAT	6550
40	TGGGAAGACA	ATAGCAGGCA	TGCTGGGGAT	GCGGTGGGCT	CTATGGGTAC	6600
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCTCT	6650
	CTCGAGGGGG	GGCCCGGTAC	CCAATTCGCC	CTATAGTGAG	TCGTATTACG	6700
	CGCGCTCACT	GGCCGTCGTT	TTACAACGTC	GTGACTGGGA	AAACCCTGGC	6750
	GTTACCCAAC	TTAATCGCCT	TGCAGCACAT	CCCCCTCTCG	CCAGCTGGCG	6800
45	TAATAGCGAA	GAGGCCCGCA	CCGATCGCCC	TTCCCAACAG	TTGCGCAGCC	6850
	TGAATGGCGA	ATGGAAATTG	TAAGCGTTAA	TATTTTGTTA	AAATTCGCGT	6900
	TAAATTTTTG	TTAAATCAGC	TCATTTTTTA	ACCAATAGGC	CGAAATCGGC	6950
	AAAATCCCTT	ATAAATCAAA	AGAATAGACC	GAGATAGGGT	TGAGTGTTGT	7000
	TCCAGTTTGG	AACAAGAGTC	CACTATTAAA	GAACGTGGAC	TCCAACGTCA	7050
50	AAGGGCGAAA	AACCGTCTAT	CAGGGCGATG	GCCCCACTACT	CCGGGATCAT	7100
	ATGACAAGAT	GTGTATCCAC	CTTAACCTAA	TGATTTTAC	CAAAATCATT	7150
	AGGGGATTCA	TCAGTGCTCA	GGGTCAACGA	GAATTAACAT	TCCGTCAGGA	7200
	AAGCTTATGA	TGATGATGTG	CTTAAAAACT	TACTCAATGG	CTGGTTATGC	7250
	ATATCGCAAT	ACATGCGAAA	AACCTAAAAG	AGCTTGCCGA	TAAAAAAGGC	7300
55	CAATTTATTG	CTATTTACCG	CGGCTTTTTA	TTGAGCTTGA	AAGATAAATA	7350
	AAATAGATAG	GTTTTATTTG	AAGCTAAATC	TTCTTTATCG	TAAAAAATGC	7400
	CCTCTTGGGT	TATCAAGAGG	GTCATTATAT	TTGCGGGAAT	AACATCATTT	7450
	GGTGACGAAA	TAACCTAAGCA	CTTGTCTCCT	GTTTACTCCC	CTGAGCTTGA	7500
	GGGGTTAACA	TGAAGGTCAT	CGATAGCAGG	ATAATAATAC	AGTAAAACGC	7550
60	TAAACCAATA	ATCCAAATCC	AGCCATCCCA	AATTGGTAGT	GAATGATTAT	7600
	AAATAACAGC	AAACAGTAAT	GGGCCAATAA	CACCGGTTGC	ATTGGTAAGG	7650

CTCACCAATA ATCCCTGTAA AGCACCTTGC TGATGACTCT TTGTTTGGAT 7700
 AGACATCACT CCCTGTAATG CAGGTAAAGC GATCCCACCA CCAGCCAATA 7750
 AAATTAAAAC AGGGAAAAC AACCACCTT CAGATATAAA CGCTAAAAAG 7800
 5 GCAAATGCAC TACTATCTGC AATAAATCCG AGCAGTACTG CCGTTTTTTC 7850
 GCCCCATTTA GTGGCTATTG TTCCTGCCAC AAAGGCTTGG AATACTGAGT 7900
 GTAAAAGACC AAGACCCGCT AATGAAAAGC CAACCATCAT GCTATTCCAT 7950
 CCAAAACGAT TTTCGGTAAA TAGCACCCAC ACCGTTGCGG GAATTTGGCC 8000
 TATCAATTGC GCTGAAAAAT AAATAATCAA CAAAATGGCA TCGTTTTAAA 8050
 TAAAGTGATG TATACCGAAT TCAGCTTTTG TTCCCTTTAG TGAGGGTTAA 8100
 10 TTGCGCGCTT GGCGTAATCA TGGTCATAGC TGTTTCCTGT GTGAAATTGT 8150
 TATCCGCTCA CAATTCCACA CAACATACGA GCCGGAAGCA TAAAGTGTA 8200
 AGCCTGGGGT GCCTAATGAG TGAGCTAACT CACATTAATT GCGTTGCGCT 8250
 CACTGCCCCG TTTCCAGTCG GGAAACCTGT CGTGCCAGCT GCATTAATGA 8300
 ATCGGCCAAC GCGCGGGGAG AGGCGGTTTG CGTATTGGGC GCTCTTCCGC 8350
 15 TTCCTCGCTC ACTGACTCGC TCGCTCGGT CGTTCGGCTG CGGCGAGCGG 8400
 TATCAGCTCA CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT 8450
 AACGCAGGAA AGAACATGTG AGCAAAAGGC CAGCAAAAGG CCAGGAACCG 8500
 TAAAAAGGCC GCGTTGCTGG CGTTTTTCCA TAGGCTCCGC CCCCTGACG 8550
 AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA CCCGACAGGA 8600
 20 CTATAAAGAT ACCAGGCGTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC 8650
 TGTTCGACC CTGCCGCTTA CCGGATACCT GTCCGCCTTT CTCCCTTCGG 8700
 GAAGCGTGGC GCTTTCTCAT AGCTCACGCT GTAGGTATCT CAGTTCGGTG 8750
 TAGGTCGTTG GCTCCAAGCT GGGCTGTGTG CACGAACCCC CCGTTCAGCC 8800
 CGACCGCTGC GCCTTATCCG GTAACATCG TCTTGAGTCC AACCCGGTAA 8850
 25 GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG GATTAGCAGA 8900
 GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCCTAACTA 8950
 CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG 9000
 TTACCTTCGG AAAAAGAGTT GGTAAGTCTT GATCCGGCAA ACAAACCACC 9050
 GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA CGCGCAGAAA 9100
 30 AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC 9150
 AGTGGAACGA AAACCTACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA 9200
 AGGATCTTCA CCTAGATCCT TTAAATTA AAATGAAGTT TTAAATCAAT 9250
 CTAAAGTATA TATGAGTAAA CTGGTCTGA CAGTTACCAA TGCTTAATCA 9300
 GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTTCATC CATAGTTGCC 9350
 35 TGACTCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG 9400
 CCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT 9450
 TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT 9500
 GCAACTTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG 9550
 AGTAAGTAGT TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA 9600
 40 CAGGCATCGT GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC 9650
 GGTTCCCAAC GATCAAGGCG AGTTACATGA TCCCCATGT TGTGCAAAAA 9700
 AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG 9750
 CAGTGTTATC ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC 9800
 ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC 9850
 45 ATTCTGAGAA TAGTGTATGC GCGGACCGAG TTGCTCTTGC CCGGCGTCAA 9900
 TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT 9950
 GGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG 10000
 ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT 10050
 50 TTACTTTCAC CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC 10100
 GCAAAAAGG GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT 10150
 CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG 10200
 GATACATaTT TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC 10250
 ACATTTCCCC GAAAAGTGCC AC 10272

55

SEQ ID NO:31 (pTnMod(Oval/ENT tag/Proins/PA) - Chicken)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTCGC 100
 60 TTTCTTCCCT TCCTTTCTCG CCACGTTCCG CCGCATCAGA TTGGCTATTG 150
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200

CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
TAGTAATCAA TTACGGGGTC ATTAGTTCAT AGCCCATATA TGGAGTTCCG 300
CGTTACATAA CTTACGGTAA ATGGCCCGCC TGGCTGACCG CCCAACGACC 350
CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
5 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGGCCA 450
CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA 550
TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
CATGGTGATG CGGTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650
10 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750
CCCATGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
15 GGAACGGTGC ATTGGAACGC GGATCCCCG TGCCAAGAGT GACGTAAGTA 950
CCGCCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
CTGTTTTTGG CTTGGGGCCT ATACACCCCC GCTTCCTTAT GCTATAGGTG 1050
ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
20 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTAGAGAC 1200
TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250
AATTCACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300
CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTC CGGACATGGG 1350
CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
25 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450
CCAGACTTAG GCACAGCACA ATGCCACCA CCACCAGTGT GCCGCACAAG 1500
GCCGTGGCGG TAGGGTATGT GTCTGAAAT GAGCGTGGAG ATTGGGCTCG 1550
CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
GCAGCTGAGT TGTGTATTTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650
30 GTGCTGTTAA CGGTGGAGGG CAGTGTAGTC TGAGCAGTAC TCGTTGCTGC 1700
CGCGCGCGCC ACCAGACATA ATAGCTGACA GACTAACAGA CTGTTCTTTT 1750
CCATGGGTCT TTTCTGCAGT CACCGTCGGA CCATGTGTGA ACTTGATATT 1800
TTACATGATT CTCTTTACCA ATTCTGCCCC GAATTACACT TAAAACGACT 1850
CAACAGCTTA ACGTTGGCTT GCCACGCATT ACTTGACTGT AAAACTCTCA 1900
35 CTCTTACCGA ACTTGGCCGT AACCTGCCAA CCAAAGCGAG AACAAAACAT 1950
AACATCAAAC GAATCGACCG ATTGTTAGGT AATCGTCACC TCCACAAAGA 2000
GCGACTCGCT GTATACCGTT GGCATGCTAG CTTTATCTGT TCGGGAATAC 2050
GATGCCCATT GTACTTGTTG ACTGGTCTGA TATTCGTGAG CAAAAACGAC 2100
TTATGGTATT GCGAGCTTCA GTCGCACTAC ACGGTCGTTT TGTTACTCTT 2150
40 TATGAGAAAG CGTTCCCGCT TTCAGAGCAA TGTTCAAAGA AAGCTCATGA 2200
CCAATTTCTA GCCGACCTTG CGAGCATTCT ACCGAGTAAC ACCACACCGC 2250
TCATTGTCAG TGATGCTGGC TTAAAGTGC CATGGTATAA ATCCGTTGAG 2300
AAGCTGGGTT GGTACTGGTT AAGTCAGTA AGAGGAAAAG TACAATATGC 2350
AGACCTAGGA GCGGAAAAC GGAACCTAT CAGCAACTTA CATGATATGT 2400
45 CATCTAGTCA CTCAAAGACT TTAGGCTATA AGAGGCTGAC TAAAAGCAAT 2450
CCAATCTCAT GCCAAATTCT ATTGTATAAA TCTCGCTCTA AAGGCCGAAA 2500
AAATCAGCGC TCGACACGGA CTCATTGTCA CCACCCGTCA CCTAAAATCT 2550
ACTCAGCGTC GGCAAAGGAG CCATGGGTTT TAGCAACTAA CTTACCTGTT 2600
GAAATTGCGA CACCCAAACA ACTTGTTAAT ATCTATTGGA AGCGAATGCA 2650
50 GATTGAAGAA ACCTTCCGAG ACTTGAAAAG TCCTGCCTAC GGAAGGAGCC 2700
TACGCCATAG CCGAACGAGC AGCTCAGAGC GTTTTGATAT CATGCTGCTA 2750
ATCGCCCTGA TGCTTCAACT AACATGTTGG CTTGCGGGCG TTCATGCTCA 2800
GAAACAAGGT TGGGACAAGC ACTTCCAGGC TAACACAGTC AGAAATCGAA 2850
ACGTACTCTC AACAGTTCGC TTAGGCATGG AAGTTTTGCG GCATTCTGGC 2900
55 TACACAATAA CAAGGGAAGA CTTACTCGTG GCTGCAACCC TACTAGCTCA 2950
AAATTTATTC ACACATGGTT ACGCTTTGGG GAAATTATGA TAATGATCCA 3000
GATCACTTCT GGCTAATAAA AGATCAGAGC TCTAGAGATC TGTGTGTTGG 3050
TTTTTTGTGG ATCTGCTGTG CTTTCTAGTT GCCAGCCATC TGTTGTTTGC 3100
CCCTCCCCCG TGCCTTCCTT GACCCTGGAA GGTGCCACTC CCACTGTCCT 3150
60 TTCCTAATAA AATGAGGAAA TTGCATCGCA TTGTCTGAGT AGGTGTCATT 3200
CTATTCTGGG GGGTGGGGTG GGCAGCACA GCAAGGGGGA GGATTGGGAA 3250

	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
5	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATCACAACA	AAAAC TGATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
10	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
15	CATGATTACG	CCAAGCGCGC	AATTAACCTT	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTCAGAA	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
	AACAATAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTACAAA	TTCCTCTGTC	4200
20	ATCTGCCAGG	CCATTAAGTT	ATTCATGGAA	GATCTTTGAG	GAACACTGCA	4250
	AGTTCATATC	ATAAACACAT	TTGAAATTGA	GTATTGTTTT	GCATTGTATG	4300
	GAGCTATGTT	TTGCTGTATC	CTCAGAAAAA	AAGTTTGTTA	TAAAGCATTC	4350
	ACACCCATAA	AAAGATAGAT	TTAAATATTC	CAGCTATAGG	AAAGAAAGTG	4400
	CGTCTGCTCT	TCACTCTAGT	CTCAGTTGGC	TCCTTCACAT	GCATGCTTCT	4450
25	TTATTTCTCC	TATTTTGTCA	AGAAAATAAT	AGGTCACGTC	TTGTTCTCAC	4500
	TTATGTCCTG	CCTAGCATGG	CTCAGATGCA	CGTTGTAGAT	ACAAGAAGGA	4550
	TCAAATGAAA	CAGACTTCTG	GTCTGTTACT	ACAACCATAG	TAATAAGCAC	4600
	ACTAACTAAT	AATTGCTAAT	TATGTTTTCC	ATCTCTAAGG	TTCCACATT	4650
	TTTCTGTTTT	CTTAAAGATC	CCATTATCTG	GTTGTAAC TG	AAGCTCAATG	4700
30	GAACATGAGC	AATATTTCCC	AGTCTTCTCT	CCCATCCAAC	AGTCCTGATG	4750
	GATTAGCAGA	ACAGGCAGAA	AACACATTGT	TACCCAGAAT	TAAAACTAA	4800
	TATTTGCTCT	CCATTCAATC	CAAAATGGAC	CTATTGAAAC	TAAAATCTAA	4850
	CCCAATCCCA	TTAAATGATT	TCTATGGCGT	CAAAGGTCAA	ACTTCTGAAG	4900
	GGAACCTGTG	GGTGGGTCAC	AATTCAAGCT	ATATATTCCC	CAGGGCTCAG	4950
35	CGGATCCATG	GGCTCCATCG	GCGCAGCAAG	CATGGAATTT	TGTTTTGATG	5000
	TATTCAAGGA	GCTCAAAGTC	CACCATGCCA	ATGAGAACAT	CTTCTACTGC	5050
	CCCATTGCCA	TCATGTCAGC	TCTAGCCATG	GTATACCTGG	GTGCAAAAGA	5100
	CAGCACCAGG	ACACAGATAA	ATAAGGTTGT	TCGCTTTGAT	AACTTCCAG	5150
	GATTCCGAGA	CAGTATTGAA	GCTCAGTGTG	GCACATCTGT	AAACGTTTAC	5200
40	TCTTCACTTA	GAGACATCCT	CAACCAAATC	ACCAAACCAA	ATGATGTTTA	5250
	TTGTTTCTAGC	CTTGCCAGTA	GACTTTATGC	TGAAGAGAGA	TACCCAATCC	5300
	TGCCAGAATA	CTTGCCAGTGT	GTGAAGGAAC	TGTATAGAGG	AGGCTTGGA	5350
	CCTATCAACT	TTCAAACAGC	TGCAGATCAA	GCCAGAGAGC	TCATCAATTC	5400
	CTGGGTAGAA	AGTCAGACAA	ATGGAATTAT	CAGAAATGTC	CTTCAGCCAA	5450
45	GCTCCGTGGA	TTCTCAAAC	GCAATGGTTC	TGGTTAATGC	CATTGTCTTC	5500
	AAAGGACTGT	GGGAGAAAAC	ATTTAAGGAT	GAAGACACAC	AAGCAATGCC	5550
	TTTCAGAGTG	ACTGAGCAAG	AAAGCAAACC	TGTGCAGATG	ATGTACCAGA	5600
	TTGGTTTATT	TAGAGTGGCA	TCAATGGCTT	CTGAGAAAAT	GAAGATCCTG	5650
	GAGCTTCCAT	TTGCCAGTGG	GACAATGAGC	ATGTTGGTGC	TGTTGCCTGA	5700
50	TGAAGTCTCA	GGCCTTGAGC	AGCTTGAGAG	TATAATCAAC	TTTGAAAAAC	5750
	TGACTGAATG	GACCAGTTCT	AATGTTATGG	AAGAGAGGAA	GATCAAAGTG	5800
	TACTTACCTC	GCATGAAGAT	GGAGGAAAAA	TACAACCTCA	CATCTGTCTT	5850
	AATGGCTATG	GGCATTACTG	ACGTGTTTAG	CTCTTCAGCC	AATCTGTCTG	5900
	GCATCTCCTC	AGCAGAGAGC	CTGAAGATAT	CTCAAGCTGT	CCATGCAGCA	5950
55	CATGCAGAAA	TCAATGAAGC	AGGCAGAGAG	GTGGTAGGGT	CAGCAGAGGC	6000
	TGGAGTGGAT	GCTGCAAGCG	TCTCTGAAGA	ATTTAGGGCT	GACCATCCAT	6050
	TCCTCTTCTG	TATCAAGCAC	ATCGCAACCA	ACGCCGTTCT	CTTCTTTGGC	6100
	AGATGTGTTT	CCCCTCCGCG	GCCAGCAGAT	GACGCACCAG	CAGATGACGC	6150
	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	6200
60	CAGATGACGC	AACAACATGT	ATCCTGAAAG	GCTCTTGTGG	CTGGATCGGC	6250
	CTGCTGGATG	ACGATGACAA	ATTTGTGAAC	CAACACCTGT	GCGGCTCACA	6300

	CCTGGTGGAA	GCTCTCTACC	TAGTGTGCGG	GGAACGAGGC	TTCTTCTACA	6350
	CACCCAAGAC	CCGCCGGGAG	GCAGAGGACC	TGCAGGTGGG	GCAGGTGGAG	6400
	CTGGGCGGGG	GCCCTGGTGC	AGGCAGCCTG	CAGCCCTTGG	CCCTGGAGGG	6450
	GTCCCTGCAG	AAGCGTGGCA	TTGTGGAACA	ATGCTGTACC	AGCATCTGCT	6500
5	CCCTCTACCA	GCTGGAGAAC	TACTGCAACT	AGGGCGCCTG	GATCCAGATC	6550
	ACTTCTGGCT	AATAAAAGAT	CAGAGCTCTA	GAGATCTGTG	TGTTGGTTTT	6600
	TTGTGGATCT	GCTGTGCCTT	CTAGTTGCCA	GCCATCTGTT	GTTTGCCCTT	6650
	CCCCCGTGCC	TTCCTTGACC	CTGGAAGGTG	CCACTCCCAC	TGTCCTTTCC	6700
	TAATAAAATG	AGGAAATTGC	ATCGCATTGT	CTGAGTAGGT	GTCATTCTAT	6750
10	TCTGGGGGGT	GGGGTGGGGC	AGCACAGCAA	GGGGGAGGAT	TGGGAAGACA	6800
	ATAGCAGGCA	TGCTGGGGAT	GCGGTGGGCT	CTATGGGTAC	CTCTCTCTCT	6850
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCTCT	CTCGAGGGGG	6900
	GGCCCGGTAC	CCAATTTCGCC	CTATAGTGAG	TCGTATTACG	CGCGCTCACT	6950
	GGCCGTCGTT	TTACAACGTC	GTGACTGGGA	AAACCCTGGC	GTTACCCAAC	7000
15	TTAATCGCCT	TGCAGCACAT	CCCCCTTTTCG	CCAGCTGGCG	TAATAGCGAA	7050
	GAGGCCCGCA	CCGATCGCCC	TTCCCAACAG	TTGCGCAGCC	TGAATGGCGA	7100
	ATGGAAATTG	TAAGCGTTAA	TATTTTGTTA	AAATTCGCGT	TAAATTTTTG	7150
	TTAAATCAGC	TCATTTTTTA	ACCAATAGGC	CGAAATCGGC	AAAATCCCTT	7200
	ATAAATCAAA	AGAATAGACC	GAGATAGGGT	TGAGTGTTGT	TCCAGTTTGG	7250
20	AACAAGAGTC	CACTATTAAA	GAACGTGGAC	TCCAACGTCA	AAGGGCGAAA	7300
	AACCGTCTAT	CAGGGCGATG	GCCCACTACT	CCGGGATCAT	ATGACAAGAT	7350
	GTGTATCCAC	CTTAAC TTAA	TGATTTTTAC	CAAAATCATT	AGGGGATTCA	7400
	TCAGTGCTCA	GGGTCAACGA	GAATTAACAT	TCCGTCAGGA	AAGCTTATGA	7450
	TGATGATGTG	CTTAAAAACT	TACTCAATGG	CTGGTTATGC	ATATCGCAAT	7500
25	ACATGCGAAA	AACCTAAAAG	AGCTTGCCGA	TAAAAAAGGC	CAATTTATTG	7550
	CTATTTACCG	CGGCTTTTTA	TTGAGCTTGA	AAGATAAATA	AAATAGATAG	7600
	GTTTTATTTG	AAGCTAAATC	TTCTTTATCG	TAAAAAATGC	CCTCTTGGGT	7650
	TATCAAGAGG	GTCATTATAT	TTGCGGAAT	AACATCATT	GGTGACGAAA	7700
	TAATAAGCA	CTTGTCTCCT	GTTTACTCCC	CTGAGCTTGA	GGGGTTAACA	7750
30	TGAAGGTCAT	CGATAGCAGG	ATAATAATAC	AGTAAAACGC	TAAACCAATA	7800
	ATCCAAATCC	AGCCATCCCA	AATTGGTAGT	GAATGATTAT	AAATAACAGC	7850
	AAACAGTAAT	GGGCCAATAA	CACCGGTTGC	ATTGGTAAGG	CTCACCAATA	7900
	ATCCCTGTAA	AGCACCTTGC	TGATGACTCT	TTGTTTGGAT	AGACATCACT	7950
	CCCTGTAATG	CAGGTAAAGC	GATCCACCA	CCAGCCAATA	AAATTAAAAC	8000
35	AGGGAAAAC	AACCAACCTT	CAGATATAAA	CGCTAAAAAG	GCAAATGCAC	8050
	TACTATCTGC	AATAAATCCG	AGCAGTACTG	CCGTTTTTTC	GCCCCATTTA	8100
	GTGGCTATT	TTCCTGCCAC	AAAGGCTTGG	AATACTGAGT	GTAAAAGACC	8150
	AAGACCCGCT	AATGAAAAGC	CAACCATCAT	GCTATTCCAT	CCAAAACGAT	8200
	TTTCGGTAAA	TAGCACCCAC	ACCGTTGCGG	GAATTTGGCC	TATCAATTGC	8250
40	GCTGAAAAAT	AAATAATCAA	CAAAATGGCA	TCGTTTTAAA	TAAAGTGATG	8300
	TATACCGAAT	TCAGCTTTTG	TTCCCTTTAG	TGAGGGTTAA	TTGCGCGCTT	8350
	GGCGTAATCA	TGGTCATAGC	TGTTTCCTGT	GTGAAATTGT	TATCCGCTCA	8400
	CAATTCCACA	CAACATACGA	GCCGGAAGCA	TAAAGTGTA	AGCCTGGGGT	8450
45	GCCTAATGAG	TGAGCTAACT	CACATTAATT	GCGTTGCGCT	CACTGCCCCG	8500
	TTTCCAGTCG	GGAAACCTGT	CGTGCCAGCT	GCATTAATGA	ATCGGCCAAC	8550
	GCGCGGGGAG	AGGCGGTTTG	CGTATTGGGC	GCTCTTCCGC	TTCCTCGCTC	8600
	ACTGACTCGC	TGCGCTCGGT	CGTTCGGCTG	CGGCGAGCGG	TATCAGCTCA	8650
	CTCAAAGGCG	GTAATACGGT	TATCCACAGA	ATCAGGGGAT	AACGCAGGAA	8700
	AGAACATGTG	AGCAAAAGGC	CAGCAAAAGG	CCAGGAACCG	TAAAAAGGCC	8750
50	GCGTTGCTGG	CGTTTTTCCA	TAGGCTCCGC	CCCCCTGACG	AGCATCACAA	8800
	AAATCGACGC	TCAAGTCAGA	GGTGGCGAAA	CCCGACAGGA	CTATAAAGAT	8850
	ACCAGGCGTT	TCCCCCTGGA	AGCTCCCTCG	TGCGCTCTCC	TGTTCCGACC	8900
	CTGCCGCTTA	CCGATACCT	GTCCGCCTTT	CTCCCTTCGG	GAAGCGTGGC	8950
	GCTTTCTCAT	AGCTCACGCT	GTAGGTATCT	CAGTTCGGTG	TAGGTCGTTT	9000
55	GCTCCAAGCT	GGGCTGTGTG	CACGAACCCC	CCGTTCCAGC	CGACCGCTGC	9050
	GCCTTATCCG	GTAACATATG	TCTTGAGTCC	AACCCGGTAA	GACACGACTT	9100
	ATCGCCACTG	GCAGCAGCCA	CTGGTAACAG	GATTAGCAGA	GCGAGGTATG	9150
	TAGGCGGTGC	TACAGAGTTC	TTGAAGTGGT	GGCCTAACTA	CGGCTACACT	9200
	AGAAGGACAG	TATTTGGTAT	CTGCGCTCTG	CTGAAGCCAG	TTACCTTCGG	9250
60	AAAAAGAGTT	GGTAGCTCTT	GATCCGGCAA	ACAAACCACC	GCTGGTAGCG	9300
	GTGGTTTTTT	TGTTTGCAAG	CAGCAGATTA	CGCGCAGAAA	AAAAGGATCT	9350

CAAGAAGATC CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA 9400
 AAACACACGT TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA 9450
 CCTAGATCCT TTAAATTAA AAATGAAGTT TTAAATCAAT CTAAAGTATA 9500
 TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC 9550
 5 TATCTCAGCG ATCTGTCTAT TTCGTTTCATC CATAGTTGCC TGACTCCCCG 9600
 TCGTGTAGAT AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT 9650
 GCAATGATAC CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT 9700
 AAACCAGCCA GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT 9750
 CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAGCTAG AGTAAGTAGT 9800
 10 TCGCCAGTTA ATAGTTTGCG CAACGTTGTT GCCATTGCTA CAGGCATCGT 9850
 GGTGTCACGC TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCTAAC 9900
 GATCAAGGCG AGTTACATGA TCCCCATGT TGTGCAAAAA AGCGGTTAGC 9950
 TCCTTCGGTC CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC 10000
 ACTCATGGTT ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG 10050
 15 TAAGATGCTT TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA 10100
 TAGTGTATGC GCGGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA 10150
 TACCCGCGCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT 10200
 CTTCCGGGCG AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTTCG 10250
 ATGTAACCCA CTCGTGCACC CAACTGATCT TCAGCATCTT TACTTTTCAC 10300
 20 CAGCGTTTCT GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAGG 10350
 GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT CCTTTTTCAC 10400
 TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT 10450
 TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCGCGC ACATTTCCCC 10500
 GAAAAGTGCC AC 10512
 25

SEQ ID NO:32 (pTnMod(Oval/ENT tag/Proins/PA) - QUAIL)

CTGACGCGCC CTGTAGCGGC GCATTAAGCG CGGCGGGTGT GGTGGTTACG 50
 30 CGCAGCGTGA CCGCTACACT TGCCAGCGCC CTAGCGCCCG CTCCTTTTCGC 100
 TTTCTTCCCT TCCTTTCTCG CCACGTTTCGC CGGCATCAGA TTGGCTATTG 150
 GCCATTGCAT ACGTTGTATC CATATCATAA TATGTACATT TATATTGGCT 200
 CATGTCCAAC ATTACCGCCA TGTTGACATT GATTATTGAC TAGTTATTAA 250
 TAGTAATCAA TTACGGGGTC ATTAGTTTCAT AGCCCATATA TGGAGTTCCG 300
 35 CGTTACATAA CTTACGGTAA ATGGCCCCGCC TGGCTGACCG CCCAACGACC 350
 CCCGCCCATT GACGTCAATA ATGACGTATG TTCCCATAGT AACGCCAATA 400
 GGGACTTTCC ATTGACGTCA ATGGGTGGAG TATTTACGGT AAAGTGGCCA 450
 CTTGGCAGTA CATCAAGTGT ATCATATGCC AAGTACGCCC CCTATTGACG 500
 TCAATGACGG TAAATGGCCC GCCTGGCATT ATGCCCAGTA CATGACCTTA 550
 40 TGGGACTTTC CTACTTGGCA GTACATCTAC GTATTAGTCA TCGCTATTAC 600
 CATGGTGATG CGGTTTTTGGC AGTACATCAA TGGGCGTGGA TAGCGGTTTG 650
 ACTCACGGGG ATTTCCAAGT CTCCACCCCA TTGACGTCAA TGGGAGTTTG 700
 TTTTGGCACC AAAATCAACG GGACTTTCCA AAATGTCGTA ACAACTCCGC 750
 CCCATTGACG CAAATGGGCG GTAGGCGTGT ACGGTGGGAG GTCTATATAA 800
 45 GCAGAGCTCG TTTAGTGAAC CGTCAGATCG CCTGGAGACG CCATCCACGC 850
 TGTTTTGACC TCCATAGAAG ACACCGGGAC CGATCCAGCC TCCGCGGCCG 900
 GGAACGGTGC ATTGGAACGC GGATTCCCCG TGCCAAGAGT GACGTAAGTA 950
 CCGCCTATAG ACTCTATAGG CACACCCCTT TGGCTCTTAT GCATGCTATA 1000
 CTGTTTTTGG CTTGGGGCCT ATACACCCCC GCTTCCTTAT GCTATAGGTG 1050
 50 ATGGTATAGC TTAGCCTATA GGTGTGGGTT ATTGACCATT ATTGACCACT 1100
 CCCCTATTGG TGACGATACT TTCCATTACT AATCCATAAC ATGGCTCTTT 1150
 GCCACAATA TCTCTATTGG CTATATGCCA ATACTCTGTC CTTGAGAGAC 1200
 TGACACGGAC TCTGTATTTT TACAGGATGG GGTCCCATTT ATTATTTACA 1250
 AATTCACATA TACAACAACG CCGTCCCCCG TGCCCGCAGT TTTTATTAAA 1300
 55 CATAGCGTGG GATCTCCACG CGAATCTCGG GTACGTGTTT CGGACATGGG 1350
 CTCTTCTCCG GTAGCGGCGG AGCTTCCACA TCCGAGCCCT GGTCCCATGC 1400
 CTCCAGCGGC TCATGGTCGC TCGGCAGCTC CTTGCTCCTA ACAGTGGAGG 1450
 CCAGACTTAG GCACAGCACA ATGCCCACCA CCACCAGTGT GCCGCACAAG 1500
 GCCGTGGCGG TAGGGTATGT GTCTGAAAT GAGCGTGGAG ATTGGGCTCG 1550
 60 CACGGCTGAC GCAGATGGAA GACTTAAGGC AGCGGCAGAA GAAGATGCAG 1600
 GCAGCTGAGT TGTTGTATTC TGATAAGAGT CAGAGGTAAC TCCCGTTGCG 1650

	GTGCTGTTAA	CGGTGGAGGG	CAGTGTAGTC	TGAGCAGTAC	TCGTTGCTGC	1700
	CGCGCGCGCC	ACCAGACATA	ATAGCTGACA	GACTAACAGA	CTGTTCCCTT	1750
	CCATGGGTCT	TTTCTGCAGT	CACCGTCGGA	CCATGTGTGA	ACTTGATATT	1800
	TTACATGATT	CTCTTTACCA	ATTCTGCCCC	GAATTACACT	TAAAACGACT	1850
5	CAACAGCTTA	ACGTTGGCTT	GCCACGCATT	ACTTGACTGT	AAAACCTCTCA	1900
	CTCTTACCGA	ACTTGGCCGT	AACCTGCCAA	CCAAAGCGAG	AACAAAACAT	1950
	AACATCAAAC	GAATCGACCG	ATTGTTAGGT	AATCGTCACC	TCCACAAAGA	2000
	GCGACTCGCT	GTATACCGTT	GGCATGCTAG	CTTTATCTGT	TCGGGAATAC	2050
	GATGCCCATT	GTACTTGTTG	ACTGGTCTGA	TATTCGTGAG	CAAAAACGAC	2100
10	TTATGGTATT	GCGAGCTTCA	GTCGCACTAC	ACGGTCGTTC	TGTTACTCTT	2150
	TATGAGAAAG	CGTTCCCGCT	TTCAGAGCAA	TGTTCAAAGA	AAGCTCATGA	2200
	CCAATTTCTA	GCCGACCTTG	CGAGCATTCT	ACCGAGTAAC	ACCACACCGC	2250
	TCATTGTCAG	TGATGCTGGC	TTTAAAGTGC	CATGGTATAA	ATCCGTTGAG	2300
	AAGCTGGGTT	GGTACTGGTT	AAGTCGAGTA	AGAGGAAAAG	TACAATATGC	2350
15	AGACCTAGGA	GCGGAAAAC	GGAAACCTAT	CAGCAACTTA	CATGATATGT	2400
	CATCTAGTCA	CTCAAAGACT	TTAGGCTATA	AGAGGCTGAC	TAAAAGCAAT	2450
	CCAATCTCAT	GCCAAATTCT	ATTGTATAAA	TCTCGCTCTA	AAGGCCGAAA	2500
	AAATCAGCGC	TCGACACGGA	CTCATTGTCA	CCACCCGTCA	CCTAAAATCT	2550
	ACTCAGCGTC	GGCAAAGGAG	CCATGGGTTT	TAGCAACTAA	CTTACCTGTT	2600
20	GAAATTCGAA	CACCCAAACA	ACTTGTTAAT	ATCTATTCGA	AGCGAATGCA	2650
	GATTGAAGAA	ACCTTCCGAG	ACTTGAAAAG	TCCTGCCTAC	GGACTAGGCC	2700
	TACGCCATAG	CCGAACGAGC	AGCTCAGAGC	GTTTTGATAT	CATGCTGCTA	2750
	ATCGCCCTGA	TGCTTCAACT	AACATGTTGG	CTTGCGGGCG	TTCATGCTCA	2800
	GAAACAAGGT	TGGGACAAGC	ACTTCCAGGC	TAACACAGTC	AGAAATCGAA	2850
25	ACGTACTCTC	AACAGTTCGC	TTAGGCATGG	AAGTTTTGCG	GCATTCTGGC	2900
	TACACAATAA	CAAGGGAAGA	CTTACTCGTG	GCTGCAACCC	TACTAGCTCA	2950
	AAATTTATTC	ACACATGGTT	ACGCTTTGGG	GAAATTATGA	TAATGATCCA	3000
	GATCACTTCT	GGCTAATAAA	AGATCAGAGC	TCTAGAGATC	TGTGTGTTGG	3050
	TTTTTTGTGG	ATCTGCTGTG	CCTTCTAGTT	GCCAGCCATC	TGTTGTTTGC	3100
30	CCCTCCCCCG	TGCCTTCCTT	GACCCTGGAA	GGTGCCACTC	CCACTGTCCT	3150
	TTCTTAATAA	AATGAGGAAA	TTGCATCGCA	TTGTCTGAGT	AGGTGTCATT	3200
	CTATTCTGGG	GGGTGGGGTG	GGGCAGCACA	GCAAGGGGGA	GGATTGGGAA	3250
	GACAATAGCA	GGCATGCTGG	GGATGCGGTG	GGCTCTATGG	GTACCTCTCT	3300
	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CTCTCGGTAC	CTCTCTCTCT	3350
35	CTCTCTCTCT	CTCTCTCTCT	CTCTCTCTCT	CGGTACCAGG	TGCTGAAGAA	3400
	TTGACCCGGT	GACCAAAGGT	GCCTTTTATC	ATCACTTTAA	AAATAAAAAA	3450
	CAATTACTCA	GTGCCTGTTA	TAAGCAGCAA	TTAATTATGA	TTGATGCCTA	3500
	CATCACAACA	AAAACCTGATT	TAACAAATGG	TTGGTCTGCC	TTAGAAAGTA	3550
	TATTTGAACA	TTATCTTGAT	TATATTATTG	ATAATAATAA	AAACCTTATC	3600
40	CCTATCCAAG	AAGTGATGCC	TATCATTGGT	TGGAATGAAC	TTGAAAAAAA	3650
	TTAGCCTTGA	ATACATTACT	GGTAAGGTAA	ACGCCATTGT	CAGCAAATTG	3700
	ATCCAAGAGA	ACCAACTTAA	AGCTTTCCTG	ACGGAATGTT	AATTCTCGTT	3750
	GACCCTGAGC	ACTGATGAAT	CCCCTAATGA	TTTTGGTAAA	AATCATTAAG	3800
	TTAAGGTGGA	TACACATCTT	GTCATATGAT	CCCGGTAATG	TGAGTTAGCT	3850
45	CACTCATTAG	GCACCCAGG	CTTTACACTT	TATGCTTCCG	GCTCGTATGT	3900
	TGTGTGGAAT	TGTGAGCGGA	TAACAATTTT	ACACAGGAAA	CAGCTATGAC	3950
	CATGATTACG	CCAAGCGCGC	AATTAACCC	CACTAAAGGG	AACAAAAGCT	4000
	GGAGCTCCAC	CGCGGTGGCG	GCCGCTCTAG	AACTAGTGGA	TCCCCCGGGG	4050
	AGGTCAGAAT	GGTTTCTTTA	CTGTTTGTCA	ATTCTATTAT	TTCAATACAG	4100
50	AACAAAAGCT	TCTATAACTG	AAATATATTT	GCTATTGTAT	ATTATGATTG	4150
	TCCCTCGAAC	CATGAACACT	CCTCCAGCTG	AATTTCACAA	TTCTCTGTCT	4200
	ATCTGCCAGG	CTGGAAGATC	ATGGAAGATC	TCTGAGGAAC	ATTGCAAGTT	4250
	CATACCATAA	ACTCATTTGG	AATTGAGTAT	TATTTTGCTT	TGAATGGAGC	4300
	TATGTTTTGC	AGTTCCCTCA	GAAGAAAAGC	TTGTTATAAA	GCGTCTACAC	4350
55	CCATC4AAAG	ATATATTTAA	ATATTCCAAC	TACAGAAAGA	TTTTGTCTGC	4400
	TCTTCACTCT	GATCTCAGTT	GGTTTCTTCA	CGTACATGCT	TCTTTATTTG	4450
	CCTATFTTGT	CAAGAAAATA	ATAGGTCAAG	TCCTGTTCTC	ACTTATCTCC	4500
	TGCCTAGCAT	GGCTTAGATG	CACGTTGTAC	ATTCAAGAAG	GATCAAATGA	4550
	AACAGACTTC	TGGTCTGTTA	CAACAACCAT	AGTAATAAAC	AGACTAACTA	4600
60	ATAATTGCTA	ATTATGTTTT	CCATCTCTAA	GGTTCCCAAC	TTTTTCTGTT	4650
	TTAAGATCCC	ATTATCTGGT	TGTAACGTAA	GCTCAATGGA	ACATGAACAG	4700

	TATTTCTCAG	TCTTTTCTCC	AGCAATCCTG	ACGGATTAGA	AGAACTGGCA	4750
	GAAAACACTT	TGTTACCCAG	AATTAAAAAC	TAATATTTGC	TCTCCCTTCA	4800
	ATCCAAAATG	GACCTATTGA	AACTAAAATC	TGACCCAATC	CCATTAAATT	4850
	ATTTCTATGG	CGTCAAAGGT	CAAACTTTGT	AAGGGAACCT	GTGGGTGGGT	4900
5	CCCAATTTCAG	GCTATATATT	CCCCAGGGCT	CAGCCAGTGG	ATCCATGGGC	4950
	TCCATCGGTG	CAGCAAGCAT	GGAATTTTGT	TTTGATGTAT	TCAAGGAGCT	5000
	CAAAGTCCAC	CATGCCAATG	ACAACATGCT	CTACTCCCCC	TTTGCCATCT	5050
	TGTCAACTCT	GGCCATGGTC	TTCTTAGGTG	CAAAAGACAG	CACCAGGACC	5100
	CAGATAAATA	AGGTGTGTTCA	CTTTGATAAA	CTTCCAGGAT	TCGGAGACAG	5150
10	TATTGAAGCT	CAGTGTGGCA	CATCTGTAAA	TGTTCACTCT	TCACTTAGAG	5200
	ACATACTCAA	CCAAATCACC	AAACAAAATG	ATGCTTATTC	GTTCAGCCTT	5250
	GCCAGTAGAC	TTTATGCTCA	AGAGACATAC	ACAGTCGTGC	CGGAATACTT	5300
	GCAATGTGTG	AAGGAACTGT	ATAGAGGAGG	CTTAGAATCC	GTCAACTTTC	5350
	AAACAGCTGC	AGATCAAGCC	AGAGGCCTCA	TCAATGCCTG	GGTAGAAAGT	5400
15	CAGACAAACG	GAATTATCAG	AAACATCCTT	CAGCCAAGCT	CCGTGGATTG	5450
	TCAAAC TGCA	ATGGTCCTGG	TTAATGCCAT	TGCCTTCAAG	GGACTGTGGG	5500
	AGAAAGCATT	TAAGGCTGAA	GACACGCAAA	CAATACCTTT	CAGAGTGACT	5550
	GAGCAAGAAA	GCAAACCTGT	GCAGATGATG	TACCAGATTG	GTTCATTTAA	5600
	AGTGGCATCA	ATGGCTTCTG	AGAAAATGAA	GATCCTGGAG	CTTCCATTTG	5650
20	CCAGTGGAAC	AATGAGCATG	TTGGTGCTGT	TGCCTGATGA	TGTCTCAGGC	5700
	CTTGAGCAGC	TTGAGAGTAT	AATCAGCTTT	GAAAAACTGA	CTGAATGGAC	5750
	CAGTTCTAGT	ATTATGGAAG	AGAGGAAGGT	CAAAGTGTAC	TTACCTCGCA	5800
	TGAAGATGGA	GGAGAAATAC	AACCTCACAT	CTCTCTTAAT	GGCTATGGGA	5850
	ATTACTGACC	TGTTTCTAGT	TTCAGCCAAT	CTGTCTGGCA	TCTCCTCAGT	5900
25	AGGGAGCCTG	AAGATATCTC	AAGCTGTCCA	TGCAGCACAT	GCAGAAATCA	5950
	ATGAAGCGGG	CAGAGATGTG	GTAGGCTCAG	CAGAGGCTGG	AGTGGATGCT	6000
	ACTGAAGAAT	TTAGGGCTGA	CCATCCATTC	CTCTTCTGTG	TCAAGCACAT	6050
	CGAAACCAAC	GCCATTCTCC	TCTTTGGCAG	ATGTGTTTCT	CCGCGGCCAG	6100
	CAGATGACGC	ACCAGCAGAT	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	6150
30	GACGCACCAG	CAGATGACGC	ACCAGCAGAT	GACGCAACAA	CATGTATCCT	6200
	GAAAGGCTCT	TGTGGCTGGA	TCGGCCTGCT	GGATGACGAT	GACAAATTTG	6250
	TGAACCAACA	CCTGTGCGGC	TCACACCTGG	TGGAAGCTCT	CTACCTAGTG	6300
	TGCGGGGAAC	GAGGCTTCTT	CTACACACCC	AAGACCCGCC	GGGAGGCAGA	6350
	GGACCTGCAG	GTGGGGCAGG	TGGAGCTGGG	CGGGGGCCCT	GGTGCAGGCA	6400
35	GCCTGCAGCC	CTTGGCCCTG	GAGGGGTCCC	TGCAGAAGCG	TGGCATTGTG	6450
	GAACAATGCT	GTACCAGCAT	CTGCTCCCTC	TACCAGCTGG	AGAACTACTG	6500
	CAACTAGGGC	GCCTGGATCC	AGATCACTTC	TGGCTAATAA	AAGATCAGAG	6550
	CTCTAGAGAT	CTGTGTGTTG	GTTTTTTGTG	GATCTGCTGT	GCCTTCTAGT	6600
	TGCCAGCCAT	CTGTTGTTTG	CCCCTCCCCC	GTGCCTTCCT	TGACCCTGGA	6650
40	AGGTGCCACT	CCCCTGTCC	TTTCTAATA	AAATGAGGAA	ATTGCATCGC	6700
	ATTGTCTGAG	TAGGTGTCAT	TCTATTCTGG	GGGGTGGGGT	GGGGCAGCAC	6750
	AGCAAGGGGG	AGGATTGGGA	AGACAATAGC	AGGCATGCTG	GGGATGCGGT	6800
	GGGCTCTATG	GGTACCTCTC	TCTCTCTCTC	TCTCTCTCTC	TCTCTCTCTC	6850
	TCTCTCGGTA	CCTCTCTCGA	GGGGGGGCC	GGTACCCAAT	TCGCCCTATA	6900
45	GTGAGTCGTA	TTACGCGCGC	TCACTGGCCG	TCGTTTTACA	ACGTCGTGAC	6950
	TGGGAAAACC	CTGGCGTTAC	CCAACCTAAT	CGCCTTGCA	CACATCCCCC	7000
	TTTCGCCAGC	TGGCGTAATA	GCGAAGAGGC	CCGCACCGAT	CGCCCTTCCC	7050
	AACAGTTGCG	CAGCCTGAAT	GGCGAATGGA	AATTGTAAGC	GTAAATATTT	7100
	TGTTAAAATT	CGCGTTAAAT	TTTTGTTAAA	TCAGCTCATT	TTTTAACCAG	7150
50	TAGGCCGAAA	TCGGCAAAAT	CCCTTATAAA	TCAAAAGAAT	AGACCGAGAT	7200
	AGGGTTGAGT	GTTGTTCCAG	TTTGGAAACA	GAGTCCACTA	TTAAAGAACG	7250
	TGGACTCCAA	CGTCAAAGGG	CGAAAAACCG	TCTATCAGGG	CGATGGCCCA	7300
	CTACTCCGGG	ATCATATGAC	AAGATGTGTA	TCCACCTTAA	CTTAATGATT	7350
	TTTACCAAAA	TCATTAGGGG	ATTCATCAGT	GCTCAGGGTC	AACGAGAATT	7400
55	AACATTCCGT	CAGGAAAGCT	TATGATGATG	ATGTGCTTAA	AACTTACTC	7450
	AATGGCTGGT	TATGCATATC	GCAATACATG	CGAAAAACCT	AAAAGAGCTT	7500
	GCCGATAAAA	AAGGCCAATT	TATTGCTATT	TACCGCGGCT	TTTTATTGAG	7550
	CTTGAAAGAT	AAATAAAATA	GATAGGTTTT	ATTTGAAGCT	AAATCTTCTT	7600
	TATCGTAAAA	AATGCCCTCT	TGGGTTATCA	AGAGGGTCAT	TATATTTTCG	7650
60	GGAATAACAT	CATTTGGTGA	CGAAATAACT	AAGCACTTGT	CTCCTGTTTA	7700
	CTCCCCTGAG	CTTGAGGGGT	TAACATGAAG	GTCATCGATA	GCAGGATAAT	7750

5 AATACAGTAA AACGCTAAAC CAATAATCCA AATCCAGCCA TCCCAAATTG 7800
GTAGTGAATG ATTATAAATA ACAGCAAACA GTAATGGGCC AATAACACCG 7850
GTTGCATTGG TAAGGCTCAC CAATAATCCC TGTAAGCAC CTTGCTGATG 7900
ACTCITTGTT TGGATAGACA TCACTCCCTG TAATGCAGGT AAAGCGATCC 7950
CACCACCAGC CAATAAAATT AAAACAGGGA AAATAACCA ACCTTCAGAT 8000
ATAAACGCTA AAAAGGCAAA TGCACTACTA TCTGCAATAA ATCCGAGCAG 8050
TACTGCCGTT TTTTCGCCCC ATTTAGTGGC TATTCTTCCT GCCACAAAGG 8100
CTTGAATAC TGAGTGTAAG AGACCAAGAC CCGCTAATGA AAAGCCAACC 8150
ATCATGCTAT TCCATCCAAA ACGATTTTCG GTAAATAGCA CCCACACCGT 8200
10 TGGCGGAATT TGGCCTATCA ATTGCGCTGA AAAATAAATA ATCAACAAAA 8250
TGGCATCGTT TTAAATAAAG TGATGTATAC CGAATTCAGC TTTTGTTCCT 8300
TTTAGTGAGG GTTAATTGCG CGCTTGGCGT AATCATGGTC ATAGCTGTTT 8350
CCTGTGTGAA ATTGTTATCC GCTCACAATT CCACACAACA TACGAGCCGG 8400
AAGCATAAAG TGTAAGCCT GGGGTGCCTA ATGAGTGAGC TAACTCACAT 8450
15 TAATTGCGTT GCGCTCACTG CCCGCTTTC AGTCGGGAAA CCTGTCGTGC 8500
CAGCTGCATT AATGAATCGG CCAACGCGCG GGGAGAGGCG GTTTGCGTAT 8550
TGGGCGCTCT TCCGCTTCCT CGCTCACTGA CTCGCTGCGC TCGGTCGTTT 8600
GGCTCGGCG AGCGGTATCA GCTCACTCAA AGGCGGTAAT ACGGTTATCC 8650
ACAGAATCAG GGGATAACGC AGGAAAGAAC ATGTGAGCAA AAGGCCAGCA 8700
20 AAAGGCCAGG AACCGTAAAA AGGCCGCGTT GCTGGCGTTT TTCCATAGGC 8750
TCCGCCCCC TGACGAGCAT CACAAAAATC GACGCTCAAG TCAGAGGTGG 8800
CGAAACCCGA CAGGACTATA AAGATACCAG GCGTTTCCCC CTGGAAGCTC 8850
CCTCGTGCGC TCTCCTGTTC CGACCCTGCC GCTTACCGGA TACCTGTCCG 8900
CCTTTCTCCC TTCGGGAAGC GTGGCGCTTT CTCATAGCTC ACGCTGTAGG 8950
25 TATCTCAGTT CGGTGTAGGT CGTTCGCTCC AAGCTGGGCT GTGTGCACGA 9000
ACCCCCGTT CAGCCCGACC GCTGCGCCTT ATCCGGTAAC TATCGTCTTG 9050
AGTCCAACCC GGTAAGACAC GACTTATCGC CACTGGCAGC AGCCACTGGT 9100
AACAGGATTA GCAGAGCGAG GTATGTAGGC GGTGCTACAG AGTTCTTGAA 9150
GTGGTGGCCT AACTACGGCT AACTAGAAG GACAGTATTT GGTATCTGCG 9200
30 CTCTGCTGAA GCCAGTTACC TTCGGAAAAA GAGTTGGTAG CTCTTGATCC 9250
GGCAAACAAA CCACCGCTGG TAGCGGTGGT TTTTTTGTTC GCAAGCAGCA 9300
GATTACGCGC AGAAAAAAG GATCTCAAGA AGATCCTTTG ATCTTTTCTA 9350
CGGGGTCTGA CGCTCAGTGG AACGAAAAC CACGTTAAGG GATTTTGGTC 9400
ATGAGATTAT CAAAAAGGAT CTTACCTAG ATCCTTTTAA ATTAATAATG 9450
35 AAGTTTTAAA TCAATCTAAA GTATATATGA GTAAACTTGG TCTGACAGTT 9500
ACCAATGCTT AATCAGTGAG GCACCTATCT CAGCGATCTG TCTATTTCGT 9550
TCATCCATAG TTGCCTGACT CCCCGTCGTG TAGATAACTA CGATACGGGA 9600
GGGCTTACCA TCTGGCCCCA GTGCTGCAAT GATACCGCGA GACCCACGCT 9650
CACC GGCTCC AGATTTATCA GCAATAAAC AGCCAGCCGG AAGGGCCGAG 9700
40 CGCAGAAGTG GTCCTGCAAC TTTATCCGCC TCCATCCAGT CTATTAATTG 9750
TTGCCGGGAA GCTAGAGTAA GTAGTTCGCC AGTTAATAGT TTGCGCAACG 9800
TTGTTGCCAT TGCTACAGGC ATCGTGGTGT CACGCTCGTC GTTTGGTATG 9850
GCTTCATTCA GCTCCGGTTC CCAACGATCA AGGCGAGTTA CATGATCCCC 9900
CATGTTGTGC AAAAAAGCGG TTAGCTCCTT CGGTCCTCCG ATCGTTGTCA 9950
45 GAAGTAAGTT GGCCGCAAGT TTATCACTCA TGGTTATGGC AGCACTGCAT 10000
AATTCTCTTA CTGTCATGCC ATCCGTAAGA TGCTTTTCTG TGA CTGGTGA 10050
GTACTCAACC AAGTCATTCT GAGAATAGTG TATGCGGCGA CCGAGTTGCT 10100
CTTGCCCGGC GTCAATACGG GATAATACCG CGCCACATAG CAGAACTTTA 10150
AAAGTGCTCA TCATTGGAAA ACGTTCTTCG GGGCGAAAAC TCTCAAGGAT 10200
50 CTTACCGCTG TTGAGATCCA GTTCGATGTA ACCCACTCGT GCACCCAACT 10250
GATCTTCAGC ATCTTTTACT TTCACCAGCG TTTCTGGGTG AGCAAAAACA 10300
GGAAGGCAAA ATGCCGCAAA AAAGGGAATA AGGGCGACAC GGAAATGTTG 10350
AATACTCATA CTCTTCCTTT TTCAATATTA TTGAAGCATT TATCAGGGTT 10400
ATTGTCTCAT GAGCGGATAC ATATTTGAAT GTATTTAGAA AAATAACAA 10450
55 ATAGGGGTTT CGCGCACATT TCCCCGAAAA GTGCCAC 10487

SEQ ID NO:33 (conalbumin polyA)

60 tctgccattg ctgcttcctc tgcccttctc cgctactctg aatgtggctt cttegtact
gccacagcaa gaaataaaat ctcaacatct aaatgggttt cctgaggttt ttcaagagtc
gttaagcaca ttccttcccc agcaccctt gctgcaggcc agtgccaggc accaacttgg

ctactgctgc ccatgagaga aatccagttc aatattttcc aaagcaaaat ggattacata
 tgccctagat cctgattaac aggcgtttgt attatctagt gctttcgctt caccagatt
 atcccattgc ctccc

5

SEQ ID NO:34 (exemplary antibody light chain sequence)

1 gagctcgtga tgaccagac tccatcctcc ctgtctgcct ctctgggaga cagagtcacc
 61 atcagttgca gggcaaatca ggacattagc aattatttaa actggtatca gcagaaacca
 121 gatggaactg ttaaactcct gatctactac acatcaagat tacactcagg ggtcccatca
 10 181 aggttcagtg gcagtgggtc tggaacagat tattctctca ccattagcaa cctggagcaa
 241 gaagattttg ccacttactt ttgccaacag ggtaatacgc ttccgtggac gttcgggtgga
 301 ggcaccaacc tggaaatcaa acgggctgat gctgcaccaa ctgtatccat cttcccacca
 361 tccagtgagc agttaacatc tggaggtgcc tcagtcgtgt gcttcttgaa caacttctac
 421 cccaaagaca tcaatgtcaa gtggaagatt gatggcagtg aacgacaaaa tggcgtcctg
 15 481 aacagttgga ctgatcagga cagcaagac agcacctaca gcatgagcag caccctcacg
 541 ttgaccaagg acgagtatga acgacataac agctatacct gtgaggccac tcacaagaca
 601 tcaacttcac ccattgtcaa gagcttcaac aggaatgagt gttaa

20

SEQ ID NO:35 (exemplary antibody heavy chain sequence)

1 ctcgagtcag gacctggcct ggtggcgccc tcacagaacc tgtccatcac ttgcactgtc
 61 tctgggtttt cattaaccag ctatggtgta cactgggttc gccagcctcc aggaaagggt
 121 ctggaatggc tgggagtaat atggactggt agaagcacia cttataattc ggctctcatg
 181 tccagactga gcatcagcaa agacaactcc aagagccaag ttttcttaaa aatgaacagt
 25 241 ctgcaaactg atgacacagc catttactac tgtggcagag ggggtctgat tacgtccttt
 301 gctatggact actgggtgca aggaacctca gtcaccgtct cctcagccaa aacgacaccc
 361 ccattctgtct atccactggc cctgggatct gctgcccata ctaactccat ggtgacctg
 421 ggatgcctgg tcaagggtca tttccctgag ccagtgcagc tgacctggaa ctctggatcc
 481 ctgtccagcg gtgtgcacac ctcccagct gtccctgcagt ctgacctcta cactctgagc
 30 541 agctcagtga ctgtcccctc cagcacctgg cccagcgaga ccgtcacctg caacgttgcc
 601 caccgggcca gcagcaccaa ggtggacaag aaaattgtgc ccagggttg tactagt

SEQ ID NO:36 (pTnMCS)

35

1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtgggttacg cgcagcgtga
 61 ccgtacact tgccagcgcc ctacgcccgc ctcttttcgc tttcttccct tcctttctcg
 121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 241 tagttattaa tagtaataa ttacgggtgc attagtccat agcccatata tggagttccg
 40 301 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca
 421 atgggtggag tatttacggt aaactgccc cttggcagta catcaagtgt atcatatgcc
 481 aagtagcccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tgcctattac
 45 601 catgggtgat cgggttttggc agtacatcaa tgggcgtgga tagcgggttg actcacgggg
 661 atttccaagt ctccaccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggag gtaggcgtgt
 781 acgggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg

841 ccataccagc tgttttgacc tccatagaag acaccgggac cgatccagcc tccgcggccg
 901 ggaacgggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgcctatag
 961 actctatagg cacacccctt tggctcttat gcatgctata ctgtttttgg cttggggcct
 1021 atacaccccc gcttcccttat gctatagggtg atgggtatagc ttacccataa ggtgtgggtt
 5 1081 attgaccatt attgaccact cccctattgg tgacgatact ttccattact aatccataac
 1141 atggctcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtcccattht attatttaca aattcacata
 1261 vacaacaacg ccgtcccccg tgcccgaggt ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtagcggcgg agcttccaca
 10 1381 rccgagccct ggtcccatgc ctccagcggc tcatggctgc tcggcagctc cttgtctcta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 1501 gccgtggcgg taggggtatgt gtctgaaat gagcgtggag attgggctcg cacggctgac
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtattc
 1621 tgataagagt cagaggtaac tcccggttgc gtgctgttaa cgggtggagg cagtgtagtc
 15 1681 tgagcagtag tctgtgtgtc cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttccctt ccatgggtct tttctgcagt caccgtcggc ccatgtgcga actcgatatt
 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 1861 acgttggctt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggccgt
 1921 aacctgccaa ccaaagcgag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
 20 1981 aatcgtcacc tccacaaaga gcgactcgct gtataccgtt ggcatgctag ctttatctgt
 2041 tcgggcaata cgatgcccct tgtacttgtt gactggctctg atattcgtga gcaaaaacga
 2101 cttatgggtat tgcgagcttc agtcgacta caccgtcgtt ctgttactct ttatgagaaa
 2161 gcgttccccg tttcagagca atgttcaaa aaagctcatg accaatttct agccgacctt
 2221 gcgagcattc taccgagtaa caccacaccg ctcatgttca gtgatgctgg ctttaaaagt
 25 2281 ccatgggtata aatccgttga gaagctgggt tggactgggt taagtcgagt aagaggaaaa
 2341 gtacaatatg cagacctagg agcggaaaac tggaaaaccta tcagcaactt acatgatatg
 2401 tcatctagtc actcaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
 2461 tggcaaatc tattgtataa atctcgtctt aaaggccgaa aaaatcagcg ctcgacacgg
 2521 actcattgtc accacccgtc acctaaaatc tactcagcgt cggcaaagga gccatgggtt
 30 2581 cttagcaacta acttacctgt tgaaattcga acacccaaac aacttgtaa tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtctgccta cggactaggc
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
 2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaaacaagg ttgggacaag
 2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg
 35 2881 gaagttttgc ggcattcttg ctacacaata acaagggaag acttactcgt ggctgcaacc
 2941 ctactagctc aaaatttatt cacacatggt tacgctttgg ggaaattatg aggggatcgc
 3001 tctagagcga tccgggatct cgggaaaagc gttgggtgacc aaagggtgcct tttatcatca
 3061 ctttaaaaaa aaaaaacaat tactcagtcg ctgttataag cagcaattaa ttatgattga
 3121 tgcctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag aaagtatatt
 40 3181 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt
 3241 gatgcctatc attgggttga atgaacttga aaaaaattag ctttgaatac attactggta
 3301 aggtaaacgc cattgtcagc aaattgatcc aagagaacca acttaaaagt ttccctgacgg
 3361 aatgttaatt ctgcttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaatc
 3421 attaaagttaa ggtggatata catcttgtca tatgatcccg gtaatgtgag tttagctcact
 45 3481 cattaggcac cccaggcttt acactttatg tttccggctc gtatgttgtg tggaaattgtg
 3541 agcggataac aatttcacac aggaacacagc tatgaccatg attacgcaa gcgcgcaatt
 3601 aacctcact aaagggaaca aaagctggag ctccaccgag gtggcggcgg ctctagaact
 3661 agtggatccc ccgggctgca ggaattcgat atcaagctta tcgataccgc tgacctcgag
 3721 gggggggccc gtacccaatt cgccctatag tgagtcgtat tacgcgcgt cactggcgtt
 50 3781 cgttttaca cgtcgtgact gggaaaacc tggcgttacc caacttaac gccttgcagc
 3841 acatccccct ttcgcccagt ggcgtaatag cgaagaggcc cgcaccgat gcccttcca
 3901 acagtgtcgc agcctgaatg gcgaatggaa attgtgaagc ttaatatatt gttaaaaatc
 3961 gcgttaaatt tttgttaaat cagctcattt ttttaaccaat aggccgaaat cggcaaaatc
 4021 ccttataaat caaaagaata gaccgagata ggggttgagt ttgttccagt ttggaacaag
 55 4081 agtccactat taaagaacgt ggactccaac gtcaaagggc gaaaaaccgt ctatcagggc
 4141 catggccac tactccggga tcatatgaca agatgtgtat ccaccttaac ttaatgattt
 4201 ttacaaaaat cattagggga ttcatcagtg ctccagggtc acgagaatta acattccgtc
 4261 aggaagctt atgatgatga tgtgtttaa aacttactca atggctgggt atgcatatcg
 4321 caatacatgc gaaaaacct aagagcttg ccgataaaaa aggccaattht attgctattt
 60 4381 accgcggctt tttattgagc ttgaaagata aataaaatag ataggtttta tttgaagcta
 4441 aatcttcttt atcgtaaaaa atgcccctct ggggttatcaa gagggctcatt atatttcgcg
 4501 gaataacatc atttgggtgac gaaataacta agcacttgtc tctgtttac tcccctgagc
 4561 ttgaggggtt aacatgaagg tcatcgatag caggataata atacagtaaa acgctaaacc
 4621 aataatccaa atccagccat ccaaaattgg tagtgaatga ttataaataa cagcaaacag
 65 4681 taatgggcca ataacacggg ttgcatgggt aaggctcacc aataatccct gtaaagcacc
 4741 ttgctgatga ctctttgttt ggatagacat cactccctgt aatgcaggta aagcgatccc
 4801 accaccagcc aataaaatta aaacagggaa aactaaccaa ccttcagata taaacgctaa
 4861 aaaggcaaat gcactactat ctgcaataaa tccgagcagt actgccgttt tttcgcccat

4921 ttagtggcta ttcttctctg cacaaggct tgggaatactg agtgtaaaag accaagaccc
 4981 gtaatgaaaa gccaacatc atgctattca tcatcacgat ttctgtaata gcaccacacc
 5041 gtgctggatt ggctatcaat gcgctgaaat aataatcaac aaatggcatc gttaaataag
 5101 :gatgtatac cgatcagctt ttgttccctt tagtgagggt taattgcgcg cttggcgtaa
 5 5161 tcatgggcat agctgtttcc tgtgtgaaat tgttatccgc tcacaattcc acacaacata
 5221 cgagccggaa gcataaagt taaagcctgg ggtgcctaata gaggtagcta actcacatta
 5281 attgcgttgc gctcactgcc cgctttccag tgggaaacc tgcgtgcca gctgcattaa
 5341 tgaatcggcc aacgcgcggg gagaggcggg ttgctgattg ggcgctcttc cgcttctctg
 10 5401 ctactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggatcagc tcaactcaag
 5461 gcggtataac gggtatccac agaatacagg gataacgcag gaaagaacat gtgagcaaaa
 5521 ggccagcaaa aggcaggaag ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc
 5581 cggcccccctg acgagcatca caaaaatcga cgctcaagtc agagggtggcg aaacccgaca
 5641 ggactataaa gataccaggc gtttccccct ggaagctccc tgcgtgcgctc tcctgttccg
 5701 accctgccgc ttaccggata cctgtccgcc ttttccctt cgggaagcgt ggcgctttct
 15 5761 catagctcac gctgtaggta tctcagttcg gtgtaggctg ttcgctccaa gctgggctgt
 5821 gtgcacgaac ccccggttca gcccgaccgc tgcgccttat ccggttaacta tgcgtcttag
 5881 tccaacccgg taagacacga cttatcgcca ctggcagcag ccactggtaa caggattagc
 5941 agagcgagggt atgtaggcgg tgcacagag ttcttgaagt ggtggcctaa ctacggctac
 20 6001 actagaagga cagtatttgg tatctgcgct ctgctgaagc cagttacctt cggaaaaaga
 6061 gttggtagct cttgatccgg caaacaacc accgctggta gcggtggttt tttgtttgc
 6121 aagcagcaga ttacgcgcag aaaaaagga tctcaagaag atcctttgat cttttctacg
 6181 yggctctgacg ctcaagtga cgaaaactca cgttaaggga ttttggtcat gagattatca
 6241 aaaaaggatct tcacctagat ccttttaaat taaaaatgaa gttttaaatc aatctaaagt
 6301 atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtaggc acctatctca
 25 6361 gcgatctgtc tatttcggtc atccatagtt gcctgactcc ccgtcgtgta gataactacg
 6421 tctacgggagg gcttaccatc tggccccagt gctgcaatga taccgcgaga cccacgctca
 6481 ccggctccag atttatcagc aataaaccag ccagccggaa gggccgagcg cagaagtggg
 6541 cctgcaactt tatccgcctc catccagctt attaatgtt gccgggaagc tagagtaagt
 30 6601 agttcgccag ttaatagttt gcgcaacggt gttgccattg ctacaggcat cgtgggtgta
 6661 cgctcgctgt ttggtatggc ttcattcagc tccggttccc aacgatcaag gcgagttaca
 6721 tgatcccca tgtgtgcaa aaaagcgggt agctccttcg gtcctccgat cgttgtcaga
 6781 agtaagtgg ccgcagtgtt atcactcatg gttatggcag cactgcataa ttctcttact
 6841 gtcattgcat ccgtaagatg cttttctgtg actggtgagt actcaacca gtcattctga
 6901 gaatagtgt tgcggcgacc gagttgctct tgcggcggt caatacggga taataccgcg
 35 6961 ccacatagca gaactttaaa agtgctcctc attggaaaac gttcttcggg gcgaaaactc
 7021 tcaaggatct taccgctgtt gagatccagt tcatgtaac ccactcgtgc acccaactga
 7081 tcttcagcat cttttacttt caccagcgtt tctgggtgag caaaaacagg aaggcaaat
 7141 gccgcaaaa aggaataag ggcgacacgg aaatgttgaa tactcatact cttcctttt
 7201 caatattatt gaagcattta tcagggttat tgtctcatga gcggatacat atttgaatgt
 40 7261 atttagaaaa ataaacaaat aggggttccg cgcacatttc cccgaaaagt gccac

SEQ ID NO:37 (chicken ovalbumin ehancer)

ccgggctgca gaaaaatgcc aggtggacta tgaactcaca tccaaaggag
 cttgaactga tacctgattt tcttcaaact ggggaaacaa cacaatccca caaaacagct
 45 cagagagaaa ccactactga tggctacagc accaaggat gcaatggcaa tccattcgac
 attcatctgt gacctgagca aaatgattta tctctccatg aatggttgct tctttccctc
 atgaaaggc aatttccaca ctcaaatat gcaacaaaga caaacagaga acaattaatg
 tgctccttcc taatgtcaaa attgtagtgg caaagaggag aaaaaaatct caagttctga
 gtaggtttta gtgattggat aagaggcttt gacctgtgag ctacactgga cttcatatcc
 50 ttttgataa aaagtgttt tataactttc aggtctccga gtctttattc atgagactgt
 tggtttaggg acagaccac aatgaaatgc ctggcatagg aaagggcagc agagccttag
 ctgacctttt cttgggacaa gcattgtcaa acaatgtgtg acaaaactat ttgtactgct
 ttgcacagct gtgctgggca gggcaatcca ttgccaccta tcccaggtaa cttccaact
 gcaagaagat tgttgcttac tctctctaga
 55

SEQ ID NO:38 (5' untranslated region)

GTGGATCAACATACAGCTAGAAAGCTGTATTGCCTTTAGCACTCAAGCTCAAAAGACAACCTCAGAGTTC
 ACC

60 SEQ ID NO:39 (putative cap site)

ACATACAGCTAG AAAGCTGTAT TGCCTTTAGC ACTCAAGCTC AAAAGACAAC TCAGAGTTCA

SEQ ID NO:40 (fragment of ovalbumin promoter - chicken)

65 GAGGTGAGAAT GGTTCCTTTA CTGTTTGTCATTCTATTAT TTCAATACAG
 AACAAATAGCT TCTATAACTG AAATATATTT GCTATTGTAT ATTATGATTG

TCCCTCGAAC CATGAACACT CCTCCAGCTG AATTTACAA TTCCTCTGTC
 ATCTGCCAGG CCATTAAGTT ATTCATGGAA GATCTTTGAG GAACACTGCA
 AGTTCATATC ATAAACACAT TTGAAATTGA GTATTGTTTT GCATTGTATG
 5 GAGCTATGTT TTGCTGTATC CTCAGAAAAA AAGTTTGTTA TAAAGCATT
 ACACCCATAA AAAGATAGAT TTAAATATTC CAGCTATAGG AAAGAAAGTG
 CGTCTGCTCT TCACTCTAGT CTCAGTTGGC TCCTTCACAT GCATGCTTCT
 TTATTTCTCC TATTTTGTCA AGAAAATAAT AGGTCACGTC TTGTTCTCAC
 TTATGTCCTG CCTAGCATGG CTCAGATGCA CGTTGTAGAT ACAAGAAGGA
 TCAAATGAAA CAGACTTCTG GTCTGTACT ACAACCATAG TAATAAGCAC
 10 ACTAATAAT AATTGCTAAT TATGTTTTCC ATCTCTAAGG TTCCCACATT
 TTTCTGTTTT CTAAAGATC CCATTATCTG GTTGTAAGT AAGCTCAATG
 GAACATGAGC AATATTTCCC AGTCTTCTCT CCCATCCAAC AGTCCTGATG
 GATTAGCAGA ACAGGCAGAA AACACATTGT TACCCAGAAT TAAAACTAA
 TATTTGCTCT CCATTCAATC CAAATGGAC CTATTGAAAC TAAATCTAA
 15 CCCAATCCCA TTAAATGATT TCTATGGCGT CAAAGGTCAA ACTTCTGAAG
 GGAACCTGTG GGTGGGTCAC AATTCAGGCT ATATATTCCC CAGGGCTCAG
 C

SEQ ID NO:41 pTnMCS (CMV-CHOVg-ent-ProInsulin-synPA)
 1 ctgacgcgcc ctgtagcggc gcattaagcg cggcggtgt ggtggttacg cgcagcgtga
 61 ccgctacact tgcagcgcc ctagegccc ctccttccgc tttcttccct tctttctcg
 121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 241 tagttattaa tagtaataca ttacgggggc attagttcat agcccatata tggagttccg
 25 301 cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgccatt
 361 gacgtcaata atgacgtatg tttccatagt aacgccaata gggactttcc attgacgtca
 421 atgggtggag tatttacggg aaactgccc cttggcagta catcaagtgt atcatatgcc
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac
 30 601 catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 gyactttcca aaatgtcgta acaactccgc cccattgacg caaatgggag gtaggcgtgt
 781 aggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 catccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tccgcggccg
 35 901 ggaacgggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgcctatag
 961 actctatagg cacacccctt tggctcttat gcattgctata ctgtttttg cttggggcct
 1021 atacaccccc gcttccttat gctatagggt atggtatagc ttagcctata ggtgtgggtt
 1081 attgaccatt attgaccact cccctattgg tgacgatact ttcattact aatccataac
 1141 atggctcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac
 40 1201 gagacggac tctgtatttt tacaggatgg ggtcccattt attatttaca aattcacata
 1261 tacaacaacg ccgtcccccg tgcccgcagt ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcgg agcttccaca
 1381 tccgagccct ggtcccatgc ctccagcggc tcatggctgc tcggcagctc cttgtccta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 45 1501 gccgtggcgg tagggtatgt gtctgaaaat gagcgtggag attgggctcg cacggctgac
 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgattc
 1621 tgataagagt cagaggtaac tccggttgcg gtgctgttaa cgggtggagg cagtgtagtc
 1681 tgagcagtac tcgttgctgc cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttctctt ccatgggtct tttctgcagt caccgtcgga ccatgtgcga actcgatatt
 50 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 1861 acgttggtct gccacgcatt acttgactgt aaaactctca ctcttaccga acttggccgt
 1921 aacctgcca ccaaagcgag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
 1981 aatcgtcacc tccacaaaga gcgactcgct gtataaccgtt ggcattgctag ctttatctgt
 2041 tccggcaata cgatgcccct tgtacttgtt gactggctct atattcgtga gcaaaaacga
 55 2101 ctatgggtat tgcgagcttc agtcgcaacta cacggctcgt ctgttactct ttatgagaaa
 2161 gcgttcccg cttcagagca atgttcaaa aaagctcatg accaatttct agccgacctt
 2221 gcgagcattc taccagata caccacaccg ctcatgtca gtgatgctgg ctttaaagt
 2281 ccatgggtata aatccgttga gaagctgggt tggactgggt taagtcgagt aagaggaaaa
 2341 gtacaatatg cagacctagg agcggaaaac tggaaaacct tcagcaactt acatgatag
 60 2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
 2461 tgcctaatc tattgtataa atctcgtctt aaaggccgaa aaaatcagcg ctgcacagg
 2521 ctcatgtgc accaccgct accataaatc tactcagcgt cggcaaggga gccatgggtt
 2581 ctacgaacta acttacctgt tgaaattcga acacccaaac aacttggtta tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtcctgccta cggactaggc
 65 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
 2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaaacaagg ttgggacaag

2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg
2881 gaagttttgc ggcattctgg ctacacaata acaagggaag acttactcgt ggctgcaacc
2941 ctactagctc aaaattttatt cacacatggg tacgctttgg ggaaattatg aggggatcgc
3001 tctagagcga tccgggatct cgggaaaagc gttggtgacc aaagggtgct tttatcatca
5 3061 ctttaaaaaat aaaaaacaat tactcagtgc ctgttataag cagcaattaa ttatgattga
3121 tgcctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag aaagtatatt
3181 tgaacattat cttgattata ttattgataa taataaaaaa cttatcccta tccaagaagt
3241 gatgcctatc attggttgga atgaacttga aaaaaattag ccttgaatac attactggta
3301 aggtaaacgc cattgtcagc aaattgatcc aagagaacca acttaaagct ttctgacgg
10 3361 aatgttaatt ctggttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaaatc
3421 attaatgtta ggtggatata catcttgta tatgatcccg gtaatgtgag ttagctcact
3481 cattaggcac cccaggcttt acactttatg cttccggctc gtatgttggt tggattgtg
3541 agcggataac aatttcacac aggaaacagc tatgaccatg attacgcaa gcgcgcaatt
3601 aaccctcact aaagggaaca aaagctggag ctccaccgag gtggcgcccg ctctagaact
15 3661 agtggatccc cggggcatca gattggctat tggccattgc atacgttgta tccatatcat
3721 aatatgtaca tttatattgg ctcatgtcca acattaccgc catgttgaca ttgattattg
3781 actagttatt aatagtaatc aattacgggg tcattagttc atagcccata tatggagttc
3841 cgcgttacat aacttacggt aaatggcccg cctggctgac cgcccaacga ccccgccca
3901 ttgacgtcaa taatgacgta tgttcccata gtaacgcaa tagggacttt ccattgacgt
20 3961 caatgggtgg agtattttac gtaaaactgcc cacttggcag tacatcaagt gtatcatatg
4021 ccaagtacgc cccctattga cgtcaatgac ggtaaatggc ccgctggca ttatgccag
4081 tacatgacct tatgggacct tctacttgg cagtacatct acgtattagt catcgctatt
4141 accatgggtga tgcgggtttg gcagtacatc aaatggcggt gatagcgggt tgactcacgg
4201 ggattttcaa gtctccaccc cattgacgtc aaatgggagtt tgttttggca ccaaatcaa
25 4261 cgggactttc caaaatgtcg taacaactcc gcccattga cgcaaatggg cggtaggcgt
4321 gtacggtggg aggtctatat aagcagagct cgttttagtg accgtcagat cgcctggaga
4381 cgccatccac gctgttttga cctccataga agacaccgg accgatccag cctccgaggc
4441 cgggaacggt gcattggaac gcggattccc cgtgccaaga gtgacgtaag taccgctat
4501 agactctata ggcacacccc tttggctctt atgcatgcta tactgttttt ggcttggggc
30 4561 ctatacacc cgccttcctt atgctatagg tgatggtata gcttagccta taggtgtggg
4621 ttattgacca ttattgacca ctcccctatt ggtgacgata ctttccatta ctaatccata
4681 acatggctct ttgccacaac tatctctatt ggctatatgc caatactctg tccctcagag
4741 actgacacgg actctgtatt tttacaggat ggggtcccat ttattattta caaatccaca
4801 tatacaacaa cgccgtcccc cgtgcccgca gtttttatta aacatagcgt gggatctcca
35 4861 cgcgaatctc gggtagctgt tccggacatg ggctcttctc cggtagcggc ggagcttcca
4921 catccgagcc ctggtcccat gcctccagcg gctcatggtc gctcggcagc tccctgtctc
4981 taacagtggg ggcagactt aggcacagca caatgcccac caccaccagt gtgcccaca
5041 aggcggtggc ggtagggtat gtgtctgaaa atgagcgtgg agattgggct cgcacggctg
5101 acgcagatgg aagacttaag gcagcggcag aagaagatgc aggcagctga gttgtgtat
40 5161 tctgataaga gtcagaggtg actccgcttg ccgtgctgtt aacgggtggg ggcagtgtag
5221 tctgagcagt actcgttgct gccgcgcgcg ccaccagaca taatagctga cagactaaca
5281 gactgttctt tccatgggt ctttctgca gtcaccgtcg ggatccatgg gctccatcgg
5341 cgcagcaagc atggaatttt gttttgatgt attcaaggag ctcaaagtc accatgccaa
5401 tgagaacatc ttctactgcc ccattgccat catgtcagct ctagccatgg tatacctggg
45 5461 tgcaaaagac agcaccagga cacagataaa taagggtgtt cgctttgata aacttccagg
5521 attcggagac agtattgaag ctcaagtgtg cacatctgta aacgttact cttcacttag
5581 agacatctc aacaaatca ccaaaccaaa tgatgtttat tccgttcagc ttgccagtag
5641 actttatgct gaagagagat acccaatcct gccagaatac ttgcagtgtg tgaaggaact
5701 gtatagagga ggcttggaa cttatcaact tcaaacagct gcagatcaag ccagagagct
50 5761 catcaattcc tgggtagaaa gtcagacaaa tgggaattatc agaaatgtcc ttcagccaag
5821 ctccgtggat tctcaactg caatggttct ggttaatgcc attgtcttca aaggactgtg
5881 ggagaaaaca tttaaggatg aagacacaca agcaatgcct ttcagagtga ctgagcaaga
5941 aagcaaacct gtgcagatga tgtaccagat tggtttattt agagtggcat caatggcttc
55 6001 tgagaaaatg aagatcctgg agcttccatt tggcagtggg acaatgagca tgttgggtgt
6061 gttgcctgat gaagtctcag gccttgagca gcttgagagt ataatcaact ttgaaaaact
6121 gactgaatgg accagtctta atgttatgga agagaggaag atcaaagtgt acttacctcg
6181 catgaagatg gaggaataa acaacctcac atctgtcttg catctcctca gcagagagcc tgaagatate
6241 cgtgttttag tcttcagcca atctgtctgg catctcctca gcagagagcc tgaagatate
60 6301 tcaagctgtc catgcagcac atgcagaaat caatgaagca ggcagagagg tggtaggggtc
6361 agcagaggct ggagtggatg ctgcaagcgt ctctgaagaa tttagggtgt accatccatt
6421 cctcttctgt atcaagcaca tgcgaaccaa cgccgttctc tcttttggca gatgtgtttc
6481 ccgcgccagc agatgacgc accagcagat gacgcaccag cagatgacgc accagcagat
6541 gacgcaccag cagatgacgc accagcagat gacgcaacaa catgtatcct gaaaggctct
6601 tgtggctgga tcggcctgct ggatgacgat gacaaatttg tgaaccaaca cctgtgcggc
65 6661 tcacacctgg tggagctct ctacctagtg tgcggggaac gaggttctt ctacacacc
6721 aagaccgccc gggaggcaga ggacctgcag gtggggcagg tggagctggg cgggggccc
6781 ggtgcaggca gcctgcagcc cttggccctg gaggggtccc tgcagaagcg tggcattgtg
6841 gaacaatgct gtaccagcat ctgctccctc taccagctgg agaactactg caactagggc

6901 gcctaaaggg cgaattatcg cggccgctct agaccaggcg cctggatcca gatcacttct
 6961 ggctaataaa agatcagagc tctagagatc tgtgtgttgg ttttttggg atctgctgtg
 7021 ccttctagtt gccagccatc tgttgtttgc cctcccccgc tgccttcctt gacctggaa
 7081 ggtgccactc ccactgtcct ttcctaataa aatgaggaaa ttgcatcgca ttgtctgagt
 5 7141 aggtgtcatt ctattctggg ggggtgggtg gggcagcaca gcaaggggga ggattgggaa
 7201 gacaatagca ggcattgctg ggatgcggtg ggctctatgg gtacctctct ctctctctct
 7261 ctctctctct ctctctctct ctctcgggtac ctctctcgag gggggggccc gtacccaatt
 7321 cgccctatag tgagtcgtat tacgcgcgct cactggccgt cgttttataa cgtcgtgact
 7381 gggaaaaccc tggcggtacc caacttaatc gccttgcagc acatccccct ttcgccagct
 10 7441 ggcgtaatag cgaagaggcc cgcaccgatc gcccttccca acagttgcgc agcctgaatg
 7501 gcgaatggaa attgtaagcg ttaatatatt gttaaaatc gcgttaaatt tttgttaa
 7561 cagctcattt ttaaccaat aggccgaaat cggcaaaatc cctataaat caaaagaata
 7621 gaccgagata gggttgagt ttgttccagt ttggaacaag agtccactat taaagaacgt
 7681 ggactccaac gtcaaagggc gaaaaaccgt ctatcagggc gatggcccac tactccggga
 15 7741 tcatatgaca agatgtgtat ccaccttaac ttaatgattt ttacccaaat cattagggga
 7801 ttcattcagt ctcagggtca acgagaatta acattccgtc aggaaagctt atgatgatga
 7861 tgtgcttaaa aacttactca atggctgggt atgcatatcg caatacatgc gaaaaaccta
 7921 aaagagcttg ccgataaaaa aggccaatat attgctattt accgcggctt tttattgagc
 7981 ttgaaagata aataaaatag ataggtttta tttgaagcta aatcttcttt atcgtaaaaa
 20 8041 atgcccctct gggttatcaa gagggtcatt atatttcgag gaataacatc atttgggtgac
 8101 gaaataacta agcacttgct tcctgtttac tcccctgagc ttgaggggtt aacatgaagg
 8161 tcatcgatag caggataata atacagtaaa acgctaaacc aataatccaa atccagccat
 8221 cccaaattgg tagtgaatga ttataaataa cagcaaacag taatgggcca ataacaccgg
 8281 ttgcattggg aaggctcacc aataatccct gtaaagcacc ttgctgatga ctctttgttt
 25 8341 ggatagacat cactccctgt aatgcaggta aagcgatccc accaccagcc aataaaatta
 8401 aaacagggaa aactaaccaa ccttcagata taaacgctaa aaaggcaaat gcactactat
 8461 ctgcaataaa tccgagcagt actgccgttt tttcgcccat ttagtggcta ttcttctgct
 8521 cacaaggctt tggaaactg agtgtaaaag accaagaccc gtaatgaaaa gccaacatc
 8581 atgctattca tcatcacgat ttctgtaata gcaccacacc gtgctggatt ggctatcaat
 30 8641 gcgctgaaat aataatcaac aaatggcctc gttaataaag tgatgtatag cgtcagctt
 8701 ttgttccctt tagtgagggt taattgcgag cttggcgtaa tcatggctat agctgtttcc
 8761 tgtgtgaaat tgttatccgc tcacaattcc acacaacata cgagccggaa gcataaagt
 8821 taaagcctgg ggtgccta at gagtgagcta actcacatta attgcgttgc gctcactgcc
 8881 cgctttccag tccgggaaacc tgcgtgcca gctgcattaa tgaatcgcc aacgcgcggg
 35 8941 gagaggcggt ttgcgtattg ggcgtctctc cgcttcctcg ctactgact cgctgcgctc
 9001 ggtcgttcgg ctgcggcgag cggatcagc tcaactcaaag gcggaataac ggttatccac
 9061 agaatcaggg gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa
 9121 ccgtaaaaag gccgcgttgc tggcgttttt ccataggctc cgcctccctg acgagcatca
 9181 caaaaatcga cgctcaagtc agagggtggc aaaccgcaga ggactataaa gataccaggc
 40 9241 gtttccccc tgaagctccc tgcgtgcctc tctgttccg accctgccgc ttaccggata
 9301 cctgtccgcc tttctccctt cgggaagcgt ggcgtttct catagctcac gctgtaggta
 9361 tctcagttcg gtgtaggctg ttcgtccaa gctgggctgt gtgcacgaac ccccggttca
 9421 gcccagccgc tgcgccttat ccggttaacta tgcgtttgag tccaaccgg taagacacga
 9481 cttatcgcca ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg
 45 9541 tgctacagag ttcttgaagt ggtggcctaa ctacggctac actagaagga cagtatttgg
 9601 tatctgcgct ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg
 9661 caaacaacc accgctggta gcggtggttt ttttgttgc aagcagcaga ttacgcgcag
 9721 aaaaaaagga tctcaagaag atcctttgat cttttctacg gggcttgacg ctcatgggaa
 9781 cgaaaactca cgttaaggga ttttggctat gagattatca aaaaggatct tcacctagat
 50 9841 ccttttaaat taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggct
 9901 tgacagttac caatgcttaa tcagttaggc acctatctca gcgatctgtc tatttcggtc
 9961 atccatagtt gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccatc
 10021 tggccccagt gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc
 10081 aataaaccag ccagccggaa gggccgagcg cagaagtggc cctgcaactt tatccgctc
 55 10141 catccagtct attaatgtt gccgggaagc tagagtaagt agttcgccag ttaatagttt
 10201 gcgcaacggt gttgccattg ctacaggcat cgtggtgtca cgtcgtcgt ttggtatggc
 10261 ttcatcagc tccggttccc aacgatcaag gcgagttaca tgatcccca tgttgtgcaa
 10321 aaaagcgggt agctccttcg gtctccgat cgttgtcaga agtaagtgg ccgcagtgtt
 10381 atcactcatg gttatggcag cactgcataa ttctcttact gtcattgcca cgttaagatg
 60 10441 cttttctgtg actggtgagt actcaaccaa gtcattctga gaatagtgtg tgcggcgacc
 10501 gagttgctct tgcgcggcgt caatacggga taataccgcg ccacatagca gaactttaaa
 10561 agtgctcatc attggaaaac gttcttcggg gcgaaaactc tcaaggatct taccgctgtt
 10621 gagatccagt tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttacttt
 10681 caccagcgtt tctgggtgag caaaaacagg aaggcaaaat gccgcaaaa agggataaag
 65 10741 ggcgacacgg aaatgttgaa tactcatact cttctttttt caatattatt gaagcattta
 10801 tcagggttat tgtctcatga gcgatacat atttgaatgt atttagaaaa ataaacaat
 10861 aggggttccg cgcacatttc cccgaaaagt gccac

SEQ ID NO:42 (pTnMOD (CMV-CHOVg-ent-ProInsulin-synPA))

1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtgggttacg cgcagcgtga
5 61 ccgctacact tgccagcgcc ctacgcggcg ctcccttcgc tttcttccct tcccttctcg
121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttggtac catatcataa
181 tatgtacatt tatattggct catgtccaac attaccgcca tggtagacatt gattattgac
241 tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagtccg
301 cgttacataa cttacggtaa atggcccgcc tggtgaccg cccaacgacc cccgcccatt
10 361 gacgtcaata atgacgtatg tcccatagt aacgccaata gggactttcc attgacgtca
421 atgggtggag tatttacggg aaactgccc cttggcagta catcaagtgt atcatatgcc
481 aagtacggcc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac
601 catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg
661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
15 721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt
781 acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tccggggcg
901 ggaacgggtgc attggaacgc ggattcccg tgccaagagt gacgtaagta ccgcctatag
961 actctatagg cacacccctt tggctcttat gcattgtata ctgttttttg cttggggcct
20 1021 atacaccccc gcttccctat gctataggtg atggtatagc ttagcctata ggtgtgggtt
1081 attgaccatt attgaccact cccctatttg tgacgatact tccattact aatccataac
1141 atggctcttt gccacaacta tctctatttg ctatatgcca atactctgtc cttcagagac
1201 tgacacggac tctgtatttt tacaggatgg ggtcccattt attatttaca aattcacata
1261 tacaacaacg ccgtcccccg tgcccgcagt ttttattaaa catagcgtgg gatctccacg
25 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtacggcgcg agcttccaca
1381 tccgagccct ggtcccatgc ctccagcggc tcatggctgc tcggcagctc cttgctccta
1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
1501 gccgtggcgg taggggtatg gtctgaaaat gagcgtggag attgggctcg cacggctgac
1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtattc
30 1621 tgataagagt cagaggtaac tcccggtgcg gtgctgttaa cgggtggaggg cagtgtagtc
1681 tgagcagtac tcgttgctgc cgcgcgcgcc accagacata atagctgaca gactaacaga
1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtgtga acttgatatt
1801 ttacatgatt ctctttacca attctgccc gaattacact taaaacgact caacagctta
35 1861 acgttggctt gccacgcatt acttgactgt aaaactctca ctcttaccga acttggcctg
1921 aacctgccaa ccaaagcgag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
1981 aatcgtcacc tccacaaaga gcgactcgt gtataccgtt ggcattgctag ctttatctgt
2041 tcgggcaata cgatgcccct tgtacttgtt gactggctct atattcgtga gcaaaaacga
2101 cttatgggtat tgcgagcttc agtcgacta cacggctcgt ctgttactct ttatgagaaa
40 2161 gcgttcccgc tttcagagca atgttcaaag aaagctcatg accaatttct agccgacctt
2221 gcgagcattc taccgagtaa caccacaccg ctcatgtca gtgatgctgg ctttaaagtg
2281 ccatgggtata aatccgttga gaagctgggt tggtagctgt taagtcgagt aagaggaaaa
2341 gtacaatatg cagacctagg agcggaaaac tggaaacctt tcagcaactt acatgatatg
2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
45 2461 tgccaaattc tattgtataa atctcgtct aaaggccgaa aaaatcagcg ctcgacacgg
2521 actcattgtc accacccgtc acctaaaatc tactcagcgt cggcaaagga gccatgggtt
2581 ctagcaacta acttacctgt tgaaattcga acacccaaac aacttggtta tatctattcg
2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtctgccta cggactaggc
2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgtgct aatcgccctg
50 2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaaacaagg ttgggacaag
2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg
2881 gaagttttgc ggcattctgg ctacacaata acaagggaag acttactcgt ggtgcaacc
2941 ctactagctc aaaatttatt cacacatggg tacgctttgg ggaaattatg ataatgatcc
3001 agatcacttc tggctaataa aagatcagag ctctagagat ctgtgtgttg gttttttgtg
55 3061 gatctgctgt gccttctagt tgccagccat ctgttgtttg cccctcccc gtgccttctt
3121 tgaccctgga aggtgccact cccactgtcc tttcctaata aaatgaggaa attgcatcgc
3181 attgtctgag taggtgtcat tctattctgg ggggtggggg ggggcagcac agcaaggggg
3241 aggattggga agacaatagc aggcattgtg gggatgcggg gggctctatg ggtacctctc
3301 tctctctctc tctctctctc tctctctctc tctctcggtt cctctctctc tctctctctc
60 3361 tctctctctc tctctctctc tcggtaccag gtgctgaaga attgaccggg tgaccaaagg
3421 tgccttttat catcacttta aaaataaaaa acaattactc agtgctgtt ataagcagca
3481 attaatatg attgatgcct acatcacaac aaaaactgat ttaacaaatg gttggtctgc
3541 cttagaaagt atatttgaac attatcttga ttatattatt gataataata aaaaccttat
3601 ccctatccaa gaagtgatgc ctatcatttg ttggaatgaa cttgaaaaaa attagccttg
65 3661 aatacattac tggtaaggta aacgccattg tcagcaaatt gatccaagag aaccaactta
3721 aagctttcct gacggaatgt taattctcgt tgaccctgag cactgatgaa tcccctaatt
3781 attttggtaa aaatcattaa gttaagggtg atacacatct tgtcatatga tccgggtaat
3841 gtgagtttag tcactcatta ggcaccccg gctttacact ttatgcttcc ggctcgtatg

3901 ttgtgtggaa ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac
 3961 gccaagcgcg caattaaccc tcaactaaagg gaacaaaagc tggagctcca ccgcggtggc
 4021 ggccgctcta gaactagtgg atcccccggg catcagattg gctattggcc attgcatacg
 4081 ttgtatccat atcataatat gtacatttat attggctcat gtccaacatt accgccatgt
 5 4141 tgacattgat tattgactag ttattaatag taatcaatta cggggtcatt agttcatagc
 4201 ccatatatgg agttccgcgt tacataaett acggtaaattg gcccgctgg ctgaccgccc
 4261 aacgaccccc gccatttgac gtcaataatg acgtatgttc ccatagtaac gccaataggg
 4321 actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt ggcagtacat
 4381 caagtgtatc atatgccaag tacgccccct attgacgtca atgacggtaa atggcccgc
 10 4441 tggcattatg cccagtacat gaccttatgg gactttccta ctggcagta catctacgta
 4501 ttagtcatcg ctattacat ggtgatgcgg ttttggcagt acatcaatgg gcgtggatag
 4561 cggtttgact cacggggatt tccaagtctc caccctattg acgtcaatgg gagtttgttt
 4621 tggcaccaaa atcaacggga ctttccaaaa tgtcgtaaca actccgcccc attgacgcaa
 4681 atgggaggta ggcgtgtacg gtgggaggtc tatataagca gagctcgttt agtgaaccgt
 15 4741 cagatcgctt ggagacgcca tccacgctgt tttgacctcc atagaagaca ccgggaccga
 4801 tccagcctcc gcggcggga acggtgcatt ggaacgcgga tccccgtgc caagagtac
 4861 gtaagtaccg cctatagact ctataggcac acccctttgg ctcttatgca tgctatactg
 4921 tttttggctt ggggcctata ccccccgct tccttatgct ataggtgatg gtatagctta
 4981 gcctataggt gtgggttatt gaccattatt gaccactccc ctattgggtga cgatactttc
 20 5041 cattaactaat ccataacatg gctctttgct acaactatct ctattggcta tatgccata
 5101 ctctgtcctt cagagactga caggactct gtatttttac aggatggggt cccattttat
 5161 atttacaaat tcacatatac aacaacgcgc tccccgtgc ccgcagtttt tattaacat
 5221 agcgtgggat ctccacgcga atctcgggta cgtgttccgg acatgggctc ttctccggt
 5281 gcggcggagc ttccacatcc gagccctggt cccatgcctc cagcggctca tggctcgtcg
 25 5341 gcagctcctt gctcctaaca gtggaggcca gacttaggca cagcacaatg cccaccacca
 5401 ccagtgtgcc gcacaaggcc gtggcggtag ggtatgtgtc tgaaaatgag cgtggagatt
 5461 gggctcgcac ggctgacgca gatggaagac ttaaggcagc ggcagaagaa gatgcaggca
 5521 gctgagttgt tgtattctga taagagtcag aggtaaactc cgttgcgggtg ctgttaacgg
 5581 tggagggcag tgtagtctga gcagtactcg ttgctgccgc gcgcgccacc agacataata
 30 5641 gctgacagac taacagactg ttcttttcca tgggtctttt ctgcagtcac cgtcgggatc
 5701 catgggctcc atcgggcgag caagcattga attttgttt gatgtattca aggagctcaa
 5761 agtccacat gccaatgaga acatcttcta ctgccccatt gccatcatgt cagctctagc
 5821 catggtatac ctgggtgcaa aagacagcac caggacacag ataaataagg ttgttcgctt
 5881 tgataaactt ccaggattcg gagacagtat tgaagctcag tgtggcacat ctgtaaacgt
 35 5941 tcaactctca cttagagaca tctcaacca aatcaccaaa ccaatgatg tttattcggt
 6001 cagccttgcc agtagacttt atgctgaaga gagataccca atcctgccag aatacttgca
 6061 gtgtgtgaag gaactgtata gaggaggctt ggaacctatc aactttcaaa cagctgcaga
 6121 tcaagccaga gagctcatca attcctgggt agaaagtcag acaaatggaa ttatcagaaa
 40 6181 tgccttcag ccaagctccg tggattctca aactgcaatg gttctggtta atgccattgt
 6241 cttcaaagga ctgtgggaga aaacatttaa ggatgaagac acacaagcaa tgcctttcag
 6301 agtgactgag caagaaagca aacctgtgca gatgatgtac cagattgggt tatttagagt
 6361 ggcataaatg gcttctgaga aaatgaagat cctggagctt ccatttgcca gtgggacaat
 6421 gagcatgttg gtgctgttgc ctgatgaagt ctcaggcctt gagcagcttg agagtataat
 45 6481 caactttgaa aaactgactg aatggaccag ttctaattgt atggaagaga ggaagatcaa
 6541 agtgtactta cctcgcatga agatggaggaa aaaatacaac ctcacatctg tcttaatggc
 6601 tatgggcatt actgacgtgt ttagctcttc agccaatctg tctggcatct cctcagcaga
 6661 gagcctgaag atatctcaag ctgtccatgc agcacatgca gaaatcaatg aagcaggcag
 6721 agaggtggta gggtcagcag aggtcggagt ggatgctgca agcgtctctg aagaatttag
 6781 ggctgaccat ccattctctc tctgtatcaa gcacatcgca accaacgcgc ttctctctct
 50 6841 tggcagatgt gtttcccgcg gccagcagat gacgcaccag cagatgacgc accagcagat
 6901 gacgcaccag cagatgacgc accagcagat gacgcaccag cagatgacgc aacaacatgt
 6961 atcctgaaag gctcttgttg ctggatcggc ctgctggatg acgatgacaa atttgtgaac
 7021 caacacctgt gcggtccaca cctgggtggaa gctctctacc tagtgtgcgg ggaacgaggc
 7081 ttcttctaca caccacagac ccgcccggag gcagaggacc tgcaggtggg gcaggtggag
 55 7141 ctgggcgggg gccctgggtg aggcagcctg cagcccttgg ccctggaggg gtccctgcag
 7201 aagcgtggca ttgtggaaca atgctgtacc agcatctgct ccctctacca gctggagaac
 7261 tactgcaact agggcgcccta agggcgcaat tatcgcggcc gctctagacc aggcgcctgg
 7321 atccagatca cttctggcta ataaaagatc agagctctag agatctgtgt gttggttttt
 7381 tgtggatctg ctgtgccttc tagttgccag ccattctgtt tttgcccctc ccccgctgct
 60 7441 tccttgaccc tggaaagggtg cactcccact gtcctttcct aataaaatga ggaaattgca
 7501 tcgcattgtc tgagtaggtg tcattctatt ctgggggggtg ggggtggggca gcacagcaag
 7561 ggggaggatt ggggaagaca tagcaggcat gctggggatg cgggtgggctc tatgggtacc
 7621 tctctctctc tctctctctc tctctctctc tctctctctc ggtacctctc ctcgaggggg
 7681 ggcccgttac ccaattcgcc ctatagttag tegtattacg cgcgctcact ggccgtcgtt
 65 7741 ttacaacgtc gtgactggga aaacctggc gttacccaac ttaatcgct tgcagacat
 7801 cccctttctg ccagctggcg taatagcgaa gagggccgca ccgatcgccc tcccaacag
 7861 ttgcgcagcc tgaatggcga atggaaattg taagcgttaa tatttgtta aaattcgcgt
 7921 taaatttttg ttaaatcagc tcattttttt accaataggc cgaaatcggc aaaatccctt

5 7981 ataaatcaaa agaataagacc gagatagggg tgagtgttgt tccagtttgg aacaagagtc
 8041 cactattaaa gaacgtggac tccaacgtca aagggcgaaa aaccgtctat cagggcgatg
 8101 gcccactact ccgggatcat atgacaagat gtgtatccac cttacttaa tgatttttac
 8161 caaaatcatt aggggattca tcagtgtcga gggcacaaga gaattaacat tccgtcagga
 8221 aagcttatga tgatgatgtg cttaaaaact tactcaatgg ctggttatgc atatcgcaat
 8281 acatgcgaaa aacctaaga agcttgccga taaaaaaggc caatttattg ctatttaccg
 8341 cggcttttta ttgagcttga aagataaata aaatagatag gttttatttg aagctaaatc
 8401 ttctttatcg taaaaaatgc cctcttgggt tatcaagagg gtcattatat ttcgcggaat
 8461 aacatcattt ggtgacgaaa taactaagca cttgtctcct gtttactccc ctgagcttga
 10 8521 ggggttaaca tgaaggatcat cgatagcagg ataataatac agtaaaacgc taaaccaata
 8581 atccaaatcc agccatccca aattggtagt gaatgattat aaataacagc aaacagtaat
 8641 gggccaataa caccggttgc attggttaagg ctcaccaata atccctgtaa agcaccttgc
 8701 tgatgactct ttgtttggat agacatcact ccctgtaatg caggtaaagc gatcccacca
 8761 ccagccaata aaattaaaac agggaaaact aaccaacctt cagatataaa cgctaaaaag
 15 8821 gcaaatacac tactatctgc aataaatccg agcagtactg ccgttttttc gccatttag
 8881 tggctattct tctgccaca aaggcttggg atactgagtg taaaagacca agaccgtaa
 8941 tgaaaagcca accatcatgc tattcatcat cacgatttct gtaatagcac cacaccgtgc
 9001 tggattggct atcaatgcgc tgaaataata atcaacaaat ggcacgtta aataagtgat
 9061 gtataccgat cagcttttgt tccctttagt gagggttaat tgcgcgcttg gcgtaatcat
 20 9121 ggtcatagct gtttcctgtg tgaaattgtt atccgctcac aattccacac aacatacgag
 9181 ccggaagcat aaagtgtaaa gcctgggggtg cctaagtgtg gagctaactc acattaattg
 9241 cgttgcgctc actgcccgtt ttccagtcgg gaaacctgtc gtgccagctg cattaatgaa
 9301 tgggccaacg cgggggaga ggcggtttgc gtattgggag ctcttccgct tctcgtca
 9361 ctgactcgct gcgctcggtc gttcggctgc ggcgagcggg atcagctcac tcaaaggcgg
 25 9421 taatacgggt atccacagaa tcaggggata acgcaggaaa gaacatgtga gcaaaaggcc
 9481 agcaaaaggc caggaaacgt aaaaaggcgg cgttgctggc gttttccat aggcctcgcc
 9541 cccctgacga gcatcacaaa aatcgacgtc caagtcagag gtggcgaaac ccgacaggac
 9601 tataaagata ccaggcgttt cccctggaa gctccctcgt gcgctctcct gttccgacc
 9661 tgcgcttac cggatacctg tccgcttttc tcccttcggg aagcgtggcg ctttctcata
 30 9721 gctcacgctg taggtatctc agttcgggtg aggtcgttcg ctccaagctg ggctgtgtgc
 9781 acgaaccccc cgttcagccc gaccgctgcg cttatccgg taactatcgt cttgagtcca
 9841 acccggttaag acacgactta tgcacttg cagcagccac tggtaacagg attagcagag
 9901 cgaggtatgt aggcggtgct acagagttct tgaagtgggt gcctaactac ggctacacta
 9961 gaaggacagt atttggatc tgcgctctgc tgaagccagt taccttcgga aaaagagttg
 35 10021 gtagctcttg atccggcaaa caaacaccg ctggtagcgg tggttttttt gtttgcaagc
 10081 agcagattac gcgcagaaaa aaaggatctc aagaagatcc tttgatcttt tctacggggg
 10141 ctgacgctca gtggaacgaa aactcacgtt aagggtttt ggtcatgaga ttatcaaaaa
 10201 ggatcttcac ctatgacctt ttaaatataa aatgaagttt taaatcaatc taaagtatat
 10261 atgagtaaac ttggtctgac agttaccaat gcttaatcag tgaggcacct atctcagcga
 40 10321 tctgtctatt tctgtcatcc atagtgtcct gactccccgt cgtgtagata actacgatac
 10381 gggaggggtt accatctggc ccagtgctg caatgatacc gcgagacca cgtcacccgg
 10441 ctccagattt atcagcaata aaccagccag ccggaagggc cgagcgaga agtggtcctg
 10501 caactttatc cgcctccatc cagtctatta attgttgccg ggaagctaga gtaagtgtt
 45 10561 cggcagttaa tagtttgccg aacgttgttg ccattgctac aggcacgtg gtgtcacgct
 10621 cgtcgtttgg tatggcttca ttcagctccg gttcccaacg atcaaggcga gttacatgat
 10681 ccccatgtt gtgcaaaaaa gcggttagct ccttcgggtc tccgatcgtt gtcagaagta
 10741 agttggcgc agtgttatca ctcatgggtta tggcagcact gcataattct cttactgtca
 10801 tgcacccgt aagatgcttt tctgtgactg gtgagtactc aaccaagtca tcttgagaat
 10861 agtgatgag gcgaccgagt tgccttgcc cggcgtcaat acgggataat accgcgccac
 50 10921 atagcagaac tttaaaagt ctcacattg gaaaacgttc ttcggggcga aaactctcaa
 10981 ggatcttacc gctgttgaga tccagttcga tgtaacccac tctgtcaccc aactgatctt
 11041 cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg
 11101 caaaaaagg aataaggcg acacggaaat gttgaatact catactcttc ctttttcaat
 11161 attattgaag catttatcag ggttatgtc tcatgagcgg atacatattt gaatgtattt
 55 11221 agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtcca c

SEQ ID NO:43 (pTnMOD(Chicken OVep+OVg'+ENT+proins+syn polyA))

60 1 ctgacgcgcc ctgtagcggc gcattaagcg cggcgggtgt ggtggttacg cgcagcgtga
 61 ccgctacact tgcagcgccc ctacgcggcg ctcttttcgc tttcttccct tctttctcgc
 121 ccacgttcgc cggcatcaga ttggctattg gccattgcat acgttgatc catatcataa
 181 tatgtacatt tatattggct catgtccaac attaccgcca tgttgacatt gattattgac
 65 241 tagttattaa tagtaatcaa ttacgggggc attagtcat agcccatata tggagtccg
 301 cgttacataa cttacggtta atggcccgcc tggctgaccg cccaacgacc cccgccatt
 361 gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca

421 atgggtggag tatttacggt aaactgccta cttggcagta catcaagtgt atcatatgcc
 481 aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta
 541 catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac
 5 601 catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg
 661 atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg
 721 ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt
 781 acggtgggag gtctatataa gcagagctcg tttagtgaac cgtcagatcg cctggagacg
 841 ccatccacgc tgttttgacc tccatagaag acaccgggac cgatccagcc tccgcggccg
 901 ggaacgggtgc attggaacgc ggattccccg tgccaagagt gacgtaagta ccgcctatag
 10 961 actctatagg cacacccctt tggctcttat gcatgctata ctgttttttg cttggggcct
 1021 atacaccccc gcttcttat gctatagggtg atggtatagc ttagcctata ggtgtgggtt
 1081 attgaccatt attgaccact cccctattgg tgacgatact ttccattact aatccataac
 1141 atggctcttt gccacaacta tctctattgg ctatatgcca atactctgtc cttcagagac
 1201 tgacacggac tctgtatttt tacaggatgg ggtcccattt attatttaca aattcacata
 15 1261 tacaacaacg ccgtcccccg tgccgcagt ttttattaaa catagcgtgg gatctccacg
 1321 cgaatctcgg gtacgtgttc cggacatggg ctcttctccg gtageggcgg agcttccaca
 1381 tccgagccct ggtcccatgc ctccagcggc tcatggctcg tcggcagctc cttgctccta
 1441 acagtggagg ccagacttag gcacagcaca atgcccacca ccaccagtgt gccgcacaag
 1501 gccgtggcgg tagggtatgt gtctgaaaat gagcgtggag attgggctcg cacggctgac
 20 1561 gcagatggaa gacttaaggc agcggcagaa gaagatgcag gcagctgagt tgttgtattc
 1621 tgataagagt cagaggtaac tcccgttgcg gtgctgttaa cgggtggaggg cagtgtagtc
 1681 tgagcagtac tcgttgctgc cgcgcgcgcc accagacata atagctgaca gactaacaga
 1741 ctgttccctt ccatgggtct tttctgcagt caccgtcgga ccatgtgcga actcgatatt
 1801 ttacacgact ctctttacca attctgcccc gaattacact taaaacgact caacagctta
 25 1861 acgttggctt gccacgcatt acttgactgt aaaaactctca ctcttaccga acttggccgt
 1921 aacctgccaa ccaaagcgag aacaaaacat aacatcaaac gaatcgaccg attgttaggt
 1981 aatcgtcacc tccacaaaga gcgactcgct gtataccgtt ggcattgctag ctttatctgt
 2041 tcgggcaata cgatgcccct tgtacttgtt gactggctcg atattcgtga gcaaaaacga
 2101 cttatgggat tgcgagcttc agtcgcacta cacggctcgt ctgttactct ttatgagaaa
 30 2161 gcgttccgc atgtcagagca atgttcaaaag aaagctcatg accaatttct agccgacctt
 2221 gcgagcattc taccgagtaa caccacaccg ctcatgttca gtgatgctgg ctttaaagtg
 2281 ccatggtata aatccgttga gaagctgggt tggtagtggg taagtcgagt aagaggaaaa
 2341 gtacaatatg cagacctagg agcggaaaac tggaaaacct tcagcaactt acatgatatg
 2401 tcatctagtc actcaaagac tttaggctat aagaggctga ctaaaagcaa tccaatctca
 35 2461 tgccaaatc tattgtataa atctcgctct aaaggccgaa aaaatcagcg ctgcacacgg
 2521 actcattgtc accaccctgc acctaaaatc tactcagcgt cggcaaagga gccatgggtt
 2581 ctagcaacta acttacctgt tgaaattcga acacccaaac aacttggtta tatctattcg
 2641 aagcgaatgc agattgaaga aaccttccga gacttgaaaa gtctgccta cggactaggc
 2701 ctacgccata gccgaacgag cagctcagag cgttttgata tcatgctgct aatcgccctg
 40 2761 atgcttcaac taacatgttg gcttgcgggc gttcatgctc agaaacaagg ttgggacaag
 2821 cacttccagg ctaacacagt cagaaatcga aacgtactct caacagttcg cttaggcatg
 2881 gaagttttgc ggcattctgg ctacacaata acaagggaag acttactcgt ggctgcaacc
 2941 ctactagctc aaaatttatt cacacatggt tacgcttttg ggaaattatg aggggatcgc
 3001 tctagagcga tccgggatct cgggaaaagc gttggtgacc aaagggtgct tttatcatca
 45 3061 ctttaaaaaat aaaaaacaat tactcagtgc ctgttataag cagcaattaa ttatgattga
 3121 tgcctacatc acaacaaaaa ctgatttaac aaatgggttg tctgccttag aaagtatatt
 3181 tgaacattat cttgattata ttattgataa taataaaaac cttatcccta tccaagaagt
 3241 gatgcctatc attggttgga atgaacttga aaaaaattag ccttgaatac attactggta
 3301 aggtaaaacgc cattgtcagc aaattgatcc aagagaacca acttaaagct ttcctgacgg
 50 3361 aatgttaatt ctcgttgacc ctgagcactg atgaatcccc taatgatttt ggtaaaaatc
 3421 attagtttaa ggtggataca catcttgtca tatgatcccg gtaatgtgag ttagctcact
 3481 cattaggcac cccaggcttt acactttatg cttccggctc gtatgttgtg tggaaattgtg
 3541 agcggataac aatttcacac aggaacacgc tatgaccatg attacgcaa gcgcgcaatt
 3601 aaccctcact aaaggggaaca aaagctggag ctccaccgcg gtggcggccg ctctagaact
 55 3661 agtggatccc ccgggctgca gaaaaatgcc aggtggacta tgaactcaca tccaaaggag
 3721 cttgacctga tacctgattt tcttcaaact ggggaaacaa cacaatccca caaaacagct
 3781 cagagagaaa ccatcactga tggctacagc accaagggtat gcaatggcaa tccattcgac
 3841 attcatctgt gacctgagca aaatgattta tctctccatg aatgggtgct tctttccctc
 60 3901 atgaaaaggc aatttccaca ctacacaata gcaacaaaga caaacagaga acaattaatg
 3961 tgctccttcc taatgtcaaa attgtagtgg caaagaggag aacaaaatct caagttctga
 4021 gtaggtttta gtgattggat aagaggcttt gacctgtgag ctacactgga cttcatatcc
 4081 ttttggataa aaagtgttt tataactttc aggtctccga gtctttatcc atgagactgt
 4141 tggtttaggg acagaccac aatgaaatgc ctggcatagg aaagggcagc agagccttag
 4201 ctgacctttt cttgggacaa gcattgtcaa acaatgtgtg acaaaaactat ttgtactgct
 65 4261 ttgcacagct gtgctgggca gggcaatcca ttgccaccta tcccaggtaa ctttccaact
 4321 gcaagaagat tgttgcttac tctctctaga aagcttctgc agactgacat gcatttcata
 4381 ggtagagata acatttactg ggaagcacat ctatcatcat aaaaagcagg caagattttc
 4441 agactttctt agtggctgaa atagaagcaa aagacgtgat taaaacaaa atgaacaaa

5
10
15
20
25
30
35
40
45
50
55
60
65

4501 aaaaatcagt tgatacctgt ggtgtagaca tccagcaaaa aaatattatt tgcactacca
4561 tcttgtctta agtcctcaga ctgggcaagg agaagttaga tttctacagt atatatgttt
4621 tcacaaaagg aaggagagaa acaaaaagaaa atggcactga ctaaaacttca gctagtggta
4681 taggaaagta attctgctta acagagattg cagtgatctc tatgtatgtc ctgaagaatt
4741 atgttgact tttttcccc atttttaaat caaacagtgc tttacagagg tcagaatggg
4801 ttctttactg ttgtcaatt ctattatttc aatacagaac aatagcttct ataactgaaa
4861 tatatttgct attgtatatt atgattgtcc ctggaacct gaacactcct ccagctgaat
4921 ttcacaattc ctctgtcatc tggcaggcca ttaagtattt catggaagat ctttgaggaa
4981 cactgcaagt tcatatcata aacacatttg aaattgagta ttgttttgca ttgtatggag
5041 ctatgttttg ctgtatcctc agaaaaaaag tttgttataa agcattcaca cccataaaaa
5101 gatagattta aatattccag ctataggaaa gaaagtgcgt ctgctcttca ctctagtctc
5161 agttggctcc ttcacatgca tgcctcttta tttctcctat tttgtcaaga aaataatagg
5221 tcacgtcttg ttctcactta tgcctgcctc agcatggctc agatgcacgt tgtagatata
5281 agaaggatca aatgaaacag acttctgggc tgttactaca accatagtaa taagcacact
5341 aactaataat tgctaattat gttttccatc tctaagggtc ccacattttt ctgttttctt
5401 aaagatccca ttatctgggt gtaactgaag ctcaatggaa catgagcaat atttccagct
5461 cttctctccc atccaacagt cctgatggat tagcagaaca ggcagaaaac acattgttac
5521 ccagaattaa aaactaatat ttgctctcca ttcaatccaa aatggaccta ttgaaactaa
5581 aatctaacc aatcccatta aatgatttct atggcgtcaa aggtcaaact tctgaaggga
5641 acctgtgggt gggtcacaat tcaggctata tattccccag ggctcagcca gtggatcaac
5701 atacagctag aaagctgtat tgcctttagc actcaagctc aaaagacaac tcagagtcca
5761 ccatgggctc catcggcgca gcaagcatgg aattttgttt tgatgtattc aaggagctca
5821 aagtcacca tgccaatgag aacatcttct actgccccat tgccatcatg tcagctctag
5881 ccatgggata cctgggtgca aaagacagca ccaggacaca gataaataag gttgttcgct
5941 ttgataaact tccaggattc ggagacagta ttgaagctca gtgtggcaca tctgtaaacc
6001 ttcactcttc acttagagac atcctcaacc aaatcaccaa accaaatgat gtttattcgt
6061 tcagccttgc cagtagactt tatgtgaaag agagataccc aatcctgcca gaatacttgc
6121 agtgtgtgaa ggaactgtat agaggaggct tggaaacctat caactttcaa acagctgcag
6181 atcaagccag agagctcatc aattcctggg tagaaagtca gacaaatgga attatcagaa
6241 atgtccttca gccaaagctc gtggattctc aaactgcaat gggtctgggt aatgccattg
6301 tcttcaaagg actgtgggag aaaacattta aggatgaaga cacacaagca atgcctttca
6361 gagtgaactg gcaagaaaagc aaacctgtgc agatgatgta ccagattggg ttatttagag
6421 tggcatcaat ggcttctgag aaaatgaaga tcttgagctc tccatttgcc agtgggacaa
6481 tgagcatgtt ggtgtgtgtt cctgatgaag tctcaggcct tgagcagctt gagagtataa
6541 tcaactttga aaaactgact gaatggacca gttctaattg tatggaagag aggaagatca
6601 aagtgtactt acctcgcatg aagatggagg aaaaatacaa cctcacatct gtcttaattg
6661 ctatgggcat tactgacgtg tttagctctt cagccaatct gtctggcacc tctcagcag
6721 agagcctgaa gatattctaa gctgtccatg cagcacatgc agaaatcaat gaagcaggca
6781 gagaggtggg agggctcagca gaggtggag tggatgctgc aagcgtctct gaagaattta
6841 gggctgacca tccattcctc ttctgtatca agcacatcgc aaccaacgcc gttctcttct
6901 ttggcagatg tgtttctccg cggccagcag atgacgcacc agcagatgac gcaccagcag
6961 atgacgcacc agcagatgac gcaccagcag atgacgcacc agcagatgac gcaacaacat
7021 gtatcctgaa aggtctctgt ggctggatcg gcctgctgga tgacgatgac aaatttgtga
7081 accaacacct gtgcggctca cacctgggtg aagctctcta cctagtgtgc ggggaacgag
7141 gcttcttcta cacacccaag acccgccggg aggcagagga cctgcagggt gggcagggtg
7201 agctgggagg gggccctggg gcaggcagcc tgcagccctt ggccctggag gggccctgc
7261 agaagcgtgg cattgtggaa caatgctgta ccagcatctg ctccctctac cagctggaga
7321 actactgcaa ctaggcgcc taaagggcga attatcgcg ccgctctaga ccaggcgct
7381 ggatccagat cacttctggc taataaaaga tcagagctct agagatctgt gtgttggttt
7441 tttgtggatc tgcgtgcct tctagtggc agccatctgt tgtttgcccc tccccgtgc
7501 cttccttgac cctggaagg gccaactcca ctgtccttct ctaataaaaat gaggaaattg
7561 catcgcatgt tctgagtagg tgtcattcta ttctgggggg tggggtgggg cagcacagca
7621 agggggagga ttgggaagac aatagcaggc atgtggggga tgcgggtggg tctatgggtg
7681 cctctctctc tctctctctc tctctctctc tctctctctc tctctctctc tctcgagggt
7741 gggcccggtg cccaattcgc cctatagtga gtcgtattac gcgcgctcac tggcgtcgt
7801 tttacaacgt cgtgactggg aaaaccctgg cgttacccaa cttaatcgcc ttgcagcaca
7861 tcccccttcc gccagctggc gtaatagcga agaggccgc accgatcgcc cttcccaaca
7921 gttgcgcagc ctgaatggcg aatggaaatt gtaagcgtta atattttgtt aaaattcgcg
7981 ttaaattttt gtttaaatcag ctcatTTTTT aaccaatagg ccgaaatcgg caaaatccct
8041 tataaatcaa aagaatagac cgagataggg ttgagtgttg ttccagtttg gaacaagagt
8101 ccactattaa agaacgtgga ctccaacgtc aaagggcgaa aaaccgtcta tcagggcgat
8161 gggccactac tccgggatca tatgacaaga tgtgtatcca ccttaactta atgattttta
8221 ccaaaatcat taggggatc atcagtgtc agggtaacag agaattaaca ttccgtcagg
8281 aaagcttatg atgatgatg gcttaaaaac ttactcaatg gctgggtatg catatcgcaa
8341 tacatgcgaa aaacctaaaa gagcttgccg ataaaaaagg ccaatttatt gctatttacc
8401 gcggcttttt attgagcttg aaagataaat aaaatagata ggttttattt gaagctaaat
8461 cttctttatc gtaaaaaatg ccctcttggg ttatcaagag ggtcattata tttcgcgga
8521 taacatcatt tggtagcga ataactaagg acttgtctcc tgtttactcc cctgagcttg

5 8581 agggggttaac atgaagggtca tcgatagcag gataataata cagtaaaacg ctaaaccaat
7641 aatccaaatc cagccatccc aaattggtag tgaatgatta taaataacag caaacagtaa
8701 tgggccaata acaccgggtg cattggtaag gctaccaat aatccctgta aagcaccttg
8761 ctgatgactc tttgtttgga tagacatcac tccctgtaat gcaggtaaag cgatcccacc
9821 accagccaat aaaattaaaa cagggaaaac taaccaacct tcagatataa acgctaaaaa
9881 ggcaaatgca ctactatctg caataaatcc gagcagtact gccgtttttt cgccatttta
9941 gtggctattc ttcttgccac aaaggcttgg aatactgagt gtaaaagacc aagaccgta
9001 atgaaaagcc aaccatcatg ctattcatca tcacgatttc tgtaatagca ccacaccgtg
9061 ctggattggc tatcaatgcg ctgaaataat aatcaacaaa tggcatcggt aaataagtga
10 9121 tgtataccga tcagcttttg ttccctttag tgagggttaa ttgcgcgctt ggcgtaatca
9181 tggtcatagc tgtttcctgt gtgaaattgt tatccgctca caattccaca caacatacga
9241 gccggaagca taaagtgtaa agcctggggg gcctaataag tgagctaact cacattaatt
9301 gcgttgcgct cactgccgcg tttccagtcg ggaaacctgt cgtgccagct gcattaatga
9361 atcgccaac gcgcggggag aggcgggttg cgtattgggc gctcttcgcg ttctcgcgc
15 9421 actgactcgc tgcgctcggg cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg
9481 gtaatacggg tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc
9541 cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc
9601 cccctgacg agcatcaca aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga
9661 ctataaagat accaggcggt tccccctgga agctccctcg tgcgctctcc tgttcgcacc
20 9721 ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcat
9781 agctcacgct gtaggtatct cagttcgggt taggtcggtt gctccaagct gggctgtgtg
9841 cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtc
9901 aaccgggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga
9961 gcgaggtatg taggcgggtg tacagagttc ttgaagtggg ggcctaacta cggctacact
25 10021 agaaggacag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt
10081 ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt tgtttgcaag
10141 cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg
10201 tctgacgctc agtggaaacg aaactcacgt taagggattt tggtcagag attatcaaaa
10261 aggatcttca cttagatcct tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata
30 10321 tatgagtaaa cttggtctga cagttaccaaa tgcttaatca gtgaggcacc tatctcagcg
10381 atctgtctat ttcggtcatc catagttgcc tgactccccg tcgtgtagat aactacgata
10441 cgggagggct taccatctgg cccagtgct gcaatgatac cgcgagaccc acgctcaccg
10501 gctccagatt tatcagcaat aaaccagcca gccggaaggg ccgagcgag aagtggctct
10561 gcaactttat ccgcctccat ccagtcctatt aattggtgcc gggaagctag agtaagtagt
35 10621 tcgccagtta atagtttgcg caacgttggt gccattgcta caggcatcgt ggtgtcacgc
10681 tcgtcgtttg gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga
10741 tccccatgt tgtgcaaaaa agcgggttagc tccttcggtc ctccgatcgt tgtcagaagt
10801 aagttggccg cagtgttatc actcatgggt atggcagcac tgcataattc tcttactgtc
10861 atgccatccg taagatgctt ttctgtgact ggtgagtact caaccaagtc attctgagaa
40 10921 tagtgtatgc ggcgaccgag ttgctcttgc ccggcgtaa tacgggataa taccgcgcca
10981 catagcagaa ctttaaaagt gctcatcatt ggaaaacgtt cttcgggcg aaaactctca
11041 aggatcttac cgctgttgag atccagttcg atgtaacca ctcgtgcacc caactgatct
11101 tcagcatctt ttactttcac cagcgtttct gggtagcaa aaacaggaag gcaaaatgcc
11161 gcaaaaaagg gaataagggc gacacggaaa tgttgaatac tcatactctt cctttttcaa
45 11221 tattattgaa gcatttatca gggttattgt ctcatgagcg gatacatatt tgaatgtatt
11281 tagaaaaata acaaaatagg gggtccgcgc acatttcccc gaaaagtgcc ac

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 January 2004 (08.01.2004)

PCT

(10) International Publication Number
WO 2004/003157 A3

(51) International Patent Classification⁷: C07H 21/24,
C12N 15/00

(21) International Application Number:
PCT/US2003/020389

(22) International Filing Date: 26 June 2003 (26.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/392,415 26 June 2002 (26.06.2002) US
60/441,377 21 January 2003 (21.01.2003) US
60/441,502 21 January 2003 (21.01.2003) US
60/441,405 21 January 2003 (21.01.2003) US
60/441,447 21 January 2003 (21.01.2003) US
60/441,392 21 January 2003 (21.01.2003) US
60/441,381 21 January 2003 (21.01.2003) US

(71) Applicants (for all designated States except US): TRANS-
GENRX, INC. [US/US]; Suite 300, 1755 Wittington Place
Drive, Dallas, TX 75234 (US). THE BOARD OF SUPER-
VISORS OF LOUISIANA STATE UNIVERSITY AND
AGRICULTURAL AND MECHANICAL COLLEGE
[US/US]; P.O. Box 25055, Baton Rouge, LA 70894-5055
(US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COOPER, Richard,
K. [US/US]; 111 Pecan Meadow Drive, Baton Rouge,
LA 70810 (US). CADD, Gary, G. [US/US]; 501 Turner
Road, Apartment 1111, Grapevine, TX 76051 (US).
FIORETTI, William, C. [US/US]; 2225 Lakeridge Road
Drive, Grapevine, TX 76051 (US). DEBOER, Kenneth,
F. [US/US]; 10720 Gee Norman Road, Belgrade, MT
59714 (US).

(74) Agents: PRATT, John, S. et al.; Kilpatrick Stockton LLP,
Suite 2800, 1100 Peachtree Street, Atlanta, GA 30309
(US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC,
SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for all designations

Published:

- with international search report

(88) Date of publication of the International search report:
28 October 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: GENE REGULATION IN TRANSGENIC ANIMALS USING A TRANSPOSON-BASED VECTOR

(57) Abstract: Administration of modified transposon-based vectors has been used to achieve stable incorporation of exogenous genes into animals. These transgenic animals produce transgenic progeny. Further, these transgenic animals produce large quantities of desired molecules encoded by the transgene. Transgenic egg-laying animals produce large quantities of desired molecules encoded by the transgene and deposit these molecules in the egg.

WO 2004/003157 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/20389

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07H 21/24; C12N 15/00

US CL : 536/23.2; 800/24

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.2; 800/24

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01/14537 A1 (THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE) 01 March 2001 (01.03.2001), entire document.	1-51
A	SHERMAN, A. et al. Transposition of the drosophila element marnier into the chicken germ line. Nature Biotechnology. November 1998, Vol. 16, pages 1050-1053.	1-51
Y	WO 99/09817 A1 (BIOTECHNOLOGY AND BIOLOGICAL SCIENCES RESEARCH COUNCIL) 04 March 1999 (04.03.1999), page 5, lines 9-10; page 5, lines 4-5; page 7, lines 15-19; page 21, lines 29-31; page 22, lines 10-24.	1,20,11,18-22,25,28,40,41 and 44
Y	US 6,218,185 B1 (SHIRK et al.) 17 April 2001 (17.04.2001), col. 3, lines 14-30; col. 6, lines 33-35; col. 7, lines 61-67; COL. 14, lines 10-18; col. 17, lines 9-11; col. 18, LINES 1-16, col. 22, lines 7-61; claim 9.	1,20,11,18-22,28 and 44
Y	SCHNEIDER, S. An epitope tagged mammalian/prokaryotic expression vector with positive selection of cloned inserts. Gene. 1997, Vol. 197, pages 337-341, specifically, Abstract, lines 6-8, page 339, col. 1, lines 12-15, col. 2, paragraph 1, line 15; Figure 1.	1, 22, 25, 40, 41, 44

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

01 February 2004 (01.02.2004)

Date of mailing of the international search report

02 APR 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Valerie Hertoglio

Telephone No. (571) 272-0532

INTERNATIONAL SEARCH REPORT

PCT/US03/20389

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KOZAK, M. At least six nucleotides preceding the AUG inhibitor codon enhance translation in mammalian cells. J. Mol. Biol. 1987, Vol. 196, pages 947-950, specifically page 947, col. 1, lines 25-33; page 949, col. 2, line 16.	1, 22, 25, 40, 41, 44
Y	WO 97/47739 A1 (BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY) 18 December 1997 (18.12.1997), page 3, lines 29-30, page 6, lines 13-24, page 9, lines 7-34.	10, 11, 18-21, 28, 46